ID	Title	Reference	Feature type	Mab(s)(Binding type)	Experimental method(s)	Position	Env feature(s)	HXB2 AA	Entropy M	Entropy B	Entropy C	Annotation
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	124	gp120	P	0.045	0.018	0.029	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	125	gp120	L	0.135	0.153	0.058	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	126	gp120, Cys 126 linked to Cys 196	C	0.034	0.028	0.008	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	127	gp120	V	0.102	0.112	0.093	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	196	gp120, Cys 126 linked to Cys 196, V2 loop end	C	0.036	0.034	0.038	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	198	gp120	T	0.430	0.264	0.469	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	283	gp120, Loop D	T	1.005	1.091	0.474	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	374	gp120, CD4 binding loop	H	0.210	0.277	0.029	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	425	gp120, beta20/beta21	N	0.295	0.138	0.177	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	426	gp120, beta20/beta21	M	0.724	0.866	0.274	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	427	gp120, beta20/beta21	W	0.083	0.061	0.038	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	429	gp120, beta20/beta21	K	1.325	0.961	1.308	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	430	gp120, beta20/beta21	V	0.267	0.080	0.073	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	431	gp120, beta20/beta21	G	0.072	0.036	0.039	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	432	gp120, beta20/beta21	K	1.037	0.339	0.564	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	471	gp120, beta24	G	0.933	0.888	0.866	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	472	gp120	G	0.035	0.012	0.043	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	473	gp120	G	0.042	0.033	0.029	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	474	gp120	D	0.696	0.681	0.752	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	475	gp120	M	0.097	0.092	0.106	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	476	gp120	R	0.663	0.615	0.711	CD4 binding site
1	CD4 contacts	Zhou2010	Env feature		X-ray crystallography	477	gp120	D	0.191	0.112	0.249	CD4 binding site
2	CD4 independence, intrinsic reactivity	Haim2011	Env feature			66	gp120	H	0.010	0.017	0.000	H66N reduces spontaneous exposure of the Coreceptor binding site and reduced Env binding of C34-Ig (C34-Ig corresponds to HR2 and interacts with the HR1 coiled coil of the six-helix bundle). Did not impact CD4bs antibody or 2F5 sensitivity.
2	CD4 independence, intrinsic reactivity	Haim2011	Env feature			197	gp120	N	0.133	0.082	0.109	197N: Loss of glycosylation site caused Ada strain to become CD4 independent, and increased CCR5 binding to gp120 in the absence of CD4. Like changes in gp41 at 625, 626 and 674, the change increased the formation/exposure of the HR1 coiled coil on gp41, promoting the infection of CD4-negative cells expressing CCR5. Increases neutralization sensitivity to CD4i antibodies, but not to CD4bs antibody b12, which interacts in this region.
2	CD4 independence, intrinsic reactivity	Haim2011	Env feature			375	gp120	S	0.668	0.753	0.372	S375W increases spontaneous sampling of the CD4 bound conformation, and exposure of the Corecptor binding site, but does not effect the formation/exposure of the HR1 coiled coil, and did not impact the ability of HIV to infect CD4- cells. Did not impact CD4bs antibody or 2F5 sensitivity, but increases sensitivity to sCD4 and CD4i MAb 17b.
2	CD4 independence, intrinsic reactivity	Haim2011	Env feature			625	gp41	H	0.197	0.185	0.214	NM625/626HT and D674N (AD8 to HXB2 mutations) additively increase CD4-independent infection, and together explained most of the contribution of the HXBc2 ectodomain to this phenotype. These changes (and 197) increase the formation/exposure of the HR1 coiled coil on gp41, promoting the infection of CD4-negative cells expressing CCR5. Increases neutralization sensitivity to CD4i antibodies, and CD4bs antibody b12.
2	CD4 independence, intrinsic reactivity	Haim2011	Env feature			626	gp41	T	0.249	0.201	0.303	NM625/626HT and D674N (AD8 to HXB2 mutations) additively increase CD4-independent infection, and together explained most of the contribution of the HXBc2 ectodomain to this phenotype. These changes (and 197) increase the formation/exposure of the HR1 coiled coil on gp41, promoting the infection of CD4-negative cells expressing CCR5. Increases neutralization sensitivity to CD4i antibodies, and CD4bs antibody b12.
2	CD4 independence, intrinsic reactivity	Haim2011	Env feature			674	gp41	N	1.179	1.029	1.344	NM625/626HT and D674N (AD8 to HXB2 mutations) additively increase CD4-independent infection, and together explained most of the contribution of the HXBc2 ectodomain to this phenotype. Increases neutralization sensitivity to CD4i antibodies, and CD4bs antibody b12.
3	Mutations associated with RV144 vaccine efficacy	Rolland2012	Env feature	polyclonal(other)	computational prediction, sequence analysis	169	gp120, V2	V	2.042	1.770	1.344	K169 (present in vaccine sequence) associated with uninfected status in preventive vaccine trial
3	Mutations associated with RV144 vaccine efficacy	Rolland2012	Env feature	polyclonal(other)	computational prediction, sequence analysis	181	gp120, V2	I	0.988	0.929	0.855	I181 (not present in vaccine sequence) associated with uninfected status in preventive vaccine trial
4	PGT121 epitope defined by competition with 10-188	Mouquet2012a	binding	PGT121(V3)	ELISA	308	gp120, V3 loop	R	1.578	0.091	0.127	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
4	PGT121 epitope defined by competition with 10-188	Mouquet2012a	binding	PGT121(V3)	ELISA	309	gp120, V3 loop	I	0.863	0.359	0.965	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
4	PGT121 epitope defined by competition with 10-188	Mouquet2012a	binding	PGT121(V3)	ELISA	312	gp120, V3 loop	G	0.237	0.362	0.008	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
4	PGT121 epitope defined by competition with 10-188	Mouquet2012a	binding	PGT121(V3)	ELISA	313	gp120, V3 loop	P	0.344	0.424	0.078	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
4	PGT121 epitope defined by competition with 10-188	Mouquet2012a	binding	PGT121(V3)	ELISA	314	gp120, V3 loop	G	0.057	0.095	0.014	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
4	PGT121 epitope defined by competition with 10-188	Mouquet2012a	binding	PGT121(V3)	ELISA	315	gp120, V3 loop	R	1.211	1.028	0.196	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
4	PGT121 epitope defined by competition with 10-188	Mouquet2012a	binding	PGT121(V3)	ELISA	316	gp120, V3 loop	A	1.056	0.736	0.966	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
4	PGT121 epitope defined by competition with 10-188	Mouquet2012a	binding	PGT121(V3)	ELISA	317	gp120, V3 loop	F	0.834	1.090	0.223	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
4	PGT121 epitope defined by competition with 10-188	Mouquet2012a	binding	PGT121(V3)	ELISA	318	gp120, V3 loop	V	0.588	0.691	0.507	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
4	PGT121 epitope defined by competition with 10-188	Mouquet2012a	binding	PGT121(V3)	ELISA	319	gp120, V3 loop	T	0.794	0.913	0.339	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
4	PGT121 epitope defined by competition with 10-188	Mouquet2012a	binding	PGT121(V3)	ELISA	320	gp120, V3 loop	I	0.711	0.564	0.782	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
5	PGT128 contacts	Pejchal2011	contacts	PGT128(V3)	X-ray crystallography	301	gp120, V3 loop	N	0.172	0.176	0.104	PGT128 contacts are in V3 at high mannose glycans at 301 and 332, with 301 being a secondary contact.
5	PGT128 contacts	Pejchal2011	contacts	PGT128(V3)	X-ray crystallography	303	gp120, V3 loop	T	0.213	0.190	0.202	PGT128 contact
5	PGT128 contacts	Pejchal2011	contacts	PGT128(V3)	X-ray crystallography	304	gp120, V3 loop	R	0.304	0.390	0.141	PGT128 contact
5	PGT128 contacts	Pejchal2011	contacts	PGT128(V3)	X-ray crystallography	323	gp120, V3 loop	I	0.476	0.531	0.263	PGT128: V3 loop beta strand contacts
5	PGT128 contacts	Pejchal2011	contacts	PGT128(V3)	X-ray crystallography	324	gp120, V3 loop	G	0.075	0.056	0.092	PGT128: V3 loop beta strand contacts
5	PGT128 contacts	Pejchal2011	contacts	PGT128(V3)	X-ray crystallography	325	gp120, V3 loop	N	0.648	0.622	0.622	PGT128: V3 loop beta strand contacts
5	PGT128 contacts	Pejchal2011	contacts	PGT128(V3)	X-ray crystallography	326	gp120, V3 loop	M	0.143	0.143	0.116	PGT128 contact
5	PGT128 contacts	Pejchal2011	contacts	PGT128(V3)	X-ray crystallography	327	gp120, V3 loop	R	0.089	0.066	0.073	PGT128 contact
5	PGT128 contacts	Pejchal2011	contacts	PGT128(V3)	X-ray crystallography	332	gp120	N	0.663	0.491	0.693	PGT128 contacts are in V3 at high mannose glycans at 301 and 332, with 332 being the primary contact. Also, Moore2012: under-represented in transmitted C's, confers PGT128 sensitivity. Antibodies in early infection initially targeted virus with no glycan at 332, the glycosylation site shifted to 332 to escape the early response, and new antibodies arose that targeted the new mannose epitope.
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	97	gp120	K	0.478	0.421	0.511	side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	123	gp120	T	0.047	0.028	0.038	main chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	192	gp120, V2	K	0.940	0.835	0.851	main chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	193	gp120, V2	L	0.200	0.202	0.055	main chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	278	gp120, Loop D	T	0.708	0.715	0.481	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	283	gp120, Loop D	T	1.005	1.091	0.474	side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	main chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	main chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	427	gp120, beta20/beta21	W	0.083	0.061	0.038	main chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	main chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	429	gp120, beta20/beta21	K	1.325	0.961	1.308	main chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	430	gp120, beta20/beta21	V	0.267	0.080	0.073	side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	main chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	main chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.567	1.466	1.517	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	466	gp120, V5 loop, beta24	E	0.205	0.091	0.239	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	467	gp120, V5 loop, beta24	I	0.912	0.955	0.870	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	472	gp120	G	0.035	0.012	0.043	main chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	473	gp120	G	0.042	0.033	0.029	main chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	474	gp120	D	0.696	0.681	0.752	main and side chain contact
6	VRC01 contacts	Zhou2010	contacts	VRC01(CD4BS)	X-ray crystallography	476	gp120	R	0.663	0.615	0.711	side chain contact
7	3BNC60 contacts	Scheid2011	contacts	3BNC60(CD4BS)		278	gp120, Loop D	T	0.708	0.715	0.481	3BNC60 contact
7	3BNC60 contacts	Scheid2011	contacts	3BNC60(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	3BNC60 contact
7	3BNC60 contacts	Scheid2011	contacts	3BNC60(CD4BS)		368	gp120, CD4 binding loop	D	0.039	0.023	0.029	3BNC60 salt bridge
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	97	gp120	K	0.478	0.421	0.511	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	123	gp120	T	0.047	0.028	0.038	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	124	gp120	P	0.045	0.018	0.029	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	198	gp120	T	0.430	0.264	0.469	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	199	gp120	S	0.094	0.108	0.068	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	257	gp120	T	0.029	0.024	0.015	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	VRC03 light chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	278	gp120, Loop D	T	0.708	0.715	0.481	VRC03 light chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	VRC03 heavy chain interaction (hydrogen bonding) and light chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	VRC03 heavy chain interaction and light chain interaction (hydrogen bonding); calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	VRC03 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	VRC03 heavy chain interaction, salt bridge; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	283	gp120, Loop D	T	1.005	1.091	0.474	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	VRC03 heavy chain interaction, hydrogen bonding and salt bridge; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	375	gp120	S	0.668	0.753	0.372	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	425	gp120, beta20/beta21	N	0.295	0.138	0.177	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	426	gp120, beta20/beta21	M	0.724	0.866	0.274	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	427	gp120, beta20/beta21	W	0.083	0.061	0.038	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	429	gp120, beta20/beta21	K	1.325	0.961	1.308	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	430	gp120, beta20/beta21	V	0.267	0.080	0.073	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	431	gp120, beta20/beta21	G	0.072	0.036	0.039	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	VRC03 heavy chain and light chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	VRC03 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	VRC03 heavy chain interaction (hydrogen bonding) and light chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	VRC03 heavy chain interaction and light chain interaction (hydrogen bonding); calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	VRC03 heavy chain interaction (hydrogen bonding) and light chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	VRC03 heavy chain and light chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	VRC03 heavy chain and light chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.567	1.466	1.517	VRC03 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	466	gp120, V5 loop, beta24	E	0.205	0.091	0.239	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	467	gp120, V5 loop, beta24	I	0.912	0.955	0.870	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	VRC03 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	472	gp120	G	0.035	0.012	0.043	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	473	gp120	G	0.042	0.033	0.029	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	474	gp120	D	0.696	0.681	0.752	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	475	gp120	M	0.097	0.092	0.106	VRC03 heavy chain interaction; calculated on the EBI PISA server
8	VRC03 contacts	Wu2011	contacts	VRC03(CD4BS)	molecular modeling, X-ray crystallography	776	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, CaM interaction, p115-RhoGEF interaction	L	0.245	0.197	0.214	VRC03 light chain interaction; calculated on the EBI PISA server
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		97	gp120	K	0.478	0.421	0.511	Env 97K interacts with NIH45-46 heavy chain 99cD, distance 3.95
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		98	gp120	N	0.042	0.045	0.022	Env 98N interacts with NIH45-46 heavy chain 99bR, distance 3.98
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		99	gp120	D	1.048	0.830	0.366	Env 99D interacts with NIH45-46 heavy chain 99bR, distance 2.74
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		102	gp120	E	0.782	0.522	0.426	Env 102E interacts with NIH45-46 heavy chain 99bR, distance 3.42
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		122	gp120	L	0.150	0.101	0.121	Env 122L interacts with NIH45-46 heavy chain 74Y, distance 3.11
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		123	gp120	T	0.047	0.028	0.038	Env 123T interacts with NIH45-46 heavy chain 74Y, distance 3.9
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		124	gp120	P	0.045	0.018	0.029	Env 124G interacts with NIH45-46 heavy chain 74Y, distance 3.41
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		276	gp120, Loop D	N	0.118	0.063	0.169	Env 276N interacts with NIH45-46 light chain 89Y, distance 3.5 ; NIH45-46, VRC01 light chains interact with carbohydrate
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		278	gp120, Loop D	T	0.708	0.715	0.481	Env 278T interacts with NIH45-46 light chain 89Y, distance 3.47
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		279	gp120, Loop D	D	0.900	0.850	0.898	Env 279N interacts with NIH45-46 heavy chain 100Y 3.72 ; interacts with NIH45-46 heavy chain 102W, distance 2.83 ; interacts with NIH45-46 light chain 89Y, distance 3.63 ; NIH45-46G54W, D279A or D279K may confer resistance
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	Env 280N interacts with NIH45-46 heavy chain 102W, distance 3.34 ; interacts with NIH45-46 heavy chain 47W, distance 3.97 ; interacts with NIH45-46 heavy chain 50W, distance 2.71 ; interacts with NIH45-46 heavy chain 58N, distance 3.75 ; interacts with NIH45-46 light chain 90E, distance 3.12 ; NIH45-46G54W, N280S may confer resistance
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		281	gp120, Loop D	A	1.129	0.814	1.357	Env 281A interacts with NIH45-46 heavy chain 50W, distance 3.8 ; interacts with NIH45-46 heavy chain 52K, distance 3.74; interacts with NIH45-46 heavy chain 99dY, distance 2.9
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		282	gp120, Loop D	K	0.336	0.337	0.297	Env 282K interacts with NIH45-46 heavy chain 99dY, distance 3.04 ; NIH45-46G54W, K282Y may confer resistance, but this change is tolerated by VRC01
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		365	gp120, CD4 binding loop	S	0.602	0.489	0.619	Env 365S interacts with NIH45-46 heavy chain 57V, distance 3.76 ; interacts with NIH45-46 heavy chain 59Y, distance 3.83 ; water median H bond network, also VRC03
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		366	gp120, CD4 binding loop	G	0.043	0.012	0.028	Env 366G interacts with NIH45-46 heavy chain 57V, distance 3.67 ; water median H bond network, also VRC03, CD4 has a direct contact
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		367	gp120, CD4 binding loop	G	0.042	0.034	0.008	Env 367G interacts with NIH45-46 heavy chain 54G, distance 3.72 ; interacts with NIH45-46 heavy chain 55G, distance 3.19
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		368	gp120, CD4 binding loop	D	0.039	0.023	0.029	Env 368D interacts with NIH45-46 heavy chain 54G, distance 2.8 ; interacts with NIH45-46 heavy chain 71R, distance 2.79 ; main chain H bond, also for CD4 and VRC03
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		371	gp120, CD4 binding loop	I	0.466	0.389	0.507	Env 371I interacts with NIH45-46 heavy chain 53R, distance 3.83 ; interacts with NIH45-46 heavy chain 54G, distance 3.24 ; interacts with NIH45-46 heavy chain 55G, distance 3.94 ; interacts with NIH45-46 heavy chain 56A, distance 3.49
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		427	gp120, beta20/beta21	W	0.083	0.061	0.038	Env 427W interacts with NIH45-46 heavy chain 53R, distance 3.9
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		430	gp120, beta20/beta21	V	0.267	0.080	0.073	Env 430T interacts with NIH45-46 heavy chain 30L, distance 3.9 ; interacts with NIH45-46 heavy chain 74Y, distance 3.7
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		431	gp120, beta20/beta21	G	0.072	0.036	0.039	Env 431G interacts with NIH45-46 heavy chain 74Y, distance 3.2
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		432	gp120, beta20/beta21	K	1.037	0.339	0.564	Env 432Q interacts with NIH45-46 heavy chain 74Y, distance 3.79
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		455	gp120, beta23	T	0.709	0.426	0.972	Env 455T interacts with NIH45-46 heavy chain 58N, distance 3.53
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		456	gp120, beta23	R	0.233	0.079	0.323	Env 456R interacts with NIH45-46 heavy chain 58N, distance 2.77 ; NIH45-46G54W, R456S or R456W may confer resistance
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		457	gp120, beta23	D	0.079	0.054	0.043	Env 457D interacts with NIH45-46 heavy chain 58N, distance 3.86; interacts with NIH45-46 heavy chain 64Q, distance 2.61
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		458	gp120, beta23	G	0.112	0.045	0.095	Env 458G interacts with NIH45-46 heavy chain 47W, distance 3.79 ; interacts with NIH45-46 heavy chain 58N, distance 3.15 ; interacts with NIH45-46 heavy chain 59Y, distance 3.6 ; interacts with NIH45-46 heavy chain 60A, distance 3.12 ; interacts with NIH45-46 heavy chain 61R, distance 3.49 ; NIH45-46G54W, G458 to other amino acids may confer resistance
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	Env 459G interacts with NIH45-46 light chain 90E, distance 3.13 ; NIH45-46G54W, G459 to other amino acids may confer resistance
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	Env 460A interacts with NIH45-46 heavy chain 61R, distance 3.67
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	Env 461N interacts with NIH45-46 light chain 3V, distance 3.41
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		465	gp120, V5-hypervariable, V5 loop, beta24	S	1.567	1.466	1.517	Env 465N interacts with NIH45-46 heavy chain 61R, distance 3.12
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		466	gp120, V5 loop, beta24	E	0.205	0.091	0.239	Env 466E interacts with NIH45-46 heavy chain 61R, distance 3.55
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		467	gp120, V5 loop, beta24	I	0.912	0.955	0.870	Env 467T interacts with NIH45-46 heavy chain 61R, distance 3.05
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	Env 469R interacts with NIH45-46 heavy chain 64Q, distance 3.33
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		474	gp120	D	0.696	0.681	0.752	Env 474N interacts with NIH45-46 heavy chain 53R, distance 3.41
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		476	gp120	R	0.663	0.615	0.711	Env 476K interacts with NIH45-46 heavy chain 99aA, distance 3.8
9	NIH45-46 contacts	Diskin2011	contacts	NIH45-46(CD4BS)		480	gp120	R	0.061	0.047	0.049	Env 480R interacts with NIH45-46 heavy chain 99bR, distance 3.82
10	Mutation affects PGV04 neutralization	Falkowska2012	neutralization	VRC-PG04(CD4BS)	alanine scanning, neutralization assay	199	gp120	S	0.094	0.108	0.068	S199A in strain JRCSF enhances PGV04, VRC01, CD4-IgG, and b12 neutralization
10	Mutation affects PGV04 neutralization	Falkowska2012	neutralization	VRC-PG04(CD4BS)	alanine scanning, neutralization assay	276	gp120, Loop D	N	0.118	0.063	0.169	N276A in strain JRCSF reduces PGV04 neutralization, enhances VRC01, no impact on CD4-IgG or b12
10	Mutation affects PGV04 neutralization	Falkowska2012	neutralization	VRC-PG04(CD4BS)	alanine scanning, neutralization assay	279	gp120, Loop D	D	0.900	0.850	0.898	D279A in strain JRCSF reduces PGV04, VRC01, CD4-IgG neutralization, no impact on b12 neutralization
10	Mutation affects PGV04 neutralization	Falkowska2012	neutralization	VRC-PG04(CD4BS)	alanine scanning, neutralization assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A in strain JRCSF reduces PGV04 and VRC01 neutralization, enhances CD4-IgG and b12 neutralization
10	Mutation affects PGV04 neutralization	Falkowska2012	neutralization	VRC-PG04(CD4BS)	alanine scanning, neutralization assay	309	gp120, V3 loop	I	0.863	0.359	0.965	I309A in strain JRCSF reduces PGV04 and VRC01 neutralization, enhances CD4-IgG and b12 neutralization
10	Mutation affects PGV04 neutralization	Falkowska2012	neutralization	VRC-PG04(CD4BS)	alanine scanning, neutralization assay	317	gp120, V3 loop	F	0.834	1.090	0.223	F317A in strain JRCSF reduces PGV04 and VRC01 neutralization, enhances CD4-IgG and b12 neutralization
10	Mutation affects PGV04 neutralization	Falkowska2012	neutralization	VRC-PG04(CD4BS)	alanine scanning, neutralization assay	318	gp120, V3 loop	V	0.588	0.691	0.507	Y318A in strain JRCSF reduces PGV04 and VRC01 neutralization, enhances CD4-IgG and b12 neutralization
10	Mutation affects PGV04 neutralization	Falkowska2012	neutralization	VRC-PG04(CD4BS)	alanine scanning, neutralization assay	420	gp120	I	0.093	0.049	0.078	I420A in strain JRCSF reduces PGV04 and VRC01 neutralization, enhances CD4-IgG and b12 neutralization
10	Mutation affects PGV04 neutralization	Falkowska2012	neutralization	VRC-PG04(CD4BS)	alanine scanning, neutralization assay	423	gp120, beta20/beta21	I	0.433	0.383	0.411	I423A in strain JRCSF reduces PGV04 and VRC01 neutralization, enhances CD4-IgG and b12 neutralization
10	Mutation affects PGV04 neutralization	Falkowska2012	neutralization	VRC-PG04(CD4BS)	alanine scanning, neutralization assay	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	N461A in strain JRCSF enhances PGV04 and VRC01 neutralization, no impact on CD4-IgG and b12
10	Mutation affects PGV04 neutralization	Falkowska2012	neutralization	VRC-PG04(CD4BS)	alanine scanning, neutralization assay	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	S463A in strain JRCSF enhances PGV04 and VRC01 neutralization, no impact on CD4-IgG and b12
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		256	gp120	S	0.081	0.070	0.078	CH103: H bond
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		279	gp120, Loop D	D	0.900	0.850	0.898	CH103 contact
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	CH103: H bond
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		364	gp120, CD4 binding loop	S	0.924	0.588	1.191	CH103 contact
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		365	gp120, CD4 binding loop	S	0.602	0.489	0.619	CH103: H bond
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		366	gp120, CD4 binding loop	G	0.043	0.012	0.028	CH103 contact
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		367	gp120, CD4 binding loop	G	0.042	0.034	0.008	CH103: H bond
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		368	gp120, CD4 binding loop	D	0.039	0.023	0.029	CH103: H bond/salt bridge
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		369	gp120, CD4 binding loop	P	0.941	0.591	0.470	CH103 contact
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		370	gp120, CD4 binding loop	E	0.049	0.017	0.055	CH103: H bond/salt bridge
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		371	gp120, CD4 binding loop	I	0.466	0.389	0.507	CH103 contact
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		455	gp120, beta23	T	0.709	0.426	0.972	CH103 contact
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		457	gp120, beta23	D	0.079	0.054	0.043	CH103 contact
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		458	gp120, beta23	G	0.112	0.045	0.095	CH103: H bond
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	CH103 contact
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	CH103 contact
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	CH103: H bond/salt bridge
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	CH103 contact
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	CH103 contact
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	CH103 contact
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		471	gp120, beta24	G	0.933	0.888	0.866	CH103 contact
11	CH103 contacts	Liao2013	contacts	CH103(CD4BS)		472	gp120	G	0.035	0.012	0.043	CH103 contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	256	gp120	S	0.081	0.070	0.078	b12 main chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	257	gp120	T	0.029	0.024	0.015	b12 main chain contact and side chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	b12 main chain contact and side chain contact; H bond
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	b12 main chain contact and side chain contact; H bond
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	364	gp120, CD4 binding loop	S	0.924	0.588	1.191	b12 side chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	b12 main chain contact and side chain contact; H bond
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	b12 main chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	b12 main chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	b12 main chain contact and side chain contact; H bond
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	b12 main chain contact and side chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	b12 main chain contact and side chain contact; H bond
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	b12 main chain contact and side chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	372	gp120, CD4 binding loop	V	1.105	0.776	0.391	b12 side chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	373	gp120, CD4 binding loop	T	1.024	0.872	0.371	b12 side chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	384	gp120	Y	0.107	0.124	0.023	b12 main chain contact and side chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	b12 main chain contact and side chain contact; H bond
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	417	gp120, V4 loop	P	0.864	0.736	0.922	b12 main chain contact and side chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	418	gp120, Cys 385 linked to Cys 418	C	0.056	0.038	0.059	b12 main chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	419	gp120	R	0.463	0.341	0.500	b12 main chain contact and side chain contact; H bond
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	430	gp120, beta20/beta21	V	0.267	0.080	0.073	b12 main chain contact and side chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	431	gp120, beta20/beta21	G	0.072	0.036	0.039	b12 main chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	432	gp120, beta20/beta21	K	1.037	0.339	0.564	b12 side chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	453	gp120, beta23	L	0.494	0.517	0.199	b12 side chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	b12 side chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	b12 main chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	b12 main chain contact and side chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	b12 main chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	470	gp120, beta24	P	0.043	0.039	0.037	b12 main chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	471	gp120, beta24	G	0.933	0.888	0.866	b12 main chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	472	gp120	G	0.035	0.012	0.043	b12 main chain contact; H bond
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	473	gp120	G	0.042	0.033	0.029	b12 main chain contact
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	474	gp120	D	0.696	0.681	0.752	b12 main chain contact and side chain contact; H bond
12	b12 contacts	Zhou2007	contacts	b12(CD4BS)	X-ray crystallography	475	gp120	M	0.097	0.092	0.106	b12 main chain contact and side chain contact
13	17b contacts	Kwong1998	contacts	17b(CD4i)	X-ray crystallography	419	gp120	R	0.463	0.341	0.500	17b contact
13	17b contacts	Kwong1998	contacts	17b(CD4i)	X-ray crystallography	421	gp120, beta20/beta21	K	0.332	0.374	0.203	17b contact
13	17b contacts	Kwong1998	contacts	17b(CD4i)	X-ray crystallography	422	gp120, beta20/beta21	Q	0.062	0.046	0.031	17b contact
14	PG9 contacts	McLellan2011	contacts	PG9(V2)	X-ray crystallography	156	gp120, V1	N	0.246	0.220	0.224	PG9 glycan contact
14	PG9 contacts	McLellan2011	contacts	PG9(V2)	X-ray crystallography	160	gp120, V2	N	0.416	0.452	0.358	PG9 glycan contact
14	PG9 contacts	McLellan2011	contacts	PG9(V2)	X-ray crystallography	166	gp120, V2	R	1.237	1.398	0.772	PG9 contact with CAP45 and ZM109 V1V2 scaffold
14	PG9 contacts	McLellan2011	contacts	PG9(V2)	X-ray crystallography	167	gp120, V2	G	0.779	1.122	0.185	PG9 contact with CAP45 and ZM109 V1V2 scaffold
14	PG9 contacts	McLellan2011	contacts	PG9(V2)	X-ray crystallography	168	gp120, V2	K	0.566	0.666	0.396	PG9 contact with CAP45 and ZM109 V1V2 scaffold
14	PG9 contacts	McLellan2011	contacts	PG9(V2)	X-ray crystallography	169	gp120, V2	V	2.042	1.770	1.344	PG9 contact with CAP45 and ZM109 V1V2 scaffold
14	PG9 contacts	McLellan2011	contacts	PG9(V2)	X-ray crystallography	170	gp120, V2	Q	1.493	1.423	1.428	PG9 contact with CAP45 and ZM109 V1V2 scaffold
14	PG9 contacts	McLellan2011	contacts	PG9(V2)	X-ray crystallography	171	gp120, V2	K	1.247	0.957	1.413	PG9 contact with CAP45 and ZM109 V1V2 scaffold
14	PG9 contacts	McLellan2011	contacts	PG9(V2)	X-ray crystallography	173	gp120, V2	Y	1.059	0.808	1.158	PG9 contact; 173 is a glycan contact in some strains
15	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PG9(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of glycan confers resistance to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
15	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PG9(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
15	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PG9(V2)	neutralization assay	171	gp120, V2	K	1.247	0.957	1.413	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
15	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PG9(V2)	neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y increases sensitivity to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
16	10E8 contacts	Huang2012a	contacts	10E8(MPER)		671	gp41	N	0.783	0.669	0.885	10E8 N671 structure and neutralization: key epitope position.
16	10E8 contacts	Huang2012a	contacts	10E8(MPER)		672	gp41	W	0.014	0.023	0.014	10E8 W672 structure and neutralization: key epitope position.
16	10E8 contacts	Huang2012a	contacts	10E8(MPER)		673	gp41	F	0.048	0.065	0.073	10E8 F673 structure and neutralization: key epitope position.
16	10E8 contacts	Huang2012a	contacts	10E8(MPER)		676	gp41	T	0.671	0.610	0.674	10E8 T676 structure and binding: key epitope position.
16	10E8 contacts	Huang2012a	contacts	10E8(MPER)		680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	10E8 W680 structure and neutralization: key epitope position.
16	10E8 contacts	Huang2012a	contacts	10E8(MPER)		683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	10E8 K/R683 structure: key epitope position.
17	2F5 contacts	Ofek2004	contacts	2F5(MPER)		662	gp41	E	1.043	0.874	0.369	2F5 contact site
17	2F5 contacts	Ofek2004	contacts	2F5(MPER)		663	gp41	L	0.092	0.094	0.053	2F5 contact site
17	2F5 contacts	Ofek2004	contacts	2F5(MPER)		664	gp41	D	0.222	0.156	0.346	2F5 contact site
17	2F5 contacts	Ofek2004	contacts	2F5(MPER)		665	gp41	K	1.039	0.656	0.879	2F5 contact site
17	2F5 contacts	Ofek2004	contacts	2F5(MPER)		666	gp41	W	0.008	0.000	0.000	2F5 contact site
17	2F5 contacts	Ofek2004	contacts	2F5(MPER)		667	gp41	A	1.424	0.545	1.537	2F5 contact site
18	4E10 epitope	Brunel2006	binding	4E10(MPER)	binding assay, surface plasmon resonance	671	gp41	N	0.783	0.669	0.885	4E10 core epitope residue
18	4E10 epitope	Brunel2006	binding	4E10(MPER)	binding assay, surface plasmon resonance	672	gp41	W	0.014	0.023	0.014	4E10 core epitope residue
18	4E10 epitope	Brunel2006	binding	4E10(MPER)	binding assay, surface plasmon resonance	673	gp41	F	0.048	0.065	0.073	4E10 core epitope residue
18	4E10 epitope	Brunel2006	binding	4E10(MPER)	binding assay, surface plasmon resonance	674	gp41	N	1.179	1.029	1.344	4E10 core epitope residue
18	4E10 epitope	Brunel2006	binding	4E10(MPER)	binding assay, surface plasmon resonance	675	gp41	I	0.063	0.059	0.069	4E10 core epitope residue
18	4E10 epitope	Brunel2006	binding	4E10(MPER)	binding assay, surface plasmon resonance	676	gp41	T	0.671	0.610	0.674	4E10 core epitope residue
18	4E10 epitope	Brunel2006	binding	4E10(MPER)	binding assay, surface plasmon resonance	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	4E10 core epitope residue
18	4E10 epitope	Brunel2006	binding	4E10(MPER)	binding assay, surface plasmon resonance	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	4E10 core epitope residue
19	Z13e1 epitope delineation	Nelson2007	binding	Z13e1(MPER)	binding assay	668	gp41	S	0.865	0.596	0.758	Z13e1 contact site
19	Z13e1 epitope delineation	Nelson2007	binding	Z13e1(MPER)	binding assay	669	gp41	L	0.017	0.023	0.000	Z13e1 contact site
19	Z13e1 epitope delineation	Nelson2007	binding	Z13e1(MPER)	binding assay	670	gp41	W	0.043	0.028	0.035	Z13e1 contact site
19	Z13e1 epitope delineation	Nelson2007	binding	Z13e1(MPER)	binding assay	671	gp41	N	0.783	0.669	0.885	Z13e1 contact site; crucial binding residue
19	Z13e1 epitope delineation	Nelson2007	binding	Z13e1(MPER)	binding assay	672	gp41	W	0.014	0.023	0.014	Z13e1 contact site
19	Z13e1 epitope delineation	Nelson2007	binding	Z13e1(MPER)	binding assay	673	gp41	F	0.048	0.065	0.073	Z13e1 contact site
19	Z13e1 epitope delineation	Nelson2007	binding	Z13e1(MPER)	binding assay	674	gp41	N	1.179	1.029	1.344	Z13e1 contact site; crucial binding residue
19	Z13e1 epitope delineation	Nelson2007	binding	Z13e1(MPER)	binding assay	675	gp41	I	0.063	0.059	0.069	Z13e1 contact site
19	Z13e1 epitope delineation	Nelson2007	binding	Z13e1(MPER)	binding assay	676	gp41	T	0.671	0.610	0.674	Z13e1 contact site
19	Z13e1 epitope delineation	Nelson2007	binding	Z13e1(MPER)	binding assay	677	gp41	N	1.203	1.199	1.100	Z13e1 contact site
20	2G12 binding sites	Trkola1996	binding	2G12(glycan)	ELISA, mutational analysis	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	N295S abrogates 2G12 binding in HXB2
20	2G12 binding sites	Trkola1996	binding	2G12(glycan)	ELISA, mutational analysis	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	297 is shown as a 2G12 binding site, based on unpublished escape mutant data
20	2G12 binding sites	Trkola1996	binding	2G12(glycan)	ELISA, mutational analysis	334	gp120	S	0.717	0.501	0.890	S334N reduces 2G12 binding in HXB2
20	2G12 binding sites	Trkola1996	binding	2G12(glycan)	ELISA, mutational analysis	341	gp120	T	0.494	0.371	0.421	341 is shown as a 2G12 binding site, based on unpublished escape mutant data
20	2G12 binding sites	Trkola1996	binding	2G12(glycan)	ELISA, mutational analysis	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	N386Q reduces 2G12 binding in HXB2
20	2G12 binding sites	Trkola1996	binding	2G12(glycan)	ELISA, mutational analysis	392	gp120, V4 loop	N	0.605	0.454	0.804	N392E + N397E double mutation abrogates 2G12 binding in HXB2
20	2G12 binding sites	Trkola1996	binding	2G12(glycan)	ELISA, mutational analysis	397	gp120, V4-hypervariable, V4 loop	N	2.653	2.682	2.344	N392E + N397E double mutation abrogates 2G12 binding in HXB2
20	2G12 binding sites	Trkola1996	binding	2G12(glycan)	ELISA, mutational analysis	450	gp120	T	0.039	0.018	0.022	T450N reduces 2G12 binding in HXB2
21	VRC03 signature predictions	West2013	signature	VRC03(CD4BS)	computational prediction	19	Signal peptide	T	1.224	1.111	0.600	VRC03: V19 is associated with increased susceptibility to neutralization; intermediate quality of support.
21	VRC03 signature predictions	West2013	signature	VRC03(CD4BS)	computational prediction	106	gp120	E	0.564	0.218	0.326	VRC03: T106 is associated with increased susceptibility to neutralization; intermediate quality of support.
22	10E8 signature predictions	West2013	signature	10E8(MPER)	computational prediction	231	gp120	K	0.799	0.578	0.780	10E8: E231 is associated with increased resistance to neutralization; intermediate quality of support.
22	10E8 signature predictions	West2013	signature	10E8(MPER)	computational prediction	301	gp120, V3 loop	N	0.172	0.176	0.104	10E8: glycosylation at N301 is associated with increased resistance to neutralization; intermediate quality of support.
22	10E8 signature predictions	West2013	signature	10E8(MPER)	computational prediction	693	gp41, gp41 transmembrane, Gly-xxx-Gly motif (GGLVG) important for self-association of transmembrane domain	V	0.541	0.700	0.067	10E8: V693 is associated with increased susceptibility to neutralization; intermediate quality of support.
23	4E10 signature predictions	West2013	signature	4E10(MPER)	computational prediction	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	4E10: K683 is associated with increased susceptibility to neutralization; high quality of support.
24	12A12 signature predictions	West2013	signature	12A12(CD4BS)	computational prediction	155	gp120, V1	K	0.758	0.423	0.831	12A12: Q155 is associated with increased resistance to neutralization; intermediate quality of support.
24	12A12 signature predictions	West2013	signature	12A12(CD4BS)	computational prediction	238	gp120	P	0.872	1.065	0.131	12A12: P238 is associated with increased resistance to neutralization; intermediate quality of support.
24	12A12 signature predictions	West2013	signature	12A12(CD4BS)	computational prediction	357	gp120	K	1.034	0.868	0.941	12A12: K357 is associated with increased susceptibility to neutralization; high quality of support.
24	12A12 signature predictions	West2013	signature	12A12(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	12A12: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
24	12A12 signature predictions	West2013	signature	12A12(CD4BS)	computational prediction	719	gp41, gp41 cytoplasmic tail	T	0.202	0.187	0.085	12A12: I719 is associated with increased susceptibility to neutralization; intermediate quality of support.
25	10-1074 signature predictions	West2013	signature	10-1074(V3)	computational prediction	240	gp120	T	1.813	1.338	1.717	10-1074: S240 is associated with increased resistance to neutralization; marginal quality of support.
25	10-1074 signature predictions	West2013	signature	10-1074(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	10-1074: glycosylation at N332 is associated with increased susceptibility to neutralization; high quality of support.
25	10-1074 signature predictions	West2013	signature	10-1074(V3)	computational prediction	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	10-1074: I369 is associated with increased resistance to neutralization; marginal quality of support.
25	10-1074 signature predictions	West2013	signature	10-1074(V3)	computational prediction	843	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	I	0.509	0.250	0.859	10-1074: V843 is associated with increased resistance to neutralization; marginal quality of support.
26	2F5 signature predictions	West2013	signature	2F5(MPER)	computational prediction	350	gp120	R	1.756	1.273	1.912	2F5: R350 is associated with increased resistance to neutralization; high quality of support.
26	2F5 signature predictions	West2013	signature	2F5(MPER)	computational prediction	518	gp41, fusion peptide	L	1.166	1.110	0.718	2F5: M518 is associated with increased susceptibility to neutralization; intermediate quality of support.
26	2F5 signature predictions	West2013	signature	2F5(MPER)	computational prediction	640	gp41	S	2.033	1.971	1.834	2F5: S640 is associated with increased susceptibility to neutralization; intermediate quality of support.
26	2F5 signature predictions	West2013	signature	2F5(MPER)	computational prediction	665	gp41	K	1.039	0.656	0.879	2F5: K665 is associated with increased susceptibility to neutralization; high quality of support.
26	2F5 signature predictions	West2013	signature	2F5(MPER)	computational prediction	667	gp41	A	1.424	0.545	1.537	2F5: A667 is associated with increased susceptibility to neutralization; high quality of support.
27	2G12 signature predictions	West2013	signature	2G12(glycan)	computational prediction	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	2G12: glycosylation at N295 is associated with increased susceptibility to neutralization; intermediate quality of support.
27	2G12 signature predictions	West2013	signature	2G12(glycan)	computational prediction	332	gp120	N	0.663	0.491	0.693	2G12: glycosylation at N332 is associated with increased susceptibility to neutralization; intermediate quality of support.
27	2G12 signature predictions	West2013	signature	2G12(glycan)	computational prediction	339	gp120	N	1.149	1.082	1.026	2G12: glycosylation at N339 is associated with increased susceptibility to neutralization; intermediate quality of support.
28	3BNC117 signature predictions	West2013	signature	3BNC117(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	3BNC117: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
28	3BNC117 signature predictions	West2013	signature	3BNC117(CD4BS)	computational prediction	471	gp120, beta24	G	0.933	0.888	0.866	3BNC117: E471 is associated with increased resistance to neutralization; marginal quality of support.
29	3BNC55 signature predictions	West2013	signature	3BNC55(CD4BS)	computational prediction	92	gp120	N	0.990	1.058	0.458	3BNC55: E92 is associated with increased susceptibility to neutralization; intermediate quality of support.
29	3BNC55 signature predictions	West2013	signature	3BNC55(CD4BS)	computational prediction	279	gp120, Loop D	D	0.900	0.850	0.898	3BNC55: D279 is associated with increased susceptibility to neutralization; high quality of support.
30	8ANC195 signature predictions	West2013	signature	8ANC195(gp120/gp41 interface)	computational prediction	230	gp120	N	0.931	0.896	0.544	8ANC195: glycosylation at N230 is associated with increased resistance to neutralization; high quality of support.
30	8ANC195 signature predictions	West2013	signature	8ANC195(gp120/gp41 interface)	computational prediction	234	gp120	N	0.598	0.757	0.341	8ANC195: glycosylation at N234 is associated with increased susceptibility to neutralization; high quality of support.
30	8ANC195 signature predictions	West2013	signature	8ANC195(gp120/gp41 interface)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	8ANC195: glycosylation at T276 is associated with increased susceptibility to neutralization; intermediate quality of support.
31	b12 signature predictions	West2013	signature	b12(CD4BS)	computational prediction	185	gp120, V2-hypervariable, V2	D	1.697	1.370	1.762	IGg1b12: D185 is associated with increased susceptibility to neutralization; intermediate quality of support.
31	b12 signature predictions	West2013	signature	b12(CD4BS)	computational prediction	364	gp120, CD4 binding loop	S	0.924	0.588	1.191	IGg1b12: S364 is associated with increased susceptibility to neutralization; intermediate quality of support.
31	b12 signature predictions	West2013	signature	b12(CD4BS)	computational prediction	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	IGg1b12: L369 is associated with increased resistance to neutralization; intermediate quality of support.
31	b12 signature predictions	West2013	signature	b12(CD4BS)	computational prediction	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	IGg1b12: glycosylation at N386 is associated with increased resistance to neutralization; intermediate quality of support.
32	NIH45-46 signature predictions	West2013	signature	NIH45-46(CD4BS)	computational prediction	234	gp120	N	0.598	0.757	0.341	NIH45-46: glycosylation at N234 is associated with increased resistance to neutralization; high quality of support.
32	NIH45-46 signature predictions	West2013	signature	NIH45-46(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	NIH45-46: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
33	NIH45-46(G54W) signature predictions	West2013	signature	NIH45-46G54W(CD4BS)	computational prediction	456	gp120, beta23	R	0.233	0.079	0.323	NIH45-46(G54W): R456 is associated with increased susceptibility to neutralization; intermediate quality of support.
33	NIH45-46(G54W) signature predictions	West2013	signature	NIH45-46G54W(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	NIH45-46(G54W): G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
33	NIH45-46(G54W) signature predictions	West2013	signature	NIH45-46G54W(CD4BS)	computational prediction	651	gp41	N	1.164	0.818	1.387	NIH45-46(G54W): S651 is associated with increased susceptibility to neutralization; marginal quality of support.
34	PG16 signature predictions	West2013	signature	PG16(V2)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	PG16: glycosylation at N160 is associated with increased susceptibility to neutralization; intermediate quality of support.
34	PG16 signature predictions	West2013	signature	PG16(V2)	computational prediction	171	gp120, V2	K	1.247	0.957	1.413	PG16: K171 is associated with increased susceptibility to neutralization; high quality of support.
35	PG9 signature predictions	West2013	signature	PG9(V2)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	PG9: N160 is associated with increased susceptibility to neutralization; intermediate quality of support.
35	PG9 signature predictions	West2013	signature	PG9(V2)	computational prediction	171	gp120, V2	K	1.247	0.957	1.413	PG9: K171 is associated with increased susceptibility to neutralization; high quality of support.
35	PG9 signature predictions	West2013	signature	PG9(V2)	computational prediction	732	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	G	0.823	0.262	0.816	PG9: G732 is associated with increased resistance to neutralization; high quality of support.
36	PGT121 signature predictions	West2013	signature	PGT121(V3)	computational prediction	184	gp120, V2	I	1.028	0.599	0.530	PGT121: M184 is associated with increased resistance to neutralization; marginal quality of support.
36	PGT121 signature predictions	West2013	signature	PGT121(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	PGT121: glycosylation at N332 is associated with increased susceptibility to neutralization; high quality of support.
36	PGT121 signature predictions	West2013	signature	PGT121(V3)	computational prediction	442	gp120	Q	2.042	1.699	0.964	PGT121: E442 is associated with increased resistance to neutralization; marginal quality of support.
36	PGT121 signature predictions	West2013	signature	PGT121(V3)	computational prediction	702	gp41, gp41 cytoplasmic tail	L	0.419	0.497	0.316	PGT121: L702 is associated with increased susceptibility to neutralization; intermediate quality of support.
36	PGT121 signature predictions	West2013	signature	PGT121(V3)	computational prediction	843	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	I	0.509	0.250	0.859	PGT121: V843 is associated with increased resistance to neutralization; intermediate quality of support.
37	sCD4 signature predictions	West2013	signature		computational prediction	364	gp120, CD4 binding loop	S	0.924	0.588	1.191	sCD4: P364 is associated with increased resistance to neutralization; intermediate quality of support.
38	VRC01 signature predictions	West2013	signature	VRC01(CD4BS)	computational prediction	106	gp120	E	0.564	0.218	0.326	VRC01: T106 is associated with increased susceptibility to neutralization; intermediate quality of support.
38	VRC01 signature predictions	West2013	signature	VRC01(CD4BS)	computational prediction	234	gp120	N	0.598	0.757	0.341	VRC01: glycosylation at N234 is associated with increased resistance to neutralization; high quality of support.
38	VRC01 signature predictions	West2013	signature	VRC01(CD4BS)	computational prediction	364	gp120, CD4 binding loop	S	0.924	0.588	1.191	VRC01: H364 is associated with increased resistance to neutralization; intermediate quality of support.
38	VRC01 signature predictions	West2013	signature	VRC01(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	VRC01: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
39	VRC02 signature predictions	West2013	signature	VRC02(CD4BS)	computational prediction	106	gp120	E	0.564	0.218	0.326	VRC02: T106 is associated with increased susceptibility to neutralization; intermediate quality of support.
39	VRC02 signature predictions	West2013	signature	VRC02(CD4BS)	computational prediction	403	gp120, V4-hypervariable, V4 loop	E	2.421	2.430	2.183	VRC02: T403 is associated with increased resistance to neutralization; intermediate quality of support.
39	VRC02 signature predictions	West2013	signature	VRC02(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	VRC02: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
39	VRC02 signature predictions	West2013	signature	VRC02(CD4BS)	computational prediction	706	gp41, gp41 cytoplasmic tail	N	0.453	0.312	0.722	VRC02: N706 is associated with increased susceptibility to neutralization; intermediate quality of support.
39	VRC02 signature predictions	West2013	signature	VRC02(CD4BS)	computational prediction	772	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	R	0.239	0.270	0.126	VRC02: R772 is associated with increased resistance to neutralization; intermediate quality of support.
40	VRC-CH31 signature predictions	West2013	signature	VRC-CH31(CD4BS)	computational prediction	640	gp41	S	2.033	1.971	1.834	VRC-CH31: G640 is associated with increased resistance to neutralization; marginal quality of support.
40	VRC-CH31 signature predictions	West2013	signature	VRC-CH31(CD4BS)	computational prediction	798	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking, Prohibin 1/2	N	0.749	0.336	0.870	VRC-CH31: S798 is associated with increased resistance to neutralization; intermediate quality of support.
41	VRC-PG04 signature predictions	West2013	signature	VRC-PG04(CD4BS)	computational prediction	106	gp120	E	0.564	0.218	0.326	VRC-PG04: E106 is associated with increased resistance to neutralization; high quality of support.
41	VRC-PG04 signature predictions	West2013	signature	VRC-PG04(CD4BS)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	VRC-PG04: glycosylation at T276 is associated with increased susceptibility to neutralization; intermediate quality of support.
41	VRC-PG04 signature predictions	West2013	signature	VRC-PG04(CD4BS)	computational prediction	364	gp120, CD4 binding loop	S	0.924	0.588	1.191	VRC-PG04: H364 is associated with increased resistance to neutralization; intermediate quality of support.
41	VRC-PG04 signature predictions	West2013	signature	VRC-PG04(CD4BS)	computational prediction	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	VRC-PG04: S365 is associated with increased susceptibility to neutralization; intermediate quality of support.
41	VRC-PG04 signature predictions	West2013	signature	VRC-PG04(CD4BS)	computational prediction	403	gp120, V4-hypervariable, V4 loop	E	2.421	2.430	2.183	VRC-PG04: T403 is associated with increased resistance to neutralization; intermediate quality of support.
42	VRC-PG04b signature predictions	West2013	signature	VRC-PG04b(CD4BS)	computational prediction	85	gp120	V	1.980	1.797	1.418	VRC-PG04b: Y85 is associated with increased resistance to neutralization; intermediate quality of support.
42	VRC-PG04b signature predictions	West2013	signature	VRC-PG04b(CD4BS)	computational prediction	232	gp120	T	1.480	1.451	0.426	VRC-PG04b: T232 is associated with increased resistance to neutralization; high quality of support.
42	VRC-PG04b signature predictions	West2013	signature	VRC-PG04b(CD4BS)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	VRC-PG04b: glycosylation at T276 is associated with increased susceptibility to neutralization; intermediate quality of support.
42	VRC-PG04b signature predictions	West2013	signature	VRC-PG04b(CD4BS)	computational prediction	364	gp120, CD4 binding loop	S	0.924	0.588	1.191	VRC-PG04b: H364 is associated with increased resistance to neutralization; intermediate quality of support.
42	VRC-PG04b signature predictions	West2013	signature	VRC-PG04b(CD4BS)	computational prediction	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	VRC-PG04b: S365 is associated with increased susceptibility to neutralization; intermediate quality of support.
43	45-46m2 signature predictions	West2013	signature	45-46m2(CD4BS)	computational prediction	456	gp120, beta23	R	0.233	0.079	0.323	45-46m2: R456 is associated with increased susceptibility to neutralization; intermediate quality of support.
43	45-46m2 signature predictions	West2013	signature	45-46m2(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	45-46m2: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
44	45-46m7 signature predictions	West2013	signature	45-46m7(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	45-46m7: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
45	10-996 signature predictions	West2013	signature	10-996(V3)	computational prediction	49	gp120	T	1.482	0.958	0.335	10-996: D49 is associated with increased susceptibility to neutralization; intermediate quality of support.
45	10-996 signature predictions	West2013	signature	10-996(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	10-996: H330 is associated with increased susceptibility to neutralization; high quality of support.
45	10-996 signature predictions	West2013	signature	10-996(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	10-996: glycosylation at N332 is associated with increased susceptibility to neutralization; high quality of support.
45	10-996 signature predictions	West2013	signature	10-996(V3)	computational prediction	444	gp120	R	1.747	1.507	0.494	10-996: S444 is associated with increased susceptibility to neutralization; intermediate quality of support.
46	35O22 contacts	Huang2014	contacts	35O22(gp120/gp41 interface)	X-ray crystallography	88	gp120	N	0.050	0.041	0.048	35O22 Heavy chain contact
46	35O22 contacts	Huang2014	contacts	35O22(gp120/gp41 interface)	X-ray crystallography	89	gp120	V	0.108	0.081	0.117	35O22 Heavy chain contact
46	35O22 contacts	Huang2014	contacts	35O22(gp120/gp41 interface)	X-ray crystallography	90	gp120	T	0.079	0.063	0.051	35O22 Heavy chain contact
46	35O22 contacts	Huang2014	contacts	35O22(gp120/gp41 interface)	X-ray crystallography	230	gp120	N	0.931	0.896	0.544	35O22 Heavy chain contact
46	35O22 contacts	Huang2014	contacts	35O22(gp120/gp41 interface)	X-ray crystallography	241	gp120	N	0.191	0.183	0.134	35O22 Heavy chain contact
46	35O22 contacts	Huang2014	contacts	35O22(gp120/gp41 interface)	X-ray crystallography	625	gp41	H	0.197	0.185	0.214	35O22 Heavy chain contact
47	PGT135 contacts	Kong2013	contacts	PGT135(V3)	X-ray crystallography	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	The glycan at N295 in JRCSF is a contact residue for PGT135; N295A diminishes neutralization sensitivity in a strain specific way.
47	PGT135 contacts	Kong2013	contacts	PGT135(V3)	X-ray crystallography	330	gp120, V3 loop	H	0.634	0.559	0.655	Contact residue for PGT135. H330A in JRCSF confers neutralization resistance.
47	PGT135 contacts	Kong2013	contacts	PGT135(V3)	X-ray crystallography	332	gp120	N	0.663	0.491	0.693	The glycan at N332 in JRCSF is a key contact residue for PGT135; N332A confers neutralization resistance in all strains tested.
47	PGT135 contacts	Kong2013	contacts	PGT135(V3)	X-ray crystallography	373	gp120, CD4 binding loop	T	1.024	0.872	0.371	M373 in JRCSF is a contact residue for PGT135.
47	PGT135 contacts	Kong2013	contacts	PGT135(V3)	X-ray crystallography	384	gp120	Y	0.107	0.124	0.023	Y384 in JRCSF is a contact residue for PGT135.
47	PGT135 contacts	Kong2013	contacts	PGT135(V3)	X-ray crystallography	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	The glycan at N386 in JRCSF is a contact residue for PGT135; N386A diminishes neutralization sensitivity, but in another context it abrogates activity, so its impact is strain specific.
47	PGT135 contacts	Kong2013	contacts	PGT135(V3)	X-ray crystallography	389	gp120, V4 loop	Q	2.033	1.567	2.120	Q389 in JRCSF is a contact residue for PGT135.
47	PGT135 contacts	Kong2013	contacts	PGT135(V3)	X-ray crystallography	392	gp120, V4 loop	N	0.605	0.454	0.804	The glycan at N392 in JRCSF is a contact residue for PGT135; N392A confers neutralization resistance, and the glycan has a large contact region with long PGT135 CDR H3 loops.
47	PGT135 contacts	Kong2013	contacts	PGT135(V3)	X-ray crystallography	409	gp120, V4-hypervariable, V4 loop	E	1.109	1.527	0.670	E409 in JRCSF is a contact residue for PGT135.
47	PGT135 contacts	Kong2013	contacts	PGT135(V3)	X-ray crystallography	415	gp120, V4 loop	T	0.754	0.760	0.656	T415 in JRCSF is a contact residue for PGT135; T415A diminishes diminishes neutralization sensitivity.
47	PGT135 contacts	Kong2013	contacts	PGT135(V3)	X-ray crystallography	417	gp120, V4 loop	P	0.864	0.736	0.922	P417 in JRCSF is a contact residue for PGT135; T415A diminishes neutralization sensitivity.
47	PGT135 contacts	Kong2013	contacts	PGT135(V3)	X-ray crystallography	418	gp120, Cys 385 linked to Cys 418	C	0.056	0.038	0.059	C418 in JRCSF is a contact residue for PGT135, and is conserved among all HIVs.
47	PGT135 contacts	Kong2013	contacts	PGT135(V3)	X-ray crystallography	419	gp120	R	0.463	0.341	0.500	R419 in JRCSF is a contact residue for PGT135; R419A diminishes diminishes neutralization sensitivity.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	132	gp120, V1-hypervariable, V1	T	1.312	0.849	1.573	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	133	gp120, V1-hypervariable, V1	D	1.376	1.052	1.360	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	134	gp120, V1-hypervariable, V1	L	2.224	2.322	1.627	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	135	gp120, V1-hypervariable, V1	K	2.230	2.373	1.848	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	136	gp120, V1-hypervariable, V1	N	2.514	2.300	2.581	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	138	gp120, V1-hypervariable, V1	T	2.312	2.112	2.504	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	139	gp120, V1-hypervariable, V1	N	2.097	1.946	2.163	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	140	gp120, V1-hypervariable, V1	T	2.235	2.104	2.340	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	141	gp120, V1-hypervariable, V1	N	2.227	2.077	2.148	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	142	gp120, V1-hypervariable, V1	S	2.145	1.992	1.972	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	143	gp120, V1-hypervariable, V1	S	1.925	1.990	1.810	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	144	gp120, V1-hypervariable, V1	S	2.222	2.072	2.207	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	145	gp120, V1-hypervariable, V1	G	2.282	2.228	2.255	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	146	gp120, V1-hypervariable, V1	R	2.649	2.583	2.629	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	147	gp120, V1-hypervariable, V1	M	2.615	2.513	2.375	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	148	gp120, V1-hypervariable, V1	I	2.742	2.671	2.548	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	149	gp120, V1-hypervariable, V1	M	2.563	2.375	2.256	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	150	gp120, V1-hypervariable, V1	E	2.403	2.019	2.328	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	151	gp120, V1-hypervariable, V1	K	2.575	2.285	2.605	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	152	gp120, V1-hypervariable, V1	G	1.800	1.271	1.966	CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	CH103: Insertions in the V5 hypervariable region conferred resistance to emerging members of the CH103 lineage.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	CH103: Insertions in the V5 hypervariable region conferred resistance to emerging members of the CH103 lineage.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	CH103: Insertions in the V5 hypervariable region conferred resistance to emerging members of the CH103 lineage.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	CH103: Insertions in the V5 hypervariable region conferred resistance to emerging members of the CH103 lineage.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	464	gp120, V5-hypervariable, V5 loop	E	2.353	2.269	2.299	CH103: Insertions in the V5 hypervariable region conferred resistance to emerging members of the CH103 lineage.
48	CH103 and CH235 evolution	Gao2014	other feature	CH103(CD4BS)	sequence analysis	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.567	1.466	1.517	CH103: Insertions in the V5 hypervariable region conferred resistance to emerging members of the CH103 lineage.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	56	gp120	S	0.037	0.017	0.022	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	57	gp120	D	0.236	0.198	0.275	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	58	gp120	A	0.046	0.036	0.029	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	59	gp120	K	0.200	0.243	0.130	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	60	gp120	A	0.520	0.461	0.396	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	61	gp120	Y	0.271	0.299	0.148	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	62	gp120	D	1.433	1.302	0.706	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	63	gp120	T	1.314	0.663	1.217	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	75	gp120	V	0.015	0.006	0.008	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	76	gp120	P	0.008	0.012	0.000	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	77	gp120	T	0.103	0.088	0.020	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	78	gp120	D	0.083	0.081	0.059	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	79	gp120	P	0.019	0.017	0.008	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	80	gp120	N	0.669	0.695	0.562	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	81	gp120	P	0.016	0.023	0.008	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	82	gp120	Q	0.290	0.200	0.268	Predicted C1 regional interactions with LCDR1 of PGT151.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	262	gp120	N	0.027	0.029	0.028	Glycan contact of PGT151, but loss of the glycan does not impact PGT151 neutralization.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	448	gp120	N	0.662	0.448	0.927	Glycan contact, but loss of the glycan does not impact PGT151 neutralization
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	611	gp41	N	0.048	0.039	0.054	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	612	gp41	A	1.631	1.525	1.055	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	613	gp41	S	0.243	0.207	0.216	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	614	gp41	W	0.016	0.033	0.015	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	615	gp41	S	0.102	0.111	0.110	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	616	gp41	N	0.231	0.238	0.269	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	617	gp41, gp41 fusion domain (595,602,603,617)	K	0.535	0.526	0.500	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	618	gp41	S	0.723	0.725	0.780	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	619	gp41	L	1.801	1.312	1.871	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	620	gp41	E	1.999	1.701	2.182	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	621	gp41	Q	1.808	2.097	1.208	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	622	gp41	I	0.026	0.088	0.053	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	623	gp41	W	0.020	0.066	0.043	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
49	PGT151 regional interactions	Blattner2014	other feature	PGT151(gp41 fusion domain)	cryo-EM, molecular modeling	624	gp41	N	1.580	1.592	1.486	611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		44	gp120	V	0.054	0.023	0.039	8ANC195: V44 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		45	gp120	W	0.018	0.018	0.028	8ANC195: W45 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		46	gp120	K	0.717	0.269	1.022	8ANC195: K46 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		47	gp120	E	0.489	0.335	0.323	8ANC195: D47 contact, in the buried surface area at the interface, and forms a hydrogen bond with the bNAb.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		89	gp120	V	0.108	0.081	0.117	8ANC195: V89 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		90	gp120	T	0.079	0.063	0.051	8ANC195: T90 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		91	gp120	E	0.028	0.033	0.023	8ANC195: E91 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		92	gp120	N	0.990	1.058	0.458	8ANC195: N92 contact, in the buried surface area at the interface and forms a hydrogen bond with the bNAb.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		93	gp120	F	0.048	0.074	0.015	8ANC195: F93 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		94	gp120	N	0.206	0.217	0.076	8ANC195: N94 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		97	gp120	K	0.478	0.421	0.511	8ANC195: K97 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		234	gp120	N	0.598	0.757	0.341	8ANC195: The glycan at N234 is in contact with 8ANC195 bound to the CRF01_AE 93TH057 gp120 core, N234 is in the buried surface area at the interface, and there is extensive hydrogen bonding with the glycan at this site.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		236	gp120	T	0.877	1.013	0.551	8ANC195 T236 contact, buried surface area at interfaces, part of the critical glycosylation site at 234.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		237	gp120	G	0.058	0.072	0.008	8ANC195: G237 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		238	gp120	P	0.872	1.065	0.131	8ANC195: P238 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		240	gp120	T	1.813	1.338	1.717	8ANC195: K240 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		275	gp120, Loop D	V	1.141	1.420	0.535	8ANC195: E275 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		276	gp120, Loop D	N	0.118	0.063	0.169	8ANC195: The glycan at N276 is in contact with 8ANC195 bound to the CRF01_AE 93TH057 gp120 core; N276 is in buried surface area at the interface, and there is extensive hydrogen bonding with the glycan at this site.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		277	gp120, Loop D	F	1.160	0.669	0.582	8ANC195: L277 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		278	gp120, Loop D	T	0.708	0.715	0.481	8ANC195: T278 is a loop D contact with 8ANC195 bound to CRF01_AE 93TH057 gp120 core, T278 is in buried surface area at the interfaces and forms a hydrogen bond with the bNAb.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		352	gp120	Q	1.607	0.842	1.079	8ANC195: H352 is an outer domain contact with 8ANC195 in a structure with CRF01_AE 93TH057 gp120; it is in buried surface area at the interfaces and forms a hydrogen bond with the bNAb.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		353	gp120	F	0.735	0.735	0.488	8ANC195: F353 is in the buried surface area at 8ANC195 interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		354	gp120	G	2.108	1.918	1.123	8ANC195: N354 is an outer domain contact with 8ANC195 in a structure with CRF01_AE 93TH057 gp120, in buried surface area at 8ANC195 interfaces and forms a hydrogen bond with the bNAb.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		357	gp120	K	1.034	0.868	0.941	8ANC195: K357 is in 8ANC195 buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		456	gp120, beta23	R	0.233	0.079	0.323	8ANC195: R456 is a V5 region contact with 8ANC195 bound to CRF01_AE 93TH057 gp120 core; in buried surface area at interfaces, and forms a hydrogen bond with the bNAb.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	8ANC195: T463 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		466	gp120, V5 loop, beta24	E	0.205	0.091	0.239	8ANC195: E466 contact, buried surface area at interfaces.
50	8ANC195 contacts	Scharf2014	contacts	8ANC195(gp120/gp41 interface)		487	gp120	K	0.030	0.012	0.043	8ANC195: K487 contact, buried surface area at the interface and forms a hydrogen bond with the bNAb.
51	8ANC195 residue prediction	Chuang2014	signature	8ANC195(gp120/gp41 interface)	computational prediction	93	gp120	F	0.048	0.074	0.015	8ANC195: F93 is ranked 6th among the 10 highest in terms of co-variation with potency and structural proximity to 8ANC195 epitope.
51	8ANC195 residue prediction	Chuang2014	signature	8ANC195(gp120/gp41 interface)	computational prediction	96	gp120	W	0.063	0.091	0.020	8ANC195: W96 is ranked 2nd among the 10 highest in terms of co-variation with potency and structural proximity to 8ANC195 epitope.
51	8ANC195 residue prediction	Chuang2014	signature	8ANC195(gp120/gp41 interface)	computational prediction	233	gp120	F	0.070	0.055	0.028	8ANC195: F233 is ranked 3rd among the 10 highest in terms of co-variation and structural proximity.
51	8ANC195 residue prediction	Chuang2014	signature	8ANC195(gp120/gp41 interface)	computational prediction	234	gp120	N	0.598	0.757	0.341	8ANC195: N234 is ranked 10th among the 10 highest in terms of co-variation with potency and structural proximity to 8ANC195 epitope.
51	8ANC195 residue prediction	Chuang2014	signature	8ANC195(gp120/gp41 interface)	computational prediction	236	gp120	T	0.877	1.013	0.551	8ANC195: T236 is ranked 4th among the 10 highest in terms of co-variation with potency and structural proximity.
51	8ANC195 residue prediction	Chuang2014	signature	8ANC195(gp120/gp41 interface)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	8ANC195: N276 is ranked 8th among the 10 highest in terms of co-variation with potency and structural proximity.
51	8ANC195 residue prediction	Chuang2014	signature	8ANC195(gp120/gp41 interface)	computational prediction	279	gp120, Loop D	D	0.900	0.850	0.898	8ANC195: T279 is ranked 9th among the 10 highest in terms of co-variation with potency and structural proximity.
51	8ANC195 residue prediction	Chuang2014	signature	8ANC195(gp120/gp41 interface)	computational prediction	280	gp120, Loop D	N	0.142	0.090	0.170	8ANC195: N280 is ranked 5th among the 10 highest in terms of co-variation with potency and structural proximity.
51	8ANC195 residue prediction	Chuang2014	signature	8ANC195(gp120/gp41 interface)	computational prediction	456	gp120, beta23	R	0.233	0.079	0.323	8ANC195: R456 is ranked 1st among the 10 highest in terms of co-variation with potency and structural proximity.
51	8ANC195 residue prediction	Chuang2014	signature	8ANC195(gp120/gp41 interface)	computational prediction	466	gp120, V5 loop, beta24	E	0.205	0.091	0.239	8ANC195: E466 is ranked 7th among the 10 highest in terms of co-variation with potency and structural proximity.
51	8ANC195 residue prediction	Chuang2014	signature	8ANC195(gp120/gp41 interface)	computational prediction	625	gp41	H	0.197	0.185	0.214	A glycan at 625 was predicted by modeling to be in contact with 8ANC195.
51	8ANC195 residue prediction	Chuang2014	signature	8ANC195(gp120/gp41 interface)	computational prediction	637	gp41	N	0.192	0.168	0.186	Predicted by modeling to be in contact with 8ANC195, however a mutant YU2 pseudovirus N637Q did not show decreased sensitivity to 8ANC195.
52	PG9 residue prediction	Chuang2014	signature	PG9(V2)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	PG9: N160 is ranked first among the 10 highest in terms of co-variation with PG9 potency
52	PG9 residue prediction	Chuang2014	signature	PG9(V2)	computational prediction	161	gp120, V2	I	1.493	0.964	1.568	PG9: I161 is ranked 7th among the 10 highest in terms of co-variation with PG9 potency.
52	PG9 residue prediction	Chuang2014	signature	PG9(V2)	computational prediction	162	gp120, V2	S	0.353	0.445	0.179	PG9: T162 is ranked third among the 10 highest in terms of co-variation with PG9 potency.
52	PG9 residue prediction	Chuang2014	signature	PG9(V2)	computational prediction	163	gp120, V2	T	0.463	0.638	0.154	PG9: T163 is ranked 5th among the 10 highest in terms of co-variation with PG9 potency.
52	PG9 residue prediction	Chuang2014	signature	PG9(V2)	computational prediction	164	gp120, V2	S	1.840	1.925	0.453	PG9: E164 is ranked 9th among the 10 highest in terms of co-variation with PG9 potency.
52	PG9 residue prediction	Chuang2014	signature	PG9(V2)	computational prediction	167	gp120, V2	G	0.779	1.122	0.185	PG9: D167 is ranked 10th among the 10 highest in terms of co-variation with PG9 potency.
52	PG9 residue prediction	Chuang2014	signature	PG9(V2)	computational prediction	168	gp120, V2	K	0.566	0.666	0.396	PG9: K168 is ranked 8th among the 10 highest in terms of co-variation with PG9 potency.
52	PG9 residue prediction	Chuang2014	signature	PG9(V2)	computational prediction	169	gp120, V2	V	2.042	1.770	1.344	PG9: K169 is ranked second among the 10 highest in terms of co-variation with PG9 potency.
52	PG9 residue prediction	Chuang2014	signature	PG9(V2)	computational prediction	170	gp120, V2	Q	1.493	1.423	1.428	PG9: Q170 is ranked fourth among the 10 highest in terms of co-variation with PG9 potency.
52	PG9 residue prediction	Chuang2014	signature	PG9(V2)	computational prediction	171	gp120, V2	K	1.247	0.957	1.413	PG9: K171 is ranked 6th among the 10 highest in terms of co-variation with PG9 potency.
53	VRC01 residue prediction	Chuang2014	signature	VRC01(CD4BS)	computational prediction	279	gp120, Loop D	D	0.900	0.850	0.898	VRC01: N279 is ranked 9th in terms of co-variation with CD4bs bNAb VRC01 and structure.
53	VRC01 residue prediction	Chuang2014	signature	VRC01(CD4BS)	computational prediction	280	gp120, Loop D	N	0.142	0.090	0.170	VRC01: N280 is ranked 2nd among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
53	VRC01 residue prediction	Chuang2014	signature	VRC01(CD4BS)	computational prediction	353	gp120	F	0.735	0.735	0.488	VRC01: F353 is ranked 10th in terms of co-variation with CD4bs bNAb VRC01 and structure.
53	VRC01 residue prediction	Chuang2014	signature	VRC01(CD4BS)	computational prediction	456	gp120, beta23	R	0.233	0.079	0.323	VRC01: R456 is ranked first among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
53	VRC01 residue prediction	Chuang2014	signature	VRC01(CD4BS)	computational prediction	457	gp120, beta23	D	0.079	0.054	0.043	VRC01: D457 is ranked 5th among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
53	VRC01 residue prediction	Chuang2014	signature	VRC01(CD4BS)	computational prediction	458	gp120, beta23	G	0.112	0.045	0.095	VRC01: G458 is ranked 3rd among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
53	VRC01 residue prediction	Chuang2014	signature	VRC01(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	VRC01: G459 is ranked 7th among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
53	VRC01 residue prediction	Chuang2014	signature	VRC01(CD4BS)	computational prediction	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	VRC01: A460 is ranked 8th among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
53	VRC01 residue prediction	Chuang2014	signature	VRC01(CD4BS)	computational prediction	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	VRC01: S461 is ranked 6th among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
53	VRC01 residue prediction	Chuang2014	signature	VRC01(CD4BS)	computational prediction	466	gp120, V5 loop, beta24	E	0.205	0.091	0.239	VRC01: E466 is ranked 4th among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
54	10E8 residue prediction	Chuang2014	signature	10E8(MPER)	computational prediction	671	gp41	N	0.783	0.669	0.885	10E8: N671 is ranked 6th among the 10 highest in terms of co-variation with potency and structure.
54	10E8 residue prediction	Chuang2014	signature	10E8(MPER)	computational prediction	672	gp41	W	0.014	0.023	0.014	10E8: W672 is ranked 2nd among the 10 highest in terms of co-variation with potency and structure.
54	10E8 residue prediction	Chuang2014	signature	10E8(MPER)	computational prediction	673	gp41	F	0.048	0.065	0.073	10E8: F673 is ranked 3rd among the 10 highest in terms of co-variation with potency and structure.
54	10E8 residue prediction	Chuang2014	signature	10E8(MPER)	computational prediction	674	gp41	N	1.179	1.029	1.344	10E8: D674 is ranked 9th among the 10 highest in terms of co-variation with potency and structure.
54	10E8 residue prediction	Chuang2014	signature	10E8(MPER)	computational prediction	675	gp41	I	0.063	0.059	0.069	10E8: I675 is ranked 8th among the 10 highest in terms of co-variation with potency and structure.
54	10E8 residue prediction	Chuang2014	signature	10E8(MPER)	computational prediction	676	gp41	T	0.671	0.610	0.674	10E8: T676 is ranked 1st among the 10 highest in terms of co-variation with potency and structure.
54	10E8 residue prediction	Chuang2014	signature	10E8(MPER)	computational prediction	677	gp41	N	1.203	1.199	1.100	10E8: N677 is ranked 4th among the 10 highest in terms of co-variation with potency and structure.
54	10E8 residue prediction	Chuang2014	signature	10E8(MPER)	computational prediction	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	10E8: N679 is ranked 7th among the 10 highest in terms of co-variation with potency and structure.
54	10E8 residue prediction	Chuang2014	signature	10E8(MPER)	computational prediction	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	10E8: W680 is ranked 5th among the 10 highest in terms of co-variation with potency and structure.
54	10E8 residue prediction	Chuang2014	signature	10E8(MPER)	computational prediction	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	10E8: R683 is ranked 10th among the 10 highest in terms of co-variation with potency and structure.
55	3BC176 binding	Klein2012	binding	3BC176(CD4i)	binding assay	160	gp120, V2	N	0.416	0.452	0.358	3BC176 and 3BC315: N160K reduces binding
55	3BC176 binding	Klein2012	binding	3BC176(CD4i)	binding assay	420	gp120	I	0.093	0.049	0.078	3BC176 and 3BC315: I420R slightly enhances binding
56	Stabilizing glycans in structure of glycosylated gp120	Kong2015	Env feature			262	gp120	N	0.027	0.029	0.028	Highly conserved glycan, buried in the cleft of gp120. Its location indicates a role in stability and folding, bridging the inner and outer domains of gp120. It is not involved with bNAb interactions.
56	Stabilizing glycans in structure of glycosylated gp120	Kong2015	Env feature			332	gp120	N	0.663	0.491	0.693	Dense packing of glycans in an oligomannose patch is centered on Asn332.
57	Mutation affects 2F5 binding	Montero2012	binding	2F5(MPER)	binding assay	664	gp41	D	0.222	0.156	0.346	Mutation to Ala decreases binding of 2F5.
57	Mutation affects 2F5 binding	Montero2012	binding	2F5(MPER)	binding assay	665	gp41	K	1.039	0.656	0.879	Mutation to Ala decreases binding of 2F5.
57	Mutation affects 2F5 binding	Montero2012	binding	2F5(MPER)	binding assay	666	gp41	W	0.008	0.000	0.000	Mutation to Ala decreases binding of 2F5.
57	Mutation affects 2F5 binding	Montero2012	binding	2F5(MPER)	binding assay	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
57	Mutation affects 2F5 binding	Montero2012	binding	2F5(MPER)	binding assay	682	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	I	0.046	0.042	0.041	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
57	Mutation affects 2F5 binding	Montero2012	binding	2F5(MPER)	binding assay	685	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	F	0.028	0.029	0.020	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
58	Mutation affects 4E10 binding	Montero2012	binding	4E10(MPER)	binding assay	672	gp41	W	0.014	0.023	0.014	Mutation to Ala decreases binding of 4E10.
58	Mutation affects 4E10 binding	Montero2012	binding	4E10(MPER)	binding assay	673	gp41	F	0.048	0.065	0.073	Mutation to Ala decreases binding of 4E10.
58	Mutation affects 4E10 binding	Montero2012	binding	4E10(MPER)	binding assay	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
58	Mutation affects 4E10 binding	Montero2012	binding	4E10(MPER)	binding assay	682	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	I	0.046	0.042	0.041	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
58	Mutation affects 4E10 binding	Montero2012	binding	4E10(MPER)	binding assay	685	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	F	0.028	0.029	0.020	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
59	Mutation affects Z13e1 binding	Montero2012	binding	Z13e1(MPER)	binding assay	674	gp41	N	1.179	1.029	1.344	Mutation to Ala decreases binding of Z13e1.
59	Mutation affects Z13e1 binding	Montero2012	binding	Z13e1(MPER)	binding assay	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
59	Mutation affects Z13e1 binding	Montero2012	binding	Z13e1(MPER)	binding assay	682	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	I	0.046	0.042	0.041	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
59	Mutation affects Z13e1 binding	Montero2012	binding	Z13e1(MPER)	binding assay	685	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	F	0.028	0.029	0.020	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	278	gp120, Loop D	T	0.708	0.715	0.481	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	3BNC117 contact
60	3BNC117 contacts	Zhou2013a	contacts	3BNC117(CD4BS)	X-ray crystallography	473	gp120	G	0.042	0.033	0.029	3BNC117 contact
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	148	gp120, V1-hypervariable, V1	I	2.742	2.671	2.548	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	171	gp120, V2	K	1.247	0.957	1.413	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	187	gp120, V2-hypervariable, V2	D	1.785	1.813	1.638	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	268	gp120	E	1.191	0.886	1.275	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	280	gp120, Loop D	N	0.142	0.090	0.170	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	306	gp120, V3 loop	R	0.714	0.860	0.338	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	339	gp120	N	1.149	1.082	1.026	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	360	gp120	I	2.183	1.624	2.270	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	394	gp120, V4 loop	T	1.077	0.715	1.439	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	412	gp120, V4 loop	D	2.245	2.094	2.182	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	429	gp120, beta20/beta21	K	1.325	0.961	1.308	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	455	gp120, beta23	T	0.709	0.426	0.972	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	Statistically significant sequence change in 2/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	Statistically significant sequence change in 2/5 patients following VRC01 infusion.
61	Sequence changes after immunotherapy with VRC01	Lynch2015	immunotherapy	VRC01(CD4BS)	sequence analysis	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.567	1.466	1.517	Statistically significant sequence change in 2/5 patients following VRC01 infusion.
62	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.25(V2)	neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	removal of N156 glycan decreased neutralization in 3/3 strains tested
62	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.25(V2)	neutralization assay	164	gp120, V2	S	1.840	1.925	0.453	Amino acids D or E statistically associated with sensitivity to VRC26.25 neutralization.
62	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.25(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	G, I, Q, S, or T statistically associated with resistance to VRC26.25 neutralization; R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
62	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.25(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	T or G statistically associated with resistance to VRC26.25 neutralization; D167N decreased neutralization of ConC by all 33 VRC26 lineage members
62	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.25(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	R or K statistically associated with sensitivity to VRC26.25 neutralization; E or V associated with resistance to VRC26.25 neutralization; K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
63	179NC75 binding-associated sites	Freund2015	binding	179NC75(CD4BS)	binding assay	276	gp120, Loop D	N	0.118	0.063	0.169	Mutation N276D abolishes binding of 179NC75.
63	179NC75 binding-associated sites	Freund2015	binding	179NC75(CD4BS)	binding assay	280	gp120, Loop D	N	0.142	0.090	0.170	Double mutation D368R + N280Y substantially impairs binding of 179NC75.
63	179NC75 binding-associated sites	Freund2015	binding	179NC75(CD4BS)	binding assay	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	Double mutation D368R + N280Y substantially impairs binding of 179NC75.
64	HJ16 binding requires N276	Balla-Jhagjhoorsingh2013	binding	HJ16(CD4BS)	binding assay	276	gp120, Loop D	N	0.118	0.063	0.169	Glycan N276 is required for binding of HJ16.
65	375S affects CD4 binding	Li2016	Env feature		binding assay, neutralization assay	375	gp120	S	0.668	0.753	0.372	Substitution of 375S by M, H, Y, F or W led to higher binding affinity to human and rhesus CD4, but without affecting Ab-mediated neutralization sensitivity.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	141	gp120, V1-hypervariable, V1	N	2.227	2.077	2.148	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	187	gp120, V2-hypervariable, V2	D	1.785	1.813	1.638	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	344	gp120	Q	1.787	1.306	1.923	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	347	gp120	S	2.085	2.161	1.508	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	398	gp120, V4-hypervariable, V4 loop	S	1.848	1.469	2.098	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	400	gp120, V4-hypervariable, V4 loop	W	2.298	1.985	2.290	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	401	gp120, V4-hypervariable, V4 loop	S	2.656	2.459	2.574	Site under significant selection in 4 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	402	gp120, V4-hypervariable, V4 loop	T	2.346	2.234	2.207	Site under significant selection in 4 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	403	gp120, V4-hypervariable, V4 loop	E	2.421	2.430	2.183	Site under significant selection in 4 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	404	gp120, V4-hypervariable, V4 loop	G	2.181	2.199	1.740	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	405	gp120, V4-hypervariable, V4 loop	S	2.186	2.388	1.715	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	410	gp120, V4-hypervariable, V4 loop	G	2.323	2.263	2.179	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	Patient 2C5 selected for the G459D mutation following 3BNC immunotherapy; this mutation was previously shnown to alter the CD4 binding site and result in resistance to 3BNC117; known 3BNC117 contact site.
66	Sites selected during 3BNC117 immunotherapy	Schoofs2016	immunotherapy	3BNC117(CD4BS)	sequence analysis	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	Site under significant selection in 4 of 9 patients sequenced following 3BNC117 immunotherapy; known 3BNC117 contact site.
67	CAP256-VRC26 lineage epitope	Doria-Rose2016	binding	VRC26.01(V2), VRC26.02(V2), VRC26.03(V2), VRC26.04(V2), VRC26.05(V2), VRC26.06(V2), VRC26.07(V2), VRC26.08(V2), VRC26.09(V2), VRC26.10(V2), VRC26.11(V2), VRC26.12(V2), VRC26.13(V2), VRC26.14(V2), VRC26.15(V2), VRC26.16(V2), VRC26.17(V2), VRC26.18(V2), VRC26.19(V2), VRC26.20(V2), VRC26.21(V2), VRC26.22(V2), VRC26.23(V2), VRC26.24(V2), VRC26.25(V2), VRC26.26(V2), VRC26.27(V2), VRC26.28(V2), VRC26.29(V2), VRC26.30(V2), VRC26.31(V2), VRC26.32(V2), VRC26.33(V2)	binding assay	160	gp120, V2	N	0.416	0.452	0.358	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
67	CAP256-VRC26 lineage epitope	Doria-Rose2016	binding	VRC26.01(V2), VRC26.02(V2), VRC26.03(V2), VRC26.04(V2), VRC26.05(V2), VRC26.06(V2), VRC26.07(V2), VRC26.08(V2), VRC26.09(V2), VRC26.10(V2), VRC26.11(V2), VRC26.12(V2), VRC26.13(V2), VRC26.14(V2), VRC26.15(V2), VRC26.16(V2), VRC26.17(V2), VRC26.18(V2), VRC26.19(V2), VRC26.20(V2), VRC26.21(V2), VRC26.22(V2), VRC26.23(V2), VRC26.24(V2), VRC26.25(V2), VRC26.26(V2), VRC26.27(V2), VRC26.28(V2), VRC26.29(V2), VRC26.30(V2), VRC26.31(V2), VRC26.32(V2), VRC26.33(V2)	binding assay	161	gp120, V2	I	1.493	0.964	1.568	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
67	CAP256-VRC26 lineage epitope	Doria-Rose2016	binding	VRC26.01(V2), VRC26.02(V2), VRC26.03(V2), VRC26.04(V2), VRC26.05(V2), VRC26.06(V2), VRC26.07(V2), VRC26.08(V2), VRC26.09(V2), VRC26.10(V2), VRC26.11(V2), VRC26.12(V2), VRC26.13(V2), VRC26.14(V2), VRC26.15(V2), VRC26.16(V2), VRC26.17(V2), VRC26.18(V2), VRC26.19(V2), VRC26.20(V2), VRC26.21(V2), VRC26.22(V2), VRC26.23(V2), VRC26.24(V2), VRC26.25(V2), VRC26.26(V2), VRC26.27(V2), VRC26.28(V2), VRC26.29(V2), VRC26.30(V2), VRC26.31(V2), VRC26.32(V2), VRC26.33(V2)	binding assay	162	gp120, V2	S	0.353	0.445	0.179	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
67	CAP256-VRC26 lineage epitope	Doria-Rose2016	binding	VRC26.01(V2), VRC26.02(V2), VRC26.03(V2), VRC26.04(V2), VRC26.05(V2), VRC26.06(V2), VRC26.07(V2), VRC26.08(V2), VRC26.09(V2), VRC26.10(V2), VRC26.11(V2), VRC26.12(V2), VRC26.13(V2), VRC26.14(V2), VRC26.15(V2), VRC26.16(V2), VRC26.17(V2), VRC26.18(V2), VRC26.19(V2), VRC26.20(V2), VRC26.21(V2), VRC26.22(V2), VRC26.23(V2), VRC26.24(V2), VRC26.25(V2), VRC26.26(V2), VRC26.27(V2), VRC26.28(V2), VRC26.29(V2), VRC26.30(V2), VRC26.31(V2), VRC26.32(V2), VRC26.33(V2)	binding assay	163	gp120, V2	T	0.463	0.638	0.154	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
67	CAP256-VRC26 lineage epitope	Doria-Rose2016	binding	VRC26.01(V2), VRC26.02(V2), VRC26.03(V2), VRC26.04(V2), VRC26.05(V2), VRC26.06(V2), VRC26.07(V2), VRC26.08(V2), VRC26.09(V2), VRC26.10(V2), VRC26.11(V2), VRC26.12(V2), VRC26.13(V2), VRC26.14(V2), VRC26.15(V2), VRC26.16(V2), VRC26.17(V2), VRC26.18(V2), VRC26.19(V2), VRC26.20(V2), VRC26.21(V2), VRC26.22(V2), VRC26.23(V2), VRC26.24(V2), VRC26.25(V2), VRC26.26(V2), VRC26.27(V2), VRC26.28(V2), VRC26.29(V2), VRC26.30(V2), VRC26.31(V2), VRC26.32(V2), VRC26.33(V2)	binding assay	164	gp120, V2	S	1.840	1.925	0.453	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
67	CAP256-VRC26 lineage epitope	Doria-Rose2016	binding	VRC26.01(V2), VRC26.02(V2), VRC26.03(V2), VRC26.04(V2), VRC26.05(V2), VRC26.06(V2), VRC26.07(V2), VRC26.08(V2), VRC26.09(V2), VRC26.10(V2), VRC26.11(V2), VRC26.12(V2), VRC26.13(V2), VRC26.14(V2), VRC26.15(V2), VRC26.16(V2), VRC26.17(V2), VRC26.18(V2), VRC26.19(V2), VRC26.20(V2), VRC26.21(V2), VRC26.22(V2), VRC26.23(V2), VRC26.24(V2), VRC26.25(V2), VRC26.26(V2), VRC26.27(V2), VRC26.28(V2), VRC26.29(V2), VRC26.30(V2), VRC26.31(V2), VRC26.32(V2), VRC26.33(V2)	binding assay	165	gp120, V2	I	1.327	1.292	1.011	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
67	CAP256-VRC26 lineage epitope	Doria-Rose2016	binding	VRC26.01(V2), VRC26.02(V2), VRC26.03(V2), VRC26.04(V2), VRC26.05(V2), VRC26.06(V2), VRC26.07(V2), VRC26.08(V2), VRC26.09(V2), VRC26.10(V2), VRC26.11(V2), VRC26.12(V2), VRC26.13(V2), VRC26.14(V2), VRC26.15(V2), VRC26.16(V2), VRC26.17(V2), VRC26.18(V2), VRC26.19(V2), VRC26.20(V2), VRC26.21(V2), VRC26.22(V2), VRC26.23(V2), VRC26.24(V2), VRC26.25(V2), VRC26.26(V2), VRC26.27(V2), VRC26.28(V2), VRC26.29(V2), VRC26.30(V2), VRC26.31(V2), VRC26.32(V2), VRC26.33(V2)	binding assay	166	gp120, V2	R	1.237	1.398	0.772	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
68	Key contacts of CH235	Bonsignori2016	contacts	CH235(CD4BS)	negative stain EM, X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	N280 forms three hydrogen bonds with two residues in the CDR L3
68	Key contacts of CH235	Bonsignori2016	contacts	CH235(CD4BS)	negative stain EM, X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368 contacts the CDR H2 loop by electrostatic interactions
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	4	Signal peptide	K	1.296	1.114	1.115	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	130	gp120	K	1.201	0.883	1.495	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	132	gp120, V1-hypervariable, V1	T	1.312	0.849	1.573	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	144	gp120, V1-hypervariable, V1	S	2.222	2.072	2.207	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	145	gp120, V1-hypervariable, V1	G	2.282	2.228	2.255	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	147	gp120, V1-hypervariable, V1	M	2.615	2.513	2.375	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	151	gp120, V1-hypervariable, V1	K	2.575	2.285	2.605	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	185	gp120, V2-hypervariable, V2	D	1.697	1.370	1.762	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	234	gp120	N	0.598	0.757	0.341	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	275	gp120, Loop D	V	1.141	1.420	0.535	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	279	gp120, Loop D	D	0.900	0.850	0.898	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	281	gp120, Loop D	A	1.129	0.814	1.357	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	300	gp120, V3 loop	N	1.017	0.738	1.054	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	302	gp120, V3 loop	N	0.170	0.215	0.157	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	325	gp120, V3 loop	N	0.648	0.622	0.622	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	330	gp120, V3 loop	H	0.634	0.559	0.655	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	332	gp120	N	0.663	0.491	0.693	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	334	gp120	S	0.717	0.501	0.890	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	347	gp120	S	2.085	2.161	1.508	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	356	gp120	N	0.938	0.741	0.894	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	398	gp120, V4-hypervariable, V4 loop	S	1.848	1.469	2.098	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	412	gp120, V4 loop	D	2.245	2.094	2.182	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	413	gp120, V4 loop	T	1.512	1.451	1.561	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	417	gp120, V4 loop	P	0.864	0.736	0.922	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	464	gp120, V5-hypervariable, V5 loop	E	2.353	2.269	2.299	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.567	1.466	1.517	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	471	gp120, beta24	G	0.933	0.888	0.866	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	620	gp41	E	1.999	1.701	2.182	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	640	gp41	S	2.033	1.971	1.834	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
69	Antibody-driven selection in donor CH505	Hraber2015	neutralization	CH103(CD4BS), CH235.12(CD4BS), CH235.9(CD4BS), CH235(CD4BS)	sequence analysis	756	gp41, gp41 cytoplasmic tail, Luman interaction	I	1.306	0.791	0.849	Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
70	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-33A(V3)	alanine scanning, neutralization assay	158	gp120, V2	S	0.263	0.185	0.291	S158A abrogates neutralization by PCDN 33A, 38A, 38B.
70	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-33A(V3)	alanine scanning, neutralization assay	159	gp120, V2	F	0.104	0.034	0.038	F159A abrogates neutralization by PCDN 33A, 38A, 38B.
70	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-33A(V3)	alanine scanning, neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	Loss of glycosylation site at N301 knocks out PCDN mAb neutralization; N301A abrogates neutralization by PCDN 33A, 38A, 38B.
70	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-33A(V3)	alanine scanning, neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A abrogates neutralization by PCDN 33A, 38A, 38B.
70	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-33A(V3)	alanine scanning, neutralization assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A abrogates neutralization by PCDN 38A, 38B.
70	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-33A(V3)	alanine scanning, neutralization assay	328	gp120, V3 loop	Q	0.923	0.816	0.882	Early E328K or later A328K, along with deletion of glycan site at N335 by mutating T337A, causes sensitivity to PCDN antibodies.
70	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-33A(V3)	alanine scanning, neutralization assay	332	gp120	N	0.663	0.491	0.693	Loss of glycosylation site at N332 knocks out PCDN mAb neutralization; N332A abrogates neutralization by PCDN 33A, 38A, 38B.
70	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-33A(V3)	alanine scanning, neutralization assay	334	gp120	S	0.717	0.501	0.890	S334A abrogates neutralization by PCDN 33A, 38A, 38B.
70	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-33A(V3)	alanine scanning, neutralization assay	335	gp120	R	1.898	1.758	1.937	Early E328K or later A328K, along with deletion of glycan site at N335 by mutating T337A, causes sensitivity to PCDN antibodies.
70	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-33A(V3)	alanine scanning, neutralization assay	337	gp120	K	2.037	1.862	2.151	Early E328K or later A328K, along with deletion of glycan site at N335 by mutating T337A, causes sensitivity to PCDN antibodies.
71	Mutation affects trimer formation	deTaeye2015	Env feature			535	gp41	M	1.280	1.414	0.742	I535 and V535 are unfavorable to trimer formation; SOSIP trimers form more efficiently with M535.
71	Mutation affects trimer formation	deTaeye2015	Env feature			543	gp41, Leu/Ile zipper-like sequence	Q	0.588	0.768	0.202	L543 is unfavorable to trimer formation; SOSIP trimers form more efficiently with N543 or Q543.
72	HJ16 contacts	Zhou2015	contacts	HJ16(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	HJ16 heavy chain contact; light chain contact
72	HJ16 contacts	Zhou2015	contacts	HJ16(CD4BS)		281	gp120, Loop D	A	1.129	0.814	1.357	HJ16 heavy chain contact
72	HJ16 contacts	Zhou2015	contacts	HJ16(CD4BS)		283	gp120, Loop D	T	1.005	1.091	0.474	HJ16 heavy chain contact
72	HJ16 contacts	Zhou2015	contacts	HJ16(CD4BS)		362	gp120	K	1.815	1.265	1.997	HJ16 heavy chain contact
72	HJ16 contacts	Zhou2015	contacts	HJ16(CD4BS)		457	gp120, beta23	D	0.079	0.054	0.043	HJ16 heavy chain contact
72	HJ16 contacts	Zhou2015	contacts	HJ16(CD4BS)		458	gp120, beta23	G	0.112	0.045	0.095	HJ16 heavy chain contact
72	HJ16 contacts	Zhou2015	contacts	HJ16(CD4BS)		459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	HJ16 light chain contact
72	HJ16 contacts	Zhou2015	contacts	HJ16(CD4BS)		460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	HJ16 heavy chain contact; light chain contact
72	HJ16 contacts	Zhou2015	contacts	HJ16(CD4BS)		461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	HJ16 light chain contact
72	HJ16 contacts	Zhou2015	contacts	HJ16(CD4BS)		471	gp120, beta24	G	0.933	0.888	0.866	HJ16 heavy chain contact; salt bridge contact
72	HJ16 contacts	Zhou2015	contacts	HJ16(CD4BS)		474	gp120	D	0.696	0.681	0.752	HJ16 heavy chain contact
73	VRC13 contacts	Zhou2015	contacts	VRC13(CD4BS)	X-ray crystallography	96	gp120	W	0.063	0.091	0.020	VRC13 heavy chain contact
73	VRC13 contacts	Zhou2015	contacts	VRC13(CD4BS)	X-ray crystallography	275	gp120, Loop D	V	1.141	1.420	0.535	VRC13 salt bridge contact
73	VRC13 contacts	Zhou2015	contacts	VRC13(CD4BS)	X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	VRC13 heavy chain contact
73	VRC13 contacts	Zhou2015	contacts	VRC13(CD4BS)	X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	VRC13 heavy chain contact; salt bridge contact
73	VRC13 contacts	Zhou2015	contacts	VRC13(CD4BS)	X-ray crystallography	283	gp120, Loop D	T	1.005	1.091	0.474	VRC13 heavy chain contact
73	VRC13 contacts	Zhou2015	contacts	VRC13(CD4BS)	X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	VRC13 heavy chain contact
73	VRC13 contacts	Zhou2015	contacts	VRC13(CD4BS)	X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	VRC13 heavy chain contact
73	VRC13 contacts	Zhou2015	contacts	VRC13(CD4BS)	X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	VRC13 heavy chain contact; salt bridge contact
73	VRC13 contacts	Zhou2015	contacts	VRC13(CD4BS)	X-ray crystallography	421	gp120, beta20/beta21	K	0.332	0.374	0.203	VRC13 heavy chain contact
73	VRC13 contacts	Zhou2015	contacts	VRC13(CD4BS)	X-ray crystallography	471	gp120, beta24	G	0.933	0.888	0.866	VRC13 heavy chain contact
73	VRC13 contacts	Zhou2015	contacts	VRC13(CD4BS)	X-ray crystallography	473	gp120	G	0.042	0.033	0.029	VRC13 heavy chain contact
74	VRC16 contacts	Zhou2015	contacts	VRC16(CD4BS)		281	gp120, Loop D	A	1.129	0.814	1.357	VRC16 heavy chain contact
74	VRC16 contacts	Zhou2015	contacts	VRC16(CD4BS)		282	gp120, Loop D	K	0.336	0.337	0.297	VRC16 heavy chain contact; salt bridge contact
74	VRC16 contacts	Zhou2015	contacts	VRC16(CD4BS)		283	gp120, Loop D	T	1.005	1.091	0.474	VRC16 heavy chain contact
74	VRC16 contacts	Zhou2015	contacts	VRC16(CD4BS)		366	gp120, CD4 binding loop	G	0.043	0.012	0.028	VRC16 heavy chain contact
74	VRC16 contacts	Zhou2015	contacts	VRC16(CD4BS)		367	gp120, CD4 binding loop	G	0.042	0.034	0.008	VRC16 light chain contact
74	VRC16 contacts	Zhou2015	contacts	VRC16(CD4BS)		368	gp120, CD4 binding loop	D	0.039	0.023	0.029	VRC16 heavy chain contact; salt bridge contact
74	VRC16 contacts	Zhou2015	contacts	VRC16(CD4BS)		431	gp120, beta20/beta21	G	0.072	0.036	0.039	VRC16 heavy chain contact
74	VRC16 contacts	Zhou2015	contacts	VRC16(CD4BS)		457	gp120, beta23	D	0.079	0.054	0.043	VRC16 light chain contact
74	VRC16 contacts	Zhou2015	contacts	VRC16(CD4BS)		474	gp120	D	0.696	0.681	0.752	VRC16 heavy chain contact
75	VRC18 contacts	Zhou2015	contacts	VRC18(CD4BS)		279	gp120, Loop D	D	0.900	0.850	0.898	VRC18 heavy chain contact
75	VRC18 contacts	Zhou2015	contacts	VRC18(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	VRC18 heavy chain contact; light chain contact
75	VRC18 contacts	Zhou2015	contacts	VRC18(CD4BS)		282	gp120, Loop D	K	0.336	0.337	0.297	VRC18 salt bridge contact
75	VRC18 contacts	Zhou2015	contacts	VRC18(CD4BS)		368	gp120, CD4 binding loop	D	0.039	0.023	0.029	VRC18 heavy chain contact; salt bridge contact
75	VRC18 contacts	Zhou2015	contacts	VRC18(CD4BS)		428	gp120, beta20/beta21	Q	0.062	0.053	0.054	VRC18 heavy chain contact
75	VRC18 contacts	Zhou2015	contacts	VRC18(CD4BS)		456	gp120, beta23	R	0.233	0.079	0.323	VRC18 heavy chain contact
75	VRC18 contacts	Zhou2015	contacts	VRC18(CD4BS)		458	gp120, beta23	G	0.112	0.045	0.095	VRC18 heavy chain contact
75	VRC18 contacts	Zhou2015	contacts	VRC18(CD4BS)		459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	VRC18 light chain contact
75	VRC18 contacts	Zhou2015	contacts	VRC18(CD4BS)		460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	VRC18 heavy chain contact
75	VRC18 contacts	Zhou2015	contacts	VRC18(CD4BS)		461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	VRC18 heavy chain contact
75	VRC18 contacts	Zhou2015	contacts	VRC18(CD4BS)		465	gp120, V5-hypervariable, V5 loop, beta24	S	1.567	1.466	1.517	VRC18 heavy chain contact
75	VRC18 contacts	Zhou2015	contacts	VRC18(CD4BS)		469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	VRC18 heavy chain contact
75	VRC18 contacts	Zhou2015	contacts	VRC18(CD4BS)		473	gp120	G	0.042	0.033	0.029	VRC18 heavy chain contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		122	gp120	L	0.150	0.101	0.121	VRC27 heavy chain contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		279	gp120, Loop D	D	0.900	0.850	0.898	VRC27 heavy chain contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	VRC27 heavy chain contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		365	gp120, CD4 binding loop	S	0.602	0.489	0.619	VRC27 heavy chain contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		368	gp120, CD4 binding loop	D	0.039	0.023	0.029	VRC27 heavy chain contact; salt bridge contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		427	gp120, beta20/beta21	W	0.083	0.061	0.038	VRC27 heavy chain contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		432	gp120, beta20/beta21	K	1.037	0.339	0.564	VRC27 heavy chain contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		455	gp120, beta23	T	0.709	0.426	0.972	VRC27 heavy chain contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		456	gp120, beta23	R	0.233	0.079	0.323	VRC27 heavy chain contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		457	gp120, beta23	D	0.079	0.054	0.043	VRC27 heavy chain contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		458	gp120, beta23	G	0.112	0.045	0.095	VRC27 heavy chain contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	VRC27 light chain contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	VRC27 heavy chain contact
76	VRC27 contacts	Zhou2015	contacts	VRC27(CD4BS)		476	gp120	R	0.663	0.615	0.711	VRC27 salt bridge contact
77	1B2530 contacts	Zhou2015	contacts	1B2530(CD4BS)		275	gp120, Loop D	V	1.141	1.420	0.535	1B2530 heavy chain contact; salt bridge contact
77	1B2530 contacts	Zhou2015	contacts	1B2530(CD4BS)		276	gp120, Loop D	N	0.118	0.063	0.169	1B2530 light chain contact
77	1B2530 contacts	Zhou2015	contacts	1B2530(CD4BS)		278	gp120, Loop D	T	0.708	0.715	0.481	1B2530 light chain contact
77	1B2530 contacts	Zhou2015	contacts	1B2530(CD4BS)		279	gp120, Loop D	D	0.900	0.850	0.898	1B2530 light chain contact
77	1B2530 contacts	Zhou2015	contacts	1B2530(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	1B2530 heavy chain contact
77	1B2530 contacts	Zhou2015	contacts	1B2530(CD4BS)		281	gp120, Loop D	A	1.129	0.814	1.357	1B2530 heavy chain contact
77	1B2530 contacts	Zhou2015	contacts	1B2530(CD4BS)		282	gp120, Loop D	K	0.336	0.337	0.297	1B2530 heavy chain contact
77	1B2530 contacts	Zhou2015	contacts	1B2530(CD4BS)		368	gp120, CD4 binding loop	D	0.039	0.023	0.029	1B2530 heavy chain contact; salt bridge contact
77	1B2530 contacts	Zhou2015	contacts	1B2530(CD4BS)		427	gp120, beta20/beta21	W	0.083	0.061	0.038	1B2530 heavy chain contact
77	1B2530 contacts	Zhou2015	contacts	1B2530(CD4BS)		459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	1B2530 light chain contact
77	1B2530 contacts	Zhou2015	contacts	1B2530(CD4BS)		461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	1B2530 light chain contact
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		102	gp120	E	0.782	0.522	0.426	8ANC131 heavy chain contact
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		276	gp120, Loop D	N	0.118	0.063	0.169	light chain interaction
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		278	gp120, Loop D	T	0.708	0.715	0.481	8ANC131 light chain contact
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		279	gp120, Loop D	D	0.900	0.850	0.898	heavy chain interaction
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	8ANC131 heavy chain contact; light chain contact
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		281	gp120, Loop D	A	1.129	0.814	1.357	8ANC131 heavy chain contact
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		282	gp120, Loop D	K	0.336	0.337	0.297	8ANC131 heavy chain contact
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		368	gp120, CD4 binding loop	D	0.039	0.023	0.029	8ANC131 heavy chain contact; salt bridge contact
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		426	gp120, beta20/beta21	M	0.724	0.866	0.274	8ANC131 heavy chain contact
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		430	gp120, beta20/beta21	V	0.267	0.080	0.073	8ANC131 heavy chain contact
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		431	gp120, beta20/beta21	G	0.072	0.036	0.039	8ANC131 heavy chain contact
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		456	gp120, beta23	R	0.233	0.079	0.323	8ANC131 heavy chain contact
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	8ANC131 light chain contact
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		474	gp120	D	0.696	0.681	0.752	8ANC131 heavy chain contact; salt bridge contact
78	8ANC131 contacts	Gristick2016	contacts	8ANC131(CD4BS)		476	gp120	R	0.663	0.615	0.711	8ANC131 heavy chain contact; salt bridge contact
79	8ANC134 contacts	Zhou2015	contacts	8ANC134(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	8ANC134 heavy chain contact; light chain contact
79	8ANC134 contacts	Zhou2015	contacts	8ANC134(CD4BS)		281	gp120, Loop D	A	1.129	0.814	1.357	8ANC134 heavy chain contact
79	8ANC134 contacts	Zhou2015	contacts	8ANC134(CD4BS)		282	gp120, Loop D	K	0.336	0.337	0.297	8ANC134 heavy chain contact; salt bridge contact
79	8ANC134 contacts	Zhou2015	contacts	8ANC134(CD4BS)		368	gp120, CD4 binding loop	D	0.039	0.023	0.029	8ANC134 salt bridge contact
79	8ANC134 contacts	Zhou2015	contacts	8ANC134(CD4BS)		426	gp120, beta20/beta21	M	0.724	0.866	0.274	8ANC134 heavy chain contact
79	8ANC134 contacts	Zhou2015	contacts	8ANC134(CD4BS)		431	gp120, beta20/beta21	G	0.072	0.036	0.039	8ANC134 heavy chain contact
79	8ANC134 contacts	Zhou2015	contacts	8ANC134(CD4BS)		456	gp120, beta23	R	0.233	0.079	0.323	8ANC134 heavy chain contact
79	8ANC134 contacts	Zhou2015	contacts	8ANC134(CD4BS)		474	gp120	D	0.696	0.681	0.752	8ANC134 heavy chain contact; salt bridge contact
79	8ANC134 contacts	Zhou2015	contacts	8ANC134(CD4BS)		476	gp120	R	0.663	0.615	0.711	8ANC134 heavy chain contact; salt bridge contact
80	PG9 escape mutations	Andrabi2015	neutralization	PG9(V2)		169	gp120, V2	V	2.042	1.770	1.344	PG9: Escape in Donor 64 at K169T
80	PG9 escape mutations	Andrabi2015	neutralization	PG9(V2)		171	gp120, V2	K	1.247	0.957	1.413	PG9: Escape in Donor 64 at K171E
81	PGT145 escape mutations	Andrabi2015	neutralization	PGT145(V2)		169	gp120, V2	V	2.042	1.770	1.344	PGT145: Escape in Donor 584 at K169S
81	PGT145 escape mutations	Andrabi2015	neutralization	PGT145(V2)		170	gp120, V2	Q	1.493	1.423	1.428	PGT145: Escape in Donor 584 at Q170K
81	PGT145 escape mutations	Andrabi2015	neutralization	PGT145(V2)		171	gp120, V2	K	1.247	0.957	1.413	PGT145: Escape in Donor 584 at K171I
82	VRC26.09 escape mutations	Andrabi2015	neutralization	VRC26.09(V2)		169	gp120, V2	V	2.042	1.770	1.344	VRC26.09: Escape in donor CAP256 at K169E
82	VRC26.09 escape mutations	Andrabi2015	neutralization	VRC26.09(V2)		170	gp120, V2	Q	1.493	1.423	1.428	VRC26.09: Escape in donor CAP256 at Q170K
82	VRC26.09 escape mutations	Andrabi2015	neutralization	VRC26.09(V2)		171	gp120, V2	K	1.247	0.957	1.413	VRC26.09: Escape in donor CAP256 by deletion of K171
83	b12 signature sites	Gnanakaran2010	signature	b12(CD4BS)	computational prediction	163	gp120, V2	T	0.463	0.638	0.154	b12 signature site
83	b12 signature sites	Gnanakaran2010	signature	b12(CD4BS)	computational prediction	173	gp120, V2	Y	1.059	0.808	1.158	b12 signature site; Y associated with sensitivity; H or S associated with resistance
83	b12 signature sites	Gnanakaran2010	signature	b12(CD4BS)	computational prediction	182	gp120, V2	I	0.830	0.957	0.587	b12 signature site
83	b12 signature sites	Gnanakaran2010	signature	b12(CD4BS)	computational prediction	185	gp120, V2-hypervariable, V2	D	1.697	1.370	1.762	b12 signature site; D, E, or N associated with sensitivity; S or T associated with resistance
83	b12 signature sites	Gnanakaran2010	signature	b12(CD4BS)	computational prediction	268	gp120	E	1.191	0.886	1.275	b12 signature site; E or S associated with sensitivity; K or R associated with resistance
83	b12 signature sites	Gnanakaran2010	signature	b12(CD4BS)	computational prediction	364	gp120, CD4 binding loop	S	0.924	0.588	1.191	b12 signature site; P or S associated with sensitivity; H associated with resistance
83	b12 signature sites	Gnanakaran2010	signature	b12(CD4BS)	computational prediction	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	b12 signature site; A or P associated with sensitivity; I, L, or Q associated with resistance
83	b12 signature sites	Gnanakaran2010	signature	b12(CD4BS)	computational prediction	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	b12 signature site; E or P associated with sensitivity
83	b12 signature sites	Gnanakaran2010	signature	b12(CD4BS)	computational prediction	651	gp41	N	1.164	0.818	1.387	b12 signature site; D, I, or S associated with resistance; this site may affect exposure of the b12 epitope in the quaternary structure
83	b12 signature sites	Gnanakaran2010	signature	b12(CD4BS)	computational prediction	655	gp41	K	0.929	0.431	1.358	b12 signature site; this site may affect exposure of the b12 epitope in the quaternary structure
84	A16 contacts	Qiao2016	contacts	A16(CD4BS)		96	gp120	W	0.063	0.091	0.020	critical for A16 binding
84	A16 contacts	Qiao2016	contacts	A16(CD4BS)		102	gp120	E	0.782	0.522	0.426	critical for A16 binding
84	A16 contacts	Qiao2016	contacts	A16(CD4BS)		109	gp120	I	0.112	0.116	0.051	critical for A16 binding
84	A16 contacts	Qiao2016	contacts	A16(CD4BS)		274	gp120	S	0.209	0.121	0.230	critical for A16 binding
84	A16 contacts	Qiao2016	contacts	A16(CD4BS)		277	gp120, Loop D	F	1.160	0.669	0.582	critical for A16 binding
84	A16 contacts	Qiao2016	contacts	A16(CD4BS)		279	gp120, Loop D	D	0.900	0.850	0.898	critical for A16 binding
84	A16 contacts	Qiao2016	contacts	A16(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	critical for A16 binding
84	A16 contacts	Qiao2016	contacts	A16(CD4BS)		427	gp120, beta20/beta21	W	0.083	0.061	0.038	critical for A16 binding
84	A16 contacts	Qiao2016	contacts	A16(CD4BS)		476	gp120	R	0.663	0.615	0.711	critical for A16 binding
85	VRC34.01 mutations affect neutralization	Kong2016a	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	88	gp120	N	0.050	0.041	0.048	N88Q (glycan deletion) greatly diminished neutralization of BG505
85	VRC34.01 mutations affect neutralization	Kong2016a	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	512	gp41, fusion peptide	A	0.188	0.260	0.110	A512W greatly diminished neutralization of BG505
85	VRC34.01 mutations affect neutralization	Kong2016a	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	V513I, V513A and V513W diminished neutralization of BG505
85	VRC34.01 mutations affect neutralization	Kong2016a	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	insertion 514b_T completely abrogated neutralization of BG505; G514W greatly diminished neutralization of BG505
85	VRC34.01 mutations affect neutralization	Kong2016a	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	I515M and I515A diminished neutralization of BG505
85	VRC34.01 mutations affect neutralization	Kong2016a	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	516	gp41, fusion peptide	G	0.066	0.038	0.048	G516A greatly diminished neutralization of BG505 and Q23.17
85	VRC34.01 mutations affect neutralization	Kong2016a	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	517	gp41, fusion peptide	A	0.113	0.109	0.058	A517W diminished neutralization of BG505
85	VRC34.01 mutations affect neutralization	Kong2016a	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	518	gp41, fusion peptide	L	1.166	1.110	0.718	V518M, V518L, and V518W, but not V518A, diminished neutralization  of BG505
85	VRC34.01 mutations affect neutralization	Kong2016a	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	519	gp41, fusion peptide	F	0.518	0.243	0.837	F519I and F519L diminished neutralization of BG505
85	VRC34.01 mutations affect neutralization	Kong2016a	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	611	gp41	N	0.048	0.039	0.054	N611Q and N611D enhanced neutralization of BG505
86	8ANC195 contacts	Kong2015a	contacts	8ANC195(gp120/gp41 interface)		234	gp120	N	0.598	0.757	0.341	8ANC195 contact
86	8ANC195 contacts	Kong2015a	contacts	8ANC195(gp120/gp41 interface)		276	gp120, Loop D	N	0.118	0.063	0.169	8ANC195 contact
86	8ANC195 contacts	Kong2015a	contacts	8ANC195(gp120/gp41 interface)		637	gp41	N	0.192	0.168	0.186	8ANC195 contact
87	PGT128 contacts	Kong2015a	contacts	PGT128(V3)		137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	PGT128 binding
87	PGT128 contacts	Kong2015a	contacts	PGT128(V3)		156	gp120, V1	N	0.246	0.220	0.224	PGT128 binding
87	PGT128 contacts	Kong2015a	contacts	PGT128(V3)		262	gp120	N	0.027	0.029	0.028	PGT128 indirect interaction
87	PGT128 contacts	Kong2015a	contacts	PGT128(V3)		301	gp120, V3 loop	N	0.172	0.176	0.104	PGT128 binding
87	PGT128 contacts	Kong2015a	contacts	PGT128(V3)		332	gp120	N	0.663	0.491	0.693	PGT128 binding
88	PGDM1400 lineage requires N160	Sok2014	binding	PGDM1400(V2), PGDM1401(V2), PGDM1402(V2), PGDM1403(V2), PGDM1404(V2), PGDM1405(V2), PGDM1406(V2), PGDM1407(V2), PGDM1408(V2), PGDM1409(V2), PGDM1410(V2), PGDM1411(V2), PGDM1412(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160 is required for neutralization by PGDM1400 lineage mAbs
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	97	gp120	K	0.478	0.421	0.511	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	102	gp120	E	0.782	0.522	0.426	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	122	gp120	L	0.150	0.101	0.121	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	124	gp120	P	0.045	0.018	0.029	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	275	gp120, Loop D	V	1.141	1.420	0.535	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	VRC-PG04 heavy chain interaction and light chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	278	gp120, Loop D	T	0.708	0.715	0.481	VRC-PG04 light chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	VRC-PG04 heavy chain interaction and light chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	VRC-PG04 heavy chain interaction and light chain interaction, both with hydrogen bonding; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	VRC-PG04 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	283	gp120, Loop D	T	1.005	1.091	0.474	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	VRC-PG04 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	VRC-PG04 heavy chain interaction, hydrogen bonding and salt bridge; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	426	gp120, beta20/beta21	M	0.724	0.866	0.274	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	427	gp120, beta20/beta21	W	0.083	0.061	0.038	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	429	gp120, beta20/beta21	K	1.325	0.961	1.308	VRC-PG04 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	431	gp120, beta20/beta21	G	0.072	0.036	0.039	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	VRC-PG04 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	VRC-PG04 heavy chain interaction, salt bridge; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	VRC-PG04 heavy chain interaction(hydrogen bonding) and light chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	VRC-PG04 heavy chain interaction and light chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	VRC-PG04 light chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	VRC-PG04 light chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	472	gp120	G	0.035	0.012	0.043	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	473	gp120	G	0.042	0.033	0.029	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	474	gp120	D	0.696	0.681	0.752	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	476	gp120	R	0.663	0.615	0.711	VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
89	VRC-PG04 contacts	Wu2011	contacts	VRC-PG04(CD4BS)	molecular modeling, X-ray crystallography	776	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, CaM interaction, p115-RhoGEF interaction	L	0.245	0.197	0.214	VRC-PG04 heavy chain interaction (hydrogen bonding) and light chain interaction; calculated on the EBI PISA server
90	Mutations coupling nAb resistance with ceniciviroc sensitivity	Kuwata2016	neutralization	0.5γ(V3)	neutralization assay, other	315	gp120, V3 loop	R	1.211	1.028	0.196	R315K causes resistance to NAbs 0.5γ and 4E9C, coupled with reversion to ceniciviroc-sensitivity
90	Mutations coupling nAb resistance with ceniciviroc sensitivity	Kuwata2016	neutralization	0.5γ(V3)	neutralization assay, other	324	gp120, V3 loop	G	0.075	0.056	0.092	G324R causes resistance to NAbs 0.5γ and 4E9C, coupled with reversion to ceniciviroc-sensitivity
90	Mutations coupling nAb resistance with ceniciviroc sensitivity	Kuwata2016	neutralization	0.5γ(V3)	neutralization assay, other	381	gp120	E	0.050	0.045	0.028	E381K causes resistance to NAbs 0.5γ and 4E9C, coupled with reversion to ceniciviroc-sensitivity
91	Mutation affects PGT151 neutralization	Falkowska2014	neutralization	PGT151(gp41 fusion domain)	neutralization assay	611	gp41	N	0.048	0.039	0.054	N611A or N611D decreases PGT151 neutralization
91	Mutation affects PGT151 neutralization	Falkowska2014	neutralization	PGT151(gp41 fusion domain)	neutralization assay	637	gp41	N	0.192	0.168	0.186	N637K decreases PGT151 neutralization
91	Mutation affects PGT151 neutralization	Falkowska2014	neutralization	PGT151(gp41 fusion domain)	neutralization assay	647	gp41	E	0.328	0.372	0.224	E647A or E647G decreases PGT151 neutralization
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	83	gp120	E	0.042	0.039	0.035	E83A in strain JRCSF decreases ACS202 neutralization 57-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	85	gp120	V	1.980	1.797	1.418	V85A in strain JRCSF decreases ACS202 neutralization >61-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	87	gp120	V	1.565	1.611	1.463	E87A in strain JRCSF decreases ACS202 neutralization >61-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	90	gp120	T	0.079	0.063	0.051	T90A (which disrupts glycosylation of N88) in strain JRCSF decreases ACS202 neutralization >61-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	229	gp120	N	0.707	0.742	0.290	N229A in strain JRCSF decreases ACS202 neutralization >61-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	512	gp41, fusion peptide	A	0.188	0.260	0.110	A512W in strain JRCSF decreases ACS202 neutralization >61-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	V513W in strain JRCSF decreases ACS202 neutralization >61-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	I515W in strain JRCSF decreases ACS202 neutralization 15-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	516	gp41, fusion peptide	G	0.066	0.038	0.048	G516W in strain JRCSF decreases ACS202 neutralization >61-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	517	gp41, fusion peptide	A	0.113	0.109	0.058	A517W in strain JRCSF decreases ACS202 neutralization >61-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	520	gp41, fusion peptide	L	0.393	0.253	0.390	L520W in strain JRCSF decreases ACS202 neutralization >61-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	521	gp41, fusion peptide	G	0.035	0.028	0.008	G521W in strain JRCSF decreases ACS202 neutralization >61-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	525	gp41, fusion peptide	A	0.375	0.263	0.387	A525W in strain JRCSF decreases ACS202 neutralization >61-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	528	gp41	S	0.030	0.012	0.022	S528W in strain JRCSF decreases ACS202 neutralization >61-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	533	gp41	A	0.086	0.103	0.041	A533W in strain JRCSF decreases ACS202 neutralization 35-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	536	gp41	T	0.378	0.396	0.366	T536W in strain JRCSF decreases ACS202 neutralization >61-fold
92	Mutation affects ACS202 neutralization	vanGils2016	neutralization	ACS202(gp41 fusion domain)	mutational analysis, neutralization assay	537	gp41	L	0.012	0.006	0.008	L537W in strain JRCSF decreases ACS202 neutralization 53-fold
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		97	gp120	K	0.478	0.421	0.511	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		124	gp120	P	0.045	0.018	0.029	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		198	gp120	T	0.430	0.264	0.469	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		275	gp120, Loop D	V	1.141	1.420	0.535	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		276	gp120, Loop D	N	0.118	0.063	0.169	N6 light chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		278	gp120, Loop D	T	0.708	0.715	0.481	N6 light chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		279	gp120, Loop D	D	0.900	0.850	0.898	N6 contact: hydrogen bond to N6 heavy chain Ser100; also light chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	N6 contact: hydrogen bond to N6 heavy chain Trp50; also hydrogen bond to N6 light chain Gln96
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		281	gp120, Loop D	A	1.129	0.814	1.357	N6 contact: hydrogen bond to N6 heavy chain Lys52
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		282	gp120, Loop D	K	0.336	0.337	0.297	N6 contact: hydrogen bond and salt bridge to N6 heavy chain Asp100
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		283	gp120, Loop D	T	1.005	1.091	0.474	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		355	gp120	N	0.693	0.893	0.297	N6 light chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		365	gp120, CD4 binding loop	S	0.602	0.489	0.619	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		366	gp120, CD4 binding loop	G	0.043	0.012	0.028	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		367	gp120, CD4 binding loop	G	0.042	0.034	0.008	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		368	gp120, CD4 binding loop	D	0.039	0.023	0.029	N6 contact: hydrogen bonds to N6 heavy chain Arg71 and Tyr54, and salt bridge to N6 heavy chain Arg71
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		370	gp120, CD4 binding loop	E	0.049	0.017	0.055	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		371	gp120, CD4 binding loop	I	0.466	0.389	0.507	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		425	gp120, beta20/beta21	N	0.295	0.138	0.177	N6 contact: hydrogen bond to N6 heavy chain Tyr54
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		426	gp120, beta20/beta21	M	0.724	0.866	0.274	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		427	gp120, beta20/beta21	W	0.083	0.061	0.038	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		430	gp120, beta20/beta21	V	0.267	0.080	0.073	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		455	gp120, beta23	T	0.709	0.426	0.972	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		456	gp120, beta23	R	0.233	0.079	0.323	N6 contact: hydrogen bond to N6 heavy chain Asn58
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		457	gp120, beta23	D	0.079	0.054	0.043	N6 contact: hydrogen bond to N6 heavy chain Arg64 and salt bridge to N6 heavy chain Arg64
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		458	gp120, beta23	G	0.112	0.045	0.095	N6 contact: hydrogen bond to N6 heavy chain Asn58; also light chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	N6 contact: hydrogen bond to N6 heavy chain Asn58; also light chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	N6 heavy chain contact; N6 light chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	N6 heavy chain contact; N6 light chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	N6 light chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	N6 light chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		471	gp120, beta24	G	0.933	0.888	0.866	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		472	gp120	G	0.035	0.012	0.043	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		473	gp120	G	0.042	0.033	0.029	N6 contact: hydrogen bond to N6 heavy chain Gln53
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		474	gp120	D	0.696	0.681	0.752	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		475	gp120	M	0.097	0.092	0.106	N6 heavy chain contact
93	N6 contacts	Huang2016a	contacts	N6(CD4BS)		476	gp120	R	0.663	0.615	0.711	N6 heavy chain contact
94	N6 alanine scanning	Huang2016a	binding	N6(CD4BS)	alanine scanning, binding assay	279	gp120, Loop D	D	0.900	0.850	0.898	D279A decreases N6 binding to JRCSF to <33% of wild type
94	N6 alanine scanning	Huang2016a	binding	N6(CD4BS)	alanine scanning, binding assay	282	gp120, Loop D	K	0.336	0.337	0.297	K282A decreases N6 binding to JRCSF to <33% of wild type
94	N6 alanine scanning	Huang2016a	binding	N6(CD4BS)	alanine scanning, binding assay	283	gp120, Loop D	T	1.005	1.091	0.474	T283A decreases N6 binding to JRCSF to <33% of wild type
94	N6 alanine scanning	Huang2016a	binding	N6(CD4BS)	alanine scanning, binding assay	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	S365A decreases N6 binding to JRCSF to <33% of wild type
94	N6 alanine scanning	Huang2016a	binding	N6(CD4BS)	alanine scanning, binding assay	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	G366A decreases N6 binding to JRCSF to <33% of wild type
94	N6 alanine scanning	Huang2016a	binding	N6(CD4BS)	alanine scanning, binding assay	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	G367A decreases N6 binding to JRCSF to <33% of wild type
94	N6 alanine scanning	Huang2016a	binding	N6(CD4BS)	alanine scanning, binding assay	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368A decreases N6 binding to JRCSF to <33% of wild type
94	N6 alanine scanning	Huang2016a	binding	N6(CD4BS)	alanine scanning, binding assay	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	E370A decreases N6 binding to JRCSF to <33% of wild type
94	N6 alanine scanning	Huang2016a	binding	N6(CD4BS)	alanine scanning, binding assay	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	I371A decreases N6 binding to JRCSF to <33% of wild type
94	N6 alanine scanning	Huang2016a	binding	N6(CD4BS)	alanine scanning, binding assay	457	gp120, beta23	D	0.079	0.054	0.043	D457A decreases N6 binding to JRCSF to <33% of wild type
94	N6 alanine scanning	Huang2016a	binding	N6(CD4BS)	alanine scanning, binding assay	474	gp120	D	0.696	0.681	0.752	D474A decreases N6 binding to JRCSF to <33% of wild type
95	mutations affecting VRC01 binding	Huang2016a	binding	VRC01(CD4BS)	alanine scanning, binding assay, mutational analysis	262	gp120	N	0.027	0.029	0.028	N262A decreases VRC01 binding to JRCSF to <33% of wild type
95	mutations affecting VRC01 binding	Huang2016a	binding	VRC01(CD4BS)	alanine scanning, binding assay, mutational analysis	279	gp120, Loop D	D	0.900	0.850	0.898	D279A eliminates VRC01 binding to JRCSF
95	mutations affecting VRC01 binding	Huang2016a	binding	VRC01(CD4BS)	alanine scanning, binding assay, mutational analysis	282	gp120, Loop D	K	0.336	0.337	0.297	K282A decreases VRC01 binding to JRCSF to <33% of wild type
95	mutations affecting VRC01 binding	Huang2016a	binding	VRC01(CD4BS)	alanine scanning, binding assay, mutational analysis	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	G366A decreases VRC01 binding to JRCSF to <33% of wild type
95	mutations affecting VRC01 binding	Huang2016a	binding	VRC01(CD4BS)	alanine scanning, binding assay, mutational analysis	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	G367A decreases VRC01 binding to JRCSF to <33% of wild type
95	mutations affecting VRC01 binding	Huang2016a	binding	VRC01(CD4BS)	alanine scanning, binding assay, mutational analysis	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368A decreases VRC01 binding to JRCSF to <33% of wild type
95	mutations affecting VRC01 binding	Huang2016a	binding	VRC01(CD4BS)	alanine scanning, binding assay, mutational analysis	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	E370A decreases VRC01 binding to JRCSF to <33% of wild type
95	mutations affecting VRC01 binding	Huang2016a	binding	VRC01(CD4BS)	alanine scanning, binding assay, mutational analysis	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	I371A decreases VRC01 binding to JRCSF to <33% of wild type
95	mutations affecting VRC01 binding	Huang2016a	binding	VRC01(CD4BS)	alanine scanning, binding assay, mutational analysis	372	gp120, CD4 binding loop	V	1.105	0.776	0.391	V372A decreases VRC01 binding to JRCSF to <33% of wild type
95	mutations affecting VRC01 binding	Huang2016a	binding	VRC01(CD4BS)	alanine scanning, binding assay, mutational analysis	457	gp120, beta23	D	0.079	0.054	0.043	D457A decreases VRC01 binding to JRCSF to <33% of wild type
95	mutations affecting VRC01 binding	Huang2016a	binding	VRC01(CD4BS)	alanine scanning, binding assay, mutational analysis	474	gp120	D	0.696	0.681	0.752	D474A decreases VRC01 binding to JRCSF to <33% of wild type
96	mutations affecting 3BNC117 binding	Huang2016a	binding	3BNC117(CD4BS)	alanine scanning, binding assay, mutational analysis	262	gp120	N	0.027	0.029	0.028	N262A decreases 3BNC117 binding to JRCSF to <33% of wild type
96	mutations affecting 3BNC117 binding	Huang2016a	binding	3BNC117(CD4BS)	alanine scanning, binding assay, mutational analysis	279	gp120, Loop D	D	0.900	0.850	0.898	D279A eliminates 3BNC117 binding to JRCSF
96	mutations affecting 3BNC117 binding	Huang2016a	binding	3BNC117(CD4BS)	alanine scanning, binding assay, mutational analysis	282	gp120, Loop D	K	0.336	0.337	0.297	K282A decreases 3BNC117 binding to JRCSF to <33% of wild type
96	mutations affecting 3BNC117 binding	Huang2016a	binding	3BNC117(CD4BS)	alanine scanning, binding assay, mutational analysis	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	G366A decreases 3BNC117 binding to JRCSF to <33% of wild type
96	mutations affecting 3BNC117 binding	Huang2016a	binding	3BNC117(CD4BS)	alanine scanning, binding assay, mutational analysis	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	G367A decreases 3BNC117 binding to JRCSF to <33% of wild type
96	mutations affecting 3BNC117 binding	Huang2016a	binding	3BNC117(CD4BS)	alanine scanning, binding assay, mutational analysis	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368A decreases 3BNC117 binding to JRCSF to <33% of wild type
96	mutations affecting 3BNC117 binding	Huang2016a	binding	3BNC117(CD4BS)	alanine scanning, binding assay, mutational analysis	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	E370A decreases 3BNC117 binding to JRCSF to <33% of wild type
97	VRC-PG04 alanine scanning	Huang2016a	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	262	gp120	N	0.027	0.029	0.028	N262A decreases VRC-PG04 binding to JRCSF to <33% of wild type
97	VRC-PG04 alanine scanning	Huang2016a	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	280	gp120, Loop D	N	0.142	0.090	0.170	N280A decreases VRC-PG04 binding to JRCSF to <33% of wild type
97	VRC-PG04 alanine scanning	Huang2016a	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	282	gp120, Loop D	K	0.336	0.337	0.297	K282A decreases VRC-PG04 binding to JRCSF to <33% of wild type
97	VRC-PG04 alanine scanning	Huang2016a	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	332	gp120	N	0.663	0.491	0.693	N332A decreases VRC-PG04 binding to JRCSF to <33% of wild type
97	VRC-PG04 alanine scanning	Huang2016a	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	G366A decreases VRC-PG04 binding to JRCSF to <33% of wild type
97	VRC-PG04 alanine scanning	Huang2016a	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	G367A decreases VRC-PG04 binding to JRCSF to <33% of wild type
97	VRC-PG04 alanine scanning	Huang2016a	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368A decreases VRC-PG04 binding to JRCSF to <33% of wild type
97	VRC-PG04 alanine scanning	Huang2016a	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	E370A decreases VRC-PG04 binding to JRCSF to <33% of wild type
97	VRC-PG04 alanine scanning	Huang2016a	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	I371A decreases VRC-PG04 binding to JRCSF to <33% of wild type
97	VRC-PG04 alanine scanning	Huang2016a	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	372	gp120, CD4 binding loop	V	1.105	0.776	0.391	V372A decreases VRC-PG04 binding to JRCSF to <33% of wild type
97	VRC-PG04 alanine scanning	Huang2016a	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	457	gp120, beta23	D	0.079	0.054	0.043	D457A eliminates VRC-PG04 binding to JRCSF
97	VRC-PG04 alanine scanning	Huang2016a	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	R469A decreases VRC-PG04 binding to JRCSF to <33% of wild type
97	VRC-PG04 alanine scanning	Huang2016a	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	474	gp120	D	0.696	0.681	0.752	D474A eliminates VRC-PG04 binding to JRCSF
98	12A21 alanine scanning	Huang2016a	binding	12A21(CD4BS)	alanine scanning, binding assay	282	gp120, Loop D	K	0.336	0.337	0.297	K282A decreases 12A21 binding to JRCSF to <33% of wild type
98	12A21 alanine scanning	Huang2016a	binding	12A21(CD4BS)	alanine scanning, binding assay	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	G366A decreases 12A21 binding to JRCSF to <33% of wild type
98	12A21 alanine scanning	Huang2016a	binding	12A21(CD4BS)	alanine scanning, binding assay	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	G367A decreases 12A21 binding to JRCSF to <33% of wild type
98	12A21 alanine scanning	Huang2016a	binding	12A21(CD4BS)	alanine scanning, binding assay	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368A decreases 12A21 binding to JRCSF to <33% of wild type
98	12A21 alanine scanning	Huang2016a	binding	12A21(CD4BS)	alanine scanning, binding assay	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	E370A decreases 12A21 binding to JRCSF to <33% of wild type
98	12A21 alanine scanning	Huang2016a	binding	12A21(CD4BS)	alanine scanning, binding assay	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	I371A decreases 12A21 binding to JRCSF to <33% of wild type
98	12A21 alanine scanning	Huang2016a	binding	12A21(CD4BS)	alanine scanning, binding assay	457	gp120, beta23	D	0.079	0.054	0.043	D457A decreases 12A21 binding to JRCSF to <33% of wild type
98	12A21 alanine scanning	Huang2016a	binding	12A21(CD4BS)	alanine scanning, binding assay	474	gp120	D	0.696	0.681	0.752	D474A decreases 12A21 binding to JRCSF to <33% of wild type
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	197	gp120	N	0.133	0.082	0.109	N197T decreases VRC27 binding to JRCSF to <33% of wild type
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	262	gp120	N	0.027	0.029	0.028	N262A eliminates VRC27 binding to JRCSF
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	279	gp120, Loop D	D	0.900	0.850	0.898	D279A decreases VRC27 binding to JRCSF to <33% of wild type
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	280	gp120, Loop D	N	0.142	0.090	0.170	N280A eliminates VRC27 binding to JRCSF
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	283	gp120, Loop D	T	1.005	1.091	0.474	T283A decreases VRC27 binding to JRCSF to <33% of wild type
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	G366A decreases VRC27 binding to JRCSF to <33% of wild type
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	G367A eliminates VRC27 binding to JRCSF
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368A eliminates VRC27 binding to JRCSF
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	E370A decreases VRC27 binding to JRCSF to <33% of wild type
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	I371A eliminates VRC27 binding to JRCSF
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	372	gp120, CD4 binding loop	V	1.105	0.776	0.391	V372A decreases VRC27 binding to JRCSF to <33% of wild type
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	373	gp120, CD4 binding loop	T	1.024	0.872	0.371	M373A decreases VRC27 binding to JRCSF to <33% of wild type
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	457	gp120, beta23	D	0.079	0.054	0.043	D457A decreases VRC27 binding to JRCSF to <33% of wild type
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	467	gp120, V5 loop, beta24	I	0.912	0.955	0.870	I467A decreases VRC27 binding to JRCSF to <33% of wild type
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	R469A eliminates VRC27 binding to JRCSF
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	472	gp120	G	0.035	0.012	0.043	G472A eliminates VRC27 binding to JRCSF
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	473	gp120	G	0.042	0.033	0.029	G473A decreases VRC27 binding to JRCSF to <33% of wild type
99	VRC27 alanine scanning	Huang2016a	binding	VRC27(CD4BS)	alanine scanning, binding assay	474	gp120	D	0.696	0.681	0.752	D474A eliminates VRC27 binding to JRCSF
100	Mutation affects 2G12 binding	Alam2017	binding	2G12(glycan)	binding assay	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	2G12 binding is decreased by the N295A mutation of JRCSF, with a fold knockdown effect of >105.
100	Mutation affects 2G12 binding	Alam2017	binding	2G12(glycan)	binding assay	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	2G12 binding is decreased by the T297A mutation of JRCSF, with a fold knockdown effect of >105.
100	Mutation affects 2G12 binding	Alam2017	binding	2G12(glycan)	binding assay	339	gp120	N	1.149	1.082	1.026	2G12 binding is decreased by the N339A mutation of JRCSF, with a fold knockdown effect of 14.33.
100	Mutation affects 2G12 binding	Alam2017	binding	2G12(glycan)	binding assay	392	gp120, V4 loop	N	0.605	0.454	0.804	2G12 binding is decreased by the N392A mutation of JRCSF, with a fold knockdown effect of >105.
101	DH511.2 contacts	Williams2017	contacts	DH511.2(MPER)	molecular modeling, X-ray crystallography	669	gp41	L	0.017	0.023	0.000	contacts VH3-15 region residues of DH511.2 and DH511.2_K3
101	DH511.2 contacts	Williams2017	contacts	DH511.2(MPER)	molecular modeling, X-ray crystallography	670	gp41	W	0.043	0.028	0.035	contacts VH3-15 region residues of DH511.2 and DH511.2_K3
101	DH511.2 contacts	Williams2017	contacts	DH511.2(MPER)	molecular modeling, X-ray crystallography	671	gp41	N	0.783	0.669	0.885	contacts VH3-15 region residues of DH511.2 and DH511.2_K3
101	DH511.2 contacts	Williams2017	contacts	DH511.2(MPER)	molecular modeling, X-ray crystallography	672	gp41	W	0.014	0.023	0.014	contacts both VH3-15 region residues and HCDR3 residues of DH511.2 and DH511.2_K3
101	DH511.2 contacts	Williams2017	contacts	DH511.2(MPER)	molecular modeling, X-ray crystallography	673	gp41	F	0.048	0.065	0.073	contacts VH3-15 region residues of DH511.2 and DH511.2_K3
101	DH511.2 contacts	Williams2017	contacts	DH511.2(MPER)	molecular modeling, X-ray crystallography	674	gp41	N	1.179	1.029	1.344	contacts VH3-15 region residues of DH511.2 and DH511.2_K3
101	DH511.2 contacts	Williams2017	contacts	DH511.2(MPER)	molecular modeling, X-ray crystallography	675	gp41	I	0.063	0.059	0.069	predicted van der Waals interaction
101	DH511.2 contacts	Williams2017	contacts	DH511.2(MPER)	molecular modeling, X-ray crystallography	676	gp41	T	0.671	0.610	0.674	contacts HCDR3 residues of DH511.2 and DH511.2_K3
101	DH511.2 contacts	Williams2017	contacts	DH511.2(MPER)	molecular modeling, X-ray crystallography	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	contacts HCDR3 residues of DH511.2 and DH511.2_K3
101	DH511.2 contacts	Williams2017	contacts	DH511.2(MPER)	molecular modeling, X-ray crystallography	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	contacts HCDR3 residues of DH511.2 and DH511.2_K3
101	DH511.2 contacts	Williams2017	contacts	DH511.2(MPER)	molecular modeling, X-ray crystallography	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	contacts HCDR3 residues of DH511.2 and DH511.2_K3
102	Mutation affects CD4 binding	Finzi2010	Env feature		binding assay	66	gp120	H	0.010	0.017	0.000	H66A decreases CD4 binding
102	Mutation affects CD4 binding	Finzi2010	Env feature		binding assay	69	gp120	W	0.015	0.000	0.008	W69L decreases CD4 binding and CCR5 binding
102	Mutation affects CD4 binding	Finzi2010	Env feature		binding assay	107	gp120	D	0.034	0.030	0.048	D107A decreases CD4 binding and CCR5 binding
102	Mutation affects CD4 binding	Finzi2010	Env feature		binding assay	111	gp120	L	0.124	0.048	0.221	L111A decreases CD4 binding and CCR5 binding
102	Mutation affects CD4 binding	Finzi2010	Env feature		binding assay	112	gp120	W	0.023	0.018	0.000	W112A decreases CD4 binding (W112 does not contact CD4, but lines the Phe 43 cavity and, along with I109, interacts with W427, a cavity-lining residue that does contact CD4)
103	Mutation affects binding to 17b and 412d	Finzi2010	binding	17b(CD4i), 412d(CD4i)	binding assay	69	gp120	W	0.015	0.000	0.008	W69L decreases binding to 17b and 412d
103	Mutation affects binding to 17b and 412d	Finzi2010	binding	17b(CD4i), 412d(CD4i)	binding assay	107	gp120	D	0.034	0.030	0.048	D107A decreases binding to 17b and 412d
103	Mutation affects binding to 17b and 412d	Finzi2010	binding	17b(CD4i), 412d(CD4i)	binding assay	111	gp120	L	0.124	0.048	0.221	L111A decreases binding to 17b and 412d
104	W69 is important for ADCC	Ding2015	other feature	A32(other)	other	69	gp120	W	0.015	0.000	0.008	W69 is important for ADCC responses mediated by anti-cluster A antibodies
105	VRC38.01 contacts	Cale2017	contacts	VRC38.01(V2)	X-ray crystallography	133	gp120, V1-hypervariable, V1	D	1.376	1.052	1.360	side-chain hydrogen bond contact
105	VRC38.01 contacts	Cale2017	contacts	VRC38.01(V2)	X-ray crystallography	156	gp120, V1	N	0.246	0.220	0.224	side-chain hydrogen bond contact
105	VRC38.01 contacts	Cale2017	contacts	VRC38.01(V2)	X-ray crystallography	158	gp120, V2	S	0.263	0.185	0.291	side-chain hydrogen bond contact
105	VRC38.01 contacts	Cale2017	contacts	VRC38.01(V2)	X-ray crystallography	168	gp120, V2	K	0.566	0.666	0.396	side-chain hydrogen bond contact
105	VRC38.01 contacts	Cale2017	contacts	VRC38.01(V2)	X-ray crystallography	171	gp120, V2	K	1.247	0.957	1.413	side-chain hydrogen bond contact
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	127	gp120	V	0.102	0.112	0.093	V127A made BG505 and JRCSF more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	129	gp120	L	0.069	0.056	0.029	L129A made BG505 more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	155	gp120, V1	K	0.758	0.423	0.831	K155A made JRCSF more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	N156A made BG505 and JRCSF more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	158	gp120, V2	S	0.263	0.185	0.291	S158A made BG505, JRCSF, and WITO more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	159	gp120, V2	F	0.104	0.034	0.038	F159A made BG505 and JRCSF more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160A made BG505, JRCSF, and WITO more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	T162A made BG505, JRCSF, and WITO more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	K168A made BG505 more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169A/V169A made BG505/JRCSF more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	171	gp120, V2	K	1.247	0.957	1.413	K171A made BG505, JRCSF, and WITO more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	K173A made BG505, JRCSF, and WITO more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	175	gp120, V2	F	0.606	0.868	0.271	L175A made BG505 more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	184	gp120, V2	I	1.028	0.599	0.530	I184 made JRCSF more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	185	gp120, V2-hypervariable, V2	D	1.697	1.370	1.762	D185 made JRCSF more resistant to neutralization by V1V2 NAbs
106	Mutation affects neutralization by V1V2 glycan mAbs	Cale2017	neutralization	CH01(V2), PG9(V2), PGT145(V2), VRC38.01(V2)	neutralization assay	189	gp120, V2-hypervariable, V2	T	1.760	1.348	1.638	T189A made JRCSF more sensitive to neutralization by CH01
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	135	gp120, V1-hypervariable, V1	K	2.230	2.373	1.848	light chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	136	gp120, V1-hypervariable, V1	N	2.514	2.300	2.581	light chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	light chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	156	gp120, V1	N	0.246	0.220	0.224	non-primary glycan contact; four-fold greater neutralization when no glycan is present
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	301	gp120, V3 loop	N	0.172	0.176	0.104	non-primary glycan contact
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	321	gp120, V3 loop	G	1.042	0.842	1.108	light chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	322	gp120, V3 loop	K	1.797	0.347	0.283	light chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	323	gp120, V3 loop	I	0.476	0.531	0.263	light chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	324	gp120, V3 loop	G	0.075	0.056	0.092	contact with GDIR motif; light chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	325	gp120, V3 loop	N	0.648	0.622	0.622	contact with GDIR motif; heavy chain interaction; light chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	326	gp120, V3 loop	M	0.143	0.143	0.116	contact with GDIR motif; heavy chain interaction; light chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	327	gp120, V3 loop	R	0.089	0.066	0.073	contact with GDIR motif; heavy chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	328	gp120, V3 loop	Q	0.923	0.816	0.882	heavy chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	329	gp120, V3 loop	A	0.043	0.034	0.022	heavy chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	330	gp120, V3 loop	H	0.634	0.559	0.655	heavy chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	332	gp120	N	0.663	0.491	0.693	primary glycan contact
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	415	gp120, V4 loop	T	0.754	0.760	0.656	heavy chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	416	gp120, V4 loop	L	0.425	0.174	0.580	heavy chain interaction
107	10-1074 contacts	Gristick2016	contacts	10-1074(V3)	X-ray crystallography	417	gp120, V4 loop	P	0.864	0.736	0.922	heavy chain interaction
108	IOMA contacts	Gristick2016	contacts	IOMA(CD4BS)	X-ray crystallography	197	gp120	N	0.133	0.082	0.109	glycan interaction
108	IOMA contacts	Gristick2016	contacts	IOMA(CD4BS)	X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	glycan interaction
108	IOMA contacts	Gristick2016	contacts	IOMA(CD4BS)	X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	primary contact; N279/N280 of BG505 interact with heavy chain D93
108	IOMA contacts	Gristick2016	contacts	IOMA(CD4BS)	X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	primary contact; N279/N280 of BG505 interact with heavy chain D93
108	IOMA contacts	Gristick2016	contacts	IOMA(CD4BS)	X-ray crystallography	363	gp120	Q	1.825	1.587	1.352	minor interaction with N363 glycan of BG505
108	IOMA contacts	Gristick2016	contacts	IOMA(CD4BS)	X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	heavy chain interaction
108	IOMA contacts	Gristick2016	contacts	IOMA(CD4BS)	X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	R456 of BG505 interacts with heavy chain D93
108	IOMA contacts	Gristick2016	contacts	IOMA(CD4BS)	X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	G459 of BG505 interacts with heavy chain D93
109	Mutation greatly reduces PGT143 neutralization	Ferguson2013	neutralization	PGT143(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
109	Mutation greatly reduces PGT143 neutralization	Ferguson2013	neutralization	PGT143(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
110	Mutation greatly reduces PGT145 neutralization	Ferguson2013	neutralization	PGT145(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
111	vFP1.01 contacts with BG505	Xu2018	contacts	vFP1.01(gp41 fusion domain)	X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	Ala (BG505): H bond and salt bridge with E34 (LC), H bond with Y98 and W99 (HC)
111	vFP1.01 contacts with BG505	Xu2018	contacts	vFP1.01(gp41 fusion domain)	X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	Val (BG505): H bond with G91 and Y98 (LC)
111	vFP1.01 contacts with BG505	Xu2018	contacts	vFP1.01(gp41 fusion domain)	X-ray crystallography	514	gp41, fusion peptide	G	0.600	0.691	0.502	Gly (BG505): H bond with Y96 (LC)
111	vFP1.01 contacts with BG505	Xu2018	contacts	vFP1.01(gp41 fusion domain)	X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	Ile (BG505): H bond with E33 (HC)
112	Mutation decreases binding of Y498	Sun2017	binding	Y498(CD4BS)	binding assay	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	mutation to alanine reduces binding
112	Mutation decreases binding of Y498	Sun2017	binding	Y498(CD4BS)	binding assay	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	mutation to alanine reduces binding
112	Mutation decreases binding of Y498	Sun2017	binding	Y498(CD4BS)	binding assay	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	mutation to alanine reduces binding
112	Mutation decreases binding of Y498	Sun2017	binding	Y498(CD4BS)	binding assay	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	mutation to alanine reduces binding
112	Mutation decreases binding of Y498	Sun2017	binding	Y498(CD4BS)	binding assay	372	gp120, CD4 binding loop	V	1.105	0.776	0.391	mutation to alanine reduces binding
112	Mutation decreases binding of Y498	Sun2017	binding	Y498(CD4BS)	binding assay	453	gp120, beta23	L	0.494	0.517	0.199	mutation to alanine reduces binding
112	Mutation decreases binding of Y498	Sun2017	binding	Y498(CD4BS)	binding assay	454	gp120, beta23	L	0.119	0.118	0.065	mutation to alanine reduces binding
112	Mutation decreases binding of Y498	Sun2017	binding	Y498(CD4BS)	binding assay	456	gp120, beta23	R	0.233	0.079	0.323	mutation to alanine reduces binding
112	Mutation decreases binding of Y498	Sun2017	binding	Y498(CD4BS)	binding assay	471	gp120, beta24	G	0.933	0.888	0.866	mutation to alanine reduces binding
112	Mutation decreases binding of Y498	Sun2017	binding	Y498(CD4BS)	binding assay	474	gp120	D	0.696	0.681	0.752	mutation to alanine reduces binding
112	Mutation decreases binding of Y498	Sun2017	binding	Y498(CD4BS)	binding assay	476	gp120	R	0.663	0.615	0.711	mutation to alanine reduces binding
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		135	gp120, V1-hypervariable, V1	K	2.230	2.373	1.848	light chain contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		136	gp120, V1-hypervariable, V1	N	2.514	2.300	2.581	light chain contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	light chain contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		138	gp120, V1-hypervariable, V1	T	2.312	2.112	2.504	light chain contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		139	gp120, V1-hypervariable, V1	N	2.097	1.946	2.163	light chain contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		156	gp120, V1	N	0.246	0.220	0.224	glycan contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		325	gp120, V3 loop	N	0.648	0.622	0.622	heavy chain contact; light chain contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		326	gp120, V3 loop	M	0.143	0.143	0.116	heavy chain contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		327	gp120, V3 loop	R	0.089	0.066	0.073	heavy chain contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		328	gp120, V3 loop	Q	0.923	0.816	0.882	heavy chain contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		329	gp120, V3 loop	A	0.043	0.034	0.022	heavy chain contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		332	gp120	N	0.663	0.491	0.693	glycan contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	glycan contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		392	gp120, V4 loop	N	0.605	0.454	0.804	glycan contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		415	gp120, V4 loop	T	0.754	0.760	0.656	heavy chain contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		416	gp120, V4 loop	L	0.425	0.174	0.580	heavy chain contact
113	BG18 contacts	Barnes2018	contacts	BG18(V3)		417	gp120, V4 loop	P	0.864	0.736	0.922	heavy chain contact
114	Mutation affects neutralization by CAP248-2B	Wibmer2017	neutralization	CAP248-2B(gp120/gp41 interface)	neutralization assay	501	gp120	A	0.107	0.017	0.221	A501C abrogates neutralization of CAP45
114	Mutation affects neutralization by CAP248-2B	Wibmer2017	neutralization	CAP248-2B(gp120/gp41 interface)	neutralization assay	502	gp120	K	0.547	0.512	0.348	R502A reduces neutralization of CAP45
114	Mutation affects neutralization by CAP248-2B	Wibmer2017	neutralization	CAP248-2B(gp120/gp41 interface)	neutralization assay	505	gp120	V	0.093	0.091	0.064	V505A reduces neutralization of CAP45
114	Mutation affects neutralization by CAP248-2B	Wibmer2017	neutralization	CAP248-2B(gp120/gp41 interface)	neutralization assay	508	gp120, RxKR Cleaved by cellular protease similar to furin	R	0.101	0.055	0.153	R508A abrogates neutralization of CAP45
114	Mutation affects neutralization by CAP248-2B	Wibmer2017	neutralization	CAP248-2B(gp120/gp41 interface)	neutralization assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	V513W abrogates neutralization of CAP45
114	Mutation affects neutralization by CAP248-2B	Wibmer2017	neutralization	CAP248-2B(gp120/gp41 interface)	neutralization assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	G514W reduces neutralization of CAP45
114	Mutation affects neutralization by CAP248-2B	Wibmer2017	neutralization	CAP248-2B(gp120/gp41 interface)	neutralization assay	652	gp41	Q	0.047	0.041	0.041	Q652A reduces neutralization of CAP45
114	Mutation affects neutralization by CAP248-2B	Wibmer2017	neutralization	CAP248-2B(gp120/gp41 interface)	neutralization assay	656	gp41	N	0.031	0.034	0.033	N656D abrogates neutralization of CAP45
114	Mutation affects neutralization by CAP248-2B	Wibmer2017	neutralization	CAP248-2B(gp120/gp41 interface)	neutralization assay	666	gp41	W	0.008	0.000	0.000	W666A abrogates neutralization of CAP45
115	Mutation affects neutralization by VRC34	Wibmer2017	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	512	gp41, fusion peptide	A	0.188	0.260	0.110	A512W abrogates neutralization of CAP45
115	Mutation affects neutralization by VRC34	Wibmer2017	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	V513W abrogates neutralization of CAP45
115	Mutation affects neutralization by VRC34	Wibmer2017	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	G514W reduces neutralization of CAP45
115	Mutation affects neutralization by VRC34	Wibmer2017	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	V515W abrogates neutralization of CAP45
115	Mutation affects neutralization by VRC34	Wibmer2017	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	518	gp41, fusion peptide	L	1.166	1.110	0.718	V518W abrogates neutralization of CAP45
115	Mutation affects neutralization by VRC34	Wibmer2017	neutralization	VRC34.01(gp41 fusion domain)	neutralization assay	613	gp41	S	0.243	0.207	0.216	S613A increases neutralization of CAP45
116	Mutation affects neutralization by 35O22	Wibmer2017	neutralization	35O22(gp120/gp41 interface)	neutralization assay	501	gp120	A	0.107	0.017	0.221	A501C abrogates neutralization of CAP45
116	Mutation affects neutralization by 35O22	Wibmer2017	neutralization	35O22(gp120/gp41 interface)	neutralization assay	510	gp120, RxKR Cleaved by cellular protease similar to furin	K	0.131	0.153	0.085	K510A reduces neutralization of CAP45
116	Mutation affects neutralization by 35O22	Wibmer2017	neutralization	35O22(gp120/gp41 interface)	neutralization assay	667	gp41	A	1.424	0.545	1.537	N667Q reduces neutralization of CAP45
117	Mutations affect neutralization by 10E8	Wibmer2017	neutralization	10E8(MPER)	neutralization assay	504	gp120	R	0.194	0.049	0.216	R504A increases neutralization of CAP45
117	Mutations affect neutralization by 10E8	Wibmer2017	neutralization	10E8(MPER)	neutralization assay	506	gp120	V	0.035	0.006	0.038	V506A increases neutralization of CAP45
117	Mutations affect neutralization by 10E8	Wibmer2017	neutralization	10E8(MPER)	neutralization assay	508	gp120, RxKR Cleaved by cellular protease similar to furin	R	0.101	0.055	0.153	R508A increases neutralization of CAP45
117	Mutations affect neutralization by 10E8	Wibmer2017	neutralization	10E8(MPER)	neutralization assay	666	gp41	W	0.008	0.000	0.000	W666A increases neutralization of CAP45
117	Mutations affect neutralization by 10E8	Wibmer2017	neutralization	10E8(MPER)	neutralization assay	672	gp41	W	0.014	0.023	0.014	W672L/F673L abrogates neutralization of CAP45
117	Mutations affect neutralization by 10E8	Wibmer2017	neutralization	10E8(MPER)	neutralization assay	673	gp41	F	0.048	0.065	0.073	W672L/F673L abrogates neutralization of CAP45
118	mutations affecting neutralization by 10-1074	Dingens2019	neutralization	10-1074(V3)	neutralization assay	140	gp120, V1-hypervariable, V1	T	2.235	2.104	2.340	D140E mediated a 1.6-fold decrease in neutralization potency in BG505.T332N
118	mutations affecting neutralization by 10-1074	Dingens2019	neutralization	10-1074(V3)	neutralization assay	151	gp120, V1-hypervariable, V1	K	2.575	2.285	2.605	R151K mediated a 1.6-fold decrease in neutralization potency in BG505.T332N
118	mutations affecting neutralization by 10-1074	Dingens2019	neutralization	10-1074(V3)	neutralization assay	322	gp120, V3 loop	K	1.797	0.347	0.283	D322E and D322G each mediated a 1.4-fold decrease in neutralization potency in BG505.T332N, D322A had no effect
118	mutations affecting neutralization by 10-1074	Dingens2019	neutralization	10-1074(V3)	neutralization assay	323	gp120, V3 loop	I	0.476	0.531	0.263	I323G mediated a 2.5-fold decrease in neutralization potency in BG505.T332N
118	mutations affecting neutralization by 10-1074	Dingens2019	neutralization	10-1074(V3)	neutralization assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325E and D325S mediated respective 27.2- and 3.0-fold decreases in neutralization potency in BG505.T332N while D325N had no effect; GDIR motif
118	mutations affecting neutralization by 10-1074	Dingens2019	neutralization	10-1074(V3)	neutralization assay	327	gp120, V3 loop	R	0.089	0.066	0.073	R327A mediated a 4.0-fold decrease in neutralization potency in BG505.T332N; GDIR motif
118	mutations affecting neutralization by 10-1074	Dingens2019	neutralization	10-1074(V3)	neutralization assay	330	gp120, V3 loop	H	0.634	0.559	0.655	H330R mediated a 35.1-fold decrease in neutralization potency
118	mutations affecting neutralization by 10-1074	Dingens2019	neutralization	10-1074(V3)	neutralization assay	415	gp120, V4 loop	T	0.754	0.760	0.656	T415R and T415Y mediated respective 4.8- and 2.7-fold decreases in neutralization potency in BG505.T332N
118	mutations affecting neutralization by 10-1074	Dingens2019	neutralization	10-1074(V3)	neutralization assay	441	gp120	G	0.045	0.041	0.037	G441P mediated a 2.2-fold decrease in neutralization potency in BG505.T332N
119	PGT122 glycan contacts	Gristick2016	contacts	PGT122(V3)		137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	PGT122 glycan contact
119	PGT122 glycan contacts	Gristick2016	contacts	PGT122(V3)		156	gp120, V1	N	0.246	0.220	0.224	PGT122 glycan contact
119	PGT122 glycan contacts	Gristick2016	contacts	PGT122(V3)		301	gp120, V3 loop	N	0.172	0.176	0.104	PGT122 glycan contact
120	PGT122 neutralization	Gristick2016	neutralization	PGT122(V3)	neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	about 2-fold more potent when glycan is present
121	NIH45-46G54W mutations causing resistance	Diskin2013	neutralization	NIH45-46G54W(CD4BS)		279	gp120, Loop D	D	0.900	0.850	0.898	Mutations at this site are found in strains resistant to NIH45-46G45W
121	NIH45-46G54W mutations causing resistance	Diskin2013	neutralization	NIH45-46G54W(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	Mutations at this site are found in strains resistant to NIH45-46G45W
121	NIH45-46G54W mutations causing resistance	Diskin2013	neutralization	NIH45-46G54W(CD4BS)		458	gp120, beta23	G	0.112	0.045	0.095	Mutations at either position found in strains resistant to NIH45-46G45W
121	NIH45-46G54W mutations causing resistance	Diskin2013	neutralization	NIH45-46G54W(CD4BS)		459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	Mutations at either position found in strains resistant to NIH45-46G45W
122	MPER membrane fusion mutations confer sensitivity	Fu2018	neutralization	17b(CD4i)	neutralization assay	670	gp41	W	0.043	0.028	0.035	W670A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
122	MPER membrane fusion mutations confer sensitivity	Fu2018	neutralization	17b(CD4i)	neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
122	MPER membrane fusion mutations confer sensitivity	Fu2018	neutralization	17b(CD4i)	neutralization assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
123	Removal of glycosylation sites confers binding to germline-reverted NIH45-46 and VRC01	McGuire2013	binding	VRC01 gHC+gLC(CD4BS)	binding assay	276	gp120, Loop D	N	0.118	0.063	0.169	Elimination of the 276 NLGS from the 426c Env confers binding to germline-reverted NIH45-46 and VRC01. If NLGS at positions 460 and 463 are also eliminated, the binding is improved.
123	Removal of glycosylation sites confers binding to germline-reverted NIH45-46 and VRC01	McGuire2013	binding	VRC01 gHC+gLC(CD4BS)	binding assay	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	In combination with the elimination of the 276 NLGS, elimination of the 460 and 463 (V5) from the 426c Env confers and improves binding to germline-reverted NIH45-46 and VRC01.
123	Removal of glycosylation sites confers binding to germline-reverted NIH45-46 and VRC01	McGuire2013	binding	VRC01 gHC+gLC(CD4BS)	binding assay	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	In combination with the elimination of the 276 NLGS, elimination of the 460 and 463 (V5) from the 426c Env confers and improves binding to germline-reverted NIH45-46 and VRC01.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	85	gp120	V	1.980	1.797	1.418	Amino acids D, Y, H are associated with resistance. Amino acid V is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	155	gp120, V1	K	0.758	0.423	0.831	Amino acid R, T are associated with resistance. Amino acid K is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	165	gp120, V2	I	1.327	1.292	1.011	Amino acid(s) L is associated with resistance. Amino acid(s) I is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	184	gp120, V2	I	1.028	0.599	0.530	Amino acid(s) M is associated with resistance. Amino acid(s) I is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	230	gp120	N	0.931	0.896	0.544	Amino acid(s) N, NxST is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	240	gp120	T	1.813	1.338	1.717	Amino acid(s) K is associated with resistance.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	252	gp120	R	0.725	0.592	0.148	Amino acid(s) K is associated with resistance. Amino acid(s) R is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid(s) D is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	289	gp120	N	0.888	0.835	0.551	Amino acid(s) NxST is associated with resistance. Amino acid(s) K is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	293	gp120	E	2.057	1.967	1.722	Amino acid(s) E is associated with resistance.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	Amino acid(s) V, I, NxST is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	Amino acid(s) T is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	300	gp120, V3 loop	N	1.017	0.738	1.054	Amino acid(s) Y, S is associated with resistance. Amino acid(s) N is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	301	gp120, V3 loop	N	0.172	0.176	0.104	Amino acid(s) N, NxST is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	304	gp120, V3 loop	R	0.304	0.390	0.141	Amino acid(s) R is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	305	gp120, V3 loop	K	0.906	0.713	0.943	Amino acid(s) T is associated with resistance. Amino acid(s) K is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	307	gp120, V3 loop	I	0.802	0.030	0.111	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	311	gp120, V3 loop	R	0.104	1.050	0.114	Amino acid(s) I is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	316	gp120, V3 loop	A	1.056	0.736	0.966	Amino acid(s) V is associated with resistance. Amino acid(s) T is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	323	gp120, V3 loop	I	0.476	0.531	0.263	Amino acid(s) T is associated with resistance. Amino acid(s) I is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	325	gp120, V3 loop	N	0.648	0.622	0.622	Amino acid(s) K is associated with resistance. Amino acid(s) D is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	328	gp120, V3 loop	Q	0.923	0.816	0.882	Amino acid(s) K is associated with resistance. Amino acid(s) Q is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) E, V, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acid(s) D, N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid(s) S, T is associated with resistance. Amino acid(s) A is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	344	gp120	Q	1.787	1.306	1.923	Amino acid(s) N, NxST is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	346	gp120	A	1.859	1.083	1.831	Amino acid(s) A is associated with resistance.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	362	gp120	K	1.815	1.265	1.997	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	413	gp120, V4 loop	T	1.512	1.451	1.561	Amino acid(s) NxST is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	415	gp120, V4 loop	T	0.754	0.760	0.656	Amino acid(s) T is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	440	gp120	S	1.844	1.712	1.017	Amino acid(s) S is associated with resistance. Amino acid(s) A is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	448	gp120	N	0.662	0.448	0.927	Amino acid(s) NxST, N is associated with resistance.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	583	gp41, Leu/Ile zipper-like sequence	V	0.955	0.424	0.701	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	612	gp41	A	1.631	1.525	1.055	Amino acid(s) S, A is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	640	gp41	S	2.033	1.971	1.834	Amino acid(s) D is associated with resistance.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	662	gp41	E	1.043	0.874	0.369	Amino acid(s) E is associated with resistance. Amino acid(s) A is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	674	gp41	N	1.179	1.029	1.344	Amino acid(s) NxST, N is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	688	gp41, gp41 transmembrane	I	0.205	0.201	0.176	Amino acid(s) I is associated with resistance. Amino acid(s) V is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	746	gp41, gp41 cytoplasmic tail	I	1.829	1.911	0.739	Amino acid(s) V is associated with resistance. Amino acid(s) G is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	750	gp41, gp41 cytoplasmic tail	N	1.669	1.692	0.891	Amino acid(s) S is associated with resistance. Amino acid(s) N, D is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	770	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction)	R	0.877	0.667	0.984	Amino acid(s) R is associated with resistance. Amino acid(s) Q is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	774	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.792	0.183	0.621	Amino acid(s) F is associated with resistance.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	801	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.653	0.355	0.328	Amino acid(s) V, L is associated with resistance. Amino acid(s) Q is associated with sensitivity.
124	V3 Signature Summary	Bricault2019	signature	PGT121(V3)	computational prediction	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.518	1.502	1.006	Amino acid(s) A is associated with resistance.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	85	gp120	V	1.980	1.797	1.418	Amino acids D, H are associated with resistance. Amino acid V is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	155	gp120, V1	K	0.758	0.423	0.831	Amino acid(s) R is associated with resistance. Amino acid(s) K is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	165	gp120, V2	I	1.327	1.292	1.011	Amino acid(s) I is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	197	gp120	N	0.133	0.082	0.109	Amino acid(s) NxST, N is associated with resistance.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	252	gp120	R	0.725	0.592	0.148	Amino acid(s) K is associated with resistance. Amino acid(s) R is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid(s) N is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	Amino acid(s) E is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	Amino acid(s) I is associated with resistance.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	300	gp120, V3 loop	N	1.017	0.738	1.054	Amino acid(s) Y is associated with resistance. Amino acid(s) N is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	301	gp120, V3 loop	N	0.172	0.176	0.104	Amino acid(s) N, NxST is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	304	gp120, V3 loop	R	0.304	0.390	0.141	Amino acid(s) R is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	305	gp120, V3 loop	K	0.906	0.713	0.943	Amino acid(s) T is associated with resistance.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	316	gp120, V3 loop	A	1.056	0.736	0.966	Amino acid(s) V is associated with resistance. Amino acid(s) T is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	325	gp120, V3 loop	N	0.648	0.622	0.622	Amino acid(s) N is associated with resistance. Amino acid(s) D is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	328	gp120, V3 loop	Q	0.923	0.816	0.882	Amino acid(s) K is associated with resistance. Amino acid(s) Q is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) E, K, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	333	gp120	I	0.837	0.855	0.293	Amino acid(s) V is associated with resistance.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S, T is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid(s) T is associated with resistance.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	344	gp120	Q	1.787	1.306	1.923	Amino acid(s) N, NxST is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	346	gp120	A	1.859	1.083	1.831	Amino acid(s) A is associated with resistance.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	362	gp120	K	1.815	1.265	1.997	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	Amino acid(s) NxST, N is associated with resistance.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	415	gp120, V4 loop	T	0.754	0.760	0.656	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	440	gp120	S	1.844	1.712	1.017	Amino acid(s) A is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	583	gp41, Leu/Ile zipper-like sequence	V	0.955	0.424	0.701	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	612	gp41	A	1.631	1.525	1.055	Amino acid(s) S is associated with resistance. Amino acid(s) V, A is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	662	gp41	E	1.043	0.874	0.369	Amino acid(s) E is associated with resistance.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	743	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	D	1.003	0.756	1.040	Amino acid(s) G, N, NxST is associated with resistance. Amino acid(s) D is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	746	gp41, gp41 cytoplasmic tail	I	1.829	1.911	0.739	Amino acid(s) V is associated with resistance. Amino acid(s) G is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	750	gp41, gp41 cytoplasmic tail	N	1.669	1.692	0.891	Amino acid(s) S is associated with resistance. Amino acid(s) H is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	801	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.653	0.355	0.328	Amino acid(s) L is associated with resistance. Amino acid(s) Q is associated with sensitivity.
125	V3 Signature Analysis Summary	Bricault2019	signature	DH270.1(V3)	computational prediction	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.518	1.502	1.006	Amino acid(s) A is associated with resistance. Amino acid(s) I is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	85	gp120	V	1.980	1.797	1.418	Amino acids D, H are associated with resistance. Amino acid V is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	155	gp120, V1	K	0.758	0.423	0.831	Amino acid(s) R is associated with resistance. Amino acid(s) K is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	165	gp120, V2	I	1.327	1.292	1.011	Amino acid(s) L is associated with resistance. Amino acid(s) I is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	184	gp120, V2	I	1.028	0.599	0.530	Amino acid(s) M is associated with resistance. Amino acid(s) I is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	230	gp120	N	0.931	0.896	0.544	Amino acid(s) D is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	240	gp120	T	1.813	1.338	1.717	Amino acid(s) K is associated with resistance.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	252	gp120	R	0.725	0.592	0.148	Amino acid(s) K is associated with resistance. Amino acid(s) R is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid(s) NxST, N is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	282	gp120, Loop D	K	0.336	0.337	0.297	Amino acid(s) K is associated with resistance.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	289	gp120	N	0.888	0.835	0.551	Amino acid(s) K is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	Amino acid(s) E is associated with resistance. Amino acid(s) V, I, NxST is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	Amino acid(s) T is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	300	gp120, V3 loop	N	1.017	0.738	1.054	Amino acid(s) D, S is associated with resistance. Amino acid(s) N is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	301	gp120, V3 loop	N	0.172	0.176	0.104	Amino acid(s) NxST is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	304	gp120, V3 loop	R	0.304	0.390	0.141	Amino acid(s) R is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	305	gp120, V3 loop	K	0.906	0.713	0.943	Amino acid(s) T is associated with resistance. Amino acid(s) K is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	307	gp120, V3 loop	I	0.802	0.030	0.111	Amino acid(s) V is associated with resistance.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	316	gp120, V3 loop	A	1.056	0.736	0.966	Amino acid(s) A, V is associated with resistance. Amino acid(s) T is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	323	gp120, V3 loop	I	0.476	0.531	0.263	Amino acid(s) T is associated with resistance. Amino acid(s) I is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	325	gp120, V3 loop	N	0.648	0.622	0.622	Amino acid(s) K is associated with resistance. Amino acid(s) D is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	328	gp120, V3 loop	Q	0.923	0.816	0.882	Amino acid(s) K, N is associated with resistance. Amino acid(s) Q is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) E, D, V, K, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid(s) T is associated with resistance. Amino acid(s) A, E is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	344	gp120	Q	1.787	1.306	1.923	Amino acid(s) K is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	346	gp120	A	1.859	1.083	1.831	Amino acid(s) S is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	362	gp120	K	1.815	1.265	1.997	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	413	gp120, V4 loop	T	1.512	1.451	1.561	Amino acid(s) NxST is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	415	gp120, V4 loop	T	0.754	0.760	0.656	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	440	gp120	S	1.844	1.712	1.017	Amino acid(s) N, S is associated with resistance. Amino acid(s) A is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	442	gp120	Q	2.042	1.699	0.964	Amino acid(s) NxST, Q is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	448	gp120	N	0.662	0.448	0.927	Amino acid(s) NxST, N is associated with resistance.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	583	gp41, Leu/Ile zipper-like sequence	V	0.955	0.424	0.701	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	612	gp41	A	1.631	1.525	1.055	Amino acid(s) S is associated with resistance. Amino acid(s) A is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	662	gp41	E	1.043	0.874	0.369	Amino acid(s) E is associated with resistance.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	674	gp41	N	1.179	1.029	1.344	Amino acid(s) D is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	746	gp41, gp41 cytoplasmic tail	I	1.829	1.911	0.739	Amino acid(s) V, T is associated with resistance.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	750	gp41, gp41 cytoplasmic tail	N	1.669	1.692	0.891	Amino acid(s) S is associated with resistance. Amino acid(s) H, N, D is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	770	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction)	R	0.877	0.667	0.984	Amino acid(s) R is associated with resistance. Amino acid(s) Q is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	774	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.792	0.183	0.621	Amino acid(s) F is associated with resistance. Amino acid(s) L is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	801	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.653	0.355	0.328	Amino acid(s) V, L is associated with resistance. Amino acid(s) Q is associated with sensitivity.
126	V3 Signature Analysis Summary	Bricault2019	signature	10-1074(V3)	computational prediction	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.518	1.502	1.006	Amino acid(s) A is associated with resistance.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	85	gp120	V	1.980	1.797	1.418	Amino acid L is associated with resistance. Amino acid V is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	240	gp120	T	1.813	1.338	1.717	Amino acid(s) R is associated with resistance. Amino acid(s) T is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	252	gp120	R	0.725	0.592	0.148	Amino acid(s) K is associated with resistance. Amino acid(s) R is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid(s) D is associated with resistance. Amino acid(s) N is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	293	gp120	E	2.057	1.967	1.722	Amino acid(s) NxST, N is associated with resistance.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	Amino acid(s) E, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	300	gp120, V3 loop	N	1.017	0.738	1.054	Amino acid(s) G is associated with resistance.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	301	gp120, V3 loop	N	0.172	0.176	0.104	Amino acid(s) N, NxST is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	304	gp120, V3 loop	R	0.304	0.390	0.141	Amino acid(s) R is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	316	gp120, V3 loop	A	1.056	0.736	0.966	Amino acid(s) T is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	323	gp120, V3 loop	I	0.476	0.531	0.263	Amino acid(s) I is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	325	gp120, V3 loop	N	0.648	0.622	0.622	Amino acid(s) D is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	328	gp120, V3 loop	Q	0.923	0.816	0.882	Amino acid(s) Q is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) K, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acid(s) D, N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid(s) T is associated with resistance. Amino acid(s) A is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	344	gp120	Q	1.787	1.306	1.923	Amino acid(s) K is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	362	gp120	K	1.815	1.265	1.997	Amino acid(s) NxST is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	392	gp120, V4 loop	N	0.605	0.454	0.804	Amino acid(s) NxST is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	415	gp120, V4 loop	T	0.754	0.760	0.656	Amino acid(s) T, I is associated with resistance. Amino acid(s) T is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	442	gp120	Q	2.042	1.699	0.964	Amino acid(s) E, K is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	612	gp41	A	1.631	1.525	1.055	Amino acid(s) S is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	688	gp41, gp41 transmembrane	I	0.205	0.201	0.176	Amino acid(s) I is associated with resistance. Amino acid(s) V is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	743	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	D	1.003	0.756	1.040	Amino acid(s) G, N is associated with resistance. Amino acid(s) D is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	746	gp41, gp41 cytoplasmic tail	I	1.829	1.911	0.739	Amino acid(s) V is associated with resistance.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	774	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.792	0.183	0.621	Amino acid(s) F is associated with resistance.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	801	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.653	0.355	0.328	Amino acid(s) L is associated with resistance. Amino acid(s) Q is associated with sensitivity.
127	V3 Signature Analysis Summary	Bricault2019	signature	PGT128(V3)	computational prediction	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.518	1.502	1.006	Amino acid(s) T is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	85	gp120	V	1.980	1.797	1.418	Amino acids Y, H are associated with resistance. Amino acid V is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	155	gp120, V1	K	0.758	0.423	0.831	Amino acid(s) R is associated with resistance. Amino acid(s) K is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	165	gp120, V2	I	1.327	1.292	1.011	Amino acid(s) I is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	184	gp120, V2	I	1.028	0.599	0.530	Amino acid(s) M is associated with resistance. Amino acid(s) I is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	240	gp120	T	1.813	1.338	1.717	Amino acid(s) K is associated with resistance. Amino acid(s) T is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	252	gp120	R	0.725	0.592	0.148	Amino acid(s) K is associated with resistance. Amino acid(s) R is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid(s) NxST, N is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	289	gp120	N	0.888	0.835	0.551	Amino acid(s) K is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	293	gp120	E	2.057	1.967	1.722	Amino acid(s) K is associated with resistance.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	Amino acid(s) E is associated with resistance. Amino acid(s) V, I, NxST is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	300	gp120, V3 loop	N	1.017	0.738	1.054	Amino acid(s) Y, S is associated with resistance. Amino acid(s) N is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	301	gp120, V3 loop	N	0.172	0.176	0.104	Amino acid(s) N, NxST is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	304	gp120, V3 loop	R	0.304	0.390	0.141	Amino acid(s) R is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	305	gp120, V3 loop	K	0.906	0.713	0.943	Amino acid(s) T is associated with resistance. Amino acid(s) K is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	307	gp120, V3 loop	I	0.802	0.030	0.111	Amino acid(s) T is associated with resistance.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	316	gp120, V3 loop	A	1.056	0.736	0.966	Amino acid(s) V is associated with resistance. Amino acid(s) T is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	323	gp120, V3 loop	I	0.476	0.531	0.263	Amino acid(s) T is associated with resistance. Amino acid(s) I is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	325	gp120, V3 loop	N	0.648	0.622	0.622	Amino acid(s) N, K is associated with resistance. Amino acid(s) D is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	328	gp120, V3 loop	Q	0.923	0.816	0.882	Amino acid(s) K is associated with resistance. Amino acid(s) Q is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) E, V, K, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	333	gp120	I	0.837	0.855	0.293	Amino acid(s) V is associated with resistance. Amino acid(s) L is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid(s) T is associated with resistance. Amino acid(s) A is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	344	gp120	Q	1.787	1.306	1.923	Amino acid(s) N, E, NxST is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	346	gp120	A	1.859	1.083	1.831	Amino acid(s) A is associated with resistance.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	362	gp120	K	1.815	1.265	1.997	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	Amino acid(s) NxST is associated with resistance.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	392	gp120, V4 loop	N	0.605	0.454	0.804	Amino acid(s) NxST is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	415	gp120, V4 loop	T	0.754	0.760	0.656	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	440	gp120	S	1.844	1.712	1.017	Amino acid(s) E, S is associated with resistance. Amino acid(s) A is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	448	gp120	N	0.662	0.448	0.927	Amino acid(s) NxST, N is associated with resistance.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	583	gp41, Leu/Ile zipper-like sequence	V	0.955	0.424	0.701	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	612	gp41	A	1.631	1.525	1.055	Amino acid(s) S is associated with resistance. Amino acid(s) D, A is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	662	gp41	E	1.043	0.874	0.369	Amino acid(s) E is associated with resistance. Amino acid(s) A is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	743	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	D	1.003	0.756	1.040	Amino acid(s) G is associated with resistance. Amino acid(s) D is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	746	gp41, gp41 cytoplasmic tail	I	1.829	1.911	0.739	Amino acid(s) V is associated with resistance. Amino acid(s) G is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	750	gp41, gp41 cytoplasmic tail	N	1.669	1.692	0.891	Amino acid(s) S is associated with resistance. Amino acid(s) H is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	770	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction)	R	0.877	0.667	0.984	Amino acid(s) Q is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	801	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.653	0.355	0.328	Amino acid(s) L is associated with resistance. Amino acid(s) Q is associated with sensitivity.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	835	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	G	0.745	0.515	0.917	Amino acid(s) G is associated with resistance.
128	V3 Signature Analysis Summary	Bricault2019	signature	DH270.6(V3)	computational prediction	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.518	1.502	1.006	Amino acid(s) A is associated with resistance. Amino acid(s) T is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	85	gp120	V	1.980	1.797	1.418	Amino acid H is associated with resistance. Amino acid V is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	155	gp120, V1	K	0.758	0.423	0.831	Amino acid(s) R is associated with resistance. Amino acid(s) K is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	165	gp120, V2	I	1.327	1.292	1.011	Amino acid(s) I is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	184	gp120, V2	I	1.028	0.599	0.530	Amino acid(s) M is associated with resistance. Amino acid(s) I is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	230	gp120	N	0.931	0.896	0.544	Amino acid(s) N, NxST is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	240	gp120	T	1.813	1.338	1.717	Amino acid(s) K is associated with resistance.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	252	gp120	R	0.725	0.592	0.148	Amino acid(s) K is associated with resistance. Amino acid(s) R is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	289	gp120	N	0.888	0.835	0.551	Amino acid(s) K is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	Amino acid(s) E is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	300	gp120, V3 loop	N	1.017	0.738	1.054	Amino acid(s) Y, S is associated with resistance. Amino acid(s) N is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	301	gp120, V3 loop	N	0.172	0.176	0.104	Amino acid(s) N, NxST is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	304	gp120, V3 loop	R	0.304	0.390	0.141	Amino acid(s) R is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	305	gp120, V3 loop	K	0.906	0.713	0.943	Amino acid(s) T is associated with resistance. Amino acid(s) K is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	316	gp120, V3 loop	A	1.056	0.736	0.966	Amino acid(s) V is associated with resistance. Amino acid(s) T is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	323	gp120, V3 loop	I	0.476	0.531	0.263	Amino acid(s) T is associated with resistance. Amino acid(s) I is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	325	gp120, V3 loop	N	0.648	0.622	0.622	Amino acid(s) N is associated with resistance. Amino acid(s) D is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	328	gp120, V3 loop	Q	0.923	0.816	0.882	Amino acid(s) K is associated with resistance. Amino acid(s) Q is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) E, K, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	333	gp120	I	0.837	0.855	0.293	Amino acid(s) V is associated with resistance.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid(s) T is associated with resistance.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	344	gp120	Q	1.787	1.306	1.923	Amino acid(s) N is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	346	gp120	A	1.859	1.083	1.831	Amino acid(s) A is associated with resistance.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	362	gp120	K	1.815	1.265	1.997	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	Amino acid(s) NxST is associated with resistance.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	392	gp120, V4 loop	N	0.605	0.454	0.804	Amino acid(s) NxST is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	415	gp120, V4 loop	T	0.754	0.760	0.656	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	440	gp120	S	1.844	1.712	1.017	Amino acid(s) S is associated with resistance. Amino acid(s) A is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	448	gp120	N	0.662	0.448	0.927	Amino acid(s) NxST is associated with resistance.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	583	gp41, Leu/Ile zipper-like sequence	V	0.955	0.424	0.701	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	612	gp41	A	1.631	1.525	1.055	Amino acid(s) S is associated with resistance. Amino acid(s) D, A is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	662	gp41	E	1.043	0.874	0.369	Amino acid(s) E is associated with resistance. Amino acid(s) A is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	743	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	D	1.003	0.756	1.040	Amino acid(s) G, N, NxST is associated with resistance. Amino acid(s) D is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	746	gp41, gp41 cytoplasmic tail	I	1.829	1.911	0.739	Amino acid(s) V is associated with resistance. Amino acid(s) G is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	750	gp41, gp41 cytoplasmic tail	N	1.669	1.692	0.891	Amino acid(s) S is associated with resistance.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	770	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction)	R	0.877	0.667	0.984	Amino acid(s) R is associated with resistance. Amino acid(s) Q is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	801	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.653	0.355	0.328	Amino acid(s) L is associated with resistance. Amino acid(s) Q is associated with sensitivity.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	835	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	G	0.745	0.515	0.917	Amino acid(s) G is associated with resistance.
129	V3 Signature Analysis Summary	Bricault2019	signature	DH270.5(V3)	computational prediction	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.518	1.502	1.006	Amino acid(s) A is associated with resistance.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	85	gp120	V	1.980	1.797	1.418	Amino acid V is associated with sensitivity.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	155	gp120, V1	K	0.758	0.423	0.831	Amino acid(s) R is associated with resistance. Amino acid(s) K is associated with sensitivity.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	Amino acid(s) NxST is associated with resistance.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	184	gp120, V2	I	1.028	0.599	0.530	Amino acid(s) M is associated with resistance. Amino acid(s) I is associated with sensitivity.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid(s) NxST is associated with sensitivity.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	289	gp120	N	0.888	0.835	0.551	Amino acid(s) K is associated with sensitivity.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	307	gp120, V3 loop	I	0.802	0.030	0.111	Amino acid(s) I is associated with sensitivity.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	316	gp120, V3 loop	A	1.056	0.736	0.966	Amino acid(s) V is associated with resistance.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	328	gp120, V3 loop	Q	0.923	0.816	0.882	Amino acid(s) K is associated with resistance.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) N, NxST is associated with sensitivity.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid(s) T is associated with resistance. Amino acid(s) A is associated with sensitivity.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	346	gp120	A	1.859	1.083	1.831	Amino acid(s) S is associated with sensitivity.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	362	gp120	K	1.815	1.265	1.997	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	612	gp41	A	1.631	1.525	1.055	Amino acid(s) S is associated with resistance. Amino acid(s) A is associated with sensitivity.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	662	gp41	E	1.043	0.874	0.369	Amino acid(s) E is associated with resistance.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	746	gp41, gp41 cytoplasmic tail	I	1.829	1.911	0.739	Amino acid(s) V is associated with resistance.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	770	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction)	R	0.877	0.667	0.984	Amino acid(s) R is associated with resistance.
130	V3 Signature Analysis Summary	Bricault2019	signature	PGT123(V3)	computational prediction	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.518	1.502	1.006	Amino acid(s) I is associated with resistance.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	85	gp120	V	1.980	1.797	1.418	Amino acid V is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	184	gp120, V2	I	1.028	0.599	0.530	Amino acid(s) M is associated with resistance.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	230	gp120	N	0.931	0.896	0.544	Amino acid(s) NxST is associated with resistance.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid(s) NxST is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	Amino acid(s) E is associated with resistance.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	307	gp120, V3 loop	I	0.802	0.030	0.111	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	316	gp120, V3 loop	A	1.056	0.736	0.966	Amino acid(s) V is associated with resistance.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	323	gp120, V3 loop	I	0.476	0.531	0.263	Amino acid I is associated withs sensitivity
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	328	gp120, V3 loop	Q	0.923	0.816	0.882	Amino acid(s) K is associated with resistance. Amino acid(s) Q is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) N, NxST is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid(s) T is associated with resistance. Amino acid(s) A is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	344	gp120	Q	1.787	1.306	1.923	Amino acid(s) K is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	346	gp120	A	1.859	1.083	1.831	Amino acid(s) S is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	362	gp120	K	1.815	1.265	1.997	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	415	gp120, V4 loop	T	0.754	0.760	0.656	Amino acid(s) T is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	440	gp120	S	1.844	1.712	1.017	Amino acid(s) A is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	612	gp41	A	1.631	1.525	1.055	Amino acid(s) S is associated with resistance. Amino acid(s) A is associated with sensitivity.
131	V3 Signature Analysis Summary	Bricault2019	signature	10-996(V3)	computational prediction	662	gp41	E	1.043	0.874	0.369	Amino acid(s) E is associated with resistance.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	85	gp120	V	1.980	1.797	1.418	Amino acid V is associated with sensitivity.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	165	gp120, V2	I	1.327	1.292	1.011	Amino acid(s) I is associated with sensitivity.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	184	gp120, V2	I	1.028	0.599	0.530	Amino acid(s) I is associated with sensitivity.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	230	gp120	N	0.931	0.896	0.544	Amino acid(s) NxST is associated with resistance.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	289	gp120	N	0.888	0.835	0.551	Amino acid(s) K is associated with sensitivity.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	Amino acid(s) E is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	Amino acid(s) T is associated with sensitivity.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	307	gp120, V3 loop	I	0.802	0.030	0.111	Amino acid(s) I is associated with sensitivity.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) N, NxST is associated with sensitivity.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid(s) A is associated with sensitivity.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	442	gp120	Q	2.042	1.699	0.964	Amino acid(s) E is associated with resistance.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	612	gp41	A	1.631	1.525	1.055	Amino acid(s) S is associated with resistance. Amino acid(s) A is associated with sensitivity.
132	V3 Signature Analysis Summary	Bricault2019	signature	PGT126(V3)	computational prediction	774	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.792	0.183	0.621	Amino acid(s) F is associated with resistance. Amino acid(s) L is associated with sensitivity.
133	V3 Signature Analysis Summary	Bricault2019	signature	PGT127(V3)	computational prediction	85	gp120	V	1.980	1.797	1.418	Amino acid V is associated with sensitivity.
133	V3 Signature Analysis Summary	Bricault2019	signature	PGT127(V3)	computational prediction	165	gp120, V2	I	1.327	1.292	1.011	Amino acid(s) I is associated with sensitivity.
133	V3 Signature Analysis Summary	Bricault2019	signature	PGT127(V3)	computational prediction	230	gp120	N	0.931	0.896	0.544	Amino acid(s) NxST is associated with resistance.
133	V3 Signature Analysis Summary	Bricault2019	signature	PGT127(V3)	computational prediction	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	Amino acid(s) T is associated with sensitivity.
133	V3 Signature Analysis Summary	Bricault2019	signature	PGT127(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
133	V3 Signature Analysis Summary	Bricault2019	signature	PGT127(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) N, NxST is associated with sensitivity.
133	V3 Signature Analysis Summary	Bricault2019	signature	PGT127(V3)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
133	V3 Signature Analysis Summary	Bricault2019	signature	PGT127(V3)	computational prediction	442	gp120	Q	2.042	1.699	0.964	Amino acid(s) E is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
133	V3 Signature Analysis Summary	Bricault2019	signature	PGT127(V3)	computational prediction	750	gp41, gp41 cytoplasmic tail	N	1.669	1.692	0.891	Amino acid(s) D is associated with sensitivity.
134	V3 Signature Analysis Summary	Bricault2019	signature	PGT125(V3)	computational prediction	165	gp120, V2	I	1.327	1.292	1.011	Amino acid I is associated with sensitivity.
134	V3 Signature Analysis Summary	Bricault2019	signature	PGT125(V3)	computational prediction	230	gp120	N	0.931	0.896	0.544	Amino acid(s) NxST is associated with resistance.
134	V3 Signature Analysis Summary	Bricault2019	signature	PGT125(V3)	computational prediction	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	Amino acid(s) NxST is associated with sensitivity.
134	V3 Signature Analysis Summary	Bricault2019	signature	PGT125(V3)	computational prediction	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	Amino acid T is associated with sensitivity.
134	V3 Signature Analysis Summary	Bricault2019	signature	PGT125(V3)	computational prediction	300	gp120, V3 loop	N	1.017	0.738	1.054	Amino acid S is associated with sensitivity.
134	V3 Signature Analysis Summary	Bricault2019	signature	PGT125(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	Amino acid H is associated with sensitivity.
134	V3 Signature Analysis Summary	Bricault2019	signature	PGT125(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) N, NxST is associated with sensitivity.
134	V3 Signature Analysis Summary	Bricault2019	signature	PGT125(V3)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acid(s) N, NxST is associated with resistance. Amino acid S is associated with sensitivity.
134	V3 Signature Analysis Summary	Bricault2019	signature	PGT125(V3)	computational prediction	442	gp120	Q	2.042	1.699	0.964	Amino acid E is associated with resistance. Amino acid NxST is associated with sensitivity.
134	V3 Signature Analysis Summary	Bricault2019	signature	PGT125(V3)	computational prediction	750	gp41, gp41 cytoplasmic tail	N	1.669	1.692	0.891	Amino acid D is associated with sensitivity.
135	V3 Signature Analysis Summary	Bricault2019	signature	PGT130(V3)	computational prediction	165	gp120, V2	I	1.327	1.292	1.011	Amino acid I is associated with sensitivity.
135	V3 Signature Analysis Summary	Bricault2019	signature	PGT130(V3)	computational prediction	184	gp120, V2	I	1.028	0.599	0.530	Amino acid L is associated with resistance.
135	V3 Signature Analysis Summary	Bricault2019	signature	PGT130(V3)	computational prediction	230	gp120	N	0.931	0.896	0.544	Amino acid N is associated with resistance.
135	V3 Signature Analysis Summary	Bricault2019	signature	PGT130(V3)	computational prediction	300	gp120, V3 loop	N	1.017	0.738	1.054	Amino acid N is associated with resistance. Amino acid S is associated with sensitivity.
135	V3 Signature Analysis Summary	Bricault2019	signature	PGT130(V3)	computational prediction	346	gp120	A	1.859	1.083	1.831	Amino acid G is associated with resistance.
135	V3 Signature Analysis Summary	Bricault2019	signature	PGT130(V3)	computational prediction	583	gp41, Leu/Ile zipper-like sequence	V	0.955	0.424	0.701	Amino acid V is associated with sensitivity.
136	V3 Signature Analysis Summary	Bricault2019	signature	10-1074V(V3)	computational prediction	305	gp120, V3 loop	K	0.906	0.713	0.943	Amino acid K is associated with sensitivity.
136	V3 Signature Analysis Summary	Bricault2019	signature	10-1074V(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	Amino acid Y is associated with resistance. Amino acid H is associated with sensitivity.
136	V3 Signature Analysis Summary	Bricault2019	signature	10-1074V(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acids D, K, T are associated with resistance. Amino acids N, NxST are associated with sensitivity.
136	V3 Signature Analysis Summary	Bricault2019	signature	10-1074V(V3)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acids N, NxST are associated with resistance. Amino acid S  is associated with sensitivity.
136	V3 Signature Analysis Summary	Bricault2019	signature	10-1074V(V3)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid T is associated with resistance.
136	V3 Signature Analysis Summary	Bricault2019	signature	10-1074V(V3)	computational prediction	413	gp120, V4 loop	T	1.512	1.451	1.561	Amino acids NxST are associated with sensitivity.
136	V3 Signature Analysis Summary	Bricault2019	signature	10-1074V(V3)	computational prediction	774	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.792	0.183	0.621	Amino acid F is associated with resistance. Amino acid L is associated with sensitivity.
137	V3 Signature Analysis Summary	Bricault2019	signature	PGT135(V3)	computational prediction	330	gp120, V3 loop	H	0.634	0.559	0.655	Amino acid Y is associated with resistance. Amino acid H is associated with sensitivity.
137	V3 Signature Analysis Summary	Bricault2019	signature	PGT135(V3)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) N, NxST is associated with sensitivity.
137	V3 Signature Analysis Summary	Bricault2019	signature	PGT135(V3)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acids N, NxST are associated with resistance. Amino acid S is associated with sensitivity.
137	V3 Signature Analysis Summary	Bricault2019	signature	PGT135(V3)	computational prediction	346	gp120	A	1.859	1.083	1.831	Amino acid S is associated with sensitivity.
137	V3 Signature Analysis Summary	Bricault2019	signature	PGT135(V3)	computational prediction	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	Amino acid(s) NxST is associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	31	gp120	T	2.159	1.529	2.035	Amino acid T is associated with resistance. Amino acids A, L are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	33	gp120	K	1.551	1.559	0.973	Amino acid(s) K are associated with resistance.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	49	gp120	T	1.482	0.958	0.335	Amino acid(s) T are associated with resistance.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	130	gp120	K	1.201	0.883	1.495	Amino acid(s) N are associated with resistance.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	Amino acid(s) K, D are associated with resistance. Amino acid(s) NxST , N  are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	161	gp120, V2	I	1.493	0.964	1.568	Amino acid(s) V are associated with resistance. Amino acid(s) M are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	162	gp120, V2	S	0.353	0.445	0.179	Amino acid(s) T are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	164	gp120, V2	S	1.840	1.925	0.453	Amino acid(s) G, S are associated with resistance. Amino acid(s) E are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	166	gp120, V2	R	1.237	1.398	0.772	Amino acid(s) G are associated with resistance. Amino acid(s) R are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	167	gp120, V2	G	0.779	1.122	0.185	Amino acid(s) G, T are associated with resistance. Amino acid(s) D are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	169	gp120, V2	V	2.042	1.770	1.344	Amino acid(s) E, V are associated with resistance. Amino acid(s) K are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	173	gp120, V2	Y	1.059	0.808	1.158	Amino acid(s) H, Y are associated with resistance. Amino acid(s) S, Y are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	177	gp120, V2	Y	0.454	0.638	0.144	Amino acid(s) N are associated with resistance. Amino acid(s) Y are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	Amino acid(s) T are associated with resistance.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	306	gp120, V3 loop	R	0.714	0.860	0.338	Amino acid(s) R are associated with resistance.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) NxST, N are associated with resistance.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	340	gp120	N	1.893	1.537	1.869	Amino acid(s) D, N are associated with resistance. Amino acid(s) E, K are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	426	gp120, beta20/beta21	M	0.724	0.866	0.274	Amino acid(s) R are associated with resistance. Amino acid(s) M are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	636	gp41	N	1.413	1.127	1.081	Amino acid(s) D are associated with resistance. Amino acid(s) S are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	644	gp41	S	2.005	1.538	1.732	Amino acid(s) T are associated with resistance. Amino acid(s) R are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	677	gp41	N	1.203	1.199	1.100	Amino acid(s) Q are associated with resistance. Amino acid(s) N are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	Amino acid(s) R are associated with resistance. Amino acid(s) K are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	717	gp41, gp41 cytoplasmic tail	F	0.493	0.533	0.386	Amino acid(s) L are associated with resistance. Amino acid(s) F are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	743	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	D	1.003	0.756	1.040	Amino acid(s) D are associated with resistance.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.919	0.166	0.579	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
138	V2 Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	805	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.962	0.214	0.405	Amino acid(s) Q are associated with resistance.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	33	gp120	K	1.551	1.559	0.973	Amino acid K is associated with resistance. Amino acid N  is associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	49	gp120	T	1.482	0.958	0.335	Amino acid(s) T are associated with resistance. Amino acid(s) E are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	130	gp120	K	1.201	0.883	1.495	Amino acid(s) NxST are associated with resistance.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	Amino acid(s) K, D, S are associated with resistance. Amino acid(s) NxST , N  are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	161	gp120, V2	I	1.493	0.964	1.568	Amino acid(s) V are associated with resistance.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	162	gp120, V2	S	0.353	0.445	0.179	Amino acid(s) T are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	164	gp120, V2	S	1.840	1.925	0.453	Amino acid(s) S are associated with resistance. Amino acid(s) E are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	166	gp120, V2	R	1.237	1.398	0.772	Amino acid(s) R are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	167	gp120, V2	G	0.779	1.122	0.185	Amino acid(s) G, T are associated with resistance. Amino acid(s) D are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	169	gp120, V2	V	2.042	1.770	1.344	Amino acid(s) V are associated with resistance. Amino acid(s) K are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	171	gp120, V2	K	1.247	0.957	1.413	Amino acid(s) E, Q are associated with resistance. Amino acid(s) K are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	172	gp120, V2	E	1.527	1.172	1.484	Amino acid(s) V are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	173	gp120, V2	Y	1.059	0.808	1.158	Amino acid(s) Y are associated with resistance.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	177	gp120, V2	Y	0.454	0.638	0.144	Amino acid(s) N are associated with resistance. Amino acid(s) Y are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	306	gp120, V3 loop	R	0.714	0.860	0.338	Amino acid(s) R are associated with resistance.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	426	gp120, beta20/beta21	M	0.724	0.866	0.274	Amino acid(s) M are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	636	gp41	N	1.413	1.127	1.081	Amino acid(s) D are associated with resistance. Amino acid(s) S, N are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	644	gp41	S	2.005	1.538	1.732	Amino acid(s) S, T are associated with resistance. Amino acid(s) T, R are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	677	gp41	N	1.203	1.199	1.100	Amino acid(s) Q are associated with resistance. Amino acid(s) N are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.919	0.166	0.579	Amino acid(s) I are associated with sensitivity.
139	V2 Signature Analysis Summary	Bricault2019	signature	PG16(V2)	computational prediction	805	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.962	0.214	0.405	Amino acid(s) Q are associated with resistance. Amino acid(s) R are associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	33	gp120	K	1.551	1.559	0.973	Amino acid K is associated with resistance. Amino acid N  is associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	130	gp120	K	1.201	0.883	1.495	Amino acid(s) NxST, N are associated with resistance. Amino acid(s) D are associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	Amino acid(s) K, D, S are associated with resistance. Amino acid(s) NxST , N  are associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	161	gp120, V2	I	1.493	0.964	1.568	Amino acid(s) V are associated with resistance.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	162	gp120, V2	S	0.353	0.445	0.179	Amino acid(s) T are associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	164	gp120, V2	S	1.840	1.925	0.453	Amino acid(s) G are associated with resistance. Amino acid(s) E are associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	166	gp120, V2	R	1.237	1.398	0.772	Amino acid(s) K are associated with resistance.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	167	gp120, V2	G	0.779	1.122	0.185	Amino acid(s) T are associated with resistance.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	169	gp120, V2	V	2.042	1.770	1.344	Amino acid(s) E, Q, V are associated with resistance. Amino acid(s) K are associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	170	gp120, V2	Q	1.493	1.423	1.428	Amino acid(s) K are associated with resistance.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	171	gp120, V2	K	1.247	0.957	1.413	Amino acid(s) K are associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	223	gp120	F	0.673	0.166	0.328	Amino acid(s) F are associated with resistance. Amino acid(s) Y are associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	306	gp120, V3 loop	R	0.714	0.860	0.338	Amino acid(s) R are associated with resistance.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	309	gp120, V3 loop	I	0.863	0.359	0.965	Amino acid(s) I are associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) NxST, N are associated with resistance.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	636	gp41	N	1.413	1.127	1.081	Amino acid(s) D are associated with resistance. Amino acid(s) S are associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	644	gp41	S	2.005	1.538	1.732	Amino acid(s) S, T are associated with resistance. Amino acid(s) T are associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	677	gp41	N	1.203	1.199	1.100	Amino acid(s) Q are associated with resistance. Amino acid(s) N are associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.919	0.166	0.579	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
140	V2 Signature Analysis Summary	Bricault2019	signature	PG9(V2)	computational prediction	805	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.962	0.214	0.405	Amino acid(s) R are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	33	gp120	K	1.551	1.559	0.973	Amino acid K is associated with resistance. Amino acid N  is associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	49	gp120	T	1.482	0.958	0.335	Amino acid(s) T are associated with resistance. Amino acid(s) D are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	130	gp120	K	1.201	0.883	1.495	Amino acid(s) D are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	Amino acid(s) NxST , N  are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	161	gp120, V2	I	1.493	0.964	1.568	Amino acid(s) V are associated with resistance. Amino acid(s) M are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	166	gp120, V2	R	1.237	1.398	0.772	Amino acid(s) S, K are associated with resistance. Amino acid(s) R are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	167	gp120, V2	G	0.779	1.122	0.185	Amino acid(s) G, N, T are associated with resistance. Amino acid(s) D are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	169	gp120, V2	V	2.042	1.770	1.344	Amino acid(s) V are associated with resistance. Amino acid(s) K are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	172	gp120, V2	E	1.527	1.172	1.484	Amino acid(s) V are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	173	gp120, V2	Y	1.059	0.808	1.158	Amino acid(s) Y are associated with resistance. Amino acid(s) S are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	Amino acid(s) T are associated with resistance.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	306	gp120, V3 loop	R	0.714	0.860	0.338	Amino acid(s) R are associated with resistance. Amino acid(s) S are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	309	gp120, V3 loop	I	0.863	0.359	0.965	Amino acid(s) L are associated with resistance.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	340	gp120	N	1.893	1.537	1.869	Amino acid(s) D are associated with resistance.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	636	gp41	N	1.413	1.127	1.081	Amino acid(s) D are associated with resistance. Amino acid(s) S are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	644	gp41	S	2.005	1.538	1.732	Amino acid(s) T are associated with resistance.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	Amino acid(s) R are associated with resistance. Amino acid(s) K are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	717	gp41, gp41 cytoplasmic tail	F	0.493	0.533	0.386	Amino acid(s) L are associated with resistance. Amino acid(s) F are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.919	0.166	0.579	Amino acid(s) I are associated with sensitivity.
141	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	805	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.962	0.214	0.405	Amino acid(s) Q are associated with resistance. Amino acid(s) R are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	49	gp120	T	1.482	0.958	0.335	Amino acid(s) NxST, N, T are associated with resistance. Amino acid K is associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	Amino acid(s) NxST , N  are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	161	gp120, V2	I	1.493	0.964	1.568	Amino acid(s) A are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	164	gp120, V2	S	1.840	1.925	0.453	Amino acid(s) S are associated with resistance. Amino acid(s) E are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	166	gp120, V2	R	1.237	1.398	0.772	Amino acid(s) S are associated with resistance. Amino acid(s) R are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	167	gp120, V2	G	0.779	1.122	0.185	Amino acid(s) G, N, T are associated with resistance. Amino acid(s) D are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	169	gp120, V2	V	2.042	1.770	1.344	Amino acid(s) E, V, T are associated with resistance. Amino acid(s) K are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	172	gp120, V2	E	1.527	1.172	1.484	Amino acid(s) V are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	173	gp120, V2	Y	1.059	0.808	1.158	Amino acid(s) Y are associated with resistance. Amino acid(s) S are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	211	gp120	E	0.829	0.366	0.364	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	223	gp120	F	0.673	0.166	0.328	Amino acid(s) F are associated with resistance. Amino acid(s) Y are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	306	gp120, V3 loop	R	0.714	0.860	0.338	Amino acid(s) R, G are associated with resistance. Amino acid(s) S are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	309	gp120, V3 loop	I	0.863	0.359	0.965	Amino acid(s) L are associated with resistance.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	316	gp120, V3 loop	A	1.056	0.736	0.966	Amino acid(s) T are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) NxST are associated with resistance.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	335	gp120	R	1.898	1.758	1.937	Amino acid(s) R are associated with resistance. Amino acid(s) K are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	426	gp120, beta20/beta21	M	0.724	0.866	0.274	Amino acid(s) M are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	588	gp41, Leu/Ile zipper-like sequence	K	1.146	1.197	0.871	Amino acid(s) K are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	632	gp41	D	0.703	0.402	0.373	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	636	gp41	N	1.413	1.127	1.081	Amino acid(s) D are associated with resistance. Amino acid(s) S are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	644	gp41	S	2.005	1.538	1.732	Amino acid(s) R are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.919	0.166	0.579	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
142	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.26(V2)	computational prediction	805	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.962	0.214	0.405	Amino acid(s) Q are associated with resistance.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	49	gp120	T	1.482	0.958	0.335	Amino acid T is associated with resistance. Amino acid K is associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	Amino acid(s) NxST , N  are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	162	gp120, V2	S	0.353	0.445	0.179	Amino acid(s) T are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	164	gp120, V2	S	1.840	1.925	0.453	Amino acid(s) N, S are associated with resistance. Amino acid(s) E are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	165	gp120, V2	I	1.327	1.292	1.011	Amino acid(s) L are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	166	gp120, V2	R	1.237	1.398	0.772	Amino acid(s) R are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	167	gp120, V2	G	0.779	1.122	0.185	Amino acid(s) G, N are associated with resistance. Amino acid(s) D are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	169	gp120, V2	V	2.042	1.770	1.344	Amino acid(s) E, M, Q, V, T are associated with resistance. Amino acid(s) K are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	172	gp120, V2	E	1.527	1.172	1.484	Amino acid(s) V are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	173	gp120, V2	Y	1.059	0.808	1.158	Amino acid(s) S are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	211	gp120	E	0.829	0.366	0.364	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	306	gp120, V3 loop	R	0.714	0.860	0.338	Amino acid(s) S are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	309	gp120, V3 loop	I	0.863	0.359	0.965	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	316	gp120, V3 loop	A	1.056	0.736	0.966	Amino acid(s) V are associated with resistance. Amino acid(s) T are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	426	gp120, beta20/beta21	M	0.724	0.866	0.274	Amino acid(s) M are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	632	gp41	D	0.703	0.402	0.373	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	636	gp41	N	1.413	1.127	1.081	Amino acid(s) D are associated with resistance.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	644	gp41	S	2.005	1.538	1.732	Amino acid(s) R are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.919	0.166	0.579	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
143	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.08(V2)	computational prediction	805	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.962	0.214	0.405	Amino acid(s) Q are associated with resistance.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	49	gp120	T	1.482	0.958	0.335	Amino acid T is associated with resistance.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	130	gp120	K	1.201	0.883	1.495	Amino acid(s) N are associated with resistance. Amino acid(s) H are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	Amino acid(s) K, D are associated with resistance. Amino acid(s) NxST , N  are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	161	gp120, V2	I	1.493	0.964	1.568	Amino acid(s) I, V are associated with resistance. Amino acid(s) A, M are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	162	gp120, V2	S	0.353	0.445	0.179	Amino acid(s) T are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	164	gp120, V2	S	1.840	1.925	0.453	Amino acid(s) S are associated with resistance. Amino acid(s) E are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	165	gp120, V2	I	1.327	1.292	1.011	Amino acid(s) I are associated with resistance. Amino acid(s) L are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	166	gp120, V2	R	1.237	1.398	0.772	Amino acid(s) S, G are associated with resistance. Amino acid(s) R are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	167	gp120, V2	G	0.779	1.122	0.185	Amino acid(s) G, T are associated with resistance. Amino acid(s) D are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	169	gp120, V2	V	2.042	1.770	1.344	Amino acid(s) E, Q, V are associated with resistance. Amino acid(s) K, R are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	172	gp120, V2	E	1.527	1.172	1.484	Amino acid(s) V are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	173	gp120, V2	Y	1.059	0.808	1.158	Amino acid(s) S are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	211	gp120	E	0.829	0.366	0.364	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	306	gp120, V3 loop	R	0.714	0.860	0.338	Amino acid(s) R are associated with resistance. Amino acid(s) S are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	318	gp120, V3 loop	V	0.588	0.691	0.507	Amino acid(s) Y are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) NxST are associated with resistance.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	426	gp120, beta20/beta21	M	0.724	0.866	0.274	Amino acid(s) R are associated with resistance. Amino acid(s) M are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	588	gp41, Leu/Ile zipper-like sequence	K	1.146	1.197	0.871	Amino acid(s) K are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	636	gp41	N	1.413	1.127	1.081	Amino acid(s) D are associated with resistance. Amino acid(s) S are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	644	gp41	S	2.005	1.538	1.732	Amino acid(s) R are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	677	gp41	N	1.203	1.199	1.100	Amino acid(s) N are associated with sensitivity.
144	V2 Signature Analysis Summary	Bricault2019	signature	PGDM1400(V2)	computational prediction	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.919	0.166	0.579	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	Amino acid(s) NxST  are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	164	gp120, V2	S	1.840	1.925	0.453	Amino acid(s) S are associated with resistance. Amino acid(s) E are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	165	gp120, V2	I	1.327	1.292	1.011	Amino acid(s) I are associated with resistance.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	166	gp120, V2	R	1.237	1.398	0.772	Amino acid(s) S, T, K are associated with resistance. Amino acid(s) R are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	167	gp120, V2	G	0.779	1.122	0.185	Amino acid(s) G, T are associated with resistance. Amino acid(s) D are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	169	gp120, V2	V	2.042	1.770	1.344	Amino acid(s) E, V, T are associated with resistance. Amino acid(s) K are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	172	gp120, V2	E	1.527	1.172	1.484	Amino acid(s) V are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	173	gp120, V2	Y	1.059	0.808	1.158	Amino acid(s) S are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	211	gp120	E	0.829	0.366	0.364	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	306	gp120, V3 loop	R	0.714	0.860	0.338	Amino acid(s) R are associated with resistance. Amino acid(s) S are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	309	gp120, V3 loop	I	0.863	0.359	0.965	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	316	gp120, V3 loop	A	1.056	0.736	0.966	Amino acid(s) T are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	332	gp120	N	0.663	0.491	0.693	Amino acid(s) NxST are associated with resistance.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	426	gp120, beta20/beta21	M	0.724	0.866	0.274	Amino acid(s) M are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	632	gp41	D	0.703	0.402	0.373	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	636	gp41	N	1.413	1.127	1.081	Amino acid(s) D are associated with resistance. Amino acid(s) S are associated with sensitivity.
145	V2 Signature Analysis Summary	Bricault2019	signature	VRC26.25(V2)	computational prediction	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.919	0.166	0.579	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
146	V2 Signature Analysis Summary	Bricault2019	signature	CH01(V2)	computational prediction	130	gp120	K	1.201	0.883	1.495	Amino acid(s) NxST, N are associated with resistance. Amino acid H is associated with sensitivity.
146	V2 Signature Analysis Summary	Bricault2019	signature	CH01(V2)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	Amino acid(s) NxST  are associated with sensitivity.
146	V2 Signature Analysis Summary	Bricault2019	signature	CH01(V2)	computational prediction	161	gp120, V2	I	1.493	0.964	1.568	Amino acid I is associated with resistance.
146	V2 Signature Analysis Summary	Bricault2019	signature	CH01(V2)	computational prediction	171	gp120, V2	K	1.247	0.957	1.413	Amino acid K is associated with sensitivity.
146	V2 Signature Analysis Summary	Bricault2019	signature	CH01(V2)	computational prediction	223	gp120	F	0.673	0.166	0.328	Amino acid F is associated with resistance. Amino acid Y is associated with sensitivity.
147	V2 Signature Analysis Summary	Bricault2019	signature	PGT142(V2)	computational prediction	130	gp120	K	1.201	0.883	1.495	Amino acid(s) NxST , N  are associated with sensitivity.
148	V2 Signature Analysis Summary	Bricault2019	signature	PGT143(V2)	computational prediction	160	gp120, V2	N	0.416	0.452	0.358	Amino acid(s) NxST , N  are associated with sensitivity.
148	V2 Signature Analysis Summary	Bricault2019	signature	PGT143(V2)	computational prediction	162	gp120, V2	S	0.353	0.445	0.179	Amino acid T is associated with sensitivity.
148	V2 Signature Analysis Summary	Bricault2019	signature	PGT143(V2)	computational prediction	166	gp120, V2	R	1.237	1.398	0.772	Amino acid K is associated with resistance. Amino acid R is associated with sensitivity.
148	V2 Signature Analysis Summary	Bricault2019	signature	PGT143(V2)	computational prediction	167	gp120, V2	G	0.779	1.122	0.185	Amino acid D is associated with sensitivity.
148	V2 Signature Analysis Summary	Bricault2019	signature	PGT143(V2)	computational prediction	173	gp120, V2	Y	1.059	0.808	1.158	Amino acid H is associated with resistance.
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	132	gp120, V1-hypervariable, V1	T	1.312	0.849	1.573	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	133	gp120, V1-hypervariable, V1	D	1.376	1.052	1.360	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	134	gp120, V1-hypervariable, V1	L	2.224	2.322	1.627	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	135	gp120, V1-hypervariable, V1	K	2.230	2.373	1.848	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	136	gp120, V1-hypervariable, V1	N	2.514	2.300	2.581	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	138	gp120, V1-hypervariable, V1	T	2.312	2.112	2.504	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	139	gp120, V1-hypervariable, V1	N	2.097	1.946	2.163	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	140	gp120, V1-hypervariable, V1	T	2.235	2.104	2.340	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	141	gp120, V1-hypervariable, V1	N	2.227	2.077	2.148	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	142	gp120, V1-hypervariable, V1	S	2.145	1.992	1.972	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	143	gp120, V1-hypervariable, V1	S	1.925	1.990	1.810	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	144	gp120, V1-hypervariable, V1	S	2.222	2.072	2.207	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	145	gp120, V1-hypervariable, V1	G	2.282	2.228	2.255	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	146	gp120, V1-hypervariable, V1	R	2.649	2.583	2.629	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	147	gp120, V1-hypervariable, V1	M	2.615	2.513	2.375	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	148	gp120, V1-hypervariable, V1	I	2.742	2.671	2.548	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	149	gp120, V1-hypervariable, V1	M	2.563	2.375	2.256	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	150	gp120, V1-hypervariable, V1	E	2.403	2.019	2.328	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	151	gp120, V1-hypervariable, V1	K	2.575	2.285	2.605	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	152	gp120, V1-hypervariable, V1	G	1.800	1.271	1.966	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	185	gp120, V2-hypervariable, V2	D	1.697	1.370	1.762	V2 hypervariable loop: length (both V2 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	186	gp120, V2-hypervariable, V2	N	1.854	1.592	1.819	V2 hypervariable loop: length (both V2 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	187	gp120, V2-hypervariable, V2	D	1.785	1.813	1.638	V2 hypervariable loop: length (both V2 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	188	gp120, V2-hypervariable, V2	T	1.866	1.618	1.850	V2 hypervariable loop: length (both V2 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	189	gp120, V2-hypervariable, V2	T	1.760	1.348	1.638	V2 hypervariable loop: length (both V2 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
149	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10-1074(V3), 10-1074V(V3), DH270.6(V3), PGT121(V3), PGT128(V3)	computational prediction	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	V2 hypervariable loop: length (both V2 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	132	gp120, V1-hypervariable, V1	T	1.312	0.849	1.573	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	133	gp120, V1-hypervariable, V1	D	1.376	1.052	1.360	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	134	gp120, V1-hypervariable, V1	L	2.224	2.322	1.627	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	135	gp120, V1-hypervariable, V1	K	2.230	2.373	1.848	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	136	gp120, V1-hypervariable, V1	N	2.514	2.300	2.581	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	138	gp120, V1-hypervariable, V1	T	2.312	2.112	2.504	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	139	gp120, V1-hypervariable, V1	N	2.097	1.946	2.163	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	140	gp120, V1-hypervariable, V1	T	2.235	2.104	2.340	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	141	gp120, V1-hypervariable, V1	N	2.227	2.077	2.148	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	142	gp120, V1-hypervariable, V1	S	2.145	1.992	1.972	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	143	gp120, V1-hypervariable, V1	S	1.925	1.990	1.810	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	144	gp120, V1-hypervariable, V1	S	2.222	2.072	2.207	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	145	gp120, V1-hypervariable, V1	G	2.282	2.228	2.255	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	146	gp120, V1-hypervariable, V1	R	2.649	2.583	2.629	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	147	gp120, V1-hypervariable, V1	M	2.615	2.513	2.375	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	148	gp120, V1-hypervariable, V1	I	2.742	2.671	2.548	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	149	gp120, V1-hypervariable, V1	M	2.563	2.375	2.256	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	150	gp120, V1-hypervariable, V1	E	2.403	2.019	2.328	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	151	gp120, V1-hypervariable, V1	K	2.575	2.285	2.605	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	152	gp120, V1-hypervariable, V1	G	1.800	1.271	1.966	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	185	gp120, V2-hypervariable, V2	D	1.697	1.370	1.762	V2 hypervariable loop: high charge associated with sensitivity; length (both V2 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	186	gp120, V2-hypervariable, V2	N	1.854	1.592	1.819	V2 hypervariable loop: high charge associated with sensitivity; length (both V2 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	187	gp120, V2-hypervariable, V2	D	1.785	1.813	1.638	V2 hypervariable loop: high charge associated with sensitivity; length (both V2 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	188	gp120, V2-hypervariable, V2	T	1.866	1.618	1.850	V2 hypervariable loop: high charge associated with sensitivity; length (both V2 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	189	gp120, V2-hypervariable, V2	T	1.760	1.348	1.638	V2 hypervariable loop: high charge associated with sensitivity; length (both V2 and V1+V2) associated with resistance for V2 Abs
150	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	PG16(V2), PG9(V2), PGDM1400(V2), PGT142(V2), PGT145(V2), VRC26.08(V2), VRC26.25(V2), VRC26.26(V2)	computational prediction	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	V2 hypervariable loop: high charge associated with sensitivity; length (both V2 and V1+V2) associated with resistance for V2 Abs
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	132	gp120, V1-hypervariable, V1	T	1.312	0.849	1.573	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	133	gp120, V1-hypervariable, V1	D	1.376	1.052	1.360	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	134	gp120, V1-hypervariable, V1	L	2.224	2.322	1.627	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	135	gp120, V1-hypervariable, V1	K	2.230	2.373	1.848	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	136	gp120, V1-hypervariable, V1	N	2.514	2.300	2.581	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	138	gp120, V1-hypervariable, V1	T	2.312	2.112	2.504	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	139	gp120, V1-hypervariable, V1	N	2.097	1.946	2.163	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	140	gp120, V1-hypervariable, V1	T	2.235	2.104	2.340	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	141	gp120, V1-hypervariable, V1	N	2.227	2.077	2.148	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	142	gp120, V1-hypervariable, V1	S	2.145	1.992	1.972	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	143	gp120, V1-hypervariable, V1	S	1.925	1.990	1.810	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	144	gp120, V1-hypervariable, V1	S	2.222	2.072	2.207	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	145	gp120, V1-hypervariable, V1	G	2.282	2.228	2.255	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	146	gp120, V1-hypervariable, V1	R	2.649	2.583	2.629	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	147	gp120, V1-hypervariable, V1	M	2.615	2.513	2.375	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	148	gp120, V1-hypervariable, V1	I	2.742	2.671	2.548	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	149	gp120, V1-hypervariable, V1	M	2.563	2.375	2.256	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	150	gp120, V1-hypervariable, V1	E	2.403	2.019	2.328	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	151	gp120, V1-hypervariable, V1	K	2.575	2.285	2.605	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	152	gp120, V1-hypervariable, V1	G	1.800	1.271	1.966	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	185	gp120, V2-hypervariable, V2	D	1.697	1.370	1.762	V2 hypervariable loop: V2 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	186	gp120, V2-hypervariable, V2	N	1.854	1.592	1.819	V2 hypervariable loop: V2 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	187	gp120, V2-hypervariable, V2	D	1.785	1.813	1.638	V2 hypervariable loop: V2 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	188	gp120, V2-hypervariable, V2	T	1.866	1.618	1.850	V2 hypervariable loop: V2 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	189	gp120, V2-hypervariable, V2	T	1.760	1.348	1.638	V2 hypervariable loop: V2 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	V2 hypervariable loop: V2 (and V1+V2) length associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	V5 hypervariable loop: high V5 length and high number of PNGs in V5 associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	V5 hypervariable loop: high V5 length and high number of PNGs in V5 associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	V5 hypervariable loop: high V5 length and high number of PNGs in V5 associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	V5 hypervariable loop: high V5 length and high number of PNGs in V5 associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	464	gp120, V5-hypervariable, V5 loop	E	2.353	2.269	2.299	V5 hypervariable loop: high V5 length and high number of PNGs in V5 associated with higher resistance
151	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	12A12(CD4BS), 3BNC117(CD4BS), 8ANC131(CD4BS), CH103(CD4BS), CH235.12(CD4BS), N6(CD4BS), NIH45-46(CD4BS), VRC01(CD4BS), VRC07-523-LS(CD4BS), VRC07(CD4BS)	computational prediction	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.567	1.466	1.517	V5 hypervariable loop: high V5 length and high number of PNGs in V5 associated with higher resistance
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	132	gp120, V1-hypervariable, V1	T	1.312	0.849	1.573	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	133	gp120, V1-hypervariable, V1	D	1.376	1.052	1.360	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	134	gp120, V1-hypervariable, V1	L	2.224	2.322	1.627	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	135	gp120, V1-hypervariable, V1	K	2.230	2.373	1.848	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	136	gp120, V1-hypervariable, V1	N	2.514	2.300	2.581	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	138	gp120, V1-hypervariable, V1	T	2.312	2.112	2.504	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	139	gp120, V1-hypervariable, V1	N	2.097	1.946	2.163	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	140	gp120, V1-hypervariable, V1	T	2.235	2.104	2.340	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	141	gp120, V1-hypervariable, V1	N	2.227	2.077	2.148	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	142	gp120, V1-hypervariable, V1	S	2.145	1.992	1.972	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	143	gp120, V1-hypervariable, V1	S	1.925	1.990	1.810	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	144	gp120, V1-hypervariable, V1	S	2.222	2.072	2.207	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	145	gp120, V1-hypervariable, V1	G	2.282	2.228	2.255	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	146	gp120, V1-hypervariable, V1	R	2.649	2.583	2.629	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	147	gp120, V1-hypervariable, V1	M	2.615	2.513	2.375	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	148	gp120, V1-hypervariable, V1	I	2.742	2.671	2.548	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	149	gp120, V1-hypervariable, V1	M	2.563	2.375	2.256	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	150	gp120, V1-hypervariable, V1	E	2.403	2.019	2.328	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	151	gp120, V1-hypervariable, V1	K	2.575	2.285	2.605	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
152	hypervariable loop characteristic correlations with bNAb sensitivity	Bricault2019	signature	10E8(MPER), 2F5(MPER), 4E10(MPER)	computational prediction	152	gp120, V1-hypervariable, V1	G	1.800	1.271	1.966	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
153	Signature Analysis Summary	Bricault2019	signature	3BNC117(CD4BS)	computational prediction	5	Signal peptide	E	0.608	0.746	0.316	Amino acid L is associated with resistance. Amino acid E is associated with sensitivity.
154	Signature Analysis Summary	Bricault2019	signature	b12(CD4BS)	computational prediction	5	Signal peptide	E	0.608	0.746	0.316	Amino acid Q is associated with resistance. Amino acid R is associated with sensitivity.
155	Signature Analysis Summary	Bricault2019	signature	3BC176(CD4i)	computational prediction	5	Signal peptide	E	0.608	0.746	0.316	Q associated with resistance
156	Signature Analysis Summary	Bricault2019	signature	CH103(CD4BS)	computational prediction	5	Signal peptide	E	0.608	0.746	0.316	Amino acids Q, M are associated with resistance. Amino acids K, G, R are associated with sensitivity.
157	Signature Analysis Summary	Bricault2019	signature	VRC03(CD4BS)	computational prediction	5	Signal peptide	E	0.608	0.746	0.316	Amino acid Q is associated with resistance. Amino acids K, R are associated with sensitivity.
158	Signature Analysis Summary	Bricault2019	signature	VRC06b(CD4BS)	computational prediction	5	Signal peptide	E	0.608	0.746	0.316	Amino acids Q, M are associated with resistance. Amino acid R is associated with sensitivity.
159	Signature Analysis Summary	Bricault2019	signature	VRC-CH31(CD4BS)	computational prediction	5	Signal peptide	E	0.608	0.746	0.316	Amino acid Q is associated with sensitivity.
160	Signature Analysis Summary	Bricault2019	signature	VRC01(CD4BS)	computational prediction	5	Signal peptide	E	0.608	0.746	0.316	Amino acid Q is associated with sensitivity.
161	Signature Analysis Summary	Bricault2019	signature	8ANC131(CD4BS)	computational prediction	5	Signal peptide	E	0.608	0.746	0.316	Amino acid Q is associated with sensitivity.
162	Signature Analysis Summary	Bricault2019	signature	VRC07-523-LS(CD4BS)	computational prediction	26	Signal peptide	M	0.712	0.183	0.949	Amino acid M is associated with resistance. Amino acid I is associated with sensitivity.
163	Signature Analysis Summary	Bricault2019	signature	NIH45-46(CD4BS)	computational prediction	26	Signal peptide	M	0.712	0.183	0.949	Amino acid M is associated with resistance. Amino acid I is associated with sensitivity.
164	Signature Analysis Summary	Bricault2019	signature	12A12(CD4BS)	computational prediction	26	Signal peptide	M	0.712	0.183	0.949	Amino acid M is associated with resistance. Amino acid I is associated with sensitivity.
165	Signature Analysis Summary	Bricault2019	signature	CH235.12(CD4BS)	computational prediction	26	Signal peptide	M	0.712	0.183	0.949	Amino acid(s) Y, M are associated with resistance.
166	Signature Analysis Summary	Bricault2019	signature	VRC-PG04(CD4BS)	computational prediction	30	Signal peptide	A	1.266	0.487	1.122	Amino acid V is associated with sensitivity.
167	Signature Analysis Summary	Bricault2019	signature	N6(CD4BS)	computational prediction	31	gp120	T	2.159	1.529	2.035	Amino acid N is associated with resistance.
168	Signature Analysis Summary	Bricault2019	signature	VRC07(CD4BS)	computational prediction	60	gp120	A	0.520	0.461	0.396	Amino acid G is associated with resistance. Amino acid A is associated with sensitivity.
169	Signature Analysis Summary	Bricault2019	signature	HJ16(CD4BS)	computational prediction	60	gp120	A	0.520	0.461	0.396	Amino acid S is associated with sensitivity.
169	Signature Analysis Summary	Bricault2019	signature	HJ16(CD4BS)	computational prediction	130	gp120	K	1.201	0.883	1.495	Amino acid(s) NxST are associated with sensitivity.
169	Signature Analysis Summary	Bricault2019	signature	HJ16(CD4BS)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid(s) NxST are associated with sensitivity.
169	Signature Analysis Summary	Bricault2019	signature	HJ16(CD4BS)	computational prediction	362	gp120	K	1.815	1.265	1.997	Amino acid T is associated with sensitivity.
170	Signature Analysis Summary	Bricault2019	signature	VRC16(CD4BS)	computational prediction	87	gp120	V	1.565	1.611	1.463	Amino acid K is associated with resistance.
170	Signature Analysis Summary	Bricault2019	signature	VRC16(CD4BS)	computational prediction	192	gp120, V2	K	0.940	0.835	0.851	Amino acid R is associated with sensitivity.
170	Signature Analysis Summary	Bricault2019	signature	VRC16(CD4BS)	computational prediction	291	gp120	S	1.161	1.292	0.739	Amino acid A is associated with resistance.
170	Signature Analysis Summary	Bricault2019	signature	VRC16(CD4BS)	computational prediction	395	gp120, V4 loop	W	1.700	0.454	2.171	Amino acid W is associated with sensitivity.
170	Signature Analysis Summary	Bricault2019	signature	VRC16(CD4BS)	computational prediction	425	gp120, beta20/beta21	N	0.295	0.138	0.177	Amino acid R is associated with resistance. Amino acid N is associated with sensitivity.
170	Signature Analysis Summary	Bricault2019	signature	VRC16(CD4BS)	computational prediction	442	gp120	Q	2.042	1.699	0.964	Amino acid(s) NxST, N are associated with resistance.
170	Signature Analysis Summary	Bricault2019	signature	VRC16(CD4BS)	computational prediction	471	gp120, beta24	G	0.933	0.888	0.866	Amino acid G is associated with sensitivity.
170	Signature Analysis Summary	Bricault2019	signature	VRC16(CD4BS)	computational prediction	833	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	V	1.619	1.417	1.296	Amino acid I is associated with resistance.
171	Signature Analysis Summary	Bricault2019	signature	3BC176(CD4i)	computational prediction	87	gp120	V	1.565	1.611	1.463	Amino acid K is associated with resistance.
171	Signature Analysis Summary	Bricault2019	signature	3BC176(CD4i)	computational prediction	442	gp120	Q	2.042	1.699	0.964	Amino acid Q is associated with sensitivity.
171	Signature Analysis Summary	Bricault2019	signature	3BC176(CD4i)	computational prediction	507	gp120	Q	0.983	0.082	0.603	Amino acid Q is associated with sensitivity.
172	Signature Analysis Summary	Bricault2019	signature	VRC-PG05(silent face)	computational prediction	99	gp120	D	1.048	0.830	0.366	Amino acid K is associated with sensitivity.
172	Signature Analysis Summary	Bricault2019	signature	VRC-PG05(silent face)	computational prediction	291	gp120	S	1.161	1.292	0.739	Amino acid S is associated with sensitivity.
172	Signature Analysis Summary	Bricault2019	signature	VRC-PG05(silent face)	computational prediction	316	gp120, V3 loop	A	1.056	0.736	0.966	Amino acid V is associated with sensitivity.
172	Signature Analysis Summary	Bricault2019	signature	VRC-PG05(silent face)	computational prediction	518	gp41, fusion peptide	L	1.166	1.110	0.718	Amino acid V is associated with resistance.
172	Signature Analysis Summary	Bricault2019	signature	VRC-PG05(silent face)	computational prediction	654	gp41	E	0.167	0.174	0.105	Amino acid E is associated with resistance. Amino acid D is associated with sensitivity.
173	Signature Analysis Summary	Bricault2019	signature	NIH45-46WPY(CD4BS)	computational prediction	130	gp120	K	1.201	0.883	1.495	Amino acid S is associated with resistance.
173	Signature Analysis Summary	Bricault2019	signature	NIH45-46WPY(CD4BS)	computational prediction	234	gp120	N	0.598	0.757	0.341	Amino acid(s) NxST are associated with resistance.
173	Signature Analysis Summary	Bricault2019	signature	NIH45-46WPY(CD4BS)	computational prediction	268	gp120	E	1.191	0.886	1.275	Amino acid E is associated with resistance.
173	Signature Analysis Summary	Bricault2019	signature	NIH45-46WPY(CD4BS)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid(s) N, NxST are associated with sensitivity.
173	Signature Analysis Summary	Bricault2019	signature	NIH45-46WPY(CD4BS)	computational prediction	395	gp120, V4 loop	W	1.700	0.454	2.171	Amino acid(s) N, NxST are associated with sensitivity.
173	Signature Analysis Summary	Bricault2019	signature	NIH45-46WPY(CD4BS)	computational prediction	456	gp120, beta23	R	0.233	0.079	0.323	Amino acid S is associated with resistance. Amino acid R is associated with sensitivity.
173	Signature Analysis Summary	Bricault2019	signature	NIH45-46WPY(CD4BS)	computational prediction	458	gp120, beta23	G	0.112	0.045	0.095	Amino acid G is associated with sensitivity.
173	Signature Analysis Summary	Bricault2019	signature	NIH45-46WPY(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	Amino acid G is associated with sensitivity.
173	Signature Analysis Summary	Bricault2019	signature	NIH45-46WPY(CD4BS)	computational prediction	616	gp41	N	0.231	0.238	0.269	Amino acid(s) NxST are associated with resistance.
173	Signature Analysis Summary	Bricault2019	signature	NIH45-46WPY(CD4BS)	computational prediction	618	gp41	S	0.723	0.725	0.780	Amino acid(s) NxST are associated with resistance.
173	Signature Analysis Summary	Bricault2019	signature	NIH45-46WPY(CD4BS)	computational prediction	833	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	V	1.619	1.417	1.296	Amino acid I is associated with resistance. Amino acid V is associated with sensitivity.
174	Signature Analysis Summary	Bricault2019	signature	NIH45-46WY(CD4BS)	computational prediction	130	gp120	K	1.201	0.883	1.495	Amino acid S is associated with resistance.
174	Signature Analysis Summary	Bricault2019	signature	NIH45-46WY(CD4BS)	computational prediction	268	gp120	E	1.191	0.886	1.275	Amino acid E is associated with resistance.
174	Signature Analysis Summary	Bricault2019	signature	NIH45-46WY(CD4BS)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid(s) N, NxST are associated with sensitivity.
174	Signature Analysis Summary	Bricault2019	signature	NIH45-46WY(CD4BS)	computational prediction	456	gp120, beta23	R	0.233	0.079	0.323	Amino acid S is associated with resistance. Amino acid R is associated with sensitivity.
174	Signature Analysis Summary	Bricault2019	signature	NIH45-46WY(CD4BS)	computational prediction	458	gp120, beta23	G	0.112	0.045	0.095	Amino acid G is associated with sensitivity.
174	Signature Analysis Summary	Bricault2019	signature	NIH45-46WY(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	Amino acid G is associated with sensitivity.
174	Signature Analysis Summary	Bricault2019	signature	NIH45-46WY(CD4BS)	computational prediction	616	gp41	N	0.231	0.238	0.269	Amino acid(s) N, NxST are associated with sensitivity.
174	Signature Analysis Summary	Bricault2019	signature	NIH45-46WY(CD4BS)	computational prediction	618	gp41	S	0.723	0.725	0.780	Amino acid NxST is associated with resistance
174	Signature Analysis Summary	Bricault2019	signature	NIH45-46WY(CD4BS)	computational prediction	833	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	V	1.619	1.417	1.296	Amino acid V is associated with sensitivity.
175	Signature Analysis Summary	Bricault2019	signature	1B2530(CD4BS)	computational prediction	183	gp120, V2	P	1.099	1.107	0.787	Amino acid S is associated with resistance.
175	Signature Analysis Summary	Bricault2019	signature	1B2530(CD4BS)	computational prediction	234	gp120	N	0.598	0.757	0.341	Amino acid N is associated with resistance.
175	Signature Analysis Summary	Bricault2019	signature	1B2530(CD4BS)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid(s) NxST are associated with sensitivity.
175	Signature Analysis Summary	Bricault2019	signature	1B2530(CD4BS)	computational prediction	456	gp120, beta23	R	0.233	0.079	0.323	Amino acid S is associated with resistance. Amino acid R is associated with sensitivity.
175	Signature Analysis Summary	Bricault2019	signature	1B2530(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	Amino acid G is associated with sensitivity.
175	Signature Analysis Summary	Bricault2019	signature	1B2530(CD4BS)	computational prediction	471	gp120, beta24	G	0.933	0.888	0.866	Amino acid G is associated with sensitivity.
176	Signature Analysis Summary	Bricault2019	signature	VRC13(CD4BS)	computational prediction	192	gp120, V2	K	0.940	0.835	0.851	Amino acid I is associated with resistance. Amino acid R is associated with sensitivity.
176	Signature Analysis Summary	Bricault2019	signature	VRC13(CD4BS)	computational prediction	275	gp120, Loop D	V	1.141	1.420	0.535	Amino acid K is associated with resistance.
176	Signature Analysis Summary	Bricault2019	signature	VRC13(CD4BS)	computational prediction	364	gp120, CD4 binding loop	S	0.924	0.588	1.191	Amino acid H is associated with resistance. Amino acid S is associated with sensitivity.
176	Signature Analysis Summary	Bricault2019	signature	VRC13(CD4BS)	computational prediction	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	Amino acid I is associated with sensitivity.
176	Signature Analysis Summary	Bricault2019	signature	VRC13(CD4BS)	computational prediction	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	Amino acid(s) N, NxST are associated with resistance.
176	Signature Analysis Summary	Bricault2019	signature	VRC13(CD4BS)	computational prediction	395	gp120, V4 loop	W	1.700	0.454	2.171	Amino acid(s) S, NxST are associated with resistance. Amino acid Y is associated with sensitivity.
176	Signature Analysis Summary	Bricault2019	signature	VRC13(CD4BS)	computational prediction	471	gp120, beta24	G	0.933	0.888	0.866	Amino acid E is associated with resistance. Amino acid G is associated with sensitivity.
176	Signature Analysis Summary	Bricault2019	signature	VRC13(CD4BS)	computational prediction	474	gp120	D	0.696	0.681	0.752	Amino acid N is associated with resistance. Amino acid D is associated with sensitivity.
176	Signature Analysis Summary	Bricault2019	signature	VRC13(CD4BS)	computational prediction	700	gp41, gp41 cytoplasmic tail	A	1.122	1.185	0.798	Amino acid A is associated with sensitivity.
176	Signature Analysis Summary	Bricault2019	signature	VRC13(CD4BS)	computational prediction	833	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	V	1.619	1.417	1.296	Amino acid I is associated with resistance. Amino acid V is associated with sensitivity.
177	Signature Analysis Summary	Bricault2019	signature	NIH45-46(CD4BS)	computational prediction	229	gp120	N	0.707	0.742	0.290	Amino acid R is associated with resistance
177	Signature Analysis Summary	Bricault2019	signature	NIH45-46(CD4BS)	computational prediction	358	gp120	T	0.802	0.513	0.929	Amino acid T is associated with sensitivity
178	Signature Analysis Summary	Bricault2019	signature	NIH45-46G54W(CD4BS)	computational prediction	234	gp120	N	0.598	0.757	0.341	Amino acid(s) N, NxST are associated with resistance.
178	Signature Analysis Summary	Bricault2019	signature	NIH45-46G54W(CD4BS)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid N is associated with sensitivity.
178	Signature Analysis Summary	Bricault2019	signature	NIH45-46G54W(CD4BS)	computational prediction	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	Amino acid I is associated with sensitivity.
178	Signature Analysis Summary	Bricault2019	signature	NIH45-46G54W(CD4BS)	computational prediction	395	gp120, V4 loop	W	1.700	0.454	2.171	Amino acid(s) K, N, NxST are associated with resistance.
178	Signature Analysis Summary	Bricault2019	signature	NIH45-46G54W(CD4BS)	computational prediction	456	gp120, beta23	R	0.233	0.079	0.323	Amino acid S is associated with resistance. Amino acid R is associated with sensitivity.
178	Signature Analysis Summary	Bricault2019	signature	NIH45-46G54W(CD4BS)	computational prediction	458	gp120, beta23	G	0.112	0.045	0.095	Amino acid G is associated with sensitivity.
178	Signature Analysis Summary	Bricault2019	signature	NIH45-46G54W(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	Amino acid G is associated with sensitivity.
178	Signature Analysis Summary	Bricault2019	signature	NIH45-46G54W(CD4BS)	computational prediction	466	gp120, V5 loop, beta24	E	0.205	0.091	0.239	Amino acid E is associated with sensitivity.
178	Signature Analysis Summary	Bricault2019	signature	NIH45-46G54W(CD4BS)	computational prediction	618	gp41	S	0.723	0.725	0.780	Amino acid(s) NxST, N are associated with resistance. Amino acid S is associated with sensitivity.
178	Signature Analysis Summary	Bricault2019	signature	NIH45-46G54W(CD4BS)	computational prediction	833	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	V	1.619	1.417	1.296	Amino acid I is associated with resistance. Amino acid V is associated with sensitivity.
179	Signature Analysis Summary	Bricault2019	signature	8ANC195(gp120/gp41 interface)	computational prediction	234	gp120	N	0.598	0.757	0.341	Amino acid S is associated with resistance. Amino acid(s) N, NxST are associated with sensitivity.
179	Signature Analysis Summary	Bricault2019	signature	8ANC195(gp120/gp41 interface)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid(s) NxST are associated with sensitivity.
180	Signature Analysis Summary	Bricault2019	signature	3BNC55(CD4BS)	computational prediction	234	gp120	N	0.598	0.757	0.341	Amino acid(s) NxST are associated with resistance.
180	Signature Analysis Summary	Bricault2019	signature	3BNC55(CD4BS)	computational prediction	276	gp120, Loop D	N	0.118	0.063	0.169	Amino acid N is associated with sensitivity.
180	Signature Analysis Summary	Bricault2019	signature	3BNC55(CD4BS)	computational prediction	279	gp120, Loop D	D	0.900	0.850	0.898	Amino acid N is associated with resistance. Amino acid D is associated with sensitivity.
180	Signature Analysis Summary	Bricault2019	signature	3BNC55(CD4BS)	computational prediction	456	gp120, beta23	R	0.233	0.079	0.323	Amino acid R is associated with sensitivity.
180	Signature Analysis Summary	Bricault2019	signature	3BNC55(CD4BS)	computational prediction	833	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	V	1.619	1.417	1.296	Amino acid V is associated with sensitivity.
181	Signature Analysis Summary	Bricault2019	signature	3BNC176(CD4BS)	computational prediction	271	gp120	V	1.126	0.623	0.635	Amino acid V is associated with sensitivity
182	Signature Analysis Summary	Bricault2019	signature	CH44(CD4BS)	computational prediction	291	gp120	S	1.161	1.292	0.739	Amino acid P is associated with resistance
183	Signature Analysis Summary	Bricault2019	signature	VRC22(CD4BS)	computational prediction	33	gp120	K	1.551	1.559	0.973	Amino acid K is associated with sensitivity.
183	Signature Analysis Summary	Bricault2019	signature	VRC22(CD4BS)	computational prediction	432	gp120, beta20/beta21	K	1.037	0.339	0.564	Amino acid Q is associated with resistance. Amino acid K is associated with sensitivity.
183	Signature Analysis Summary	Bricault2019	signature	VRC22(CD4BS)	computational prediction	507	gp120	Q	0.983	0.082	0.603	Amino acid Q is associated with sensitivity.
184	Signature Analysis Summary	Bricault2019	signature	VRC07-523-LS(CD4BS)	computational prediction	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	Amino acid D is associated with resistance
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	65	gp120	V	1.017	1.023	0.310	Amino acid V is associated with resistance. Amino acid K is associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	158	gp120, V2	S	0.263	0.185	0.291	Amino acid(s) T are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	240	gp120	T	1.813	1.338	1.717	Amino acid(s) N, H are associated with resistance. Amino acid(s) K are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	268	gp120	E	1.191	0.886	1.275	Amino acid(s) G are associated with resistance.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	270	gp120	V	0.811	0.669	0.297	Amino acid(s) I are associated with resistance. Amino acid(s) V are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	277	gp120, Loop D	F	1.160	0.669	0.582	Amino acid(s) L are associated with resistance. Amino acid(s) F, I are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	281	gp120, Loop D	A	1.129	0.814	1.357	Amino acid(s) V are associated with resistance. Amino acid(s) A are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	300	gp120, V3 loop	N	1.017	0.738	1.054	Amino acid(s) G are associated with resistance. Amino acid(s) S are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	301	gp120, V3 loop	N	0.172	0.176	0.104	Amino acid(s) NxST, N are associated with resistance.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	308	gp120, V3 loop	R	1.578	0.091	0.127	Amino acid(s) R are associated with resistance. Amino acid(s) H, T are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acid(s) S are associated with resistance. Amino acid(s) NxST, N are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid(s) E, D are associated with resistance. Amino acid(s) T, A are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	346	gp120	A	1.859	1.083	1.831	Amino acid(s) G, K, S are associated with resistance. Amino acid(s) A, V are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	354	gp120	G	2.108	1.918	1.123	Amino acid(s) NxST, P are associated with resistance. Amino acid(s) G are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	413	gp120, V4 loop	T	1.512	1.451	1.561	Amino acid(s) NxST are associated with resistance. Amino acid(s) T are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	432	gp120, beta20/beta21	K	1.037	0.339	0.564	Amino acid(s) R are associated with resistance. Amino acid(s) Q, K are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	440	gp120	S	1.844	1.712	1.017	Amino acid(s) E, A are associated with resistance. Amino acid(s) S, P, Q are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	446	gp120	S	1.957	1.139	1.774	Amino acid(s) N, NxST, K are associated with resistance. Amino acid(s) S, E, V are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	471	gp120, beta24	G	0.933	0.888	0.866	Amino acid(s) E are associated with resistance.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	515	gp41, fusion peptide	I	1.103	1.147	0.877	Amino acid(s) L are associated with resistance. Amino acid(s) M are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	618	gp41	S	0.723	0.725	0.780	Amino acid(s) S are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	619	gp41	L	1.801	1.312	1.871	Amino acid(s) Q are associated with resistance. Amino acid(s) L are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	620	gp41	E	1.999	1.701	2.182	Amino acid(s) T are associated with resistance. Amino acid(s) E are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	662	gp41	E	1.043	0.874	0.369	Amino acid(s) A, K are associated with resistance. Amino acid(s) E are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	664	gp41	D	0.222	0.156	0.346	Amino acid(s) D are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	665	gp41	K	1.039	0.656	0.879	Amino acid(s) Q, S are associated with resistance. Amino acid(s) K are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	667	gp41	A	1.424	0.545	1.537	Amino acid(s) D, E, K, N are associated with resistance. Amino acid(s) A are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	668	gp41	S	0.865	0.596	0.758	Amino acid(s) N are associated with resistance. Amino acid(s) S are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	671	gp41	N	0.783	0.669	0.885	Amino acid(s) S are associated with resistance.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	674	gp41	N	1.179	1.029	1.344	Amino acid(s) S are associated with resistance. Amino acid(s) D are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	725	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	R	0.447	0.214	0.471	Amino acid(s) G are associated with resistance. Amino acid(s) R are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	726	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	G	0.581	0.251	0.717	Amino acid(s) D are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	742	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	R	0.614	0.389	0.785	Amino acid(s) K are associated with resistance. Amino acid(s) R are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	788	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, CaM interaction, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	R	0.673	0.131	0.670	Amino acid(s) K are associated with resistance. Amino acid(s) L are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	809	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	N	1.260	0.673	0.545	Amino acid(s) K, R are associated with resistance. Amino acid(s) N, I are associated with sensitivity.
185	Signature Analysis Summary	Bricault2019	signature	2F5(MPER)	computational prediction	837	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	C	1.647	1.664	1.096	Amino acid(s) C are associated with resistance. Amino acid(s) W are associated with sensitivity.
186	Signature Analysis Summary	Bricault2019	signature	DH511.2(MPER)	computational prediction	65	gp120	V	1.017	1.023	0.310	Amino acid K is associated with resistance.
186	Signature Analysis Summary	Bricault2019	signature	DH511.2(MPER)	computational prediction	80	gp120	N	0.669	0.695	0.562	Amino acid(s) N are associated with sensitivity.
186	Signature Analysis Summary	Bricault2019	signature	DH511.2(MPER)	computational prediction	268	gp120	E	1.191	0.886	1.275	Amino acid(s) K are associated with resistance.
186	Signature Analysis Summary	Bricault2019	signature	DH511.2(MPER)	computational prediction	277	gp120, Loop D	F	1.160	0.669	0.582	Amino acid(s) I are associated with resistance.
186	Signature Analysis Summary	Bricault2019	signature	DH511.2(MPER)	computational prediction	301	gp120, V3 loop	N	0.172	0.176	0.104	Amino acid(s) NxST are associated with resistance.
186	Signature Analysis Summary	Bricault2019	signature	DH511.2(MPER)	computational prediction	446	gp120	S	1.957	1.139	1.774	Amino acid(s) E are associated with resistance.
186	Signature Analysis Summary	Bricault2019	signature	DH511.2(MPER)	computational prediction	672	gp41	W	0.014	0.023	0.014	Amino acid(s) L are associated with resistance. Amino acid(s) W are associated with sensitivity.
186	Signature Analysis Summary	Bricault2019	signature	DH511.2(MPER)	computational prediction	673	gp41	F	0.048	0.065	0.073	Amino acid(s) L are associated with resistance. Amino acid(s) F are associated with sensitivity.
186	Signature Analysis Summary	Bricault2019	signature	DH511.2(MPER)	computational prediction	674	gp41	N	1.179	1.029	1.344	Amino acid(s) S are associated with resistance. Amino acid(s) NxST are associated with sensitivity.
186	Signature Analysis Summary	Bricault2019	signature	DH511.2(MPER)	computational prediction	676	gp41	T	0.671	0.610	0.674	Amino acid(s) S are associated with resistance. Amino acid(s) T are associated with sensitivity.
186	Signature Analysis Summary	Bricault2019	signature	DH511.2(MPER)	computational prediction	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	Amino acid(s) G are associated with resistance. Amino acid(s) W are associated with sensitivity.
186	Signature Analysis Summary	Bricault2019	signature	DH511.2(MPER)	computational prediction	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	Amino acid(s) R are associated with resistance. Amino acid(s) K are associated with sensitivity.
186	Signature Analysis Summary	Bricault2019	signature	DH511.2(MPER)	computational prediction	809	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	N	1.260	0.673	0.545	Amino acid(s) K are associated with resistance.
187	Signature Analysis Summary	Bricault2019	signature	DH511.2_K3(MPER)	computational prediction	65	gp120	V	1.017	1.023	0.310	Amino acid K is associated with resistance.
187	Signature Analysis Summary	Bricault2019	signature	DH511.2_K3(MPER)	computational prediction	268	gp120	E	1.191	0.886	1.275	Amino acid(s) K are associated with resistance.
187	Signature Analysis Summary	Bricault2019	signature	DH511.2_K3(MPER)	computational prediction	301	gp120, V3 loop	N	0.172	0.176	0.104	Amino acid(s) NxST, N are associated with resistance.
187	Signature Analysis Summary	Bricault2019	signature	DH511.2_K3(MPER)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid(s) S are associated with sensitivity.
187	Signature Analysis Summary	Bricault2019	signature	DH511.2_K3(MPER)	computational prediction	620	gp41	E	1.999	1.701	2.182	Amino acid(s) Q are associated with resistance.
187	Signature Analysis Summary	Bricault2019	signature	DH511.2_K3(MPER)	computational prediction	662	gp41	E	1.043	0.874	0.369	Amino acid(s) A are associated with resistance.
187	Signature Analysis Summary	Bricault2019	signature	DH511.2_K3(MPER)	computational prediction	672	gp41	W	0.014	0.023	0.014	Amino acid(s) L are associated with resistance. Amino acid(s) W are associated with sensitivity.
187	Signature Analysis Summary	Bricault2019	signature	DH511.2_K3(MPER)	computational prediction	673	gp41	F	0.048	0.065	0.073	Amino acid(s) L are associated with resistance. Amino acid(s) F are associated with sensitivity.
187	Signature Analysis Summary	Bricault2019	signature	DH511.2_K3(MPER)	computational prediction	674	gp41	N	1.179	1.029	1.344	Amino acid(s) S are associated with resistance.
187	Signature Analysis Summary	Bricault2019	signature	DH511.2_K3(MPER)	computational prediction	676	gp41	T	0.671	0.610	0.674	Amino acid(s) S are associated with resistance. Amino acid(s) T are associated with sensitivity.
187	Signature Analysis Summary	Bricault2019	signature	DH511.2_K3(MPER)	computational prediction	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	Amino acid(s) G are associated with resistance. Amino acid(s) W are associated with sensitivity.
187	Signature Analysis Summary	Bricault2019	signature	DH511.2_K3(MPER)	computational prediction	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	Amino acid(s) R are associated with resistance. Amino acid(s) K are associated with sensitivity.
187	Signature Analysis Summary	Bricault2019	signature	DH511.2_K3(MPER)	computational prediction	809	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	N	1.260	0.673	0.545	Amino acid(s) K are associated with resistance.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	65	gp120	V	1.017	1.023	0.310	Amino acid K is associated with resistance.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	80	gp120	N	0.669	0.695	0.562	Amino acid(s) N are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	268	gp120	E	1.191	0.886	1.275	Amino acid(s) K are associated with resistance. Amino acid(s) E are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	270	gp120	V	0.811	0.669	0.297	Amino acid(s) I are associated with resistance. Amino acid(s) V are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	277	gp120, Loop D	F	1.160	0.669	0.582	Amino acid(s) I are associated with resistance. Amino acid(s) F are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	300	gp120, V3 loop	N	1.017	0.738	1.054	Amino acid(s) D are associated with resistance. Amino acid(s) S, Y are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	301	gp120, V3 loop	N	0.172	0.176	0.104	Amino acid(s) NxST are associated with resistance.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	308	gp120, V3 loop	R	1.578	0.091	0.127	Amino acid(s) H are associated with resistance.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	334	gp120	S	0.717	0.501	0.890	Amino acid(s) NxST are associated with resistance.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid(s) T are associated with resistance.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	432	gp120, beta20/beta21	K	1.037	0.339	0.564	Amino acid(s) K are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	440	gp120	S	1.844	1.712	1.017	Amino acid(s) Q are associated with resistance. Amino acid(s) S are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	446	gp120	S	1.957	1.139	1.774	Amino acid(s) E are associated with resistance. Amino acid(s) S are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	620	gp41	E	1.999	1.701	2.182	Amino acid(s) Q, S are associated with resistance. Amino acid(s) E are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	662	gp41	E	1.043	0.874	0.369	Amino acid(s) A, T are associated with resistance. Amino acid(s) E are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	667	gp41	A	1.424	0.545	1.537	Amino acid(s) S are associated with resistance.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	671	gp41	N	0.783	0.669	0.885	Amino acid(s) T are associated with resistance. Amino acid(s) N are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	672	gp41	W	0.014	0.023	0.014	Amino acid(s) L are associated with resistance. Amino acid(s) W are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	673	gp41	F	0.048	0.065	0.073	Amino acid(s) L are associated with resistance. Amino acid(s) F are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	674	gp41	N	1.179	1.029	1.344	Amino acid(s) S are associated with resistance. Amino acid(s) N, NxST are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	676	gp41	T	0.671	0.610	0.674	Amino acid(s) S are associated with resistance. Amino acid(s) T are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	Amino acid(s) G are associated with resistance. Amino acid(s) W are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	702	gp41, gp41 cytoplasmic tail	L	0.419	0.497	0.316	Amino acid(s) I are associated with resistance. Amino acid(s) L are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	725	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	R	0.447	0.214	0.471	Amino acid(s) R are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	726	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	G	0.581	0.251	0.717	Amino acid(s) D are associated with resistance. Amino acid(s) G are associated with sensitivity.
188	Signature Analysis Summary	Bricault2019	signature	10E8(MPER)	computational prediction	837	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	C	1.647	1.664	1.096	Amino acid(s) C are associated with resistance. Amino acid(s) W, Y are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	240	gp120	T	1.813	1.338	1.717	Amino acid T is associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	268	gp120	E	1.191	0.886	1.275	Amino acid(s) K are associated with resistance. Amino acid(s) E are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	277	gp120, Loop D	F	1.160	0.669	0.582	Amino acid(s) I are associated with resistance. Amino acid(s) L are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	281	gp120, Loop D	A	1.129	0.814	1.357	Amino acid(s) V are associated with resistance. Amino acid(s) A are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	300	gp120, V3 loop	N	1.017	0.738	1.054	Amino acid(s) D are associated with resistance. Amino acid(s) Y are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	301	gp120, V3 loop	N	0.172	0.176	0.104	Amino acid(s) NxST, N are associated with resistance.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	336	gp120	A	2.208	1.826	2.418	Amino acid(s) T, S are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	440	gp120	S	1.844	1.712	1.017	Amino acid(s) S are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	446	gp120	S	1.957	1.139	1.774	Amino acid(s) E are associated with resistance.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	471	gp120, beta24	G	0.933	0.888	0.866	Amino acid(s) G, A are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	616	gp41	N	0.231	0.238	0.269	Amino acid(s) NxST are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	618	gp41	S	0.723	0.725	0.780	Amino acid(s) NxST, N are associated with resistance. Amino acid(s) S are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	619	gp41	L	1.801	1.312	1.871	Amino acid(s) I, Q are associated with resistance. Amino acid(s) K, Y are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	620	gp41	E	1.999	1.701	2.182	Amino acid(s) A are associated with resistance. Amino acid(s) E are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	662	gp41	E	1.043	0.874	0.369	Amino acid(s) T are associated with resistance.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	664	gp41	D	0.222	0.156	0.346	Amino acid(s) G are associated with resistance.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	667	gp41	A	1.424	0.545	1.537	Amino acid(s) E are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	671	gp41	N	0.783	0.669	0.885	Amino acid(s) S are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	672	gp41	W	0.014	0.023	0.014	Amino acid(s) L are associated with resistance. Amino acid(s) W are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	673	gp41	F	0.048	0.065	0.073	Amino acid(s) L are associated with resistance. Amino acid(s) F are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	674	gp41	N	1.179	1.029	1.344	Amino acid(s) S are associated with resistance. Amino acid(s) D, N, NxST are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	676	gp41	T	0.671	0.610	0.674	Amino acid(s) S, A are associated with resistance. Amino acid(s) T are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	Amino acid(s) G are associated with resistance. Amino acid(s) W are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	Amino acid(s) R are associated with resistance. Amino acid(s) K are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	702	gp41, gp41 cytoplasmic tail	L	0.419	0.497	0.316	Amino acid(s) L are associated with sensitivity.
189	Signature Analysis Summary	Bricault2019	signature	4E10(MPER)	computational prediction	726	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	G	0.581	0.251	0.717	Amino acid(s) D are associated with resistance.
190	Signature Analysis Summary	Bricault2019	signature	Z13e1(MPER)	computational prediction	674	gp41	N	1.179	1.029	1.344	Amino acid D is associated with sensitivity.
190	Signature Analysis Summary	Bricault2019	signature	Z13e1(MPER)	computational prediction	788	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, CaM interaction, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	R	0.673	0.131	0.670	Amino acid R is associated with resistance.
191	Mutations allowing binding of germline variants of CD4bs mAbs	McGuire2016	binding	gl12A21(CD4BS), glNIH45-46(CD4BS), glVRC-PG19(CD4BS), glVRC-PG20(CD4BS), VRC01 gHC+gLC(CD4BS)	binding assay	278	gp120, Loop D	T	0.708	0.715	0.481	On a background of N276D, N460D and N463D, introducing S278R alone, or with G471S, permits the binding of germline variants of VRC01, NIH45-46, VRC-PG19, VRC-PG20 and 12A21
191	Mutations allowing binding of germline variants of CD4bs mAbs	McGuire2016	binding	gl12A21(CD4BS), glNIH45-46(CD4BS), glVRC-PG19(CD4BS), glVRC-PG20(CD4BS), VRC01 gHC+gLC(CD4BS)	binding assay	471	gp120, beta24	G	0.933	0.888	0.866	On a background of N276D, N460D and N463D, introducing S278R alone, or with G471S, permits the binding of germline variants of VRC01, NIH45-46, VRC-PG19, VRC-PG20 and 12A21
192	Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs	LaBranche2018	neutralization	12A12(CD4BS), 3BNC117(CD4BS), VRC01(CD4BS), VRC03(CD4BS), VRC07(CD4BS), VRC18b(CD4BS), VRC-PG20(CD4BS)	neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	Glycan deletions of 426c env-pseudotyped viruses at sites 278, 471, 460 and 463 (S278R/G471S/N460D/N463D) increased neutralization sensitivity to 3BNC117, VRC01, VRC03, VRC07, VRC18b, VRC-PG20, and 12A12.
192	Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs	LaBranche2018	neutralization	12A12(CD4BS), 3BNC117(CD4BS), VRC01(CD4BS), VRC03(CD4BS), VRC07(CD4BS), VRC18b(CD4BS), VRC-PG20(CD4BS)	neutralization assay	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	Glycan deletions of 426c env-pseudotyped viruses at sites 278, 471, 460 and 463 (S278R/G471S/N460D/N463D) increased neutralization sensitivity to 3BNC117, VRC01, VRC03, VRC07, VRC18b, VRC-PG20, and 12A12.
192	Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs	LaBranche2018	neutralization	12A12(CD4BS), 3BNC117(CD4BS), VRC01(CD4BS), VRC03(CD4BS), VRC07(CD4BS), VRC18b(CD4BS), VRC-PG20(CD4BS)	neutralization assay	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	Glycan deletions of 426c env-pseudotyped viruses at sites 278, 471, 460 and 463 (S278R/G471S/N460D/N463D) increased neutralization sensitivity to 3BNC117, VRC01, VRC03, VRC07, VRC18b, VRC-PG20, and 12A12.
192	Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs	LaBranche2018	neutralization	12A12(CD4BS), 3BNC117(CD4BS), VRC01(CD4BS), VRC03(CD4BS), VRC07(CD4BS), VRC18b(CD4BS), VRC-PG20(CD4BS)	neutralization assay	471	gp120, beta24	G	0.933	0.888	0.866	Glycan deletions of 426c env-pseudotyped viruses at sites 278, 471, 460 and 463 (S278R/G471S/N460D/N463D) increased neutralization sensitivity to 3BNC117, VRC01, VRC03, VRC07, VRC18b, VRC-PG20, and 12A12.
193	Altered glycosylation affects neutralization by CD4BS bnAbs	LaBranche2018	neutralization	3BNC117(CD4BS), VRC03(CD4BS), VRC-PG20(CD4BS)	neutralization assay	276	gp120, Loop D	N	0.118	0.063	0.169	When viruses were produced in 293s GnT1- cells, N276D alone increased VRC03 and VRC-PG20 neutralization, while N460D and N463D increased 3BNC117, VRC03, and VRC-PG20 neutralization
193	Altered glycosylation affects neutralization by CD4BS bnAbs	LaBranche2018	neutralization	3BNC117(CD4BS), VRC03(CD4BS), VRC-PG20(CD4BS)	neutralization assay	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	When viruses were produced in 293s GnT1- cells, N276D alone increased VRC03 and VRC-PG20 neutralization, while N460D and N463D increased 3BNC117, VRC03, and VRC-PG20 neutralization
193	Altered glycosylation affects neutralization by CD4BS bnAbs	LaBranche2018	neutralization	3BNC117(CD4BS), VRC03(CD4BS), VRC-PG20(CD4BS)	neutralization assay	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	When viruses were produced in 293s GnT1- cells, N276D alone increased VRC03 and VRC-PG20 neutralization, while N460D and N463D increased 3BNC117, VRC03, and VRC-PG20 neutralization
194	Selects for breadth-driven Abs in CAP256 lineages	Sacks2019	neutralization	VRC26.20(V2)	neutralization assay, sequence analysis	169	gp120, V2	V	2.042	1.770	1.344	~66% of C viruses present K169; however, the rarer form 169Q (~6.5% of C viruses) improves neutralization breadth of CAP26.20, suggesting it helped select bNAbs in the CAP256 lineage
195	SF12 interaction sites	Schoofs2019	contacts	SF12(silent face)	X-ray crystallography	59	gp120	K	0.200	0.243	0.130	hydrogen interaction with CDRH3
195	SF12 interaction sites	Schoofs2019	contacts	SF12(silent face)	X-ray crystallography	60	gp120	A	0.520	0.461	0.396	hydrogen interaction with CDRH3
195	SF12 interaction sites	Schoofs2019	contacts	SF12(silent face)	X-ray crystallography	252	gp120	R	0.725	0.592	0.148	hydrogen interaction with CDRH3
195	SF12 interaction sites	Schoofs2019	contacts	SF12(silent face)	X-ray crystallography	262	gp120	N	0.027	0.029	0.028	SF12 recognizes a mostly glycan-focused epitope on HIV-1 Env, interacting with glycans N448, N262, and N295.
195	SF12 interaction sites	Schoofs2019	contacts	SF12(silent face)	X-ray crystallography	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	SF12 recognizes a mostly glycan-focused epitope on HIV-1 Env, interacting with glycans N448, N262, and N295.
195	SF12 interaction sites	Schoofs2019	contacts	SF12(silent face)	X-ray crystallography	444	gp120	R	1.747	1.507	0.494	hydrogen interaction with CDRH1/2
195	SF12 interaction sites	Schoofs2019	contacts	SF12(silent face)	X-ray crystallography	446	gp120	S	1.957	1.139	1.774	hydrogen interaction with CDRH1/2
195	SF12 interaction sites	Schoofs2019	contacts	SF12(silent face)	X-ray crystallography	448	gp120	N	0.662	0.448	0.927	SF12 recognizes a mostly glycan-focused epitope on HIV-1 Env, interacting with glycans N448, N262, and N295.
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	278	gp120, Loop D	T	0.708	0.715	0.481	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	357	gp120	K	1.034	0.868	0.941	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	466	gp120, V5 loop, beta24	E	0.205	0.091	0.239	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	DRVIA7 contact
196	DRVIA7 contacts	Kong2016	contacts	DRVIA7(CD4BS)	cryo-EM, X-ray crystallography	473	gp120	G	0.042	0.033	0.029	DRVIA7 contact
197	PGT121 resistance after immunotherapy	Stephenson2021	immunotherapy	PGT121(V3)	sequence analysis	325	gp120, V3 loop	N	0.648	0.622	0.622	mutations at 325, particularly mutations from D to N, E or K, were associated with resistance to PGT121 in multiple patients during PGT121 immunotherapy
197	PGT121 resistance after immunotherapy	Stephenson2021	immunotherapy	PGT121(V3)	sequence analysis	332	gp120	N	0.663	0.491	0.693	loss of glycan N332, often together with certain mutations at 325, were associated with resistance to PGT121 in multiple patients during PGT121 immunotherapy
198	2F5 and 4E10 signature sites	Wang2011b	signature	2F5(MPER), 4E10(MPER)	computational prediction	22	Signal peptide	L	0.732	0.187	0.227	L associated with sensitivity; 22L and 29S sites were always coincident
198	2F5 and 4E10 signature sites	Wang2011b	signature	2F5(MPER), 4E10(MPER)	computational prediction	29	Signal peptide	S	1.060	0.660	1.376	S associated with sensitivity; 22L and 29S sites were always coincident
198	2F5 and 4E10 signature sites	Wang2011b	signature	2F5(MPER), 4E10(MPER)	computational prediction	706	gp41, gp41 cytoplasmic tail	N	0.453	0.312	0.722	N associated with sensitivity
199	PGZL1 contacts	Zhang2019a	contacts	PGZL1(MPER)		672	gp41	W	0.014	0.023	0.014	PGZL1 contact
199	PGZL1 contacts	Zhang2019a	contacts	PGZL1(MPER)		673	gp41	F	0.048	0.065	0.073	PGZL1 contact
199	PGZL1 contacts	Zhang2019a	contacts	PGZL1(MPER)		674	gp41	N	1.179	1.029	1.344	MPER polymorphisms D674S, D674T, and D674E are predicted to contact PGZL1
199	PGZL1 contacts	Zhang2019a	contacts	PGZL1(MPER)		675	gp41	I	0.063	0.059	0.069	PGZL1 contact
199	PGZL1 contacts	Zhang2019a	contacts	PGZL1(MPER)		676	gp41	T	0.671	0.610	0.674	PGZL1 contact
199	PGZL1 contacts	Zhang2019a	contacts	PGZL1(MPER)		677	gp41	N	1.203	1.199	1.100	PGZL1 contact
199	PGZL1 contacts	Zhang2019a	contacts	PGZL1(MPER)		679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	PGZL1 contact
199	PGZL1 contacts	Zhang2019a	contacts	PGZL1(MPER)		680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	PGZL1 contact
199	PGZL1 contacts	Zhang2019a	contacts	PGZL1(MPER)		681	gp41, gp41 transmembrane	Y	0.020	0.012	0.036	PGZL1 contact
200	LN01 contacts	Pinto2019	contacts	LN01(MPER)		671	gp41	N	0.783	0.669	0.885	contact with LN01 heavy chain residue Tyr 58
200	LN01 contacts	Pinto2019	contacts	LN01(MPER)		673	gp41	F	0.048	0.065	0.073	contact with LN01 heavy chain residues Thr 50 and Trp 100h; contact with light chain residue Trp 96
200	LN01 contacts	Pinto2019	contacts	LN01(MPER)		674	gp41	N	1.179	1.029	1.344	contact with LN01 light chain residues Ser 93 and Thr 94
200	LN01 contacts	Pinto2019	contacts	LN01(MPER)		676	gp41	T	0.671	0.610	0.674	contact with LN01 heavy chain residues Ser 100f and Trp 100h
200	LN01 contacts	Pinto2019	contacts	LN01(MPER)		677	gp41	N	1.203	1.199	1.100	contact with LN01 light chain residues Tyr 32 and His 92
200	LN01 contacts	Pinto2019	contacts	LN01(MPER)		680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	contact with LN01 heavy chain residues Phe 100e and Ser 100f
200	LN01 contacts	Pinto2019	contacts	LN01(MPER)		683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	contact with LN01 heavy chain residues Phe 100, Trp 100a, and Ser 100b
200	LN01 contacts	Pinto2019	contacts	LN01(MPER)		687	gp41, gp41 transmembrane	M	0.293	0.263	0.330	contact with LN01 heavy chain residue Trp 100a
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		123	gp120	T	0.047	0.028	0.038	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		276	gp120, Loop D	N	0.118	0.063	0.169	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		278	gp120, Loop D	T	0.708	0.715	0.481	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		279	gp120, Loop D	D	0.900	0.850	0.898	N60P23 contact (based on 93TH057 strain with 279N)
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		281	gp120, Loop D	A	1.129	0.814	1.357	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		282	gp120, Loop D	K	0.336	0.337	0.297	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		365	gp120, CD4 binding loop	S	0.602	0.489	0.619	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		366	gp120, CD4 binding loop	G	0.043	0.012	0.028	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		367	gp120, CD4 binding loop	G	0.042	0.034	0.008	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		368	gp120, CD4 binding loop	D	0.039	0.023	0.029	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		371	gp120, CD4 binding loop	I	0.466	0.389	0.507	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		430	gp120, beta20/beta21	V	0.267	0.080	0.073	N60P23 contact (based on 93TH057 strain with 430T)
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		431	gp120, beta20/beta21	G	0.072	0.036	0.039	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		432	gp120, beta20/beta21	K	1.037	0.339	0.564	N60P23 contact (based on 93TH057 strain with 432Q)
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		455	gp120, beta23	T	0.709	0.426	0.972	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		456	gp120, beta23	R	0.233	0.079	0.323	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		457	gp120, beta23	D	0.079	0.054	0.043	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		458	gp120, beta23	G	0.112	0.045	0.095	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	N60P23 contact (based on 93TH057 strain with 460A)
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	N60P23 contact (based on 93TH057 strain with 461N)
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		472	gp120	G	0.035	0.012	0.043	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		473	gp120	G	0.042	0.033	0.029	N60P23 contact
201	N60P23 contacts	Sajadi2018	contacts	N60P23(CD4BS)		474	gp120	D	0.696	0.681	0.752	N60P23 contact (based on 93TH057 strain with 474N)
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		97	gp120	K	0.478	0.421	0.511	N49P7 contact, hydrogen bond with CDR H3
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		275	gp120, Loop D	V	1.141	1.420	0.535	N49P7 contact, based on 93TH057 strain with 275E
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		276	gp120, Loop D	N	0.118	0.063	0.169	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		278	gp120, Loop D	T	0.708	0.715	0.481	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		279	gp120, Loop D	D	0.900	0.850	0.898	N49P7 contact, based on 93TH057 strain with 279N
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		281	gp120, Loop D	A	1.129	0.814	1.357	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		282	gp120, Loop D	K	0.336	0.337	0.297	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		365	gp120, CD4 binding loop	S	0.602	0.489	0.619	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		366	gp120, CD4 binding loop	G	0.043	0.012	0.028	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		367	gp120, CD4 binding loop	G	0.042	0.034	0.008	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		368	gp120, CD4 binding loop	D	0.039	0.023	0.029	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		371	gp120, CD4 binding loop	I	0.466	0.389	0.507	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		428	gp120, beta20/beta21	Q	0.062	0.053	0.054	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		429	gp120, beta20/beta21	K	1.325	0.961	1.308	N49P7 contact, based on 93TH057 strain with 429G
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		455	gp120, beta23	T	0.709	0.426	0.972	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		456	gp120, beta23	R	0.233	0.079	0.323	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		457	gp120, beta23	D	0.079	0.054	0.043	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		458	gp120, beta23	G	0.112	0.045	0.095	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		471	gp120, beta24	G	0.933	0.888	0.866	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		473	gp120	G	0.042	0.033	0.029	N49P7 contact
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		474	gp120	D	0.696	0.681	0.752	N49P7 contact, hydrogen bond with CDR H2, based on 93TH057 strain with 474N
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		476	gp120	R	0.663	0.615	0.711	N49P7 contact, based on 93TH057 strain with 476K
202	N49P7 contacts	Sajadi2018	contacts	N49P7(CD4BS)		477	gp120	D	0.191	0.112	0.249	N49P7 contact, salt bridge with CDR H3
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		61	gp120	Y	0.271	0.299	0.148	N49P6 contact: hydrogen bond with CDR H3
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		64	gp120	E	0.025	0.022	0.008	N49P6 contacts: hydrogen bonds with CDR H1 & CDR H3
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		65	gp120	V	1.017	1.023	0.310	N49P6 contact: hydrogen bond & van der Waals with HC FWR1 (based on BG505 SOSIP.664 strain 65K)
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		66	gp120	H	0.010	0.017	0.000	N49P6 contact: hydrogen bond with HC FWR1
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		96	gp120	W	0.063	0.091	0.020	N49P6 contact
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		102	gp120	E	0.782	0.522	0.426	N49P6 contacts: CDR H2 & CDR H3
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		275	gp120, Loop D	V	1.141	1.420	0.535	N49P6 contact: CDR H3 (based on 93TH057 strain with 275E)
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		276	gp120, Loop D	N	0.118	0.063	0.169	N49P6 contacts: CDR H3, CDR L1, CDR L3; CDR L3 also contacts 276-linked carbohydrate
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		278	gp120, Loop D	T	0.708	0.715	0.481	N49P6 contact: van der Waals with CDR L3
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		279	gp120, Loop D	D	0.900	0.850	0.898	N49P6 contacts: hydrogen bond with CDR H3, & van der Waals with CDR L3 (based on BG505 SOSIP.664 & 93TH057 strains with 279N)
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		280	gp120, Loop D	N	0.142	0.090	0.170	N49P6 contacts: hydrogen bonds with CDR H2 & CDR L3
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		281	gp120, Loop D	A	1.129	0.814	1.357	N49P6 contact: CDR H3
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		282	gp120, Loop D	K	0.336	0.337	0.297	N49P6 contact: CDR H3
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		365	gp120, CD4 binding loop	S	0.602	0.489	0.619	N49P6 contact: CDR H2 antiparallel beta-sheet
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		366	gp120, CD4 binding loop	G	0.043	0.012	0.028	N49P6 contacts: CDR H2 antiparallel beta-sheet, weak hydrogen bond with CDR H2
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		367	gp120, CD4 binding loop	G	0.042	0.034	0.008	N49P6 contact: CDR H2 antiparallel beta-sheet
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		368	gp120, CD4 binding loop	D	0.039	0.023	0.029	N49P6 contacts: CDR H2 antiparallel beta-sheet; salt bridge with HC FWR3
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		371	gp120, CD4 binding loop	I	0.466	0.389	0.507	N49P6 contact (based on BG505 SOSIP.664 strain with 371V & 93TH057 strain with 371I)
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		428	gp120, beta20/beta21	Q	0.062	0.053	0.054	N49P6 contact
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		430	gp120, beta20/beta21	V	0.267	0.080	0.073	N49P6 contact (based on BG505 SOSIP.664 strain with 430I & 93TH057 strain with 430V)
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		455	gp120, beta23	T	0.709	0.426	0.972	N49P6 contact: CDR H2
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		456	gp120, beta23	R	0.233	0.079	0.323	N49P6 contact: CDR H2
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		457	gp120, beta23	D	0.079	0.054	0.043	N49P6 contact: CDR H2
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		458	gp120, beta23	G	0.112	0.045	0.095	N49P6 contacts: CDR H2 & CDR L3
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	N49P6 contacts: CDR H2; hydrogen bond with CDR L3
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	N49P6 contact (based on BG505 SOSIP.664 strain with 460S)
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		465	gp120, V5-hypervariable, V5 loop, beta24	S	1.567	1.466	1.517	N49P6 contact (based on BG505 SOSIP.664 strain with 465T)
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		466	gp120, V5 loop, beta24	E	0.205	0.091	0.239	N49P6 contact
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		467	gp120, V5 loop, beta24	I	0.912	0.955	0.870	N49P6 contact (based on BG505 SOSIP.664 strain with 467T)
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	N49P6 contact
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		472	gp120	G	0.035	0.012	0.043	N49P6 contact
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		473	gp120	G	0.042	0.033	0.029	N49P6 contact: CDR H2 & CDR H3
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		474	gp120	D	0.696	0.681	0.752	N49P6 contact: CDR H2 & CDR H3 (based on BG505 SOSIP.664 strain with 474D & 93TH057 strain with 474N)
203	N49P6 contacts	Tolbert2021	contacts	N49P6(CD4BS)		476	gp120	R	0.663	0.615	0.711	N49P6 contact: CDR H2 & CDR H3 (based on BG505 SOSIP.664 strain with 476R & 93TH057 strain with 476K)
204	VRC-PG05 contacts	Zhou2018	contacts	VRC-PG05(silent face)		262	gp120	N	0.027	0.029	0.028	VRC-PG05 contact
204	VRC-PG05 contacts	Zhou2018	contacts	VRC-PG05(silent face)		293	gp120	E	2.057	1.967	1.722	VRC-PG05 contact
204	VRC-PG05 contacts	Zhou2018	contacts	VRC-PG05(silent face)		295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	VRC-PG05 contact
204	VRC-PG05 contacts	Zhou2018	contacts	VRC-PG05(silent face)		446	gp120	S	1.957	1.139	1.774	VRC-PG05 contact
204	VRC-PG05 contacts	Zhou2018	contacts	VRC-PG05(silent face)		447	gp120	S	0.034	0.024	0.023	VRC-PG05 contact
204	VRC-PG05 contacts	Zhou2018	contacts	VRC-PG05(silent face)		448	gp120	N	0.662	0.448	0.927	VRC-PG05 contact
205	VRC-PG05 sensitivity and escape	Zhou2018	neutralization	VRC-PG05(silent face)	neutralization assay	291	gp120	S	1.161	1.292	0.739	S291 required for sensitivity to VRC-PG05, based on neutralization panel data
205	VRC-PG05 sensitivity and escape	Zhou2018	neutralization	VRC-PG05(silent face)	neutralization assay	293	gp120	E	2.057	1.967	1.722	E293 required for sensitivity to VRC-PG05, based on neutralization panel data; mutation of N448 or E293 were dominant means of escape from VRC-PG05
205	VRC-PG05 sensitivity and escape	Zhou2018	neutralization	VRC-PG05(silent face)	neutralization assay	362	gp120	K	1.815	1.265	1.997	362 associated with sensitivity to VRC-PG05, based on neutralization panel data
205	VRC-PG05 sensitivity and escape	Zhou2018	neutralization	VRC-PG05(silent face)	neutralization assay	375	gp120	S	0.668	0.753	0.372	375 associated with sensitivity to VRC-PG05, based on neutralization panel data
205	VRC-PG05 sensitivity and escape	Zhou2018	neutralization	VRC-PG05(silent face)	neutralization assay	448	gp120	N	0.662	0.448	0.927	mutation of N448 or E293 were dominant means of escape from VRC-PG05
206	Q563R affects neutralization of MPER mAbs	Joshi2020	neutralization	10E8(MPER), 2F5(MPER), 4E10(MPER), 7H6(MPER), Z13e1(MPER)	neutralization assay	563	gp41, Leu/Ile zipper-like sequence	Q	0.093	0.086	0.050	Q563R allows for better binding and increased sensitivity to neutralization by MPER mAbs; Q563R dramatically decreases viral infectivity by disrupting membrane fusion and 6-helix bundle formation
207	m36 contacts	Wan2013	contacts	m36(CD4i)	computational prediction, molecular modeling, mutational analysis	123	gp120	T	0.047	0.028	0.038	m36 contact
207	m36 contacts	Wan2013	contacts	m36(CD4i)	computational prediction, molecular modeling, mutational analysis	124	gp120	P	0.045	0.018	0.029	m36 contact
207	m36 contacts	Wan2013	contacts	m36(CD4i)	computational prediction, molecular modeling, mutational analysis	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	m36 contact
207	m36 contacts	Wan2013	contacts	m36(CD4i)	computational prediction, molecular modeling, mutational analysis	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	m36 contact
207	m36 contacts	Wan2013	contacts	m36(CD4i)	computational prediction, molecular modeling, mutational analysis	426	gp120, beta20/beta21	M	0.724	0.866	0.274	m36 contact
207	m36 contacts	Wan2013	contacts	m36(CD4i)	computational prediction, molecular modeling, mutational analysis	427	gp120, beta20/beta21	W	0.083	0.061	0.038	m36 contact
208	CAP257-RH1 contacts	Wibmer2016	contacts	CAP257-RH1(CD4BS)		276	gp120, Loop D	N	0.118	0.063	0.169	RH1 contact
208	CAP257-RH1 contacts	Wibmer2016	contacts	CAP257-RH1(CD4BS)		460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	RH1 contact
208	CAP257-RH1 contacts	Wibmer2016	contacts	CAP257-RH1(CD4BS)		461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	RH1 contact
208	CAP257-RH1 contacts	Wibmer2016	contacts	CAP257-RH1(CD4BS)		462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	RH1 contact
208	CAP257-RH1 contacts	Wibmer2016	contacts	CAP257-RH1(CD4BS)		463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	RH1 contact
208	CAP257-RH1 contacts	Wibmer2016	contacts	CAP257-RH1(CD4BS)		465	gp120, V5-hypervariable, V5 loop, beta24	S	1.567	1.466	1.517	RH1 contact
209	Mutation affects CAP257-RH1 neutralization	Wibmer2016	neutralization	CAP257-RH1(CD4BS)	neutralization assay	276	gp120, Loop D	N	0.118	0.063	0.169	N276Q abrogates neutralization of strain RHPA
209	Mutation affects CAP257-RH1 neutralization	Wibmer2016	neutralization	CAP257-RH1(CD4BS)	neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	T278A abrogates neutralization of strain RHPA
210	PGT145 contacts	Chuang2019	contacts	PGT145(V2)	X-ray crystallography	121	gp120	K	0.349	0.360	0.187	PGT145 contact
210	PGT145 contacts	Chuang2019	contacts	PGT145(V2)	X-ray crystallography	123	gp120	T	0.047	0.028	0.038	PGT145 contact
210	PGT145 contacts	Chuang2019	contacts	PGT145(V2)	X-ray crystallography	124	gp120	P	0.045	0.018	0.029	PGT145 contact
210	PGT145 contacts	Chuang2019	contacts	PGT145(V2)	X-ray crystallography	127	gp120	V	0.102	0.112	0.093	PGT145 contact
210	PGT145 contacts	Chuang2019	contacts	PGT145(V2)	X-ray crystallography	160	gp120, V2	N	0.416	0.452	0.358	PGT145 glycan contact
210	PGT145 contacts	Chuang2019	contacts	PGT145(V2)	X-ray crystallography	161	gp120, V2	I	1.493	0.964	1.568	PGT145 contact
210	PGT145 contacts	Chuang2019	contacts	PGT145(V2)	X-ray crystallography	162	gp120, V2	S	0.353	0.445	0.179	PGT145 contact
210	PGT145 contacts	Chuang2019	contacts	PGT145(V2)	X-ray crystallography	166	gp120, V2	R	1.237	1.398	0.772	PGT145 contact
210	PGT145 contacts	Chuang2019	contacts	PGT145(V2)	X-ray crystallography	167	gp120, V2	G	0.779	1.122	0.185	PGT145 contact
210	PGT145 contacts	Chuang2019	contacts	PGT145(V2)	X-ray crystallography	168	gp120, V2	K	0.566	0.666	0.396	PGT145 contact
210	PGT145 contacts	Chuang2019	contacts	PGT145(V2)	X-ray crystallography	169	gp120, V2	V	2.042	1.770	1.344	PGT145 contact
210	PGT145 contacts	Chuang2019	contacts	PGT145(V2)	X-ray crystallography	309	gp120, V3 loop	I	0.863	0.359	0.965	PGT145 contact
210	PGT145 contacts	Chuang2019	contacts	PGT145(V2)	X-ray crystallography	315	gp120, V3 loop	R	1.211	1.028	0.196	PGT145 contact
211	PG9 contacts	Chuang2019	contacts	PG9(V2)	X-ray crystallography	157	gp120, Cys 131 linked to Cys 157 forms V1 loop	C	0.024	0.017	0.031	PG9 contact
211	PG9 contacts	Chuang2019	contacts	PG9(V2)	X-ray crystallography	158	gp120, V2	S	0.263	0.185	0.291	PG9 contact
211	PG9 contacts	Chuang2019	contacts	PG9(V2)	X-ray crystallography	160	gp120, V2	N	0.416	0.452	0.358	PG9 glycan contact
211	PG9 contacts	Chuang2019	contacts	PG9(V2)	X-ray crystallography	162	gp120, V2	S	0.353	0.445	0.179	PG9 contact
211	PG9 contacts	Chuang2019	contacts	PG9(V2)	X-ray crystallography	163	gp120, V2	T	0.463	0.638	0.154	PG9 contact
211	PG9 contacts	Chuang2019	contacts	PG9(V2)	X-ray crystallography	166	gp120, V2	R	1.237	1.398	0.772	PG9 contact
211	PG9 contacts	Chuang2019	contacts	PG9(V2)	X-ray crystallography	167	gp120, V2	G	0.779	1.122	0.185	PG9 contact
211	PG9 contacts	Chuang2019	contacts	PG9(V2)	X-ray crystallography	168	gp120, V2	K	0.566	0.666	0.396	PG9 contact
211	PG9 contacts	Chuang2019	contacts	PG9(V2)	X-ray crystallography	169	gp120, V2	V	2.042	1.770	1.344	PG9 contact
211	PG9 contacts	Chuang2019	contacts	PG9(V2)	X-ray crystallography	170	gp120, V2	Q	1.493	1.423	1.428	PG9 contact
211	PG9 contacts	Chuang2019	contacts	PG9(V2)	X-ray crystallography	171	gp120, V2	K	1.247	0.957	1.413	PG9 contact
211	PG9 contacts	Chuang2019	contacts	PG9(V2)	X-ray crystallography	172	gp120, V2	E	1.527	1.172	1.484	PG9 contact
211	PG9 contacts	Chuang2019	contacts	PG9(V2)	X-ray crystallography	173	gp120, V2	Y	1.059	0.808	1.158	PG9 glycan contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	134	gp120, V1-hypervariable, V1	L	2.224	2.322	1.627	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	135	gp120, V1-hypervariable, V1	K	2.230	2.373	1.848	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	136	gp120, V1-hypervariable, V1	N	2.514	2.300	2.581	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	139	gp120, V1-hypervariable, V1	N	2.097	1.946	2.163	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	140	gp120, V1-hypervariable, V1	T	2.235	2.104	2.340	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	156	gp120, V1	N	0.246	0.220	0.224	PGT121 glycan contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	301	gp120, V3 loop	N	0.172	0.176	0.104	PGT121 glycan contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	321	gp120, V3 loop	G	1.042	0.842	1.108	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	322	gp120, V3 loop	K	1.797	0.347	0.283	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	323	gp120, V3 loop	I	0.476	0.531	0.263	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	324	gp120, V3 loop	G	0.075	0.056	0.092	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	325	gp120, V3 loop	N	0.648	0.622	0.622	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	326	gp120, V3 loop	M	0.143	0.143	0.116	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	327	gp120, V3 loop	R	0.089	0.066	0.073	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	328	gp120, V3 loop	Q	0.923	0.816	0.882	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	330	gp120, V3 loop	H	0.634	0.559	0.655	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	332	gp120	N	0.663	0.491	0.693	PGT121 glycan contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	415	gp120, V4 loop	T	0.754	0.760	0.656	PGT121 contact
212	PGT121 contacts	Chuang2019	contacts	PGT121(V3)	X-ray crystallography	417	gp120, V4 loop	P	0.864	0.736	0.922	PGT121 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	105	gp120	H	0.342	0.429	0.187	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	122	gp120	L	0.150	0.101	0.121	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	123	gp120	T	0.047	0.028	0.038	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	124	gp120	P	0.045	0.018	0.029	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	198	gp120	T	0.430	0.264	0.469	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	199	gp120	S	0.094	0.108	0.068	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	257	gp120	T	0.029	0.024	0.015	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	275	gp120, Loop D	V	1.141	1.420	0.535	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	283	gp120, Loop D	T	1.005	1.091	0.474	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	364	gp120, CD4 binding loop	S	0.924	0.588	1.191	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	375	gp120	S	0.668	0.753	0.372	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	425	gp120, beta20/beta21	N	0.295	0.138	0.177	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	426	gp120, beta20/beta21	M	0.724	0.866	0.274	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	427	gp120, beta20/beta21	W	0.083	0.061	0.038	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	429	gp120, beta20/beta21	K	1.325	0.961	1.308	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	431	gp120, beta20/beta21	G	0.072	0.036	0.039	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	432	gp120, beta20/beta21	K	1.037	0.339	0.564	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	467	gp120, V5 loop, beta24	I	0.912	0.955	0.870	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	470	gp120, beta24	P	0.043	0.039	0.037	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	471	gp120, beta24	G	0.933	0.888	0.866	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	472	gp120	G	0.035	0.012	0.043	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	473	gp120	G	0.042	0.033	0.029	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	474	gp120	D	0.696	0.681	0.752	VRC16 contact
213	VRC16 contacts	Chuang2019	contacts	VRC16(CD4BS)	X-ray crystallography	477	gp120	D	0.191	0.112	0.249	VRC16 contact
214	VRC34.01 contacts	Kong2016a	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	88	gp120	N	0.050	0.041	0.048	glycan forms H-bonds and favorable interactions (Kong2016a)
214	VRC34.01 contacts	Kong2016a	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	interacts with hydrophobic pocket (Kong2016a)
214	VRC34.01 contacts	Kong2016a	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	interacts with hydrophobic pocket (Kong2016a)
214	VRC34.01 contacts	Kong2016a	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	interacts with hydrophobic pocket (Kong2016a)
214	VRC34.01 contacts	Kong2016a	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	interacts with hydrophobic pocket (Kong2016a)
214	VRC34.01 contacts	Kong2016a	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	interacts with hydrophobic pocket (Kong2016a)
214	VRC34.01 contacts	Kong2016a	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	518	gp41, fusion peptide	L	1.166	1.110	0.718	interacts with hydrophobic pocket (Kong2016a)
214	VRC34.01 contacts	Kong2016a	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	stacks side chains with CDRH2  (Kong2016a)
215	Mutation affects NC-Cow1 binding	Sok2017	binding	NC-Cow1(CD4BS)	alanine scanning, binding assay	262	gp120	N	0.027	0.029	0.028	N262A reduces NC-Cow1 binding to JRCSF
215	Mutation affects NC-Cow1 binding	Sok2017	binding	NC-Cow1(CD4BS)	alanine scanning, binding assay	282	gp120, Loop D	K	0.336	0.337	0.297	K282A reduces NC-Cow1 binding to BG505
215	Mutation affects NC-Cow1 binding	Sok2017	binding	NC-Cow1(CD4BS)	alanine scanning, binding assay	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	G367A reduces NC-Cow1 binding to BG505
215	Mutation affects NC-Cow1 binding	Sok2017	binding	NC-Cow1(CD4BS)	alanine scanning, binding assay	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	L369A reduces NC-Cow1 binding to BG505
215	Mutation affects NC-Cow1 binding	Sok2017	binding	NC-Cow1(CD4BS)	alanine scanning, binding assay	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	V371A reduces NC-Cow1 binding to BG505
215	Mutation affects NC-Cow1 binding	Sok2017	binding	NC-Cow1(CD4BS)	alanine scanning, binding assay	372	gp120, CD4 binding loop	V	1.105	0.776	0.391	T372A reduces NC-Cow1 binding to JRCSF
215	Mutation affects NC-Cow1 binding	Sok2017	binding	NC-Cow1(CD4BS)	alanine scanning, binding assay	472	gp120	G	0.035	0.012	0.043	G472A reduces NC-Cow1 binding to BG505 and JRCSF
215	Mutation affects NC-Cow1 binding	Sok2017	binding	NC-Cow1(CD4BS)	alanine scanning, binding assay	473	gp120	G	0.042	0.033	0.029	G473A reduces NC-Cow1 binding to JRCSF
215	Mutation affects NC-Cow1 binding	Sok2017	binding	NC-Cow1(CD4BS)	alanine scanning, binding assay	476	gp120	R	0.663	0.615	0.711	R476A reduces NC-Cow1 binding to JRCSF
216	Mutation affects binding of MEL-1872	Heydarchi2022	binding	MEL-1872(CD4BS)	alanine scanning, binding assay	262	gp120	N	0.027	0.029	0.028	N262A decreases binding
216	Mutation affects binding of MEL-1872	Heydarchi2022	binding	MEL-1872(CD4BS)	alanine scanning, binding assay	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	G366A decreases binding
216	Mutation affects binding of MEL-1872	Heydarchi2022	binding	MEL-1872(CD4BS)	alanine scanning, binding assay	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	I371A decreases binding and significantly affects neutralization
216	Mutation affects binding of MEL-1872	Heydarchi2022	binding	MEL-1872(CD4BS)	alanine scanning, binding assay	455	gp120, beta23	T	0.709	0.426	0.972	T455A decreases binding
216	Mutation affects binding of MEL-1872	Heydarchi2022	binding	MEL-1872(CD4BS)	alanine scanning, binding assay	457	gp120, beta23	D	0.079	0.054	0.043	D457A decreases binding
216	Mutation affects binding of MEL-1872	Heydarchi2022	binding	MEL-1872(CD4BS)	alanine scanning, binding assay	471	gp120, beta24	G	0.933	0.888	0.866	G471A decreases binding and significantly affects neutralization
216	Mutation affects binding of MEL-1872	Heydarchi2022	binding	MEL-1872(CD4BS)	alanine scanning, binding assay	472	gp120	G	0.035	0.012	0.043	G472A decreases binding
216	Mutation affects binding of MEL-1872	Heydarchi2022	binding	MEL-1872(CD4BS)	alanine scanning, binding assay	473	gp120	G	0.042	0.033	0.029	G473A decreases binding
216	Mutation affects binding of MEL-1872	Heydarchi2022	binding	MEL-1872(CD4BS)	alanine scanning, binding assay	474	gp120	D	0.696	0.681	0.752	D474A decreases binding
217	7-269 contacts	Lorin2022	contacts	7-269(glycan)	cryo-EM	262	gp120	N	0.027	0.029	0.028	glycan contact
217	7-269 contacts	Lorin2022	contacts	7-269(glycan)	cryo-EM	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	glycan contact
217	7-269 contacts	Lorin2022	contacts	7-269(glycan)	cryo-EM	332	gp120	N	0.663	0.491	0.693	glycan contact
217	7-269 contacts	Lorin2022	contacts	7-269(glycan)	cryo-EM	334	gp120	S	0.717	0.501	0.890	Van der Waals contact
217	7-269 contacts	Lorin2022	contacts	7-269(glycan)	cryo-EM	411	gp120, V4 loop	S	1.657	1.682	1.577	Van der Waals contact
217	7-269 contacts	Lorin2022	contacts	7-269(glycan)	cryo-EM	412	gp120, V4 loop	D	2.245	2.094	2.182	Van der Waals contact
217	7-269 contacts	Lorin2022	contacts	7-269(glycan)	cryo-EM	413	gp120, V4 loop	T	1.512	1.451	1.561	Van der Waals contact
217	7-269 contacts	Lorin2022	contacts	7-269(glycan)	cryo-EM	444	gp120	R	1.747	1.507	0.494	Van der Waals contact
217	7-269 contacts	Lorin2022	contacts	7-269(glycan)	cryo-EM	446	gp120	S	1.957	1.139	1.774	Van der Waals contact
218	VRC01.23LS primary contacts	Kwon2021	contacts	VRC01.23LS(CD4BS)	cryo-EM	276	gp120, Loop D	N	0.118	0.063	0.169	hydrogen bonding networks between glycan at 276 of gp120 and Arg66 of VRC01.23 light chain
218	VRC01.23LS primary contacts	Kwon2021	contacts	VRC01.23LS(CD4BS)	cryo-EM	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	distance of 9.5A between Thr461 of gp120 and Leu4 of VRC01.23
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	117	gp120	K	0.159	0.084	0.120	PGT145 contact
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	121	gp120	K	0.349	0.360	0.187	PGT145 contact
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	156	gp120, V1	N	0.246	0.220	0.224	N156 interaction with PGT145 paratope residue Y173 stabilizes V1/V2 and restricts glycan conformations
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	160	gp120, V2	N	0.416	0.452	0.358	N160 interaction with PGT145 paratope residue K171 stabilizes V1/V2 and restricts glycan conformations
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	161	gp120, V2	I	1.493	0.964	1.568	PGT145 contact
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	162	gp120, V2	S	0.353	0.445	0.179	PGT145 contact
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	164	gp120, V2	S	1.840	1.925	0.453	PGT145 contact
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	165	gp120, V2	I	1.327	1.292	1.011	PGT145 contact
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	166	gp120, V2	R	1.237	1.398	0.772	PGT145 contact
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	167	gp120, V2	G	0.779	1.122	0.185	PGT145 contact
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	168	gp120, V2	K	0.566	0.666	0.396	PGT145 contact
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	169	gp120, V2	V	2.042	1.770	1.344	PGT145 contact
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	170	gp120, V2	Q	1.493	1.423	1.428	PGT145 contact
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	171	gp120, V2	K	1.247	0.957	1.413	PGT145 contact
219	PGT145 epitope	Lee2017	contacts	PGT145(V2)	X-ray crystallography	315	gp120, V3 loop	R	1.211	1.028	0.196	PGT145 contact
220	Mutation affects 3BNC117 neutralization	Schommers2020	neutralization	3BNC117(CD4BS)	neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	YU2 double mutation N278I/A281T decreases 3BNC117 neutralization >80 fold
220	Mutation affects 3BNC117 neutralization	Schommers2020	neutralization	3BNC117(CD4BS)	neutralization assay	279	gp120, Loop D	D	0.900	0.850	0.898	YU2 mutation N279K decreases 3BNC117 neutralization >80 fold
220	Mutation affects 3BNC117 neutralization	Schommers2020	neutralization	3BNC117(CD4BS)	neutralization assay	280	gp120, Loop D	N	0.142	0.090	0.170	YU2 mutation N280Y decreases 3BNC117 neutralization >9 fold
220	Mutation affects 3BNC117 neutralization	Schommers2020	neutralization	3BNC117(CD4BS)	neutralization assay	281	gp120, Loop D	A	1.129	0.814	1.357	YU2 mutation A281T, or double mutation N278I/A281T, decreases 3BNC117 neutralization >80 fold
221	Mutation affects VRC01 neutralization	Kong2016a	neutralization	VRC01(CD4BS)	neutralization assay	197	gp120	N	0.133	0.082	0.109	N197D enhances neutralization of BG505
222	Mutation affects N6 neutralization	Schommers2020	neutralization	N6(CD4BS)	neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	YU2 mutation A281T decreases N6 neutralization 15 fold; double mutation T278I/A281T decreases N6 neutralization >50 fold
222	Mutation affects N6 neutralization	Schommers2020	neutralization	N6(CD4BS)	neutralization assay	281	gp120, Loop D	A	1.129	0.814	1.357	YU2 double mutation T278I/A281T decreases N6 neutralization >50 fold
223	Mutation affects 8ANC131 neutralization	Schommers2020	neutralization	8ANC131(CD4BS)	neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	YU2 double mutation T278I/A281T decreases 8ANC195 neutralization >9 fold
223	Mutation affects 8ANC131 neutralization	Schommers2020	neutralization	8ANC131(CD4BS)	neutralization assay	279	gp120, Loop D	D	0.900	0.850	0.898	YU2 N279K decreases 8ANC131 neutralization >9 fold
223	Mutation affects 8ANC131 neutralization	Schommers2020	neutralization	8ANC131(CD4BS)	neutralization assay	280	gp120, Loop D	N	0.142	0.090	0.170	YU2 N280Y decreases 8ANC131 neutralization >9 fold
223	Mutation affects 8ANC131 neutralization	Schommers2020	neutralization	8ANC131(CD4BS)	neutralization assay	281	gp120, Loop D	A	1.129	0.814	1.357	YU2 A281T decreases 8ANC131 neutralization >9 fold; double mutation T278I/A281T decreases 8ANC195 neutralization >9 fold
223	Mutation affects 8ANC131 neutralization	Schommers2020	neutralization	8ANC131(CD4BS)	neutralization assay	458	gp120, beta23	G	0.112	0.045	0.095	YU2 G458D decreases 8ANC131 neutralization 5 fold
223	Mutation affects 8ANC131 neutralization	Schommers2020	neutralization	8ANC131(CD4BS)	neutralization assay	471	gp120, beta24	G	0.933	0.888	0.866	YU2 G471R decreases 8ANC131 neutralization >9 fold
224	Mutation affects 8ANC195 neutralization	Kong2016a	neutralization	8ANC195(gp120/gp41 interface)	neutralization assay	234	gp120	N	0.598	0.757	0.341	N234A abrogates neutralization of BG505
224	Mutation affects 8ANC195 neutralization	Kong2016a	neutralization	8ANC195(gp120/gp41 interface)	neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	T278A abrogates neutralization of BG505
225	Mutation affects neutralization of PGDM1400 and PG16	Schommers2020	neutralization	PG16(V2), PGDM1400(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	YU2 mutations N160K or N160T decrease neutralization >6 fold
225	Mutation affects neutralization of PGDM1400 and PG16	Schommers2020	neutralization	PG16(V2), PGDM1400(V2)	neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	YU2 mutations T162I or T162N decrease neutralization >6 fold
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	197	gp120	N	0.133	0.082	0.109	CDRH1 contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	198	gp120	T	0.430	0.264	0.469	heavy chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	207	gp120	K	0.065	0.029	0.029	CDRH1 contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	276	gp120, Loop D	N	0.118	0.063	0.169	light chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	279	gp120, Loop D	D	0.900	0.850	0.898	light chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	280	gp120, Loop D	N	0.142	0.090	0.170	light chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	281	gp120, Loop D	A	1.129	0.814	1.357	light and heavy chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	282	gp120, Loop D	K	0.336	0.337	0.297	heavy chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	283	gp120, Loop D	T	1.005	1.091	0.474	heavy chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	304	gp120, V3 loop	R	0.304	0.390	0.141	CDRH1 contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	306	gp120, V3 loop	R	0.714	0.860	0.338	CDRH1 contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	308	gp120, V3 loop	R	1.578	0.091	0.127	CDRH1 contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	316	gp120, V3 loop	A	1.056	0.736	0.966	CDRH1 contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	318	gp120, V3 loop	V	0.588	0.691	0.507	CDRH1 contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	heavy chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	heavy chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	heavy chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	heavy chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	heavy chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	457	gp120, beta23	D	0.079	0.054	0.043	heavy chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	458	gp120, beta23	G	0.112	0.045	0.095	heavy chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	heavy chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	heavy chain contact
226	561_01_18 contacts	Schommers2020	contacts	561_01_18(CD4BS)	cryo-EM	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	light chain contact
227	561_01_18 escape mutations	Schommers2020	neutralization	561_01_18(CD4BS)	mutational analysis	119	gp120, Cys 119 linked to Cys 205	C	0.022	0.012	0.022	escape mutations in BG505; mutations at C119 may reduce accessibility to the highly conserved K207 by disordering the V1/V2 loop structure
227	561_01_18 escape mutations	Schommers2020	neutralization	561_01_18(CD4BS)	mutational analysis	207	gp120	K	0.065	0.029	0.029	escape mutations in BG505 through disruption of interaction with CDRH1
227	561_01_18 escape mutations	Schommers2020	neutralization	561_01_18(CD4BS)	mutational analysis	304	gp120, V3 loop	R	0.304	0.390	0.141	escape mutations in BG505 through disruption of interaction with CDRH1
227	561_01_18 escape mutations	Schommers2020	neutralization	561_01_18(CD4BS)	mutational analysis	318	gp120, V3 loop	V	0.588	0.691	0.507	escape mutations in BG505 through disruption of interaction with CDRH1
228	Mutation decreases binding of m66 and m66.6	Zhu2011	binding	m66.6(CD4BS), m66(CD4BS)	alanine scanning, surface plasmon resonance	660	gp41	L	0.020	0.006	0.000	L660A abrogates binding to MPER peptide (Env residues 657-670)
228	Mutation decreases binding of m66 and m66.6	Zhu2011	binding	m66.6(CD4BS), m66(CD4BS)	alanine scanning, surface plasmon resonance	663	gp41	L	0.092	0.094	0.053	L663A abrogates binding to MPER peptide (Env residues 657-670)
228	Mutation decreases binding of m66 and m66.6	Zhu2011	binding	m66.6(CD4BS), m66(CD4BS)	alanine scanning, surface plasmon resonance	664	gp41	D	0.222	0.156	0.346	D664A abrogates binding to MPER peptide (Env residues 657-670)
228	Mutation decreases binding of m66 and m66.6	Zhu2011	binding	m66.6(CD4BS), m66(CD4BS)	alanine scanning, surface plasmon resonance	665	gp41	K	1.039	0.656	0.879	K665A abrogates binding to MPER peptide (Env residues 657-670)
228	Mutation decreases binding of m66 and m66.6	Zhu2011	binding	m66.6(CD4BS), m66(CD4BS)	alanine scanning, surface plasmon resonance	666	gp41	W	0.008	0.000	0.000	W666A abrogates binding to MPER peptide (Env residues 657-670)
229	CH58 contacts	Liao2013b	contacts	CH58(V2)	alanine scanning, binding assay, X-ray crystallography	168	gp120, V2	K	0.566	0.666	0.396	CH58 contact
229	CH58 contacts	Liao2013b	contacts	CH58(V2)	alanine scanning, binding assay, X-ray crystallography	169	gp120, V2	V	2.042	1.770	1.344	CH58 contact
229	CH58 contacts	Liao2013b	contacts	CH58(V2)	alanine scanning, binding assay, X-ray crystallography	171	gp120, V2	K	1.247	0.957	1.413	CH58 contact
229	CH58 contacts	Liao2013b	contacts	CH58(V2)	alanine scanning, binding assay, X-ray crystallography	172	gp120, V2	E	1.527	1.172	1.484	CH58 contact
229	CH58 contacts	Liao2013b	contacts	CH58(V2)	alanine scanning, binding assay, X-ray crystallography	173	gp120, V2	Y	1.059	0.808	1.158	CH58 contact
229	CH58 contacts	Liao2013b	contacts	CH58(V2)	alanine scanning, binding assay, X-ray crystallography	176	gp120, V2	F	0.189	0.303	0.042	CH58 contact
229	CH58 contacts	Liao2013b	contacts	CH58(V2)	alanine scanning, binding assay, X-ray crystallography	177	gp120, V2	Y	0.454	0.638	0.144	CH58 contact
229	CH58 contacts	Liao2013b	contacts	CH58(V2)	alanine scanning, binding assay, X-ray crystallography	178	gp120, V2	K	1.346	1.386	0.988	CH58 contact
229	CH58 contacts	Liao2013b	contacts	CH58(V2)	alanine scanning, binding assay, X-ray crystallography	180	gp120, V2	D	0.054	0.033	0.029	CH58 contact
229	CH58 contacts	Liao2013b	contacts	CH58(V2)	alanine scanning, binding assay, X-ray crystallography	183	gp120, V2	P	1.099	1.107	0.787	CH58 contact
230	CAP228-16H contacts	vanEeden2018	contacts	CAP228-16H(V2)	X-ray crystallography	168	gp120, V2	K	0.566	0.666	0.396	buried surface area >50A
230	CAP228-16H contacts	vanEeden2018	contacts	CAP228-16H(V2)	X-ray crystallography	172	gp120, V2	E	1.527	1.172	1.484	buried surface area >50A
230	CAP228-16H contacts	vanEeden2018	contacts	CAP228-16H(V2)	X-ray crystallography	173	gp120, V2	Y	1.059	0.808	1.158	buried surface area >50A
230	CAP228-16H contacts	vanEeden2018	contacts	CAP228-16H(V2)	X-ray crystallography	175	gp120, V2	F	0.606	0.868	0.271	buried surface area >50A
230	CAP228-16H contacts	vanEeden2018	contacts	CAP228-16H(V2)	X-ray crystallography	176	gp120, V2	F	0.189	0.303	0.042	buried surface area >50A
230	CAP228-16H contacts	vanEeden2018	contacts	CAP228-16H(V2)	X-ray crystallography	177	gp120, V2	Y	0.454	0.638	0.144	potential interaction between CAP228-16H and a sulfated tyrosine
230	CAP228-16H contacts	vanEeden2018	contacts	CAP228-16H(V2)	X-ray crystallography	178	gp120, V2	K	1.346	1.386	0.988	buried surface area >50A
230	CAP228-16H contacts	vanEeden2018	contacts	CAP228-16H(V2)	X-ray crystallography	180	gp120, V2	D	0.054	0.033	0.029	buried surface area >50A
231	438-B11 contacts	Kumar2020	contacts	438-B11(V3)	X-ray crystallography	156	gp120, V1	N	0.246	0.220	0.224	438-B11 contact
231	438-B11 contacts	Kumar2020	contacts	438-B11(V3)	X-ray crystallography	301	gp120, V3 loop	N	0.172	0.176	0.104	438-B11 contact
231	438-B11 contacts	Kumar2020	contacts	438-B11(V3)	X-ray crystallography	332	gp120	N	0.663	0.491	0.693	438-B11 contact
231	438-B11 contacts	Kumar2020	contacts	438-B11(V3)	X-ray crystallography	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	438-B11 contact
231	438-B11 contacts	Kumar2020	contacts	438-B11(V3)	X-ray crystallography	392	gp120, V4 loop	N	0.605	0.454	0.804	438-B11 contact
232	BG24 contacts	Barnes2022	contacts	BG24(CD4BS)	cryo-EM, X-ray crystallography	63	gp120	T	1.314	0.663	1.217	potential H bond
232	BG24 contacts	Barnes2022	contacts	BG24(CD4BS)	cryo-EM, X-ray crystallography	64	gp120	E	0.025	0.022	0.008	potential H bond
232	BG24 contacts	Barnes2022	contacts	BG24(CD4BS)	cryo-EM, X-ray crystallography	197	gp120	N	0.133	0.082	0.109	glycan contact
232	BG24 contacts	Barnes2022	contacts	BG24(CD4BS)	cryo-EM, X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	glycan contact
232	BG24 contacts	Barnes2022	contacts	BG24(CD4BS)	cryo-EM, X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	potential H bond
232	BG24 contacts	Barnes2022	contacts	BG24(CD4BS)	cryo-EM, X-ray crystallography	301	gp120, V3 loop	N	0.172	0.176	0.104	glycan contact
232	BG24 contacts	Barnes2022	contacts	BG24(CD4BS)	cryo-EM, X-ray crystallography	363	gp120	Q	1.825	1.587	1.352	glycan contact
232	BG24 contacts	Barnes2022	contacts	BG24(CD4BS)	cryo-EM, X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	potential H bond
232	BG24 contacts	Barnes2022	contacts	BG24(CD4BS)	cryo-EM, X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	potential H bond
232	BG24 contacts	Barnes2022	contacts	BG24(CD4BS)	cryo-EM, X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	potential H bond
232	BG24 contacts	Barnes2022	contacts	BG24(CD4BS)	cryo-EM, X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	potential H bond
232	BG24 contacts	Barnes2022	contacts	BG24(CD4BS)	cryo-EM, X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	potential H bond
233	Predicted association with Env-mediated apoptosis	Joshi2014	other feature		mutational analysis, sequence analysis, X-ray crystallography	134	gp120, V1-hypervariable, V1	L	2.224	2.322	1.627	Env with Y or W associated with low apoptosis induction
233	Predicted association with Env-mediated apoptosis	Joshi2014	other feature		mutational analysis, sequence analysis, X-ray crystallography	139	gp120, V1-hypervariable, V1	N	2.097	1.946	2.163	glycosylation associated with low apoptosis induction
233	Predicted association with Env-mediated apoptosis	Joshi2014	other feature		mutational analysis, sequence analysis, X-ray crystallography	189	gp120, V2-hypervariable, V2	T	1.760	1.348	1.638	T189 only found in Envs with low apoptosis induction
233	Predicted association with Env-mediated apoptosis	Joshi2014	other feature		mutational analysis, sequence analysis, X-ray crystallography	328	gp120, V3 loop	Q	0.923	0.816	0.882	positively-charged amino acids associated with high apoptosis induction
233	Predicted association with Env-mediated apoptosis	Joshi2014	other feature		mutational analysis, sequence analysis, X-ray crystallography	330	gp120, V3 loop	H	0.634	0.559	0.655	T330 (instead of H330) associated with high apoptosis induction
233	Predicted association with Env-mediated apoptosis	Joshi2014	other feature		mutational analysis, sequence analysis, X-ray crystallography	332	gp120	N	0.663	0.491	0.693	glycosylation associated with low apoptosis induction
233	Predicted association with Env-mediated apoptosis	Joshi2014	other feature		mutational analysis, sequence analysis, X-ray crystallography	334	gp120	S	0.717	0.501	0.890	glycosylation associated with high apoptosis induction
233	Predicted association with Env-mediated apoptosis	Joshi2014	other feature		mutational analysis, sequence analysis, X-ray crystallography	362	gp120	K	1.815	1.265	1.997	glycosylation associated with high apoptosis induction
233	Predicted association with Env-mediated apoptosis	Joshi2014	other feature		mutational analysis, sequence analysis, X-ray crystallography	363	gp120	Q	1.825	1.587	1.352	prolinated amino acids associated with low apoptosis induction
233	Predicted association with Env-mediated apoptosis	Joshi2014	other feature		mutational analysis, sequence analysis, X-ray crystallography	425	gp120, beta20/beta21	N	0.295	0.138	0.177	N425 (not a glyco site) associated with high apoptosis induction; N425R and R476K were the two mutations most strongly associated with loss of apoptosis induction
233	Predicted association with Env-mediated apoptosis	Joshi2014	other feature		mutational analysis, sequence analysis, X-ray crystallography	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	glycosylation associated with high apoptosis induction
233	Predicted association with Env-mediated apoptosis	Joshi2014	other feature		mutational analysis, sequence analysis, X-ray crystallography	476	gp120	R	0.663	0.615	0.711	R476 (instead of K476) associated with high apoptosis induction; N425R and R476K were the two mutations most strongly associated with loss of apoptosis induction
234	Ab1485 contacts	Wang2020	contacts	Ab1485(V3)	other, X-ray crystallography	134	gp120, V1-hypervariable, V1	L	2.224	2.322	1.627	secondary interaction, hydrogen bond
234	Ab1485 contacts	Wang2020	contacts	Ab1485(V3)	other, X-ray crystallography	135	gp120, V1-hypervariable, V1	K	2.230	2.373	1.848	secondary interaction, hydrogen bonds
234	Ab1485 contacts	Wang2020	contacts	Ab1485(V3)	other, X-ray crystallography	156	gp120, V1	N	0.246	0.220	0.224	secondary interaction with glycan, deglycosylation mutation ablates neutralization
234	Ab1485 contacts	Wang2020	contacts	Ab1485(V3)	other, X-ray crystallography	323	gp120, V3 loop	I	0.476	0.531	0.263	hydrogen bond
234	Ab1485 contacts	Wang2020	contacts	Ab1485(V3)	other, X-ray crystallography	324	gp120, V3 loop	G	0.075	0.056	0.092	primary interaction, hydrogen bonds
234	Ab1485 contacts	Wang2020	contacts	Ab1485(V3)	other, X-ray crystallography	325	gp120, V3 loop	N	0.648	0.622	0.622	primary interaction, hydrogen bonds
234	Ab1485 contacts	Wang2020	contacts	Ab1485(V3)	other, X-ray crystallography	327	gp120, V3 loop	R	0.089	0.066	0.073	cation-pi stacking, hydrogen bond
234	Ab1485 contacts	Wang2020	contacts	Ab1485(V3)	other, X-ray crystallography	332	gp120	N	0.663	0.491	0.693	primary interaction with glycan, deglycosylation mutation ablates neutralization
235	Mutations affecting neutralization by 19.3H-L3	Murphy2013	neutralization	19.3H-L3(other)	mutational analysis, sequence analysis, X-ray crystallography	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	I295R/N and I295T independently mediated full & partial nAb escape respectively.
235	Mutations affecting neutralization by 19.3H-L3	Murphy2013	neutralization	19.3H-L3(other)	mutational analysis, sequence analysis, X-ray crystallography	334	gp120	S	0.717	0.501	0.890	S335N and S335Q independently mediated full and slight neutralization escape. Note: Paper assigns this as residue 335, but it aligns with HXB2 residue 334.
235	Mutations affecting neutralization by 19.3H-L3	Murphy2013	neutralization	19.3H-L3(other)	mutational analysis, sequence analysis, X-ray crystallography	337	gp120	K	2.037	1.862	2.151	E338K and K338/G/I/Q/R all independently mediated increased neutralization resistance. Residue 338 may form a salt bridge with antigen-binding site. Note: Paper assigns this as residue 338, but it aligns with HXB2 residue 337.
235	Mutations affecting neutralization by 19.3H-L3	Murphy2013	neutralization	19.3H-L3(other)	mutational analysis, sequence analysis, X-ray crystallography	340	gp120	N	1.893	1.537	1.869	D341N independently increased neutralization sensitivity. Note: Paper assigns this as residue 341, but it aligns with HXB2 residue 340.
236	Mutations affecting binding of VRC34.01 to fusion peptide epitope	Shen2020	binding	VRC34.01(gp41 fusion domain)	alanine scanning, X-ray crystallography	88	gp120	N	0.050	0.041	0.048	glycan deletion reduced binding
236	Mutations affecting binding of VRC34.01 to fusion peptide epitope	Shen2020	binding	VRC34.01(gp41 fusion domain)	alanine scanning, X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	alanine or glycine ablated binding
236	Mutations affecting binding of VRC34.01 to fusion peptide epitope	Shen2020	binding	VRC34.01(gp41 fusion domain)	alanine scanning, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	hydrogen bond and hydrophobic contacts; alanine or glycine ablated binding
236	Mutations affecting binding of VRC34.01 to fusion peptide epitope	Shen2020	binding	VRC34.01(gp41 fusion domain)	alanine scanning, X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	hydrogen bonds; alanine ablated binding
237	VRC34.05 contacts	Shen2020	contacts	VRC34.05(gp41 fusion domain)	surface plasmon resonance, X-ray crystallography	88	gp120	N	0.050	0.041	0.048	deglycosylation reduced binding to BG505 DS-SOSIP Env trimer
237	VRC34.05 contacts	Shen2020	contacts	VRC34.05(gp41 fusion domain)	surface plasmon resonance, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	hydrogen bonds
237	VRC34.05 contacts	Shen2020	contacts	VRC34.05(gp41 fusion domain)	surface plasmon resonance, X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	hydrogen bonds
238	VRC26.25 contacts	Gorman2020	contacts	VRC26.25(V2)	cryo-EM	130	gp120	K	1.201	0.883	1.495	N130 and N160 have direct contacts with CDR H1
238	VRC26.25 contacts	Gorman2020	contacts	VRC26.25(V2)	cryo-EM	156	gp120, V1	N	0.246	0.220	0.224	the density of glycan N156 was evident close to the surface of Env, and extended to contact the CDR L2
238	VRC26.25 contacts	Gorman2020	contacts	VRC26.25(V2)	cryo-EM	160	gp120, V2	N	0.416	0.452	0.358	N130 and N160 have direct contacts with CDR H1
238	VRC26.25 contacts	Gorman2020	contacts	VRC26.25(V2)	cryo-EM	166	gp120, V2	R	1.237	1.398	0.772	direct Ab contact; escape mutations often removed direct electrostatic interactions from Env positions 166 and 169
238	VRC26.25 contacts	Gorman2020	contacts	VRC26.25(V2)	cryo-EM	168	gp120, V2	K	0.566	0.666	0.396	K168 interacts with heavy chain
238	VRC26.25 contacts	Gorman2020	contacts	VRC26.25(V2)	cryo-EM	169	gp120, V2	V	2.042	1.770	1.344	direct Ab contact; escape mutations often removed direct electrostatic interactions from Env positions 166 and 169
238	VRC26.25 contacts	Gorman2020	contacts	VRC26.25(V2)	cryo-EM	170	gp120, V2	Q	1.493	1.423	1.428	R170 interacts with heavy chain
239	L184F escapes V2-targeting bnAbs	Mishra2020	neutralization	CH01(V2), PG16(V2), PG9(V2), PGDM1400(V2), PGT145(V2), VRC26.25(V2)	neutralization assay, X-ray crystallography	184	gp120, V2	I	1.028	0.599	0.530	L184 is critical in modulating interprotomer interactions at the trimer apex; L184F allows escape from neutralization by V2-targeting bnAbs PG9, PG16, PGT145, PGDM1400, CAP256.25, and CH01.
240	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	Nogal2020	contacts	PGT128(V3)	cryo-EM	137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	Ab side chain contact, BG505 SOSIP.664 has N137 while HXB2 has D137
240	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	Nogal2020	contacts	PGT128(V3)	cryo-EM	301	gp120, V3 loop	N	0.172	0.176	0.104	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have N137
240	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	Nogal2020	contacts	PGT128(V3)	cryo-EM	321	gp120, V3 loop	G	1.042	0.842	1.108	Ab side chain contact, BG505 SOSIP.664 has D321 while HXB2 has G321
240	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	Nogal2020	contacts	PGT128(V3)	cryo-EM	322	gp120, V3 loop	K	1.797	0.347	0.283	Ab side chain contact, BG505 SOSIP.664 has I322 while HXB2 has K322
240	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	Nogal2020	contacts	PGT128(V3)	cryo-EM	323	gp120, V3 loop	I	0.476	0.531	0.263	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have I323
240	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	Nogal2020	contacts	PGT128(V3)	cryo-EM	324	gp120, V3 loop	G	0.075	0.056	0.092	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have G324
240	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	Nogal2020	contacts	PGT128(V3)	cryo-EM	325	gp120, V3 loop	N	0.648	0.622	0.622	Ab side chain contact, BG505 SOSIP.664 has D325 while HXB2 has N325
240	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	Nogal2020	contacts	PGT128(V3)	cryo-EM	326	gp120, V3 loop	M	0.143	0.143	0.116	Ab side chain contact, BG505 SOSIP.664 has I326 while HXB2 has M326
240	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	Nogal2020	contacts	PGT128(V3)	cryo-EM	327	gp120, V3 loop	R	0.089	0.066	0.073	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have R327
240	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	Nogal2020	contacts	PGT128(V3)	cryo-EM	442	gp120	Q	2.042	1.699	0.964	Ab side chain contact, BG505 SOSIP.664 has V442 while HXB2 has Q442
240	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	Nogal2020	contacts	PGT128(V3)	cryo-EM	444	gp120	R	1.747	1.507	0.494	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have R444
241	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	Nogal2020	contacts	BG18(V3)	cryo-EM	137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	Ab side chain contact, BG505 SOSIP.664 has N137 but HXB2 has D137
241	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	Nogal2020	contacts	BG18(V3)	cryo-EM	138	gp120, V1-hypervariable, V1	T	2.312	2.112	2.504	Ab side chain contact, BG505 SOSIP.664 has I138 but HXB2 has T138
241	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	Nogal2020	contacts	BG18(V3)	cryo-EM	139	gp120, V1-hypervariable, V1	N	2.097	1.946	2.163	Ab side chain contact, BG505 SOSIP.664 has T139 but HXB2 has N139
241	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	Nogal2020	contacts	BG18(V3)	cryo-EM	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have N295
241	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	Nogal2020	contacts	BG18(V3)	cryo-EM	325	gp120, V3 loop	N	0.648	0.622	0.622	Ab side chain contact, BG505 SOSIP.664 has D325 but HXB2 has N325
241	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	Nogal2020	contacts	BG18(V3)	cryo-EM	326	gp120, V3 loop	M	0.143	0.143	0.116	Ab side chain contact, BG505 SOSIP.664 has I326 but HXB2 has M326
241	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	Nogal2020	contacts	BG18(V3)	cryo-EM	327	gp120, V3 loop	R	0.089	0.066	0.073	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have R327
241	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	Nogal2020	contacts	BG18(V3)	cryo-EM	328	gp120, V3 loop	Q	0.923	0.816	0.882	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have Q328
241	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	Nogal2020	contacts	BG18(V3)	cryo-EM	330	gp120, V3 loop	H	0.634	0.559	0.655	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have H330
241	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	Nogal2020	contacts	BG18(V3)	cryo-EM	332	gp120	N	0.663	0.491	0.693	Ab side chain contact, BG505 SOSIP.664 has HXB2 both have N332
242	35O22 mutations affecting neutralization	Huang2014	neutralization	35O22(gp120/gp41 interface)	alanine scanning, neutralization assay	88	gp120	N	0.050	0.041	0.048	Ala scanning, N88A mutation makes JRFL and LAI neutralization resistant.
242	35O22 mutations affecting neutralization	Huang2014	neutralization	35O22(gp120/gp41 interface)	alanine scanning, neutralization assay	89	gp120	V	0.108	0.081	0.117	V89A mutation makes JRFL and LAI neutralization resistant.
242	35O22 mutations affecting neutralization	Huang2014	neutralization	35O22(gp120/gp41 interface)	alanine scanning, neutralization assay	90	gp120	T	0.079	0.063	0.051	T90A mutation makes JRFL neutralization resistant.
242	35O22 mutations affecting neutralization	Huang2014	neutralization	35O22(gp120/gp41 interface)	alanine scanning, neutralization assay	227	gp120	K	0.272	0.288	0.161	K227A mutation makes JRFL neutralization resistant.
242	35O22 mutations affecting neutralization	Huang2014	neutralization	35O22(gp120/gp41 interface)	alanine scanning, neutralization assay	230	gp120	N	0.931	0.896	0.544	N230A mutation makes JRFL neutralization resistant.
242	35O22 mutations affecting neutralization	Huang2014	neutralization	35O22(gp120/gp41 interface)	alanine scanning, neutralization assay	232	gp120	T	1.480	1.451	0.426	T232A mutation makes JRFL and LAI neutralization resistant.
242	35O22 mutations affecting neutralization	Huang2014	neutralization	35O22(gp120/gp41 interface)	alanine scanning, neutralization assay	241	gp120	N	0.191	0.183	0.134	N241A mutation makes JRFL and LAI neutralization resistant.
242	35O22 mutations affecting neutralization	Huang2014	neutralization	35O22(gp120/gp41 interface)	alanine scanning, neutralization assay	243	gp120	S	0.067	0.058	0.051	S243A mutation makes JRFL neutralization resistant.
242	35O22 mutations affecting neutralization	Huang2014	neutralization	35O22(gp120/gp41 interface)	alanine scanning, neutralization assay	244	gp120	T	0.262	0.157	0.178	T244V mutation makes LAI neutralization resistant.
242	35O22 mutations affecting neutralization	Huang2014	neutralization	35O22(gp120/gp41 interface)	alanine scanning, neutralization assay	489	gp120	V	0.144	0.132	0.133	V489A mutation makes LAI neutralization resistant.
242	35O22 mutations affecting neutralization	Huang2014	neutralization	35O22(gp120/gp41 interface)	alanine scanning, neutralization assay	624	gp41	N	1.580	1.592	1.486	N624Q mutation makes LAI neutralization resistant.
242	35O22 mutations affecting neutralization	Huang2014	neutralization	35O22(gp120/gp41 interface)	alanine scanning, neutralization assay	625	gp41	H	0.197	0.185	0.214	N625A mutation makes JRFL neutralization resistant, but T627A did not, suggesting that N625 may be binding directly, and not glycosylated; N625Q in JRCSF also dramatically reduced binding.
243	447-52D contacts	Dhillon2008	contacts	447-52D(V3)	X-ray crystallography	305	gp120, V3 loop	K	0.906	0.713	0.943	main chain contact
243	447-52D contacts	Dhillon2008	contacts	447-52D(V3)	X-ray crystallography	307	gp120, V3 loop	I	0.802	0.030	0.111	main chain contact
243	447-52D contacts	Dhillon2008	contacts	447-52D(V3)	X-ray crystallography	308	gp120, V3 loop	R	1.578	0.091	0.127	H bond
243	447-52D contacts	Dhillon2008	contacts	447-52D(V3)	X-ray crystallography	309	gp120, V3 loop	I	0.863	0.359	0.965	main chain contact
243	447-52D contacts	Dhillon2008	contacts	447-52D(V3)	X-ray crystallography	312	gp120, V3 loop	G	0.237	0.362	0.008	linear epitope position
243	447-52D contacts	Dhillon2008	contacts	447-52D(V3)	X-ray crystallography	313	gp120, V3 loop	P	0.344	0.424	0.078	linear epitope position
243	447-52D contacts	Dhillon2008	contacts	447-52D(V3)	X-ray crystallography	314	gp120, V3 loop	G	0.057	0.095	0.014	linear epitope position
243	447-52D contacts	Dhillon2008	contacts	447-52D(V3)	X-ray crystallography	315	gp120, V3 loop	R	1.211	1.028	0.196	linear epitope position; salt bridge and cation interactions
244	HK20 contacts	Sabin2010	contacts	HK20(gp41 fusion domain)	X-ray crystallography	564	gp41, Leu/Ile zipper-like sequence	H	0.236	0.262	0.108	HK20 contact, H bonding with heavy chain
244	HK20 contacts	Sabin2010	contacts	HK20(gp41 fusion domain)	X-ray crystallography	567	gp41, Leu/Ile zipper-like sequence	Q	0.318	0.139	0.056	HK20 contact
244	HK20 contacts	Sabin2010	contacts	HK20(gp41 fusion domain)	X-ray crystallography	568	gp41, Leu/Ile zipper-like sequence	L	0.019	0.018	0.029	HK20 contact
244	HK20 contacts	Sabin2010	contacts	HK20(gp41 fusion domain)	X-ray crystallography	571	gp41, Leu/Ile zipper-like sequence	W	0.016	0.006	0.015	HK20 contact, H bonding with heavy chain
244	HK20 contacts	Sabin2010	contacts	HK20(gp41 fusion domain)	X-ray crystallography	573	gp41, Leu/Ile zipper-like sequence	I	0.072	0.079	0.050	HK20 contact
244	HK20 contacts	Sabin2010	contacts	HK20(gp41 fusion domain)	X-ray crystallography	574	gp41, Leu/Ile zipper-like sequence	K	0.020	0.036	0.022	HK20 contact
244	HK20 contacts	Sabin2010	contacts	HK20(gp41 fusion domain)	X-ray crystallography	575	gp41, Leu/Ile zipper-like sequence	Q	0.017	0.012	0.008	HK20 contact, H bonding with heavy chain
244	HK20 contacts	Sabin2010	contacts	HK20(gp41 fusion domain)	X-ray crystallography	577	gp41, Leu/Ile zipper-like sequence	Q	0.108	0.121	0.104	HK20 contact
244	HK20 contacts	Sabin2010	contacts	HK20(gp41 fusion domain)	X-ray crystallography	579	gp41, Leu/Ile zipper-like sequence	R	0.022	0.030	0.028	HK20 contact
244	HK20 contacts	Sabin2010	contacts	HK20(gp41 fusion domain)	X-ray crystallography	636	gp41	N	1.413	1.127	1.081	HK20 contact
245	QA255.105 epitope	Williams2015	binding	QA255.105(V3)	binding assay	313	gp120, V3 loop	P	0.344	0.424	0.078	QA255.105 linear epitope PGQAF
245	QA255.105 epitope	Williams2015	binding	QA255.105(V3)	binding assay	314	gp120, V3 loop	G	0.057	0.095	0.014	QA255.105 linear epitope PGQAF
245	QA255.105 epitope	Williams2015	binding	QA255.105(V3)	binding assay	315	gp120, V3 loop	R	1.211	1.028	0.196	QA255.105 linear epitope PGQAF
245	QA255.105 epitope	Williams2015	binding	QA255.105(V3)	binding assay	316	gp120, V3 loop	A	1.056	0.736	0.966	QA255.105 linear epitope PGQAF
245	QA255.105 epitope	Williams2015	binding	QA255.105(V3)	binding assay	317	gp120, V3 loop	F	0.834	1.090	0.223	QA255.105 linear epitope PGQAF
246	10A3 epitope	Qin2015	binding	10A3(V3)	binding assay	304	gp120, V3 loop	R	0.304	0.390	0.141	10A3 linear epitope RKSIRIG
246	10A3 epitope	Qin2015	binding	10A3(V3)	binding assay	305	gp120, V3 loop	K	0.906	0.713	0.943	10A3 linear epitope RKSIRIG
246	10A3 epitope	Qin2015	binding	10A3(V3)	binding assay	306	gp120, V3 loop	R	0.714	0.860	0.338	10A3 linear epitope RKSIRIG
246	10A3 epitope	Qin2015	binding	10A3(V3)	binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	10A3 linear epitope RKSIRIG
246	10A3 epitope	Qin2015	binding	10A3(V3)	binding assay	308	gp120, V3 loop	R	1.578	0.091	0.127	10A3 linear epitope RKSIRIG
246	10A3 epitope	Qin2015	binding	10A3(V3)	binding assay	309	gp120, V3 loop	I	0.863	0.359	0.965	10A3 linear epitope RKSIRIG
246	10A3 epitope	Qin2015	binding	10A3(V3)	binding assay	310	gp120, V3 loop	Q	0.067	1.479	0.283	10A3 linear epitope RKSIRIG
247	10A37 epitope	Qin2015	binding	10A37(V3)	binding assay	314	gp120, V3 loop	G	0.057	0.095	0.014	10A37 linear epitope GQAFYATGDII
247	10A37 epitope	Qin2015	binding	10A37(V3)	binding assay	315	gp120, V3 loop	R	1.211	1.028	0.196	10A37 linear epitope GQAFYATGDII
247	10A37 epitope	Qin2015	binding	10A37(V3)	binding assay	316	gp120, V3 loop	A	1.056	0.736	0.966	10A37 linear epitope GQAFYATGDII
247	10A37 epitope	Qin2015	binding	10A37(V3)	binding assay	317	gp120, V3 loop	F	0.834	1.090	0.223	10A37 linear epitope GQAFYATGDII
247	10A37 epitope	Qin2015	binding	10A37(V3)	binding assay	318	gp120, V3 loop	V	0.588	0.691	0.507	10A37 linear epitope GQAFYATGDII
247	10A37 epitope	Qin2015	binding	10A37(V3)	binding assay	319	gp120, V3 loop	T	0.794	0.913	0.339	10A37 linear epitope GQAFYATGDII
247	10A37 epitope	Qin2015	binding	10A37(V3)	binding assay	320	gp120, V3 loop	I	0.711	0.564	0.782	10A37 linear epitope GQAFYATGDII
247	10A37 epitope	Qin2015	binding	10A37(V3)	binding assay	321	gp120, V3 loop	G	1.042	0.842	1.108	10A37 linear epitope GQAFYATGDII
247	10A37 epitope	Qin2015	binding	10A37(V3)	binding assay	322	gp120, V3 loop	K	1.797	0.347	0.283	10A37 linear epitope GQAFYATGDII
247	10A37 epitope	Qin2015	binding	10A37(V3)	binding assay	323	gp120, V3 loop	I	0.476	0.531	0.263	10A37 linear epitope GQAFYATGDII
247	10A37 epitope	Qin2015	binding	10A37(V3)	binding assay	324	gp120, V3 loop	G	0.075	0.056	0.092	10A37 linear epitope GQAFYATGDII
248	0.5γ epitope	RamirezValdez2015	binding	0.5γ(V3)	binding assay	308	gp120, V3 loop	R	1.578	0.091	0.127	0.5γ epitope SIHIGPGRAF
248	0.5γ epitope	RamirezValdez2015	binding	0.5γ(V3)	binding assay	309	gp120, V3 loop	I	0.863	0.359	0.965	0.5γ epitope SIHIGPGRAF
248	0.5γ epitope	RamirezValdez2015	binding	0.5γ(V3)	binding assay	310	gp120, V3 loop	Q	0.067	1.479	0.283	0.5γ epitope SIHIGPGRAF
248	0.5γ epitope	RamirezValdez2015	binding	0.5γ(V3)	binding assay	311	gp120, V3 loop	R	0.104	1.050	0.114	0.5γ epitope SIHIGPGRAF
248	0.5γ epitope	RamirezValdez2015	binding	0.5γ(V3)	binding assay	312	gp120, V3 loop	G	0.237	0.362	0.008	0.5γ epitope SIHIGPGRAF
248	0.5γ epitope	RamirezValdez2015	binding	0.5γ(V3)	binding assay	313	gp120, V3 loop	P	0.344	0.424	0.078	0.5γ epitope SIHIGPGRAF
248	0.5γ epitope	RamirezValdez2015	binding	0.5γ(V3)	binding assay	314	gp120, V3 loop	G	0.057	0.095	0.014	0.5γ epitope SIHIGPGRAF
248	0.5γ epitope	RamirezValdez2015	binding	0.5γ(V3)	binding assay	315	gp120, V3 loop	R	1.211	1.028	0.196	0.5γ epitope SIHIGPGRAF
248	0.5γ epitope	RamirezValdez2015	binding	0.5γ(V3)	binding assay	316	gp120, V3 loop	A	1.056	0.736	0.966	0.5γ epitope SIHIGPGRAF
248	0.5γ epitope	RamirezValdez2015	binding	0.5γ(V3)	binding assay	317	gp120, V3 loop	F	0.834	1.090	0.223	0.5γ epitope SIHIGPGRAF
249	KD-247 epitope	Eda2006a	binding	KD-247(V3)	binding assay	311	gp120, V3 loop	R	0.104	1.050	0.114	KD-247 epitope IGPGR
249	KD-247 epitope	Eda2006a	binding	KD-247(V3)	binding assay	312	gp120, V3 loop	G	0.237	0.362	0.008	KD-247 epitope IGPGR
249	KD-247 epitope	Eda2006a	binding	KD-247(V3)	binding assay	313	gp120, V3 loop	P	0.344	0.424	0.078	KD-247 epitope IGPGR
249	KD-247 epitope	Eda2006a	binding	KD-247(V3)	binding assay	314	gp120, V3 loop	G	0.057	0.095	0.014	KD-247 epitope IGPGR
249	KD-247 epitope	Eda2006a	binding	KD-247(V3)	binding assay	315	gp120, V3 loop	R	1.211	1.028	0.196	KD-247 epitope IGPGR
250	HGN194 epitope	Corti2010	binding	HGN194(V3)	binding assay	306	gp120, V3 loop	R	0.714	0.860	0.338	HGN194 epitope RRSVRIGPGQTF
250	HGN194 epitope	Corti2010	binding	HGN194(V3)	binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	HGN194 epitope RRSVRIGPGQTF
250	HGN194 epitope	Corti2010	binding	HGN194(V3)	binding assay	308	gp120, V3 loop	R	1.578	0.091	0.127	HGN194 epitope RRSVRIGPGQTF
250	HGN194 epitope	Corti2010	binding	HGN194(V3)	binding assay	309	gp120, V3 loop	I	0.863	0.359	0.965	HGN194 epitope RRSVRIGPGQTF
250	HGN194 epitope	Corti2010	binding	HGN194(V3)	binding assay	310	gp120, V3 loop	Q	0.067	1.479	0.283	HGN194 epitope RRSVRIGPGQTF
250	HGN194 epitope	Corti2010	binding	HGN194(V3)	binding assay	311	gp120, V3 loop	R	0.104	1.050	0.114	HGN194 epitope RRSVRIGPGQTF
250	HGN194 epitope	Corti2010	binding	HGN194(V3)	binding assay	312	gp120, V3 loop	G	0.237	0.362	0.008	HGN194 epitope RRSVRIGPGQTF
250	HGN194 epitope	Corti2010	binding	HGN194(V3)	binding assay	313	gp120, V3 loop	P	0.344	0.424	0.078	HGN194 epitope RRSVRIGPGQTF
250	HGN194 epitope	Corti2010	binding	HGN194(V3)	binding assay	314	gp120, V3 loop	G	0.057	0.095	0.014	HGN194 epitope RRSVRIGPGQTF
250	HGN194 epitope	Corti2010	binding	HGN194(V3)	binding assay	315	gp120, V3 loop	R	1.211	1.028	0.196	HGN194 epitope RRSVRIGPGQTF
250	HGN194 epitope	Corti2010	binding	HGN194(V3)	binding assay	316	gp120, V3 loop	A	1.056	0.736	0.966	HGN194 epitope RRSVRIGPGQTF
250	HGN194 epitope	Corti2010	binding	HGN194(V3)	binding assay	317	gp120, V3 loop	F	0.834	1.090	0.223	HGN194 epitope RRSVRIGPGQTF
251	Residues that affect neutralization by VRC42.01	Krebs2019	neutralization	VRC42.01(MPER)	alanine scanning, neutralization assay	662	gp41	E	1.043	0.874	0.369	Ala mediates a 0.54 fold decrease (founder) and 2.9 fold decrease (BG1168) in neutralization sensitivity
251	Residues that affect neutralization by VRC42.01	Krebs2019	neutralization	VRC42.01(MPER)	alanine scanning, neutralization assay	672	gp41	W	0.014	0.023	0.014	Ala mediates a 105 fold decrease (founder) and 15 fold decrease (BG1168) in neutralization sensitivity
251	Residues that affect neutralization by VRC42.01	Krebs2019	neutralization	VRC42.01(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	Ala mediates a 2.1 fold decrease (founder) and 2.9 fold decrease (BG1168) in neutralization sensitivity
251	Residues that affect neutralization by VRC42.01	Krebs2019	neutralization	VRC42.01(MPER)	alanine scanning, neutralization assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	Ala mediates a 47 fold decrease (founder) and 2.7 fold decrease (BG1168) in neutralization sensitivity
252	ACS101 contacts	vanSchooten2022a	contacts	ACS101(CD4BS)	cryo-EM	279	gp120, Loop D	D	0.900	0.850	0.898	heavy chain and light chain interaction
252	ACS101 contacts	vanSchooten2022a	contacts	ACS101(CD4BS)	cryo-EM	280	gp120, Loop D	N	0.142	0.090	0.170	heavy chain and light chain interaction
252	ACS101 contacts	vanSchooten2022a	contacts	ACS101(CD4BS)	cryo-EM	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	heavy chain interaction
252	ACS101 contacts	vanSchooten2022a	contacts	ACS101(CD4BS)	cryo-EM	456	gp120, beta23	R	0.233	0.079	0.323	heavy chain and light chain interaction
252	ACS101 contacts	vanSchooten2022a	contacts	ACS101(CD4BS)	cryo-EM	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	light chain interaction
252	ACS101 contacts	vanSchooten2022a	contacts	ACS101(CD4BS)	cryo-EM	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	heavy chain interaction
252	ACS101 contacts	vanSchooten2022a	contacts	ACS101(CD4BS)	cryo-EM	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	heavy chain interaction
253	ACS114 contacts	vanSchooten2022	contacts	ACS114(silent face)	cryo-EM, X-ray crystallography	262	gp120	N	0.027	0.029	0.028	contact
253	ACS114 contacts	vanSchooten2022	contacts	ACS114(silent face)	cryo-EM, X-ray crystallography	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	contact
253	ACS114 contacts	vanSchooten2022	contacts	ACS114(silent face)	cryo-EM, X-ray crystallography	301	gp120, V3 loop	N	0.172	0.176	0.104	contact
253	ACS114 contacts	vanSchooten2022	contacts	ACS114(silent face)	cryo-EM, X-ray crystallography	332	gp120	N	0.663	0.491	0.693	contact
253	ACS114 contacts	vanSchooten2022	contacts	ACS114(silent face)	cryo-EM, X-ray crystallography	339	gp120	N	1.149	1.082	1.026	contact
253	ACS114 contacts	vanSchooten2022	contacts	ACS114(silent face)	cryo-EM, X-ray crystallography	448	gp120	N	0.662	0.448	0.927	contact
254	ACS122 contacts	vanSchooten2022	contacts	ACS122(gp120/gp41 interface)	X-ray crystallography	88	gp120	N	0.050	0.041	0.048	contact
254	ACS122 contacts	vanSchooten2022	contacts	ACS122(gp120/gp41 interface)	X-ray crystallography	528	gp41	S	0.030	0.012	0.022	contact
254	ACS122 contacts	vanSchooten2022	contacts	ACS122(gp120/gp41 interface)	X-ray crystallography	531	gp41	G	0.010	0.006	0.000	contact
254	ACS122 contacts	vanSchooten2022	contacts	ACS122(gp120/gp41 interface)	X-ray crystallography	532	gp41	A	0.057	0.055	0.058	contact
254	ACS122 contacts	vanSchooten2022	contacts	ACS122(gp120/gp41 interface)	X-ray crystallography	536	gp41	T	0.378	0.396	0.366	contact
254	ACS122 contacts	vanSchooten2022	contacts	ACS122(gp120/gp41 interface)	X-ray crystallography	623	gp41	W	0.020	0.066	0.043	contact
254	ACS122 contacts	vanSchooten2022	contacts	ACS122(gp120/gp41 interface)	X-ray crystallography	624	gp41	N	1.580	1.592	1.486	contact
254	ACS122 contacts	vanSchooten2022	contacts	ACS122(gp120/gp41 interface)	X-ray crystallography	625	gp41	H	0.197	0.185	0.214	contact
254	ACS122 contacts	vanSchooten2022	contacts	ACS122(gp120/gp41 interface)	X-ray crystallography	628	gp41	W	0.010	0.000	0.008	contact
255	Mutation affects ACS114 neutralization	vanSchooten2022	neutralization	ACS114(silent face)	alanine scanning, neutralization assay	262	gp120	N	0.027	0.029	0.028	N262A in JRCSF enhanced neutralization of ACS114
255	Mutation affects ACS114 neutralization	vanSchooten2022	neutralization	ACS114(silent face)	alanine scanning, neutralization assay	283	gp120, Loop D	T	1.005	1.091	0.474	T283A in JRCSF enhanced neutralization of ACS114
255	Mutation affects ACS114 neutralization	vanSchooten2022	neutralization	ACS114(silent face)	alanine scanning, neutralization assay	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	N295A in JRCSF completely abrogated neutralization of ACS114
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	198	gp120	T	0.430	0.264	0.469	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	VRC-PG19 contact with amino acid and glycan
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	278	gp120, Loop D	T	0.708	0.715	0.481	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	283	gp120, Loop D	T	1.005	1.091	0.474	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	352	gp120	Q	1.607	0.842	1.079	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	353	gp120	F	0.735	0.735	0.488	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	430	gp120, beta20/beta21	V	0.267	0.080	0.073	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.567	1.466	1.517	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	466	gp120, V5 loop, beta24	E	0.205	0.091	0.239	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	467	gp120, V5 loop, beta24	I	0.912	0.955	0.870	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	VRC-PG19 contact
256	VRC-PG19 contacts	Dubrovskaya2019	contacts	VRC-PG19(CD4BS)	cryo-EM, X-ray crystallography	473	gp120	G	0.042	0.033	0.029	VRC-PG19 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	234	gp120	N	0.598	0.757	0.341	E70 glycan contact; deletion of the N-glycan at N234 rendered viruses resistant to E70
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	278	gp120, Loop D	T	0.708	0.715	0.481	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	353	gp120	F	0.735	0.735	0.488	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	354	gp120	G	2.108	1.918	1.123	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	356	gp120	N	0.938	0.741	0.894	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	357	gp120	K	1.034	0.868	0.941	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	464	gp120, V5-hypervariable, V5 loop	E	2.353	2.269	2.299	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	466	gp120, V5 loop, beta24	E	0.205	0.091	0.239	E70 contact
257	E70 contacts	Dubrovskaya2019	contacts	E70(CD4BS)	cryo-EM, X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	E70 contact
258	1C2 contacts	Dubrovskaya2019	contacts	1C2(gp120/gp41 interface)	cryo-EM	31	gp120	T	2.159	1.529	2.035	HCDR3 of 1C2 is near the tryptophan clasp of gp41, marked by residue W31 (Fig 6A)
258	1C2 contacts	Dubrovskaya2019	contacts	1C2(gp120/gp41 interface)	cryo-EM	88	gp120	N	0.050	0.041	0.048	1C2 HC framework regions interact with glycan N88 and stabilize in a position close to glycan N625; removal of N-glycans N88 and N625 improved 1C2 cell-surface binding, consistent with glycan impediment
258	1C2 contacts	Dubrovskaya2019	contacts	1C2(gp120/gp41 interface)	cryo-EM	623	gp41	W	0.020	0.066	0.043	1C2 is shown in proximity with W623 (Fig 6B)
258	1C2 contacts	Dubrovskaya2019	contacts	1C2(gp120/gp41 interface)	cryo-EM	625	gp41	H	0.197	0.185	0.214	removal of N-glycans N88 and N625 improved 1C2 cell-surface binding, consistent with glycan impediment
259	2E7 contacts	Strokappe2019	contacts	2E7(MPER)	X-ray crystallography	588	gp41, Leu/Ile zipper-like sequence	K	1.146	1.197	0.871	llama VHH 2E7 contact
259	2E7 contacts	Strokappe2019	contacts	2E7(MPER)	X-ray crystallography	589	gp41, Leu/Ile zipper-like sequence	D	0.053	0.035	0.029	llama VHH 2E7 contact
259	2E7 contacts	Strokappe2019	contacts	2E7(MPER)	X-ray crystallography	596	gp41	W	0.014	0.028	0.000	llama VHH 2E7 contact
260	Mutation affects M4008_N1 neutralization	Chan2021	neutralization	M4008_N1(V3)	mutational analysis, neutralization assay	137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	N137A mutation in BG505 improves neutralization potency
260	Mutation affects M4008_N1 neutralization	Chan2021	neutralization	M4008_N1(V3)	mutational analysis, neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	N156Q mutation in BG505 improves neutralization potency; N156Q in JR-FL decreases neutralization potency
260	Mutation affects M4008_N1 neutralization	Chan2021	neutralization	M4008_N1(V3)	mutational analysis, neutralization assay	197	gp120	N	0.133	0.082	0.109	N197Q mutation in BG505 improves neutralization potency; D197N in JR-FL decreases neutralization potency
260	Mutation affects M4008_N1 neutralization	Chan2021	neutralization	M4008_N1(V3)	mutational analysis, neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A mutation in BG505 or JR-FL decreases neutralization potency
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	65	gp120	V	1.017	1.023	0.310	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	163	gp120, V2	T	0.463	0.638	0.154	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	164	gp120, V2	S	1.840	1.925	0.453	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	170	gp120, V2	Q	1.493	1.423	1.428	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	172	gp120, V2	E	1.527	1.172	1.484	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	197	gp120	N	0.133	0.082	0.109	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	198	gp120	T	0.430	0.264	0.469	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	206	gp120	P	0.053	0.035	0.022	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	207	gp120	K	0.065	0.029	0.029	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	303	gp120, V3 loop	T	0.213	0.190	0.202	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	304	gp120, V3 loop	R	0.304	0.390	0.141	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	305	gp120, V3 loop	K	0.906	0.713	0.943	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	306	gp120, V3 loop	R	0.714	0.860	0.338	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	308	gp120, V3 loop	R	1.578	0.091	0.127	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	314	gp120, V3 loop	G	0.057	0.095	0.014	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	316	gp120, V3 loop	A	1.056	0.736	0.966	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	318	gp120, V3 loop	V	0.588	0.691	0.507	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	321	gp120, V3 loop	G	1.042	0.842	1.108	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	323	gp120, V3 loop	I	0.476	0.531	0.263	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	324	gp120, V3 loop	G	0.075	0.056	0.092	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	430	gp120, beta20/beta21	V	0.267	0.080	0.073	key contact
261	M4000_N1 contacts	Chan2021	contacts	M4008_N1(V3)	cryo-EM	440	gp120	S	1.844	1.712	1.017	key contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	183	gp120, V2	P	1.099	1.107	0.787	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	185	gp120, V2-hypervariable, V2	D	1.697	1.370	1.762	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	194	gp120, V2	T	0.662	0.906	0.161	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	195	gp120, V2	S	1.015	1.019	0.466	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	280	gp120, Loop D	N	0.142	0.090	0.170	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	384	gp120	Y	0.107	0.124	0.023	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	421	gp120, beta20/beta21	K	0.332	0.374	0.203	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	424	gp120, beta20/beta21	I	0.549	0.566	0.347	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	425	gp120, beta20/beta21	N	0.295	0.138	0.177	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	457	gp120, beta23	D	0.079	0.054	0.043	contact
262	M1214_N1 contacts	Jia2020	contacts	M1214_N1(other)	cryo-EM	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	contact
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	323	gp120, V3 loop	I	0.476	0.531	0.263	BG505.T332N (I): significant site of viral escape; greatest effect with G (moderate)
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	325	gp120, V3 loop	N	0.648	0.622	0.622	BG505.T332N (D): significant site of viral escape; greatest effects with K (substantial magnitude) and R/L/W (moderate); GDIR motif
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	326	gp120, V3 loop	M	0.143	0.143	0.116	BG505.T332N (I): significant site of viral escape; greatest effects with K (moderate); GDIR motif
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	327	gp120, V3 loop	R	0.089	0.066	0.073	BG505.T332N (R): significant site of viral escape; greatest effects with H/S/V/A/I/E/T (strong); GDIR motif
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	330	gp120, V3 loop	H	0.634	0.559	0.655	BG505.T332N (H): significant site of viral escape; greatest effects with E/T/N/A/K/Q (moderate)
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	332	gp120	N	0.663	0.491	0.693	BG505.T332N (N): significant site of viral escape; greatest effects with D/K/T/R/Y (moderate)
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	334	gp120	S	0.717	0.501	0.890	BG505.T332N (S): significant site of viral escape; greatest effects with H/Q/L/V/R/P/G/N (moderate); glycosylation motif
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	380	gp120	G	0.035	0.029	0.008	BG505.T332N (G): significant site of viral escape; greatest effect with K (moderate)
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	406	gp120, V4-hypervariable, V4 loop	N	1.939	2.211	1.307	BG505.T332N (N): significant site of viral escape
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	408	gp120, V4-hypervariable, V4 loop	T	1.109	1.334	0.554	BG505.T332N (T): significant site of viral escape; greatest effect with K (moderate)
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	415	gp120, V4 loop	T	0.754	0.760	0.656	BG505.T332N (T): significant site of viral escape; greatest effects with R/E (strong) and F/Y (moderate)
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	419	gp120	R	0.463	0.341	0.500	BG505.T332N (N): significant site of viral escape
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	BG505.T332N (Q): significant site of viral escape
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	443	gp120	I	0.151	0.119	0.131	BG505.T332N (I): significant site of viral escape
263	PGT121 functional escape mutation mapping	Dingens2019	other feature	PGT121(V3)	mutational analysis, other, sequence analysis	471	gp120, beta24	G	0.933	0.888	0.866	BG505.T332N (G): significant site of viral escape
264	mutations affecting neutralization by PGT121	Dingens2019	neutralization	PGT121(V3)	mutational analysis, neutralization assay	119	gp120, Cys 119 linked to Cys 205	C	0.022	0.012	0.022	BG505: C119R mediated a 1.2-fold decrease in neutralization potency
264	mutations affecting neutralization by PGT121	Dingens2019	neutralization	PGT121(V3)	mutational analysis, neutralization assay	140	gp120, V1-hypervariable, V1	T	2.235	2.104	2.340	BG505: D140E mediated a 1.6-fold decrease in neutralization potency
264	mutations affecting neutralization by PGT121	Dingens2019	neutralization	PGT121(V3)	mutational analysis, neutralization assay	151	gp120, V1-hypervariable, V1	K	2.575	2.285	2.605	BG505: R151K mediated a 1.3-fold decrease in neutralization potency
264	mutations affecting neutralization by PGT121	Dingens2019	neutralization	PGT121(V3)	mutational analysis, neutralization assay	322	gp120, V3 loop	K	1.797	0.347	0.283	BG505: D322E and D322G each mediated a 1.4-fold decrease in neutralization potency
264	mutations affecting neutralization by PGT121	Dingens2019	neutralization	PGT121(V3)	mutational analysis, neutralization assay	323	gp120, V3 loop	I	0.476	0.531	0.263	BG505: I323G mediated a 1.9-fold decrease in neutralization potency
264	mutations affecting neutralization by PGT121	Dingens2019	neutralization	PGT121(V3)	mutational analysis, neutralization assay	325	gp120, V3 loop	N	0.648	0.622	0.622	BG505: D325E and D325S mediated respective 1.7- and 1.2-fold decreases in neutralization potency while D325N had no effect; GDIR motif
264	mutations affecting neutralization by PGT121	Dingens2019	neutralization	PGT121(V3)	mutational analysis, neutralization assay	326	gp120, V3 loop	M	0.143	0.143	0.116	BG505: I326Y mediated a 1.3-fold decrease in neutralization potency; GDIR motif
264	mutations affecting neutralization by PGT121	Dingens2019	neutralization	PGT121(V3)	mutational analysis, neutralization assay	327	gp120, V3 loop	R	0.089	0.066	0.073	BG505: R327A mediated a 3.4-fold decrease in neutralization potency; GDIR motif
264	mutations affecting neutralization by PGT121	Dingens2019	neutralization	PGT121(V3)	mutational analysis, neutralization assay	330	gp120, V3 loop	H	0.634	0.559	0.655	BG505: H330R mediated a 1.6-fold decrease in IC50 neutralization potency
264	mutations affecting neutralization by PGT121	Dingens2019	neutralization	PGT121(V3)	mutational analysis, neutralization assay	415	gp120, V4 loop	T	0.754	0.760	0.656	BG505: T415R and T415Y mediated respective 3.8- and 2.4-fold decreases in neutralization potency
264	mutations affecting neutralization by PGT121	Dingens2019	neutralization	PGT121(V3)	mutational analysis, neutralization assay	441	gp120	G	0.045	0.041	0.037	BG505: G441P mediated a 2.6-fold decrease in neutralization potency
265	PGT121 contacts	Dingens2019	contacts	PGT121(V3)	molecular modeling, X-ray crystallography	135	gp120, V1-hypervariable, V1	K	2.230	2.373	1.848	PGT121 contact with BG505
265	PGT121 contacts	Dingens2019	contacts	PGT121(V3)	molecular modeling, X-ray crystallography	136	gp120, V1-hypervariable, V1	N	2.514	2.300	2.581	PGT121 contact with BG505
265	PGT121 contacts	Dingens2019	contacts	PGT121(V3)	molecular modeling, X-ray crystallography	137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	PGT121 contact with BG505
265	PGT121 contacts	Dingens2019	contacts	PGT121(V3)	molecular modeling, X-ray crystallography	156	gp120, V1	N	0.246	0.220	0.224	PGT121 contact with BG505
265	PGT121 contacts	Dingens2019	contacts	PGT121(V3)	molecular modeling, X-ray crystallography	322	gp120, V3 loop	K	1.797	0.347	0.283	PGT121 contact with BG505
265	PGT121 contacts	Dingens2019	contacts	PGT121(V3)	molecular modeling, X-ray crystallography	324	gp120, V3 loop	G	0.075	0.056	0.092	PGT121 contact with BG505, GDIR motif
265	PGT121 contacts	Dingens2019	contacts	PGT121(V3)	molecular modeling, X-ray crystallography	325	gp120, V3 loop	N	0.648	0.622	0.622	PGT121 contact with BG505, GDIR motif
265	PGT121 contacts	Dingens2019	contacts	PGT121(V3)	molecular modeling, X-ray crystallography	326	gp120, V3 loop	M	0.143	0.143	0.116	PGT121 contact with BG505, GDIR motif
265	PGT121 contacts	Dingens2019	contacts	PGT121(V3)	molecular modeling, X-ray crystallography	327	gp120, V3 loop	R	0.089	0.066	0.073	PGT121 contact with BG505, GDIR motif
265	PGT121 contacts	Dingens2019	contacts	PGT121(V3)	molecular modeling, X-ray crystallography	328	gp120, V3 loop	Q	0.923	0.816	0.882	PGT121 contact with BG505
265	PGT121 contacts	Dingens2019	contacts	PGT121(V3)	molecular modeling, X-ray crystallography	330	gp120, V3 loop	H	0.634	0.559	0.655	PGT121 contact with BG505
265	PGT121 contacts	Dingens2019	contacts	PGT121(V3)	molecular modeling, X-ray crystallography	332	gp120	N	0.663	0.491	0.693	PGT121 contact with BG505; glycosylation motif
265	PGT121 contacts	Dingens2019	contacts	PGT121(V3)	molecular modeling, X-ray crystallography	417	gp120, V4 loop	P	0.864	0.736	0.922	PGT121 contact with BG505
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	135	gp120, V1-hypervariable, V1	K	2.230	2.373	1.848	10-1074 contact with BG505.T332N
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	136	gp120, V1-hypervariable, V1	N	2.514	2.300	2.581	10-1074 contact with BG505.T332N
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	10-1074 contact with BG505.T332N
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	156	gp120, V1	N	0.246	0.220	0.224	10-1074 contact with BG505.T332N
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	301	gp120, V3 loop	N	0.172	0.176	0.104	10-1074 contact with BG505.T332N
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	322	gp120, V3 loop	K	1.797	0.347	0.283	10-1074 contact with BG505.T332N
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	324	gp120, V3 loop	G	0.075	0.056	0.092	10-1074 contact with BG505.T332N, GDIR motif
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	325	gp120, V3 loop	N	0.648	0.622	0.622	10-1074 contact with BG505.T332N, GDIR motif
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	326	gp120, V3 loop	M	0.143	0.143	0.116	10-1074 contact with BG505.T332N, GDIR motif
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	327	gp120, V3 loop	R	0.089	0.066	0.073	10-1074 contact with BG505.T332N, GDIR motif
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	328	gp120, V3 loop	Q	0.923	0.816	0.882	10-1074 contact with BG505.T332N
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	330	gp120, V3 loop	H	0.634	0.559	0.655	10-1074 contact with BG505.T332N
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	332	gp120	N	0.663	0.491	0.693	10-1074 contact with BG505.T332N; glycosylation motif
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	334	gp120	S	0.717	0.501	0.890	10-1074 contact with BG505.T332N; glycosylation motif
266	10-1074 contacts	Dingens2019	contacts	10-1074(V3)	molecular modeling, X-ray crystallography	417	gp120, V4 loop	P	0.864	0.736	0.922	10-1074 contact with BG505.T332N
267	10-1074 functional escape mutation mapping	Dingens2019	other feature	10-1074(V3)	mutational analysis, other, sequence analysis	67	gp120	N	0.026	0.012	0.022	BG505.T332N (N): site of viral escape; greatest effect with A (moderate)
267	10-1074 functional escape mutation mapping	Dingens2019	other feature	10-1074(V3)	mutational analysis, other, sequence analysis	204	gp120	A	0.156	0.127	0.131	BG505.T332N (A): significant site of viral escape
267	10-1074 functional escape mutation mapping	Dingens2019	other feature	10-1074(V3)	mutational analysis, other, sequence analysis	323	gp120, V3 loop	I	0.476	0.531	0.263	BG505.T332N (I): significant site of viral escape
267	10-1074 functional escape mutation mapping	Dingens2019	other feature	10-1074(V3)	mutational analysis, other, sequence analysis	325	gp120, V3 loop	N	0.648	0.622	0.622	BG505.T332N (D): significant site of viral escape; greatest effects with R/Q/W/L/I/G/Y (strong) and K/C/F/V/E/M/T (moderate); GDIR motif
267	10-1074 functional escape mutation mapping	Dingens2019	other feature	10-1074(V3)	mutational analysis, other, sequence analysis	327	gp120, V3 loop	R	0.089	0.066	0.073	BG505.T332N (R): significant site of viral escape; greatest effect with S (moderate); GDIR motif
267	10-1074 functional escape mutation mapping	Dingens2019	other feature	10-1074(V3)	mutational analysis, other, sequence analysis	328	gp120, V3 loop	Q	0.923	0.816	0.882	BG505.T332N (Q): site of viral escape; greatest effect with P (moderate)
267	10-1074 functional escape mutation mapping	Dingens2019	other feature	10-1074(V3)	mutational analysis, other, sequence analysis	330	gp120, V3 loop	H	0.634	0.559	0.655	BG505.T332N (H): significant site of viral escape
267	10-1074 functional escape mutation mapping	Dingens2019	other feature	10-1074(V3)	mutational analysis, other, sequence analysis	332	gp120	N	0.663	0.491	0.693	BG505.T332N (N): significant site of viral escape; greatest effects with I (strong) and Q/D/R/F/V/K/H/E/T/A/Y/S (moderate); glycosylation motif
267	10-1074 functional escape mutation mapping	Dingens2019	other feature	10-1074(V3)	mutational analysis, other, sequence analysis	334	gp120	S	0.717	0.501	0.890	BG505.T332N (S): significant site of viral escape; greatest effects with L/R/F/Q/A/V/N (strong) and G/H/Y/K/D/I/E (moderate); glycosylation motif
267	10-1074 functional escape mutation mapping	Dingens2019	other feature	10-1074(V3)	mutational analysis, other, sequence analysis	415	gp120, V4 loop	T	0.754	0.760	0.656	BG505.T332N (T): significant site of viral escape; greatest effect with R (moderate)
267	10-1074 functional escape mutation mapping	Dingens2019	other feature	10-1074(V3)	mutational analysis, other, sequence analysis	441	gp120	G	0.045	0.041	0.037	BG505.T332N (G): significant site of viral escape
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	105	gp120	H	0.342	0.429	0.187	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	198	gp120	T	0.430	0.264	0.469	contact with strain JR-FL, glycosylation motif
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	199	gp120	S	0.094	0.108	0.068	contact with strain JR-FL, glycosylation motif
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	contact with strain JR-FL, glycosylation motif
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	278	gp120, Loop D	T	0.708	0.715	0.481	contact with strain JR-FL, glycosylation motif
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	362	gp120	K	1.815	1.265	1.997	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	427	gp120, beta20/beta21	W	0.083	0.061	0.038	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	467	gp120, V5 loop, beta24	I	0.912	0.955	0.870	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	contact with strain JR-FL
268	VRC01 contacts	Dingens2019	contacts	VRC01(CD4BS)	molecular modeling, X-ray crystallography	473	gp120	G	0.042	0.033	0.029	contact with strain JR-FL
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	197	gp120	N	0.133	0.082	0.109	contact with BG505.T332N; glycosylation motif
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	207	gp120	K	0.065	0.029	0.029	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	contact with BG505.T332N; glycosylation motif
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	278	gp120, Loop D	T	0.708	0.715	0.481	contact with BG505.T332N; glycosylation motif
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	306	gp120, V3 loop	R	0.714	0.860	0.338	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	308	gp120, V3 loop	R	1.578	0.091	0.127	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	316	gp120, V3 loop	A	1.056	0.736	0.966	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	392	gp120, V4 loop	N	0.605	0.454	0.804	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	430	gp120, beta20/beta21	V	0.267	0.080	0.073	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	464	gp120, V5-hypervariable, V5 loop	E	2.353	2.269	2.299	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.567	1.466	1.517	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	contact with BG505.T332N
269	3BNC117 contacts	Dingens2019	contacts	3BNC117(CD4BS)	molecular modeling, X-ray crystallography	471	gp120, beta24	G	0.933	0.888	0.866	contact with BG505.T332N
270	PG9 functional escape mutation mapping	Dingens2019	other feature	PG9(V2)	mutational analysis, other, sequence analysis	50	gp120	T	0.321	0.133	0.502	BG505.T332N (T): site of viral escape, greatest effect with H (moderate)
270	PG9 functional escape mutation mapping	Dingens2019	other feature	PG9(V2)	mutational analysis, other, sequence analysis	160	gp120, V2	N	0.416	0.452	0.358	BG505.T332N (N): significant site of viral escape, greatest effects with I/L/R (strong) and D/P/H/K/V/Y/T (moderate), glycosylation motif
270	PG9 functional escape mutation mapping	Dingens2019	other feature	PG9(V2)	mutational analysis, other, sequence analysis	162	gp120, V2	S	0.353	0.445	0.179	BG505.T332N (T): significant site of viral escape, greatest effects with N/P (moderate), glycosylation motif
270	PG9 functional escape mutation mapping	Dingens2019	other feature	PG9(V2)	mutational analysis, other, sequence analysis	166	gp120, V2	R	1.237	1.398	0.772	BG505.T332N (R): site of viral escape, greatest effect with E (moderate)
270	PG9 functional escape mutation mapping	Dingens2019	other feature	PG9(V2)	mutational analysis, other, sequence analysis	169	gp120, V2	V	2.042	1.770	1.344	BG505.T332N (K): significant site of viral escape, greatest effects with D/N/E (moderate)
270	PG9 functional escape mutation mapping	Dingens2019	other feature	PG9(V2)	mutational analysis, other, sequence analysis	171	gp120, V2	K	1.247	0.957	1.413	BG505.T332N (K): significant site of viral escape, greatest effects with E (strong) and T/F/S/V (moderate)
270	PG9 functional escape mutation mapping	Dingens2019	other feature	PG9(V2)	mutational analysis, other, sequence analysis	231	gp120	K	0.799	0.578	0.780	BG505.T332N (K): site of viral escape, greatest effect with D (moderate)
270	PG9 functional escape mutation mapping	Dingens2019	other feature	PG9(V2)	mutational analysis, other, sequence analysis	327	gp120, V3 loop	R	0.089	0.066	0.073	BG505.T332N (R): site of viral escape, greatest effect with Q (moderate)
270	PG9 functional escape mutation mapping	Dingens2019	other feature	PG9(V2)	mutational analysis, other, sequence analysis	335	gp120	R	1.898	1.758	1.937	BG505.T332N (K): site of viral escape, greatest effect with Y (moderate)
270	PG9 functional escape mutation mapping	Dingens2019	other feature	PG9(V2)	mutational analysis, other, sequence analysis	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	BG505.T332N (Q): site of viral escape, greatest effect with Y (moderate)
270	PG9 functional escape mutation mapping	Dingens2019	other feature	PG9(V2)	mutational analysis, other, sequence analysis	433	gp120, beta20/beta21	A	0.054	0.023	0.037	BG505.T332N (A): site of viral escape, greatest effect with I
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	156	gp120, V1	N	0.246	0.220	0.224	contact with CAP45 strain, glycosylation motif
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	158	gp120, V2	S	0.263	0.185	0.291	contact with CAP45 strain, glycosylation motif
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	160	gp120, V2	N	0.416	0.452	0.358	contact with CAP45 strain, glycosylation motif
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	162	gp120, V2	S	0.353	0.445	0.179	contact with CAP45 strain, glycosylation motif
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	164	gp120, V2	S	1.840	1.925	0.453	contact with CAP45 strain
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	165	gp120, V2	I	1.327	1.292	1.011	contact with CAP45 strain
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	166	gp120, V2	R	1.237	1.398	0.772	contact with CAP45 strain
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	167	gp120, V2	G	0.779	1.122	0.185	contact with CAP45 strain
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	168	gp120, V2	K	0.566	0.666	0.396	contact with CAP45 strain
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	169	gp120, V2	V	2.042	1.770	1.344	contact with CAP45 strain
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	170	gp120, V2	Q	1.493	1.423	1.428	contact with CAP45 strain
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	171	gp120, V2	K	1.247	0.957	1.413	contact with CAP45 strain
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	172	gp120, V2	E	1.527	1.172	1.484	contact with CAP45 strain
271	PG9 contacts	Dingens2019	contacts	PG9(V2)	molecular modeling, X-ray crystallography	173	gp120, V2	Y	1.059	0.808	1.158	contact with CAP45 strain
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	121	gp120	K	0.349	0.360	0.187	BG505.T332N (K): significant site of viral escape, greatest effects with E/L/Q/C (moderate)
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	123	gp120	T	0.047	0.028	0.038	BG505.T332N (T): significant site of viral escape, greatest effect with R (moderate effect)
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	124	gp120	P	0.045	0.018	0.029	BG505.T332N (P): significant site of viral escape, greatest effects with D (strong) or R (moderate)
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	127	gp120	V	0.102	0.112	0.093	BG505.T332N (V): significant site of viral escape, greatest effect with R (moderate)
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	160	gp120, V2	N	0.416	0.452	0.358	BG505.T332N (N): significant site of viral escape, greatest effects with D (strong) or L/I/T/C/W/M/E/P/Q (moderate), glycosylation motif
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	162	gp120, V2	S	0.353	0.445	0.179	BG505.T332N (T): significant site of viral escape, greatest effects with R/P (moderate), glyscosylation motif
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	166	gp120, V2	R	1.237	1.398	0.772	BG505.T332N (R): significant site of viral escape, greatest effects with M/T/V (strong) or L/A/S/N/Y/I/F/G/Q (moderate)
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	169	gp120, V2	V	2.042	1.770	1.344	BG505.T332N (K): significant site of viral escape, greatest effects with E (strong) or F/N/Y (moderate)
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	197	gp120	N	0.133	0.082	0.109	BG505.T332N (N): significant site of viral escape
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	202	gp120	T	0.506	0.291	0.547	BG505.T332N (T): significant site of viral escape, greatest effects with R/K (moderate)
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	203	gp120	Q	0.089	0.090	0.048	BG505.T332N (Q): significant site of viral escape, greatest effects with R (moderate)
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	312	gp120, V3 loop	G	0.237	0.362	0.008	BG505.T332N (G): significant site of viral escape, greatest effects with R (moderate)
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	313	gp120, V3 loop	P	0.344	0.424	0.078	BG505.T332N (P): site of viral escape, greatest effect with R (moderate)
272	PGT145 functional escape mutation mapping	Dingens2019	other feature	PGT145(V2)	mutational analysis, other, sequence analysis	315	gp120, V3 loop	R	1.211	1.028	0.196	BG505.T332N (Q): significant site of viral escape
273	PGT145 contacts	Dingens2019	contacts	PGT145(V2)	molecular modeling, X-ray crystallography	121	gp120	K	0.349	0.360	0.187	contact with BG505.T332N
273	PGT145 contacts	Dingens2019	contacts	PGT145(V2)	molecular modeling, X-ray crystallography	124	gp120	P	0.045	0.018	0.029	contact with BG505.T332N
273	PGT145 contacts	Dingens2019	contacts	PGT145(V2)	molecular modeling, X-ray crystallography	127	gp120	V	0.102	0.112	0.093	contact with BG505.T332N
273	PGT145 contacts	Dingens2019	contacts	PGT145(V2)	molecular modeling, X-ray crystallography	160	gp120, V2	N	0.416	0.452	0.358	contact with BG505.T332N, glycosylation motif
273	PGT145 contacts	Dingens2019	contacts	PGT145(V2)	molecular modeling, X-ray crystallography	161	gp120, V2	I	1.493	0.964	1.568	contact with BG505.T332N, glycosylation motif
273	PGT145 contacts	Dingens2019	contacts	PGT145(V2)	molecular modeling, X-ray crystallography	162	gp120, V2	S	0.353	0.445	0.179	contact with BG505.T332N, glycosylation motif
273	PGT145 contacts	Dingens2019	contacts	PGT145(V2)	molecular modeling, X-ray crystallography	166	gp120, V2	R	1.237	1.398	0.772	contact with BG505.T332N
273	PGT145 contacts	Dingens2019	contacts	PGT145(V2)	molecular modeling, X-ray crystallography	167	gp120, V2	G	0.779	1.122	0.185	contact with BG505.T332N
273	PGT145 contacts	Dingens2019	contacts	PGT145(V2)	molecular modeling, X-ray crystallography	168	gp120, V2	K	0.566	0.666	0.396	contact with BG505.T332N
273	PGT145 contacts	Dingens2019	contacts	PGT145(V2)	molecular modeling, X-ray crystallography	169	gp120, V2	V	2.042	1.770	1.344	contact with BG505.T332N
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	44	gp120	V	0.054	0.023	0.039	BG505.T332N (V): site of viral escape, greatest effect with L (strong)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	85	gp120	V	1.980	1.797	1.418	BG505.T332N (H): significant site of viral escape; greatest effects with Q/V (strong) or S/N/D (moderate)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	88	gp120	N	0.050	0.041	0.048	BG505.T332N (N): significant site of viral escape; greatest effects with T/G (strong) or S/H/R/W/L/A/F/Q/M/E (moderate); glycosylation motif
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	90	gp120	T	0.079	0.063	0.051	BG505.T332N (T): significant site of viral escape; greatest effects with R/G/N/V/A/H/I/K/E/L (moderate); glycosylation motif
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	229	gp120	N	0.707	0.742	0.290	BG505.T332N (K): significant site of viral escape; greatest effects with M/R/L/S (moderate)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	243	gp120	S	0.067	0.058	0.051	BG505.T332N (S): significant site of viral escape; greatest effects with Q/D/R (moderate)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	287	gp120	Q	0.693	0.363	0.618	BG505.T332N (Q): site of viral escape; greatest effect with H (moderate)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	343	gp120	K	2.058	1.978	1.742	BG505.T332N (G): site of viral escape; greatest effect with M (moderate)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	491	gp120	I	0.423	0.358	0.441	BG505.T332N (I): site of viral escape; greatest effect with Y (moderate)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	512	gp41, fusion peptide	A	0.188	0.260	0.110	BG505.T332N (A): significant site of viral escape; greatest effects with L/E/M/G/I/T (moderate)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	513	gp41, fusion peptide	V	0.761	0.736	0.506	BG505.T332N (V): significant site of viral escape; greatest effects with P (strong) and L/G/F/N/S/M (moderate)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	514	gp41, fusion peptide	G	0.600	0.691	0.502	BG505.T332N (G): significant site of viral escape; greatest effects with V/I/M (moderate)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	515	gp41, fusion peptide	I	1.103	1.147	0.877	BG505.T332N (I): significant site of viral escape; greatest effects with P/S (strong) or T/Y/M/F (moderate)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	516	gp41, fusion peptide	G	0.066	0.038	0.048	BG505.T332N (G): significant site of viral escape; greatest effects with A/L/V/E/Y (moderate)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	518	gp41, fusion peptide	L	1.166	1.110	0.718	BG505.T332N (L): significant site of viral escape; greatest effect with W (moderate)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	524	gp41, fusion peptide	G	0.152	0.129	0.125	BG505.T332N (G): significant site of viral escape; greatest effects with A/S/V/I/Q/H/E/T (moderate)
274	VRC34.01 functional escape mutation mapping	Dingens2019	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	629	gp41	M	0.563	0.350	0.132	BG505.T332N (L): significant site of viral escape; greatest effect with A (moderate)
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	80	gp120	N	0.669	0.695	0.562	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	84	gp120	V	1.366	0.916	1.327	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	85	gp120	V	1.980	1.797	1.418	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	87	gp120	V	1.565	1.611	1.463	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	88	gp120	N	0.050	0.041	0.048	contact with BG505.T332N, glycosylation motif
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	229	gp120	N	0.707	0.742	0.290	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	230	gp120	N	0.931	0.896	0.544	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	231	gp120	K	0.799	0.578	0.780	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	241	gp120	N	0.191	0.183	0.134	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	514	gp41, fusion peptide	G	0.600	0.691	0.502	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	518	gp41, fusion peptide	L	1.166	1.110	0.718	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	contact with BG505.T332N
275	VRC34.01 contacts	Dingens2019	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	520	gp41, fusion peptide	L	0.393	0.253	0.390	contact with BG505.T332N
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	122	gp120	L	0.150	0.101	0.121	BG505.T332N (L): site of viral escape; greatest effect with V (moderate)
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	142	gp120, V1-hypervariable, V1	S	2.145	1.992	1.972	BG505.T332N (M): significant site of viral escape
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	224	gp120	A	0.092	0.115	0.034	BG505.T332N (A): significant site of viral escape; greatest effect with K (moderate)
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	318	gp120, V3 loop	V	0.588	0.691	0.507	BG505.T332N (Y): significant site of viral escape
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	327	gp120, V3 loop	R	0.089	0.066	0.073	BG505.T332N (R): significant site of viral escape
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	448	gp120	N	0.662	0.448	0.927	BG505.T332N (G): site of viral escape; greatest effect with H (moderate)
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	512	gp41, fusion peptide	A	0.188	0.260	0.110	BG505.T332N (A): significant site of viral escape; greatest effects with L/E (strong) and Y/Q (moderate)
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	514	gp41, fusion peptide	G	0.600	0.691	0.502	BG505.T332N (G): significant site of viral escape; greatest effect with Y (moderate)
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	611	gp41	N	0.048	0.039	0.054	BG505.T332N (N): significant site of viral escape; greatest effects with S/R (strong) and K/M/A/Y/I/H/Q/E/L/C/V (moderate); glycosylation motif
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	612	gp41	A	1.631	1.525	1.055	BG505.T332N (S): site of viral escape; greatest effect with P (strong); glycosylation motif
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	613	gp41	S	0.243	0.207	0.216	BG505.T332N (S): significant site of viral escape; greatest effects with Y/D/L/V/K/I/Q (strong) and M/C/A/R/N/G/E/H/F (moderate); glycosylation motif
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	629	gp41	M	0.563	0.350	0.132	BG505.T332N (L): significant site of viral escape
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	637	gp41	N	0.192	0.168	0.186	BG505.T332N (N): significant site of viral escape; greatest effects with R/Q (moderate); glycosylation motif
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	639	gp41	T	0.158	0.049	0.189	BG505.T332N (T): significant site of viral escape; greatest effects with A/K/R (moderate); glycosylation motif
276	PGT151 functional escape mutation mapping	Dingens2019	other feature	PGT151(gp41 fusion domain)	mutational analysis, other, sequence analysis	647	gp41	E	0.328	0.372	0.224	BG505.T332N (E): significant site of viral escape; greatest effect with F (moderate)
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	58	gp120	A	0.046	0.036	0.029	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	82	gp120	Q	0.290	0.200	0.268	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	83	gp120	E	0.042	0.039	0.035	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	84	gp120	V	1.366	0.916	1.327	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	245	gp120	V	0.098	0.077	0.079	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	246	gp120	Q	0.091	0.072	0.098	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	262	gp120	N	0.027	0.029	0.028	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	448	gp120	N	0.662	0.448	0.927	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	514	gp41, fusion peptide	G	0.600	0.691	0.502	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	521	gp41, fusion peptide	G	0.035	0.028	0.008	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	522	gp41, fusion peptide	F	0.092	0.061	0.165	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	542	gp41, Leu/Ile zipper-like sequence	R	0.057	0.052	0.062	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	543	gp41, Leu/Ile zipper-like sequence	Q	0.588	0.768	0.202	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	549	gp41, Leu/Ile zipper-like sequence	V	0.024	0.017	0.022	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	550	gp41, Leu/Ile zipper-like sequence	Q	0.040	0.023	0.031	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	554	gp41, Leu/Ile zipper-like sequence	N	0.044	0.050	0.057	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	592	gp41	L	0.109	0.093	0.126	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	611	gp41	N	0.048	0.039	0.054	contact with strain JR-FL; glycosylation motif
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	637	gp41	N	0.192	0.168	0.186	contact with strain JR-FL; glycosylation motif
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	638	gp41	Y	0.105	0.096	0.110	contact with strain JR-FL; glycosylation motif
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	640	gp41	S	2.033	1.971	1.834	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	641	gp41	L	1.694	1.530	0.830	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	643	gp41	H	0.084	0.065	0.084	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	644	gp41	S	2.005	1.538	1.732	contact with strain JR-FL
277	PGT151 contacts	Dingens2019	contacts	PGT151(gp41 fusion domain)	molecular modeling, X-ray crystallography	647	gp41	E	0.328	0.372	0.224	contact with strain JR-FL
278	10E8 functional escape mutation mapping	Dingens2019	other feature	10E8(MPER)	mutational analysis, other, sequence analysis	609	gp41	P	0.222	0.053	0.403	BG505.T332N (P): significant site of viral escape
278	10E8 functional escape mutation mapping	Dingens2019	other feature	10E8(MPER)	mutational analysis, other, sequence analysis	643	gp41	H	0.084	0.065	0.084	BG505.T332N (Y): significant site of viral escape
278	10E8 functional escape mutation mapping	Dingens2019	other feature	10E8(MPER)	mutational analysis, other, sequence analysis	671	gp41	N	0.783	0.669	0.885	BG505.T332N (N): significant site of viral escape; greatest effects with T/L (strong) and A/Y/R/V (moderate)
278	10E8 functional escape mutation mapping	Dingens2019	other feature	10E8(MPER)	mutational analysis, other, sequence analysis	672	gp41	W	0.014	0.023	0.014	BG505.T332N (W): significant site of viral escape; greatest effect with V (moderate)
278	10E8 functional escape mutation mapping	Dingens2019	other feature	10E8(MPER)	mutational analysis, other, sequence analysis	673	gp41	F	0.048	0.065	0.073	BG505.T332N (F): significant site of viral escape; greatest effects with R/L/V/A (moderate)
278	10E8 functional escape mutation mapping	Dingens2019	other feature	10E8(MPER)	mutational analysis, other, sequence analysis	676	gp41	T	0.671	0.610	0.674	BG505.T332N (S): significant site of viral escape
278	10E8 functional escape mutation mapping	Dingens2019	other feature	10E8(MPER)	mutational analysis, other, sequence analysis	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	BG505.T332N (W): significant site of viral escape
278	10E8 functional escape mutation mapping	Dingens2019	other feature	10E8(MPER)	mutational analysis, other, sequence analysis	682	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	I	0.046	0.042	0.041	BG505.T332N (I): significant site of viral escape
278	10E8 functional escape mutation mapping	Dingens2019	other feature	10E8(MPER)	mutational analysis, other, sequence analysis	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	BG505.T332N (K): significant site of viral escape; greatest effect with Y (strong)
279	10E8 contacts	Dingens2019	contacts	10E8(MPER)	molecular modeling, X-ray crystallography	665	gp41	K	1.039	0.656	0.879	10E8 contact
279	10E8 contacts	Dingens2019	contacts	10E8(MPER)	molecular modeling, X-ray crystallography	668	gp41	S	0.865	0.596	0.758	10E8 contact
279	10E8 contacts	Dingens2019	contacts	10E8(MPER)	molecular modeling, X-ray crystallography	669	gp41	L	0.017	0.023	0.000	10E8 contact
279	10E8 contacts	Dingens2019	contacts	10E8(MPER)	molecular modeling, X-ray crystallography	670	gp41	W	0.043	0.028	0.035	10E8 contact
279	10E8 contacts	Dingens2019	contacts	10E8(MPER)	molecular modeling, X-ray crystallography	671	gp41	N	0.783	0.669	0.885	10E8 contact
279	10E8 contacts	Dingens2019	contacts	10E8(MPER)	molecular modeling, X-ray crystallography	672	gp41	W	0.014	0.023	0.014	10E8 contact
279	10E8 contacts	Dingens2019	contacts	10E8(MPER)	molecular modeling, X-ray crystallography	673	gp41	F	0.048	0.065	0.073	10E8 contact
279	10E8 contacts	Dingens2019	contacts	10E8(MPER)	molecular modeling, X-ray crystallography	676	gp41	T	0.671	0.610	0.674	10E8 contact
279	10E8 contacts	Dingens2019	contacts	10E8(MPER)	molecular modeling, X-ray crystallography	677	gp41	N	1.203	1.199	1.100	10E8 contact
279	10E8 contacts	Dingens2019	contacts	10E8(MPER)	molecular modeling, X-ray crystallography	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	10E8 contact
279	10E8 contacts	Dingens2019	contacts	10E8(MPER)	molecular modeling, X-ray crystallography	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	10E8 contact
279	10E8 contacts	Dingens2019	contacts	10E8(MPER)	molecular modeling, X-ray crystallography	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	10E8 contact
280	VRC03 signature predictions	Liu2019	signature	VRC03(CD4BS)	computational prediction, neutralization assay	65	gp120	V	1.017	1.023	0.310	K65 was associated with 1.5 fold or greater increased or decreased neutralization by VRC03
280	VRC03 signature predictions	Liu2019	signature	VRC03(CD4BS)	computational prediction, neutralization assay	304	gp120, V3 loop	R	0.304	0.390	0.141	R304 was associated with 1.5 fold or greater increased or decreased neutralization by VRC03
280	VRC03 signature predictions	Liu2019	signature	VRC03(CD4BS)	computational prediction, neutralization assay	318	gp120, V3 loop	V	0.588	0.691	0.507	Y318 was associated with 1.5 fold or greater increased or decreased neutralization by VRC03
280	VRC03 signature predictions	Liu2019	signature	VRC03(CD4BS)	computational prediction, neutralization assay	440	gp120	S	1.844	1.712	1.017	Q440 was associated with 1.5 fold or greater increased or decreased neutralization by VRC03
281	Mutation affects neutralization by VRC01_FR3-03	Liu2019	neutralization	VRC01_FR3-03(CD4BS)	mutational analysis, neutralization assay	207	gp120	K	0.065	0.029	0.029	BG505 mutation K207A decreases VRC01_FR3-03 neutralization 1.5 fold or more
281	Mutation affects neutralization by VRC01_FR3-03	Liu2019	neutralization	VRC01_FR3-03(CD4BS)	mutational analysis, neutralization assay	304	gp120, V3 loop	R	0.304	0.390	0.141	BG505 mutation R304A, R304E or R304A/R308A decreases VRC01_FR3-03 neutralization 1.5 fold or more
281	Mutation affects neutralization by VRC01_FR3-03	Liu2019	neutralization	VRC01_FR3-03(CD4BS)	mutational analysis, neutralization assay	308	gp120, V3 loop	R	1.578	0.091	0.127	BG505 mutation R308A, R308E or R304A/R308A decreases VRC01_FR3-03 neutralization 1.5 fold or more
281	Mutation affects neutralization by VRC01_FR3-03	Liu2019	neutralization	VRC01_FR3-03(CD4BS)	mutational analysis, neutralization assay	318	gp120, V3 loop	V	0.588	0.691	0.507	BG505 mutation Y318F or Y318E decreases VRC01_FR3-03 neutralization 1.5 fold or more
282	Mutation affects neutralization by VRC07_FR3-03	Liu2019	neutralization	VRC07_FR3-03(CD4BS)	mutational analysis, neutralization assay	304	gp120, V3 loop	R	0.304	0.390	0.141	BG505 mutation R304E decreases VRC07_FR3-03 neutralization 1.5 fold or more
282	Mutation affects neutralization by VRC07_FR3-03	Liu2019	neutralization	VRC07_FR3-03(CD4BS)	mutational analysis, neutralization assay	308	gp120, V3 loop	R	1.578	0.091	0.127	BG505 mutation R308E decreases VRC07_FR3-03 neutralization 1.5 fold or more
282	Mutation affects neutralization by VRC07_FR3-03	Liu2019	neutralization	VRC07_FR3-03(CD4BS)	mutational analysis, neutralization assay	318	gp120, V3 loop	V	0.588	0.691	0.507	BG505 mutation Y318E decreases VRC07_FR3-03 neutralization 1.5 fold or more
283	Mutation affects neutralization by VRC07-523-LS_FR3-03	Liu2019	neutralization	VRC07-523-LS_FR3-03(CD4BS)	mutational analysis, neutralization assay	207	gp120	K	0.065	0.029	0.029	BG505 mutation K207A decreases VRC07-523-LS_FR3-0 neutralization 1.5 fold or more
283	Mutation affects neutralization by VRC07-523-LS_FR3-03	Liu2019	neutralization	VRC07-523-LS_FR3-03(CD4BS)	mutational analysis, neutralization assay	304	gp120, V3 loop	R	0.304	0.390	0.141	BG505 mutation R304A, R304E or R304A/R308A decreases VRC07-523-LS_FR3-0 neutralization 1.5 fold or more
283	Mutation affects neutralization by VRC07-523-LS_FR3-03	Liu2019	neutralization	VRC07-523-LS_FR3-03(CD4BS)	mutational analysis, neutralization assay	308	gp120, V3 loop	R	1.578	0.091	0.127	BG505 mutation R308E or R304A/R308A decreases VRC07-523-LS_FR3-0 neutralization 1.5 fold or more
283	Mutation affects neutralization by VRC07-523-LS_FR3-03	Liu2019	neutralization	VRC07-523-LS_FR3-03(CD4BS)	mutational analysis, neutralization assay	318	gp120, V3 loop	V	0.588	0.691	0.507	BG505 mutation Y318E decreases VRC07-523-LS_FR3-0 neutralization 1.5 fold or more
284	Mutation affects neutralization by N6_FR3-03	Liu2019	neutralization	N6-FR3_03(CD4BS)	mutational analysis, neutralization assay	207	gp120	K	0.065	0.029	0.029	BG505 mutation K207A decreases N6_FR3-03 neutralization 1.5 fold or more
284	Mutation affects neutralization by N6_FR3-03	Liu2019	neutralization	N6-FR3_03(CD4BS)	mutational analysis, neutralization assay	304	gp120, V3 loop	R	0.304	0.390	0.141	BG505 mutation R304A, R304E or R304A/R308A decreases N6_FR3-0 neutralization 2 fold or more
284	Mutation affects neutralization by N6_FR3-03	Liu2019	neutralization	N6-FR3_03(CD4BS)	mutational analysis, neutralization assay	308	gp120, V3 loop	R	1.578	0.091	0.127	BG505 mutation R308A, R308E or R304A/R308A decreases N6_FR3-0 neutralization 2 fold or more
284	Mutation affects neutralization by N6_FR3-03	Liu2019	neutralization	N6-FR3_03(CD4BS)	mutational analysis, neutralization assay	318	gp120, V3 loop	V	0.588	0.691	0.507	BG505 mutation Y318A, Y318F or Y318E decreases N6_FR3-0 neutralization 2 fold or more
285	VRC42.01 contacts	Krebs2019	contacts	VRC42.01(MPER)	X-ray crystallography	671	gp41	N	0.783	0.669	0.885	VRC42.01 contact
285	VRC42.01 contacts	Krebs2019	contacts	VRC42.01(MPER)	X-ray crystallography	673	gp41	F	0.048	0.065	0.073	VRC42.01 contact
285	VRC42.01 contacts	Krebs2019	contacts	VRC42.01(MPER)	X-ray crystallography	674	gp41	N	1.179	1.029	1.344	VRC42.01 contact (D674 for founder MPER in structure)
285	VRC42.01 contacts	Krebs2019	contacts	VRC42.01(MPER)	X-ray crystallography	675	gp41	I	0.063	0.059	0.069	VRC42.01 contact
285	VRC42.01 contacts	Krebs2019	contacts	VRC42.01(MPER)	X-ray crystallography	676	gp41	T	0.671	0.610	0.674	VRC42.01 contact
285	VRC42.01 contacts	Krebs2019	contacts	VRC42.01(MPER)	X-ray crystallography	677	gp41	N	1.203	1.199	1.100	VRC42.01 contact
285	VRC42.01 contacts	Krebs2019	contacts	VRC42.01(MPER)	X-ray crystallography	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	VRC42.01 contact
285	VRC42.01 contacts	Krebs2019	contacts	VRC42.01(MPER)	X-ray crystallography	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	VRC42.01 contact
285	VRC42.01 contacts	Krebs2019	contacts	VRC42.01(MPER)	X-ray crystallography	681	gp41, gp41 transmembrane	Y	0.020	0.012	0.036	VRC42.01 contact
285	VRC42.01 contacts	Krebs2019	contacts	VRC42.01(MPER)	X-ray crystallography	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	VRC42.01 contact
286	Residues that affect neutralization by VRC42.04	Krebs2019	neutralization	VRC42.04(MPER)	alanine scanning, neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A results in 25.6-fold decrease (founder) and 3.03-fold decrease (BG1168) in neutralization sensitivity
286	Residues that affect neutralization by VRC42.04	Krebs2019	neutralization	VRC42.04(MPER)	alanine scanning, neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A results in 25.6-fold decrease (founder) and 2.78-fold decrease (BG1168) in neutralization sensitivity
286	Residues that affect neutralization by VRC42.04	Krebs2019	neutralization	VRC42.04(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A results in 2.1-fold decrease (founder) and 2.59-fold decrease (BG1168) in neutralization sensitivity
286	Residues that affect neutralization by VRC42.04	Krebs2019	neutralization	VRC42.04(MPER)	alanine scanning, neutralization assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A results in 20-fold decrease (founder) and 3.03-fold decrease (BG1168) in neutralization sensitivity
287	VRC42.04 contacts	Krebs2019	contacts	VRC42.04(MPER)	X-ray crystallography	671	gp41	N	0.783	0.669	0.885	contact residue
287	VRC42.04 contacts	Krebs2019	contacts	VRC42.04(MPER)	X-ray crystallography	672	gp41	W	0.014	0.023	0.014	contact residue
287	VRC42.04 contacts	Krebs2019	contacts	VRC42.04(MPER)	X-ray crystallography	674	gp41	N	1.179	1.029	1.344	contact residue (D674 in MPER in structure)
287	VRC42.04 contacts	Krebs2019	contacts	VRC42.04(MPER)	X-ray crystallography	675	gp41	I	0.063	0.059	0.069	contact residue
287	VRC42.04 contacts	Krebs2019	contacts	VRC42.04(MPER)	X-ray crystallography	676	gp41	T	0.671	0.610	0.674	contact residue
287	VRC42.04 contacts	Krebs2019	contacts	VRC42.04(MPER)	X-ray crystallography	677	gp41	N	1.203	1.199	1.100	contact residue
287	VRC42.04 contacts	Krebs2019	contacts	VRC42.04(MPER)	X-ray crystallography	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	contact residue
287	VRC42.04 contacts	Krebs2019	contacts	VRC42.04(MPER)	X-ray crystallography	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	contact residue
287	VRC42.04 contacts	Krebs2019	contacts	VRC42.04(MPER)	X-ray crystallography	681	gp41, gp41 transmembrane	Y	0.020	0.012	0.036	contact residue
287	VRC42.04 contacts	Krebs2019	contacts	VRC42.04(MPER)	X-ray crystallography	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	contact residue
288	VRC42.N1 contacts	Krebs2019	contacts	VRC42.N1(MPER)	X-ray crystallography	671	gp41	N	0.783	0.669	0.885	VRC42.N1 contact
288	VRC42.N1 contacts	Krebs2019	contacts	VRC42.N1(MPER)	X-ray crystallography	672	gp41	W	0.014	0.023	0.014	VRC42.N1 contact
288	VRC42.N1 contacts	Krebs2019	contacts	VRC42.N1(MPER)	X-ray crystallography	673	gp41	F	0.048	0.065	0.073	VRC42.N1 contact
288	VRC42.N1 contacts	Krebs2019	contacts	VRC42.N1(MPER)	X-ray crystallography	674	gp41	N	1.179	1.029	1.344	VRC42.N1 contact (D674 in founder MPER in structure)
288	VRC42.N1 contacts	Krebs2019	contacts	VRC42.N1(MPER)	X-ray crystallography	675	gp41	I	0.063	0.059	0.069	VRC42.N1 contact
288	VRC42.N1 contacts	Krebs2019	contacts	VRC42.N1(MPER)	X-ray crystallography	676	gp41	T	0.671	0.610	0.674	VRC42.N1 contact
288	VRC42.N1 contacts	Krebs2019	contacts	VRC42.N1(MPER)	X-ray crystallography	677	gp41	N	1.203	1.199	1.100	VRC42.N1 contact
288	VRC42.N1 contacts	Krebs2019	contacts	VRC42.N1(MPER)	X-ray crystallography	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	VRC42.N1 contact
288	VRC42.N1 contacts	Krebs2019	contacts	VRC42.N1(MPER)	X-ray crystallography	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	VRC42.N1 contact
288	VRC42.N1 contacts	Krebs2019	contacts	VRC42.N1(MPER)	X-ray crystallography	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	VRC42.N1 contact
289	Residues that affect neutralization by VRC43.01	Krebs2019	neutralization	VRC43.01(MPER)	alanine scanning, computational prediction, neutralization assay	662	gp41	E	1.043	0.874	0.369	E662A results in 0.46-fold decrease (founder) and 6.4-fold decrease (BG1168) in neutralization sensitivity.
289	Residues that affect neutralization by VRC43.01	Krebs2019	neutralization	VRC43.01(MPER)	alanine scanning, computational prediction, neutralization assay	667	gp41	A	1.424	0.545	1.537	G was found only in neutralization resistant strains while Q and D were preferentially found in neutralization-resistant strains.
289	Residues that affect neutralization by VRC43.01	Krebs2019	neutralization	VRC43.01(MPER)	alanine scanning, computational prediction, neutralization assay	671	gp41	N	0.783	0.669	0.885	N671A results in 2.5-fold decrease (founder) and 15-fold decrease (BG1168) n neutralization sensitivity. T and S were preferentially found in neutralization-resistant strains
289	Residues that affect neutralization by VRC43.01	Krebs2019	neutralization	VRC43.01(MPER)	alanine scanning, computational prediction, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A results in 39-fold decrease (founder) and 93-fold decrease (BG1168) in neutralization sensitivity. G and S were preferentially found in neutralization-resistant strains
289	Residues that affect neutralization by VRC43.01	Krebs2019	neutralization	VRC43.01(MPER)	alanine scanning, computational prediction, neutralization assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A results in 3.9-old decrease (founder) and 30-fold decrease (BG1168) in neutralization sensitivity
289	Residues that affect neutralization by VRC43.01	Krebs2019	neutralization	VRC43.01(MPER)	alanine scanning, computational prediction, neutralization assay	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	R683A results in 6.1-fold decrease in BG1168 neutralization sensitivity; Founder Env with K683A was non-functional
290	Residues that affect neutralization by VRC46.01	Krebs2019	neutralization	VRC46.01(MPER)	alanine scanning, neutralization assay	662	gp41	E	1.043	0.874	0.369	E662A results in 0.32 fold-decrease (founder) and 5.7-fold decrease (BG1168) in neutralization sensitivity
290	Residues that affect neutralization by VRC46.01	Krebs2019	neutralization	VRC46.01(MPER)	alanine scanning, neutralization assay	664	gp41	D	0.222	0.156	0.346	D664A results in 3-fold decrease in neutralization sensitivity vs. both founder and BG1168 WT
290	Residues that affect neutralization by VRC46.01	Krebs2019	neutralization	VRC46.01(MPER)	alanine scanning, neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A results in 50.4-fold decrease (founder) and 7.39-fold decrease (BG1168) in neutralization sensitivity
290	Residues that affect neutralization by VRC46.01	Krebs2019	neutralization	VRC46.01(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A results in 50.4-fold decrease (founder) and 6.39-fold decrease (BG1168) in neutralization sensitivity
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	665	gp41	K	1.039	0.656	0.879	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	666	gp41	W	0.008	0.000	0.000	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	667	gp41	A	1.424	0.545	1.537	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	668	gp41	S	0.865	0.596	0.758	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	669	gp41	L	0.017	0.023	0.000	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	670	gp41	W	0.043	0.028	0.035	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	671	gp41	N	0.783	0.669	0.885	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	673	gp41	F	0.048	0.065	0.073	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	674	gp41	N	1.179	1.029	1.344	VRC46.01 contact (D674 in founder MPER in structure)
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	675	gp41	I	0.063	0.059	0.069	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	676	gp41	T	0.671	0.610	0.674	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	677	gp41	N	1.203	1.199	1.100	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	VRC46.01 contact
291	VRC46.01 contacts	Krebs2019	contacts	VRC46.01(MPER)	X-ray crystallography	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	VRC46.01 contact
292	4E10 contacts	Krebs2019	contacts	4E10(MPER)	molecular modeling	671	gp41	N	0.783	0.669	0.885	4E10 contact
292	4E10 contacts	Krebs2019	contacts	4E10(MPER)	molecular modeling	672	gp41	W	0.014	0.023	0.014	4E10 contact
292	4E10 contacts	Krebs2019	contacts	4E10(MPER)	molecular modeling	673	gp41	F	0.048	0.065	0.073	4E10 contact
292	4E10 contacts	Krebs2019	contacts	4E10(MPER)	molecular modeling	674	gp41	N	1.179	1.029	1.344	4E10 contact (D672 in MPER peptide in structure)
292	4E10 contacts	Krebs2019	contacts	4E10(MPER)	molecular modeling	675	gp41	I	0.063	0.059	0.069	4E10 contact
292	4E10 contacts	Krebs2019	contacts	4E10(MPER)	molecular modeling	676	gp41	T	0.671	0.610	0.674	4E10 contact
292	4E10 contacts	Krebs2019	contacts	4E10(MPER)	molecular modeling	677	gp41	N	1.203	1.199	1.100	4E10 contact
292	4E10 contacts	Krebs2019	contacts	4E10(MPER)	molecular modeling	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	4E10 contact
292	4E10 contacts	Krebs2019	contacts	4E10(MPER)	molecular modeling	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	4E10 contact
292	4E10 contacts	Krebs2019	contacts	4E10(MPER)	molecular modeling	681	gp41, gp41 transmembrane	Y	0.020	0.012	0.036	4E10 contact
292	4E10 contacts	Krebs2019	contacts	4E10(MPER)	molecular modeling	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	4E10 contact
293	Residues that affect neutralization by 4E10	Krebs2019	neutralization	4E10(MPER)	alanine scanning, binding assay, neutralization assay	662	gp41	E	1.043	0.874	0.369	E662A results in 0.35-fold decrease (founder) and 2.88-fold decrease (BG1168) in neutralization sensitivity
293	Residues that affect neutralization by 4E10	Krebs2019	neutralization	4E10(MPER)	alanine scanning, binding assay, neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A results in 0.29-fold decrease (founder) and 4.30-fold decrease (BG1168) in neutralization sensitivity
294	Residues that affect 10E8 binding	Krebs2019	binding	10E8(MPER)	alanine scanning, binding assay	671	gp41	N	0.783	0.669	0.885	N671A results in ~4 fold reduction in MPER peptide binding
294	Residues that affect 10E8 binding	Krebs2019	binding	10E8(MPER)	alanine scanning, binding assay	672	gp41	W	0.014	0.023	0.014	W672A results in ~100 fold reduction in MPER peptide binding
294	Residues that affect 10E8 binding	Krebs2019	binding	10E8(MPER)	alanine scanning, binding assay	673	gp41	F	0.048	0.065	0.073	F673A results in ~700 fold reduction in MPER peptide binding
294	Residues that affect 10E8 binding	Krebs2019	binding	10E8(MPER)	alanine scanning, binding assay	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	R683A results in ~40 fold reduction in MPER peptide binding
295	Residues that affect neutralization by VRC42.02	Krebs2019	neutralization	VRC42.02(MPER)	alanine scanning, binding assay, neutralization assay	662	gp41	E	1.043	0.874	0.369	Ala mediates a 0.28-fold decrease (founder) and 5.90-fold decrease (BG1168) in neutralization sensitivity.
295	Residues that affect neutralization by VRC42.02	Krebs2019	neutralization	VRC42.02(MPER)	alanine scanning, binding assay, neutralization assay	672	gp41	W	0.014	0.023	0.014	Ala mediates a 0.46-fold decrease (founder) and 4.42-fold decrease (BG1168) in neutralization sensitivity
295	Residues that affect neutralization by VRC42.02	Krebs2019	neutralization	VRC42.02(MPER)	alanine scanning, binding assay, neutralization assay	673	gp41	F	0.048	0.065	0.073	Ala mediates a 2.06-fold decrease (founder) and 8.90-fold decrease (BG1168) in neutralization sensitivity
295	Residues that affect neutralization by VRC42.02	Krebs2019	neutralization	VRC42.02(MPER)	alanine scanning, binding assay, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A mediates a 2.85 fold decrease (founder) and 3.27 fold decrease (BG1168) in neutralization sensitivity
296	Residues that affect neutralization by VRC42.03	Krebs2019	neutralization	VRC42.03(MPER)	alanine scanning, binding assay, neutralization assay	662	gp41	E	1.043	0.874	0.369	Ala mediates a 0.26-fold decrease (founder) and 2.69-fold decrease (BG1168) in neutralization sensitivity
296	Residues that affect neutralization by VRC42.03	Krebs2019	neutralization	VRC42.03(MPER)	alanine scanning, binding assay, neutralization assay	672	gp41	W	0.014	0.023	0.014	Ala mediates a 66.3-fold decrease (founder) and 6.17-fold decrease (BG1168) in neutralization sensitivity
296	Residues that affect neutralization by VRC42.03	Krebs2019	neutralization	VRC42.03(MPER)	alanine scanning, binding assay, neutralization assay	673	gp41	F	0.048	0.065	0.073	Ala mediates a 2.28-fold decrease (founder) and 4.00-fold decrease (BG1168) in neutralization sensitivity
296	Residues that affect neutralization by VRC42.03	Krebs2019	neutralization	VRC42.03(MPER)	alanine scanning, binding assay, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A mediates a 2.72-fold decrease (founder) and 3.64-fold decrease (BG1168) in neutralization sensitivity
297	Residues important for neutralization by VRC43.02	Krebs2019	neutralization	VRC43.02(MPER)	alanine scanning, neutralization assay	662	gp41	E	1.043	0.874	0.369	Ala mediates a 0.48 fold decrease (founder) and 9.06 fold decrease (BG1168) in neutralization sensitivity
297	Residues important for neutralization by VRC43.02	Krebs2019	neutralization	VRC43.02(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A mediates a 12.4 fold decrease (founder) and 41.3 fold decrease (BG1168) in neutralization sensitivity
297	Residues important for neutralization by VRC43.02	Krebs2019	neutralization	VRC43.02(MPER)	alanine scanning, neutralization assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A mediates a 2.70 fold decrease (founder) and 2.06 fold decrease (BG1168) in neutralization sensitivity
298	Residues important for neutralization by VRC43.03	Krebs2019	neutralization	VRC43.03(MPER)	alanine scanning, neutralization assay	662	gp41	E	1.043	0.874	0.369	Ala mediates a 0.44 fold decrease (founder) and 8.94 fold decrease (BG1168) in neutralization sensitivity
298	Residues important for neutralization by VRC43.03	Krebs2019	neutralization	VRC43.03(MPER)	alanine scanning, neutralization assay	671	gp41	N	0.783	0.669	0.885	N671A mediates a 2.14 fold decrease (founder) and 9.71 fold decrease (BG1168) in neutralization sensitivity
298	Residues important for neutralization by VRC43.03	Krebs2019	neutralization	VRC43.03(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A mediates a 21.0 fold decrease (founder) and 48.1 fold decrease (BG1168) in neutralization sensitivity
298	Residues important for neutralization by VRC43.03	Krebs2019	neutralization	VRC43.03(MPER)	alanine scanning, neutralization assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A mediates a 12.3 fold decrease (founder) and 18.3 fold decrease (BG1168) in neutralization sensitivity
299	RHA1.V2.01 contacts	Roark2021	contacts	RHA1.V2.01(V2)	cryo-EM, mutational analysis, neutralization assay	121	gp120	K	0.349	0.360	0.187	Heavy chain contact
299	RHA1.V2.01 contacts	Roark2021	contacts	RHA1.V2.01(V2)	cryo-EM, mutational analysis, neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	Heavy chain contact; R166G, R166S, R169T, or R166K+R169K associated with resistance to neutralization
299	RHA1.V2.01 contacts	Roark2021	contacts	RHA1.V2.01(V2)	cryo-EM, mutational analysis, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	Heavy chain contact; R166G, R166S, R169T, or R166K+R169K associated with resistance to neutralization
300	RHA1.V2.01 signatures	Roark2021	signature	RHA1.V2.01(V2)	computational prediction, neutralization assay	130	gp120	K	1.201	0.883	1.495	glycan or N associated with resistance
300	RHA1.V2.01 signatures	Roark2021	signature	RHA1.V2.01(V2)	computational prediction, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	glycan associated with sensitivity
300	RHA1.V2.01 signatures	Roark2021	signature	RHA1.V2.01(V2)	computational prediction, neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R associated with sensitivity; K associated with resistance
300	RHA1.V2.01 signatures	Roark2021	signature	RHA1.V2.01(V2)	computational prediction, neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D associated with sensitivity
300	RHA1.V2.01 signatures	Roark2021	signature	RHA1.V2.01(V2)	computational prediction, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	R associated with sensitivity; V associated with resistance
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	130	gp120	K	1.201	0.883	1.495	N or glycan associated with resistance
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	glycan associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	161	gp120, V2	I	1.493	0.964	1.568	I associated with resistance; M associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	T associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	164	gp120, V2	S	1.840	1.925	0.453	S or N associated with resistance; E associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	165	gp120, V2	I	1.327	1.292	1.011	I associated with resistance; L associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	V, M or Q associated with resistance; K or R associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	170	gp120, V2	Q	1.493	1.423	1.428	Q associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	172	gp120, V2	E	1.527	1.172	1.484	E associated with resistance; V associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y associated with resistance
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	184	gp120, V2	I	1.028	0.599	0.530	I associated with resistance; L associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	200	gp120	V	1.270	0.683	0.916	V associated with resistance; A associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	211	gp120	E	0.829	0.366	0.364	E associated with resistance; D associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	281	gp120, Loop D	A	1.129	0.814	1.357	A associated with resistance; V associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I associated with resistance; V associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	308	gp120, V3 loop	R	1.578	0.091	0.127	H associated with resistance; R associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	309	gp120, V3 loop	I	0.863	0.359	0.965	M or L associated with resistance; I associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	315	gp120, V3 loop	R	1.211	1.028	0.196	R associated with resistance; Q associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	362	gp120	K	1.815	1.265	1.997	glycan associated with resistance; Q, A or E associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	419	gp120	R	0.463	0.341	0.500	R associated with resistance; K associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	426	gp120, beta20/beta21	M	0.724	0.866	0.274	R or L associated with resistance; M associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	518	gp41, fusion peptide	L	1.166	1.110	0.718	L associated with resistance; V associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	588	gp41, Leu/Ile zipper-like sequence	K	1.146	1.197	0.871	Q associated with resistance; K associated with sensitivity
301	PCT64-35M signature sites	Roark2021	signature	PCT64-35M(V2)	computational prediction, neutralization assay	788	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, CaM interaction, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	R	0.673	0.131	0.670	R associated with resistance; L associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	128	gp120	S	0.267	0.339	0.088	T associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	glycan associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	161	gp120, V2	I	1.493	0.964	1.568	V associated with resistance; M associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	T associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	164	gp120, V2	S	1.840	1.925	0.453	S associated with resistance; E associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	165	gp120, V2	I	1.327	1.292	1.011	I associated with resistance; L associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	G associated with resistance; R associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	N associated with resistance; D associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	V associated with resistance; K associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	170	gp120, V2	Q	1.493	1.423	1.428	Q associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	172	gp120, V2	E	1.527	1.172	1.484	E or D associated with resistance; V associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	182	gp120, V2	I	0.830	0.957	0.587	V associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	200	gp120	V	1.270	0.683	0.916	V associated with resistance
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	232	gp120	T	1.480	1.451	0.426	T associated with resistance
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	275	gp120, Loop D	V	1.141	1.420	0.535	K associated with resistance; E associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	306	gp120, V3 loop	R	0.714	0.860	0.338	R associated with resistance
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	308	gp120, V3 loop	R	1.578	0.091	0.127	T associated with resistance
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	309	gp120, V3 loop	I	0.863	0.359	0.965	L associated with resistance
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	313	gp120, V3 loop	P	0.344	0.424	0.078	P associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	315	gp120, V3 loop	R	1.211	1.028	0.196	R associated with resistance; Q associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	332	gp120	N	0.663	0.491	0.693	glycan associated with resistance
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	362	gp120	K	1.815	1.265	1.997	glycan associated with resistance
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	426	gp120, beta20/beta21	M	0.724	0.866	0.274	R associated with resistance; M associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	636	gp41	N	1.413	1.127	1.081	D associated with resistance; S associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	654	gp41	E	0.167	0.174	0.105	D associated with resistance; E associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	784	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, CaM interaction, p115-RhoGEF interaction	L	0.576	0.534	0.440	I associated with resistance; L associated with sensitivity
302	PGDM signature sites	Roark2021	signature	PGDM1400(V2)	computational prediction, neutralization assay	835	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	G	0.745	0.515	0.917	R associated with resistance; G associated with sensitivity
303	PG9 signature sites	Roark2021	signature	PG9(V2)	computational prediction, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	glycan associated with sensitivity
303	PG9 signature sites	Roark2021	signature	PG9(V2)	computational prediction, neutralization assay	161	gp120, V2	I	1.493	0.964	1.568	V associated with resistance; M associated with sensitivity
303	PG9 signature sites	Roark2021	signature	PG9(V2)	computational prediction, neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	T associated with sensitivity
303	PG9 signature sites	Roark2021	signature	PG9(V2)	computational prediction, neutralization assay	164	gp120, V2	S	1.840	1.925	0.453	S associated with resistance
303	PG9 signature sites	Roark2021	signature	PG9(V2)	computational prediction, neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D associated with sensitivity
303	PG9 signature sites	Roark2021	signature	PG9(V2)	computational prediction, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	V associated with resistance; K associated with sensitivity
303	PG9 signature sites	Roark2021	signature	PG9(V2)	computational prediction, neutralization assay	170	gp120, V2	Q	1.493	1.423	1.428	K associated with resistance; Q associated with sensitivity
303	PG9 signature sites	Roark2021	signature	PG9(V2)	computational prediction, neutralization assay	171	gp120, V2	K	1.247	0.957	1.413	K associated with sensitivity
303	PG9 signature sites	Roark2021	signature	PG9(V2)	computational prediction, neutralization assay	305	gp120, V3 loop	K	0.906	0.713	0.943	Q associated with resistance
303	PG9 signature sites	Roark2021	signature	PG9(V2)	computational prediction, neutralization assay	306	gp120, V3 loop	R	0.714	0.860	0.338	R associated with resistance
303	PG9 signature sites	Roark2021	signature	PG9(V2)	computational prediction, neutralization assay	313	gp120, V3 loop	P	0.344	0.424	0.078	P associated with sensitivity
303	PG9 signature sites	Roark2021	signature	PG9(V2)	computational prediction, neutralization assay	315	gp120, V3 loop	R	1.211	1.028	0.196	R associated with resistance; Q associated with sensitivity
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	130	gp120	K	1.201	0.883	1.495	N or glycan associated with resistance;  D associated with sensitivity
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	159	gp120, V2	F	0.104	0.034	0.038	Y associated with sensitivity
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	glycan associated with sensitivity
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	161	gp120, V2	I	1.493	0.964	1.568	I associated with resistance; M associated with sensitivity
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	165	gp120, V2	I	1.327	1.292	1.011	I associated with resistance; L associated with sensitivity
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D associated with sensitivity
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	V associated with resistance
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	170	gp120, V2	Q	1.493	1.423	1.428	associated with resistance
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	171	gp120, V2	K	1.247	0.957	1.413	Q associated with resistance; K associated with sensitivity
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	172	gp120, V2	E	1.527	1.172	1.484	D associated with resistance
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	174	gp120, V2	A	0.333	0.155	0.145	A associated with resistance; S associated with sensitivity
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	305	gp120, V3 loop	K	0.906	0.713	0.943	Q associated with resistance
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	306	gp120, V3 loop	R	0.714	0.860	0.338	R associated with resistance
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	309	gp120, V3 loop	I	0.863	0.359	0.965	L associated with resistance; I associated with sensitivity
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	315	gp120, V3 loop	R	1.211	1.028	0.196	R associated with resistance; Q associated with sensitivity
304	CH01 signature sites	Roark2021	signature	CH01(V2)	computational prediction, neutralization assay	337	gp120	K	2.037	1.862	2.151	N or glycan associated with resistance
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	128	gp120	S	0.267	0.339	0.088	T associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	glycan associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	161	gp120, V2	I	1.493	0.964	1.568	V associated with resistance; M associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	T associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	Q associated with resistance; R associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	V associated with resistance; K associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	170	gp120, V2	Q	1.493	1.423	1.428	associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	172	gp120, V2	E	1.527	1.172	1.484	V associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	N associated with resistance; Y associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	202	gp120	T	0.506	0.291	0.547	A associated with resistance; T associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	306	gp120, V3 loop	R	0.714	0.860	0.338	R associated with resistance
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	313	gp120, V3 loop	P	0.344	0.424	0.078	P associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	315	gp120, V3 loop	R	1.211	1.028	0.196	R associated with resistance; Q associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	320	gp120, V3 loop	I	0.711	0.564	0.782	T associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	332	gp120	N	0.663	0.491	0.693	N or glycan associated with resistance
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	334	gp120	S	0.717	0.501	0.890	S associated with resistance; N or glycan associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	426	gp120, beta20/beta21	M	0.724	0.866	0.274	R associated with resistance; M associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	446	gp120	S	1.957	1.139	1.774	S or I associated with resistance; V associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	R associated with resistance; K associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	717	gp41, gp41 cytoplasmic tail	F	0.493	0.533	0.386	L associated with resistance; F associated with sensitivity
305	PGT145 signature sites	Roark2021	signature	PGT145(V2)	computational prediction, neutralization assay	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.919	0.166	0.579	L associated with resistance; I associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	glycan associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	164	gp120, V2	S	1.840	1.925	0.453	S or N associated with resistance; E associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	165	gp120, V2	I	1.327	1.292	1.011	L associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	K associated with resistance; R associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	N associated with resistance; D associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	M, Q, or V associated with resistance; K associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	170	gp120, V2	Q	1.493	1.423	1.428	associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	172	gp120, V2	E	1.527	1.172	1.484	D associated with resistance; V associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y associated with resistance
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	181	gp120, V2	I	0.988	0.929	0.855	V associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	184	gp120, V2	I	1.028	0.599	0.530	I associated with resistance; L associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	192	gp120, V2	K	0.940	0.835	0.851	T associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	200	gp120	V	1.270	0.683	0.916	V associated with resistance; T or A associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	306	gp120, V3 loop	R	0.714	0.860	0.338	R associated with resistance; S associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	308	gp120, V3 loop	R	1.578	0.091	0.127	H or N associated with resistance; R associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	309	gp120, V3 loop	I	0.863	0.359	0.965	L associated with resistance; I associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	315	gp120, V3 loop	R	1.211	1.028	0.196	R associated with resistance; Q associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	362	gp120	K	1.815	1.265	1.997	N or glycan associated with resistance; E associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	387	gp120, V4 loop	S	0.431	0.647	0.045	S associated with resistance; T associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	393	gp120, V4 loop	S	1.501	0.650	2.132	S associated with resistance; G or N associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	426	gp120, beta20/beta21	M	0.724	0.866	0.274	L associated with resistance; M associated with sensitivity
306	VRC26.08 signature sites	Roark2021	signature	VRC26.08(V2)	computational prediction, neutralization assay	732	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	G	0.823	0.262	0.816	G associated with resistance; R associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	121	gp120	K	0.349	0.360	0.187	associated with resistance
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	glycan associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	T associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	164	gp120, V2	S	1.840	1.925	0.453	S or G associated with resistance; E associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	165	gp120, V2	I	1.327	1.292	1.011	I associated with resistance; L associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	I associated with resistance; R associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	I associated with resistance; D associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	K associated with resistance; R associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	V associated with resistance; K associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	170	gp120, V2	Q	1.493	1.423	1.428	associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	172	gp120, V2	E	1.527	1.172	1.484	D associated with resistance; V associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	184	gp120, V2	I	1.028	0.599	0.530	I associated with resistance; L associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	200	gp120	V	1.270	0.683	0.916	V associated with resistance; T or A associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I associated with resistance; V associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	308	gp120, V3 loop	R	1.578	0.091	0.127	N associated with resistance; R associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	309	gp120, V3 loop	I	0.863	0.359	0.965	L associated with resistance; I associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	315	gp120, V3 loop	R	1.211	1.028	0.196	R or K associated with resistance; Q associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	352	gp120	Q	1.607	0.842	1.079	Q associated with resistance; H associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	362	gp120	K	1.815	1.265	1.997	glycan associated with resistance; E associated with sensitivity
307	VRC26.25 signature sites	Roark2021	signature	VRC26.25(V2)	computational prediction, neutralization assay	518	gp41, fusion peptide	L	1.166	1.110	0.718	L or M associated with resistance; V associated with sensitivity
308	DF1W-a.01 neutralization-associated sites	Kong2019	neutralization	DF1W-a.01(gp41 fusion domain)	neutralization assay	80	gp120	N	0.669	0.695	0.562	differential neutralization selection >10%
308	DF1W-a.01 neutralization-associated sites	Kong2019	neutralization	DF1W-a.01(gp41 fusion domain)	neutralization assay	84	gp120	V	1.366	0.916	1.327	differential neutralization selection >10%
308	DF1W-a.01 neutralization-associated sites	Kong2019	neutralization	DF1W-a.01(gp41 fusion domain)	neutralization assay	512	gp41, fusion peptide	A	0.188	0.260	0.110	differential neutralization selection >10%
308	DF1W-a.01 neutralization-associated sites	Kong2019	neutralization	DF1W-a.01(gp41 fusion domain)	neutralization assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	differential neutralization selection >10%
308	DF1W-a.01 neutralization-associated sites	Kong2019	neutralization	DF1W-a.01(gp41 fusion domain)	neutralization assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	differential neutralization selection >10%
308	DF1W-a.01 neutralization-associated sites	Kong2019	neutralization	DF1W-a.01(gp41 fusion domain)	neutralization assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	differential neutralization selection >10%
308	DF1W-a.01 neutralization-associated sites	Kong2019	neutralization	DF1W-a.01(gp41 fusion domain)	neutralization assay	516	gp41, fusion peptide	G	0.066	0.038	0.048	differential neutralization selection >10%
308	DF1W-a.01 neutralization-associated sites	Kong2019	neutralization	DF1W-a.01(gp41 fusion domain)	neutralization assay	517	gp41, fusion peptide	A	0.113	0.109	0.058	differential neutralization selection >10%
308	DF1W-a.01 neutralization-associated sites	Kong2019	neutralization	DF1W-a.01(gp41 fusion domain)	neutralization assay	519	gp41, fusion peptide	F	0.518	0.243	0.837	differential neutralization selection >10%
309	0PV-a.01 neutralization-associated sites	Kong2019	neutralization	0PV-a.01(gp41 fusion domain)	neutralization assay	85	gp120	V	1.980	1.797	1.418	differential neutralization selection >10%
309	0PV-a.01 neutralization-associated sites	Kong2019	neutralization	0PV-a.01(gp41 fusion domain)	neutralization assay	512	gp41, fusion peptide	A	0.188	0.260	0.110	differential neutralization selection >10%
309	0PV-a.01 neutralization-associated sites	Kong2019	neutralization	0PV-a.01(gp41 fusion domain)	neutralization assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	differential neutralization selection >10%
309	0PV-a.01 neutralization-associated sites	Kong2019	neutralization	0PV-a.01(gp41 fusion domain)	neutralization assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	differential neutralization selection >10%
309	0PV-a.01 neutralization-associated sites	Kong2019	neutralization	0PV-a.01(gp41 fusion domain)	neutralization assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	differential neutralization selection >10%
309	0PV-a.01 neutralization-associated sites	Kong2019	neutralization	0PV-a.01(gp41 fusion domain)	neutralization assay	516	gp41, fusion peptide	G	0.066	0.038	0.048	differential neutralization selection >10%
309	0PV-a.01 neutralization-associated sites	Kong2019	neutralization	0PV-a.01(gp41 fusion domain)	neutralization assay	517	gp41, fusion peptide	A	0.113	0.109	0.058	differential neutralization selection >10%
309	0PV-a.01 neutralization-associated sites	Kong2019	neutralization	0PV-a.01(gp41 fusion domain)	neutralization assay	518	gp41, fusion peptide	L	1.166	1.110	0.718	differential neutralization selection >10%
310	0PV-b.01 neutralization-associated sites	Kong2019	neutralization	0PV-b.01(gp41 fusion domain)	neutralization assay	512	gp41, fusion peptide	A	0.188	0.260	0.110	differential neutralization selection >10%
310	0PV-b.01 neutralization-associated sites	Kong2019	neutralization	0PV-b.01(gp41 fusion domain)	neutralization assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	differential neutralization selection >10%
310	0PV-b.01 neutralization-associated sites	Kong2019	neutralization	0PV-b.01(gp41 fusion domain)	neutralization assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	differential neutralization selection >10%
310	0PV-b.01 neutralization-associated sites	Kong2019	neutralization	0PV-b.01(gp41 fusion domain)	neutralization assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	differential neutralization selection >10%
310	0PV-b.01 neutralization-associated sites	Kong2019	neutralization	0PV-b.01(gp41 fusion domain)	neutralization assay	516	gp41, fusion peptide	G	0.066	0.038	0.048	differential neutralization selection >10%
310	0PV-b.01 neutralization-associated sites	Kong2019	neutralization	0PV-b.01(gp41 fusion domain)	neutralization assay	517	gp41, fusion peptide	A	0.113	0.109	0.058	differential neutralization selection >10%
310	0PV-b.01 neutralization-associated sites	Kong2019	neutralization	0PV-b.01(gp41 fusion domain)	neutralization assay	518	gp41, fusion peptide	L	1.166	1.110	0.718	differential neutralization selection >10%
310	0PV-b.01 neutralization-associated sites	Kong2019	neutralization	0PV-b.01(gp41 fusion domain)	neutralization assay	524	gp41, fusion peptide	G	0.152	0.129	0.125	differential neutralization selection >10%
311	DFPH-a.01 neutralization-associated sites	Kong2019	neutralization	DFPH-a.01(gp41 fusion domain)	neutralization assay	512	gp41, fusion peptide	A	0.188	0.260	0.110	differential neutralization selection >10%
311	DFPH-a.01 neutralization-associated sites	Kong2019	neutralization	DFPH-a.01(gp41 fusion domain)	neutralization assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	differential neutralization selection >10%
311	DFPH-a.01 neutralization-associated sites	Kong2019	neutralization	DFPH-a.01(gp41 fusion domain)	neutralization assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	differential neutralization selection >10%
311	DFPH-a.01 neutralization-associated sites	Kong2019	neutralization	DFPH-a.01(gp41 fusion domain)	neutralization assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	differential neutralization selection >10%
311	DFPH-a.01 neutralization-associated sites	Kong2019	neutralization	DFPH-a.01(gp41 fusion domain)	neutralization assay	516	gp41, fusion peptide	G	0.066	0.038	0.048	differential neutralization selection >10%
311	DFPH-a.01 neutralization-associated sites	Kong2019	neutralization	DFPH-a.01(gp41 fusion domain)	neutralization assay	518	gp41, fusion peptide	L	1.166	1.110	0.718	differential neutralization selection >10%
312	DFPH-a.15 neutralization-associated sites	Kong2019	neutralization	DFPH-a.15(gp41 fusion domain)	neutralization assay	512	gp41, fusion peptide	A	0.188	0.260	0.110	differential neutralization selection >10%
312	DFPH-a.15 neutralization-associated sites	Kong2019	neutralization	DFPH-a.15(gp41 fusion domain)	neutralization assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	differential neutralization selection >10%
312	DFPH-a.15 neutralization-associated sites	Kong2019	neutralization	DFPH-a.15(gp41 fusion domain)	neutralization assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	differential neutralization selection >10%
312	DFPH-a.15 neutralization-associated sites	Kong2019	neutralization	DFPH-a.15(gp41 fusion domain)	neutralization assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	differential neutralization selection >10%
312	DFPH-a.15 neutralization-associated sites	Kong2019	neutralization	DFPH-a.15(gp41 fusion domain)	neutralization assay	516	gp41, fusion peptide	G	0.066	0.038	0.048	differential neutralization selection >10%
312	DFPH-a.15 neutralization-associated sites	Kong2019	neutralization	DFPH-a.15(gp41 fusion domain)	neutralization assay	518	gp41, fusion peptide	L	1.166	1.110	0.718	differential neutralization selection >10%
312	DFPH-a.15 neutralization-associated sites	Kong2019	neutralization	DFPH-a.15(gp41 fusion domain)	neutralization assay	519	gp41, fusion peptide	F	0.518	0.243	0.837	differential neutralization selection >10%
313	A12V163-a.01 neutralization-associated sites	Kong2019	neutralization	A12V163-a.01(gp41 fusion domain)	neutralization assay	84	gp120	V	1.366	0.916	1.327	differential neutralization selection >10%
313	A12V163-a.01 neutralization-associated sites	Kong2019	neutralization	A12V163-a.01(gp41 fusion domain)	neutralization assay	85	gp120	V	1.980	1.797	1.418	differential neutralization selection >10%
313	A12V163-a.01 neutralization-associated sites	Kong2019	neutralization	A12V163-a.01(gp41 fusion domain)	neutralization assay	91	gp120	E	0.028	0.033	0.023	differential neutralization selection >10%
313	A12V163-a.01 neutralization-associated sites	Kong2019	neutralization	A12V163-a.01(gp41 fusion domain)	neutralization assay	512	gp41, fusion peptide	A	0.188	0.260	0.110	differential neutralization selection >10%
313	A12V163-a.01 neutralization-associated sites	Kong2019	neutralization	A12V163-a.01(gp41 fusion domain)	neutralization assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	differential neutralization selection >10%
313	A12V163-a.01 neutralization-associated sites	Kong2019	neutralization	A12V163-a.01(gp41 fusion domain)	neutralization assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	differential neutralization selection >10%
313	A12V163-a.01 neutralization-associated sites	Kong2019	neutralization	A12V163-a.01(gp41 fusion domain)	neutralization assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	differential neutralization selection >10%
313	A12V163-a.01 neutralization-associated sites	Kong2019	neutralization	A12V163-a.01(gp41 fusion domain)	neutralization assay	516	gp41, fusion peptide	G	0.066	0.038	0.048	differential neutralization selection >10%
313	A12V163-a.01 neutralization-associated sites	Kong2019	neutralization	A12V163-a.01(gp41 fusion domain)	neutralization assay	518	gp41, fusion peptide	L	1.166	1.110	0.718	differential neutralization selection >10%
313	A12V163-a.01 neutralization-associated sites	Kong2019	neutralization	A12V163-a.01(gp41 fusion domain)	neutralization assay	521	gp41, fusion peptide	G	0.035	0.028	0.008	differential neutralization selection >10%
313	A12V163-a.01 neutralization-associated sites	Kong2019	neutralization	A12V163-a.01(gp41 fusion domain)	neutralization assay	524	gp41, fusion peptide	G	0.152	0.129	0.125	differential neutralization selection >10%
313	A12V163-a.01 neutralization-associated sites	Kong2019	neutralization	A12V163-a.01(gp41 fusion domain)	neutralization assay	629	gp41	M	0.563	0.350	0.132	differential neutralization selection >10%
314	0PV-c.01 contacts	Kong2019	contacts	0PV-a.01(gp41 fusion domain)	cryo-EM, X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	0PV-c.01 contact
314	0PV-c.01 contacts	Kong2019	contacts	0PV-a.01(gp41 fusion domain)	cryo-EM, X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	0PV-c.01 contact
314	0PV-c.01 contacts	Kong2019	contacts	0PV-a.01(gp41 fusion domain)	cryo-EM, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	0PV-c.01 contact
314	0PV-c.01 contacts	Kong2019	contacts	0PV-a.01(gp41 fusion domain)	cryo-EM, X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	0PV-c.01 contact
314	0PV-c.01 contacts	Kong2019	contacts	0PV-a.01(gp41 fusion domain)	cryo-EM, X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	0PV-c.01 contact
315	DFPH-a.15 contacts	Kong2019	contacts	DFPH-a.15(gp41 fusion domain)	cryo-EM, X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	DFPH-a.15 contact
315	DFPH-a.15 contacts	Kong2019	contacts	DFPH-a.15(gp41 fusion domain)	cryo-EM, X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	DFPH-a.15 contact
315	DFPH-a.15 contacts	Kong2019	contacts	DFPH-a.15(gp41 fusion domain)	cryo-EM, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	DFPH-a.15 contact
315	DFPH-a.15 contacts	Kong2019	contacts	DFPH-a.15(gp41 fusion domain)	cryo-EM, X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	DFPH-a.15 contact
315	DFPH-a.15 contacts	Kong2019	contacts	DFPH-a.15(gp41 fusion domain)	cryo-EM, X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	DFPH-a.15 contact
316	mutations affecting PGT121 binding	Kwon2015	binding	PGT121(V3)	binding assay, mutational analysis	191	gp120, V2	Y	0.163	0.187	0.106	BG505 SOSIP.664: Y191W reduced binding
316	mutations affecting PGT121 binding	Kwon2015	binding	PGT121(V3)	binding assay, mutational analysis	432	gp120, beta20/beta21	K	1.037	0.339	0.564	BG505 SOSIP.664: Q432P enhanced binding
316	mutations affecting PGT121 binding	Kwon2015	binding	PGT121(V3)	binding assay, mutational analysis	433	gp120, beta20/beta21	A	0.054	0.023	0.037	BG505 SOSIP.664: A433P enhanced binding
317	mutations affecting PGT128 binding	Kwon2015	binding	PGT128(V3)	binding assay, mutational analysis	191	gp120, V2	Y	0.163	0.187	0.106	BG505 SOSIP.664: Y191W reduced binding
317	mutations affecting PGT128 binding	Kwon2015	binding	PGT128(V3)	binding assay, mutational analysis	432	gp120, beta20/beta21	K	1.037	0.339	0.564	BG505 SOSIP.664: Q432P reduced binding
317	mutations affecting PGT128 binding	Kwon2015	binding	PGT128(V3)	binding assay, mutational analysis	433	gp120, beta20/beta21	A	0.054	0.023	0.037	BG505 SOSIP.664: A433P enhanced binding
318	mutations affecting 2G12 binding	Kwon2015	binding	2G12(glycan)	binding assay, mutational analysis	191	gp120, V2	Y	0.163	0.187	0.106	BG505 SOSIP.664: Y191W reduced binding
318	mutations affecting 2G12 binding	Kwon2015	binding	2G12(glycan)	binding assay, mutational analysis	432	gp120, beta20/beta21	K	1.037	0.339	0.564	BG505 SOSIP.664: Q432P enhanced binding
318	mutations affecting 2G12 binding	Kwon2015	binding	2G12(glycan)	binding assay, mutational analysis	433	gp120, beta20/beta21	A	0.054	0.023	0.037	BG505 SOSIP.664: A433P enhanced binding
319	mutations affecting PGT151 binding	Kwon2015	binding	PGT151(gp41 fusion domain)	binding assay, mutational analysis	191	gp120, V2	Y	0.163	0.187	0.106	BG505 SOSIP.664: Y191W reduced binding
319	mutations affecting PGT151 binding	Kwon2015	binding	PGT151(gp41 fusion domain)	binding assay, mutational analysis	432	gp120, beta20/beta21	K	1.037	0.339	0.564	BG505 SOSIP.664: Q432P enhanced binding
319	mutations affecting PGT151 binding	Kwon2015	binding	PGT151(gp41 fusion domain)	binding assay, mutational analysis	433	gp120, beta20/beta21	A	0.054	0.023	0.037	BG505 SOSIP.664: A433P enhanced binding
320	mutations affecting 35O22 binding	Kwon2015	binding	35O22(gp120/gp41 interface)	binding assay, mutational analysis	191	gp120, V2	Y	0.163	0.187	0.106	BG505 SOSIP.664: Y191W reduced binding
320	mutations affecting 35O22 binding	Kwon2015	binding	35O22(gp120/gp41 interface)	binding assay, mutational analysis	432	gp120, beta20/beta21	K	1.037	0.339	0.564	BG505 SOSIP.664: Q432P enhanced binding
320	mutations affecting 35O22 binding	Kwon2015	binding	35O22(gp120/gp41 interface)	binding assay, mutational analysis	433	gp120, beta20/beta21	A	0.054	0.023	0.037	BG505 SOSIP.664: A433P enhanced binding
321	mutation affecting 8ANC195 binding	Kwon2015	binding	8ANC195(gp120/gp41 interface)	binding assay, mutational analysis	432	gp120, beta20/beta21	K	1.037	0.339	0.564	BG505 SOSIP.664: Q432P enhanced binding
322	mutations affecting 447-52D binding	Kwon2015	binding	447-52D(V3)	binding assay, mutational analysis	191	gp120, V2	Y	0.163	0.187	0.106	BG505 SOSIP.664 with sCD4: Y191W reduced binding
322	mutations affecting 447-52D binding	Kwon2015	binding	447-52D(V3)	binding assay, mutational analysis	432	gp120, beta20/beta21	K	1.037	0.339	0.564	BG505 SOSIP.664 with sCD4: Q432P reduced binding
322	mutations affecting 447-52D binding	Kwon2015	binding	447-52D(V3)	binding assay, mutational analysis	433	gp120, beta20/beta21	A	0.054	0.023	0.037	BG505 SOSIP.664 with sCD4: A433P abrogated binding
323	mutations affecting VRC01 binding	Kwon2015	binding	VRC01(CD4BS)	binding assay, mutational analysis	125	gp120	L	0.135	0.153	0.058	BG505 SOSIP.664: L125W reduced binding
323	mutations affecting VRC01 binding	Kwon2015	binding	VRC01(CD4BS)	binding assay, mutational analysis	129	gp120	L	0.069	0.056	0.029	BG505 SOSIP.664: V129F strongly reduced binding
323	mutations affecting VRC01 binding	Kwon2015	binding	VRC01(CD4BS)	binding assay, mutational analysis	177	gp120, V2	Y	0.454	0.638	0.144	BG505 SOSIP.664: Y177W/F reduced binding
323	mutations affecting VRC01 binding	Kwon2015	binding	VRC01(CD4BS)	binding assay, mutational analysis	180	gp120, V2	D	0.054	0.033	0.029	BG505 SOSIP.664: D180F/W strongly reduced binding
323	mutations affecting VRC01 binding	Kwon2015	binding	VRC01(CD4BS)	binding assay, mutational analysis	181	gp120, V2	I	0.988	0.929	0.855	BG505 SOSIP.664: V181F/W reduced binding
323	mutations affecting VRC01 binding	Kwon2015	binding	VRC01(CD4BS)	binding assay, mutational analysis	191	gp120, V2	Y	0.163	0.187	0.106	BG505 SOSIP.664: Y191W reduced binding
323	mutations affecting VRC01 binding	Kwon2015	binding	VRC01(CD4BS)	binding assay, mutational analysis	194	gp120, V2	T	0.662	0.906	0.161	BG505 SOSIP.664: I194F, but not I194W, reduced binding
323	mutations affecting VRC01 binding	Kwon2015	binding	VRC01(CD4BS)	binding assay, mutational analysis	421	gp120, beta20/beta21	K	0.332	0.374	0.203	BG505 SOSIP.664: K421W, but not K421F, reduced binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	112	gp120	W	0.023	0.018	0.000	BG505 SOSIP.664: W112A/S strongly reduced and W112R abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	121	gp120	K	0.349	0.360	0.187	BG505 SOSIP.664: K121W/F strongly reduced binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	125	gp120	L	0.135	0.153	0.058	BG505 SOSIP.664: L125W abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	127	gp120	V	0.102	0.112	0.093	BG505 SOSIP.664: V127F/W abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	129	gp120	L	0.069	0.056	0.029	BG505 SOSIP.664: V129F abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	153	gp120, V1	E	0.996	0.592	1.034	BG505 SOSIP.664: E153F, but not E153W, reduced binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	162	gp120, V2	S	0.353	0.445	0.179	BG505 SOSIP.664: T162F/W abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	163	gp120, V2	T	0.463	0.638	0.154	BG505 SOSIP.664: T163F/W abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	165	gp120, V2	I	1.327	1.292	1.011	BG505 SOSIP.664: L165F/W/Y abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	166	gp120, V2	R	1.237	1.398	0.772	BG505 SOSIP.664: R166Y/F/W abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	167	gp120, V2	G	0.779	1.122	0.185	BG505 SOSIP.664: D167F/W abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	175	gp120, V2	F	0.606	0.868	0.271	BG505 SOSIP.664: L175F/W reduced binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	177	gp120, V2	Y	0.454	0.638	0.144	BG505 SOSIP.664: Y177F/W abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	179	gp120, V2	L	0.986	0.857	1.159	BG505 SOSIP.664: L179F, but not L179W, reduced binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	180	gp120, V2	D	0.054	0.033	0.029	BG505 SOSIP.664: D180F/W abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	181	gp120, V2	I	0.988	0.929	0.855	BG505 SOSIP.664: V181F/W abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	182	gp120, V2	I	0.830	0.957	0.587	BG505 SOSIP.664: V182F abrogated and V182W strongly reduced binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	191	gp120, V2	Y	0.163	0.187	0.106	BG505 SOSIP.664: Y191F/W reduced binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	193	gp120, V2	L	0.200	0.202	0.055	BG505 SOSIP.664: L193W, but not L193F, reduced binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	194	gp120, V2	T	0.662	0.906	0.161	BG505 SOSIP.664: I194F abrogated and I194W strongly reduced binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	210	gp120	F	0.138	0.056	0.107	BG505 SOSIP.664: F210A/S/R reduced binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	421	gp120, beta20/beta21	K	0.332	0.374	0.203	BG505 SOSIP.664: K421F/W abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	422	gp120, beta20/beta21	Q	0.062	0.046	0.031	BG505 SOSIP.664: Q422F/W abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	423	gp120, beta20/beta21	I	0.433	0.383	0.411	BG505 SOSIP.664: I423W, but not I423F, abrogated binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	432	gp120, beta20/beta21	K	1.037	0.339	0.564	BG505 SOSIP.664: Q432P, but not Q432F/W, reduced binding
324	mutations affecting VRC26.09 binding	Kwon2015	binding	VRC26.09(V2)	binding assay, mutational analysis	530	gp41	M	0.022	0.024	0.000	BG505 SOSIP.664: M530W reduced binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	112	gp120	W	0.023	0.018	0.000	BG505 SOSIP.664: W112R, but not W112A/S, strongly reduced binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	121	gp120	K	0.349	0.360	0.187	BG505 SOSIP.664: K121W/F reduced binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	125	gp120	L	0.135	0.153	0.058	BG505 SOSIP.664: L125W abrogated binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	127	gp120	V	0.102	0.112	0.093	BG505 SOSIP.664: V127F/W abrogated binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	129	gp120	L	0.069	0.056	0.029	BG505 SOSIP.664: V129F abrogated binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	162	gp120, V2	S	0.353	0.445	0.179	BG505 SOSIP.664: T162F/W abrogated binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	163	gp120, V2	T	0.463	0.638	0.154	BG505 SOSIP.664: T163F/W reduced binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	165	gp120, V2	I	1.327	1.292	1.011	BG505 SOSIP.664: L165F/W/Y reduced binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	166	gp120, V2	R	1.237	1.398	0.772	BG505 SOSIP.664: R166Y abrogated and R166F/W reduced binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	167	gp120, V2	G	0.779	1.122	0.185	BG505 SOSIP.664: D167F/W abrogated binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	177	gp120, V2	Y	0.454	0.638	0.144	BG505 SOSIP.664: Y177F/W abrogated binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	180	gp120, V2	D	0.054	0.033	0.029	BG505 SOSIP.664: D180F/W abrogated binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	181	gp120, V2	I	0.988	0.929	0.855	BG505 SOSIP.664: V181F/W abrogated binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	194	gp120, V2	T	0.662	0.906	0.161	BG505 SOSIP.664: I194F, but not I194W, reduced binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	421	gp120, beta20/beta21	K	0.332	0.374	0.203	BG505 SOSIP.664: K421F/W abrogated binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	422	gp120, beta20/beta21	Q	0.062	0.046	0.031	BG505 SOSIP.664: Q422F/W abrogated binding
325	mutations affecting PGT145 binding	Kwon2015	binding	PGT145(V2)	binding assay, mutational analysis	423	gp120, beta20/beta21	I	0.433	0.383	0.411	BG505 SOSIP.664: I423W, but not I423F, abrogated binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	112	gp120	W	0.023	0.018	0.000	BG505 SOSIP.664: W112R/A/S reduced binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	121	gp120	K	0.349	0.360	0.187	BG505 SOSIP.664: K121W, but not K121F, reduced binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	125	gp120	L	0.135	0.153	0.058	BG505 SOSIP.664: L125W reduced binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	127	gp120	V	0.102	0.112	0.093	BG505 SOSIP.664: V127F/W reduced binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	129	gp120	L	0.069	0.056	0.029	BG505 SOSIP.664: V129F strongly reduced binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	163	gp120, V2	T	0.463	0.638	0.154	BG505 SOSIP.664: T163F/W reduced binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	165	gp120, V2	I	1.327	1.292	1.011	BG505 SOSIP.664: L165F/Y, but not L165W, reduced binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	167	gp120, V2	G	0.779	1.122	0.185	BG505 SOSIP.664: D167F, but not D167W, abrogated binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	177	gp120, V2	Y	0.454	0.638	0.144	BG505 SOSIP.664: Y177F/W reduced binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	180	gp120, V2	D	0.054	0.033	0.029	BG505 SOSIP.664: D180F/W strongly reduced binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	181	gp120, V2	I	0.988	0.929	0.855	BG505 SOSIP.664: V181F/W reduced binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	194	gp120, V2	T	0.662	0.906	0.161	BG505 SOSIP.664: I194F, but not I194W, reduced binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	421	gp120, beta20/beta21	K	0.332	0.374	0.203	BG505 SOSIP.664: K421F/W strongly reduced binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	422	gp120, beta20/beta21	Q	0.062	0.046	0.031	BG505 SOSIP.664: Q422F/W strongly reduced binding
326	mutations affecting PGT122 binding	Kwon2015	binding	PGT122(V3)	binding assay, mutational analysis	423	gp120, beta20/beta21	I	0.433	0.383	0.411	BG505 SOSIP.664: I423W, but not I423F, reduced binding
327	mutations affecting F105 binding	Kwon2015	binding	F105(CD4BS)	binding assay, mutational analysis	121	gp120	K	0.349	0.360	0.187	BG505 SOSIP.664: K121W, but not K121F, enhanced binding
327	mutations affecting F105 binding	Kwon2015	binding	F105(CD4BS)	binding assay, mutational analysis	125	gp120	L	0.135	0.153	0.058	BG505 SOSIP.664: L125W enhanced binding
327	mutations affecting F105 binding	Kwon2015	binding	F105(CD4BS)	binding assay, mutational analysis	127	gp120	V	0.102	0.112	0.093	BG505 SOSIP.664: V127F/W enhanced binding
327	mutations affecting F105 binding	Kwon2015	binding	F105(CD4BS)	binding assay, mutational analysis	129	gp120	L	0.069	0.056	0.029	BG505 SOSIP.664: V129F enhanced binding
327	mutations affecting F105 binding	Kwon2015	binding	F105(CD4BS)	binding assay, mutational analysis	153	gp120, V1	E	0.996	0.592	1.034	BG505 SOSIP.664: E153F, but not E153W, enhanced binding
327	mutations affecting F105 binding	Kwon2015	binding	F105(CD4BS)	binding assay, mutational analysis	172	gp120, V2	E	1.527	1.172	1.484	BG505 SOSIP.664: V172W, but not V172F, enhanced binding
327	mutations affecting F105 binding	Kwon2015	binding	F105(CD4BS)	binding assay, mutational analysis	180	gp120, V2	D	0.054	0.033	0.029	BG505 SOSIP.664: D180F/W enhanced binding
327	mutations affecting F105 binding	Kwon2015	binding	F105(CD4BS)	binding assay, mutational analysis	181	gp120, V2	I	0.988	0.929	0.855	BG505 SOSIP.664: V181F/W enhanced binding
327	mutations affecting F105 binding	Kwon2015	binding	F105(CD4BS)	binding assay, mutational analysis	182	gp120, V2	I	0.830	0.957	0.587	BG505 SOSIP.664: V182F abrogated and V182W strongly reduced binding
327	mutations affecting F105 binding	Kwon2015	binding	F105(CD4BS)	binding assay, mutational analysis	423	gp120, beta20/beta21	I	0.433	0.383	0.411	BG505 SOSIP.664: I423W, but not I423F,  enhanced binding
327	mutations affecting F105 binding	Kwon2015	binding	F105(CD4BS)	binding assay, mutational analysis	430	gp120, beta20/beta21	V	0.267	0.080	0.073	BG505 SOSIP.664: I430W, but not I430F, enhanced binding
327	mutations affecting F105 binding	Kwon2015	binding	F105(CD4BS)	binding assay, mutational analysis	530	gp41	M	0.022	0.024	0.000	BG505 SOSIP.664: M530W enhanced binding
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	125	gp120	L	0.135	0.153	0.058	BG505 SOSIP.664: L125W enhanced binding w/out sCD4, and reduced binding w/ sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	127	gp120	V	0.102	0.112	0.093	BG505 SOSIP.664: V127F/W enhanced binding w/out sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	129	gp120	L	0.069	0.056	0.029	BG505 SOSIP.664: V129F enhanced binding w/out sCD4, and reduced binding w/ sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	153	gp120, V1	E	0.996	0.592	1.034	BG505 SOSIP.664: E153F/W enhanced binding w/out sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	154	gp120, V1	I	1.175	1.013	1.150	BG505 SOSIP.664: L154F/W enhanced binding w/out sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	163	gp120, V2	T	0.463	0.638	0.154	BG505 SOSIP.664: T163F/W enhanced binding w/out sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	164	gp120, V2	S	1.840	1.925	0.453	BG505 SOSIP.664: E164F/W enhanced binding w/out sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	165	gp120, V2	I	1.327	1.292	1.011	BG505 SOSIP.664: L165F/W/Y enhanced binding w/out sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	166	gp120, V2	R	1.237	1.398	0.772	BG505 SOSIP.664: R166Y, but not R166F/W, strongly reduced binding w/ sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	167	gp120, V2	G	0.779	1.122	0.185	BG505 SOSIP.664: D167F/W enhanced binding w/out sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	172	gp120, V2	E	1.527	1.172	1.484	BG505 SOSIP.664: V172F/W enhanced binding w/out sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	175	gp120, V2	F	0.606	0.868	0.271	BG505 SOSIP.664: L175F/W enhanced binding w/out sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	177	gp120, V2	Y	0.454	0.638	0.144	BG505 SOSIP.664: Y177W strongly reduced and Y177F abrogated binding, both w/ sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	179	gp120, V2	L	0.986	0.857	1.159	BG505 SOSIP.664: L179W, but not L179F, enhanced binding w/out sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	180	gp120, V2	D	0.054	0.033	0.029	BG505 SOSIP.664: D180F/W abrogated binding w/ sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	181	gp120, V2	I	0.988	0.929	0.855	BG505 SOSIP.664: V181F/W reduced binding w/ sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	182	gp120, V2	I	0.830	0.957	0.587	BG505 SOSIP.664: V182F/W enhanced binding w/out sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	191	gp120, V2	Y	0.163	0.187	0.106	BG505 SOSIP.664: Y191F/W reduced binding w/ sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	194	gp120, V2	T	0.662	0.906	0.161	BG505 SOSIP.664: I194F, but not I194W, strongly reduced binding w/ sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	198	gp120	T	0.430	0.264	0.469	BG505 SOSIP.664: T198F/W enhanced binding w/out sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	307	gp120, V3 loop	I	0.802	0.030	0.111	BG505 SOSIP.664: I307F, but not I307W, enhanced binding w/out sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	421	gp120, beta20/beta21	K	0.332	0.374	0.203	BG505 SOSIP.664: K421F/W reduced binding w/ sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	422	gp120, beta20/beta21	Q	0.062	0.046	0.031	BG505 SOSIP.664: Q422F/W reduced binding w/ sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	432	gp120, beta20/beta21	K	1.037	0.339	0.564	BG505 SOSIP.664: Q432P, but not Q432F/W, reduced binding w/ sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	433	gp120, beta20/beta21	A	0.054	0.023	0.037	BG505 SOSIP.664: A433P abrogated binding w/ sCD4
328	mutations affecting 17b binding	Kwon2015	binding	17b(CD4i)	binding assay, mutational analysis	530	gp41	M	0.022	0.024	0.000	BG505 SOSIP.664: M530W enhanced binding w/out sCD4
329	mutations affecting VRC26.09 binding	Chuang2017	binding	VRC26.09(V2)	binding assay, mutational analysis	69	gp120	W	0.015	0.000	0.008	BG505 SOSIP.664: W69P reduced binding
329	mutations affecting VRC26.09 binding	Chuang2017	binding	VRC26.09(V2)	binding assay, mutational analysis	110	gp120	S	0.216	0.214	0.196	BG505 SOSIP.664: S110W reduced binding
329	mutations affecting VRC26.09 binding	Chuang2017	binding	VRC26.09(V2)	binding assay, mutational analysis	117	gp120	K	0.159	0.084	0.120	BG505 SOSIP.664: K117W reduced binding
329	mutations affecting VRC26.09 binding	Chuang2017	binding	VRC26.09(V2)	binding assay, mutational analysis	118	gp120	P	0.016	0.006	0.022	BG505 SOSIP.664: P118W reduced binding
329	mutations affecting VRC26.09 binding	Chuang2017	binding	VRC26.09(V2)	binding assay, mutational analysis	223	gp120	F	0.673	0.166	0.328	BG505 SOSIP.664: F223W reduced binding
329	mutations affecting VRC26.09 binding	Chuang2017	binding	VRC26.09(V2)	binding assay, mutational analysis	316	gp120, V3 loop	A	1.056	0.736	0.966	BG505 SOSIP.664: 316W reduced binding
329	mutations affecting VRC26.09 binding	Chuang2017	binding	VRC26.09(V2)	binding assay, mutational analysis	427	gp120, beta20/beta21	W	0.083	0.061	0.038	BG505 SOSIP.664: W427I, but not W427M, reduced binding
329	mutations affecting VRC26.09 binding	Chuang2017	binding	VRC26.09(V2)	binding assay, mutational analysis	429	gp120, beta20/beta21	K	1.325	0.961	1.308	BG505 SOSIP.664: R429L, but not R429N, reduced binding
330	mutations affecting PGT145 binding	Chuang2017	binding	PGT145(V2)	binding assay, mutational analysis	110	gp120	S	0.216	0.214	0.196	BG505 SOSIP.664: S110W reduced binding
330	mutations affecting PGT145 binding	Chuang2017	binding	PGT145(V2)	binding assay, mutational analysis	117	gp120	K	0.159	0.084	0.120	BG505 SOSIP.664: K117W reduced binding
331	mutations affecting PGT122 binding	Chuang2017	binding	PGT122(V3)	binding assay, mutational analysis	110	gp120	S	0.216	0.214	0.196	BG505 SOSIP.664: S110W reduced binding
331	mutations affecting PGT122 binding	Chuang2017	binding	PGT122(V3)	binding assay, mutational analysis	208	gp120	V	0.629	0.750	0.262	BG505 SOSIP.664: V208F, but not V208W, reduced binding
332	mutation affecting PGT151 binding	Chuang2017	binding	PGT151(gp41 fusion domain)	binding assay, mutational analysis	69	gp120	W	0.015	0.000	0.008	BG505 SOSIP.664: W69P reduced binding
333	mutations affecting F105 binding	Chuang2017	binding	F105(CD4BS)	binding assay, mutational analysis	115	gp120	S	0.159	0.058	0.167	BG505 SOSIP.664: S115W enhanced binding
333	mutations affecting F105 binding	Chuang2017	binding	F105(CD4BS)	binding assay, mutational analysis	202	gp120	T	0.506	0.291	0.547	BG505 SOSIP.664: T202P enhanced binding
333	mutations affecting F105 binding	Chuang2017	binding	F105(CD4BS)	binding assay, mutational analysis	208	gp120	V	0.629	0.750	0.262	BG505 SOSIP.664: V208F, but not V208W, enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	70	gp120	A	0.023	0.017	0.023	BG505 SOSIP.664: without sCD4, A70Y/F enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	75	gp120	V	0.015	0.006	0.008	BG505 SOSIP.664: without sCD4, V75W/F/M enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	110	gp120	S	0.216	0.214	0.196	BG505 SOSIP.664: without sCD4, S110W enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	111	gp120	L	0.124	0.048	0.221	BG505 SOSIP.664: without sCD4, L111F (but not F111Y) enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	115	gp120	S	0.159	0.058	0.167	BG505 SOSIP.664: without sCD4, S115W enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	118	gp120	P	0.016	0.006	0.022	BG505 SOSIP.664: without sCD4, P118W enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	120	gp120	V	0.070	0.046	0.046	BG505 SOSIP.664: without sCD4, V120W/T strongly enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	159	gp120, V2	F	0.104	0.034	0.038	BG505 SOSIP.664: with sCD4, F159Y reduced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	202	gp120	T	0.506	0.291	0.547	BG505 SOSIP.664: without sCD4, T202P very strongly enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	208	gp120	V	0.629	0.750	0.262	BG505 SOSIP.664: without sCD4, V208W/F enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	223	gp120	F	0.673	0.166	0.328	BG505 SOSIP.664: with sCD4, F223W strongly reduced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	309	gp120, V3 loop	I	0.863	0.359	0.965	BG505 SOSIP.664: without sCD4, I309W strongly enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	316	gp120, V3 loop	A	1.056	0.736	0.966	BG505 SOSIP.664: without sCD4, 316W enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	323	gp120, V3 loop	I	0.476	0.531	0.263	BG505 SOSIP.664: without sCD4, I323Y enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	427	gp120, beta20/beta21	W	0.083	0.061	0.038	BG505 SOSIP.664: with sCD4, W427I (but not W427M) strongly reduced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	429	gp120, beta20/beta21	K	1.325	0.961	1.308	BG505 SOSIP.664: without sCD4, R429N (but not R429L) enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	573	gp41, Leu/Ile zipper-like sequence	I	0.072	0.079	0.050	BG505 SOSIP.664: without sCD4, I573T strongly enhanced binding
334	mutations affecting 17b binding	Chuang2017	binding	17b(CD4i)	binding assay, mutational analysis	594	gp41	G	0.054	0.042	0.073	BG505 SOSIP.664: without sCD4, G594N enhanced binding
335	mutations affecting 447-52D binding	Chuang2017	binding	447-52D(V3)	binding assay, mutational analysis	159	gp120, V2	F	0.104	0.034	0.038	BG505 SOSIP.664: without sCD4, F159Y reduced binding
335	mutations affecting 447-52D binding	Chuang2017	binding	447-52D(V3)	binding assay, mutational analysis	223	gp120	F	0.673	0.166	0.328	BG505 SOSIP.664: without sCD4, F223W reduced binding
335	mutations affecting 447-52D binding	Chuang2017	binding	447-52D(V3)	binding assay, mutational analysis	309	gp120, V3 loop	I	0.863	0.359	0.965	BG505 SOSIP.664: I309W reduced binding with or without sCD4
335	mutations affecting 447-52D binding	Chuang2017	binding	447-52D(V3)	binding assay, mutational analysis	427	gp120, beta20/beta21	W	0.083	0.061	0.038	BG505 SOSIP.664: with sCD4, W427I (but not W427M) reduced binding
335	mutations affecting 447-52D binding	Chuang2017	binding	447-52D(V3)	binding assay, mutational analysis	544	gp41, Leu/Ile zipper-like sequence	L	0.173	0.069	0.311	BG505 SOSIP.664: without sCD4, L544Y reduced binding
335	mutations affecting 447-52D binding	Chuang2017	binding	447-52D(V3)	binding assay, mutational analysis	580	gp41, Leu/Ile zipper-like sequence	I	0.379	0.440	0.134	BG505 SOSIP.664: without sCD4, V580L reduced binding
335	mutations affecting 447-52D binding	Chuang2017	binding	447-52D(V3)	binding assay, mutational analysis	583	gp41, Leu/Ile zipper-like sequence	V	0.955	0.424	0.701	BG505 SOSIP.664: without sCD4, V583L strongly reduced binding
336	12A21 contacts	Umotoy2019	contacts	12A21(CD4BS)	computational prediction, X-ray crystallography	62	gp120	D	1.433	1.302	0.706	BG505 SOSIP contact
336	12A21 contacts	Umotoy2019	contacts	12A21(CD4BS)	computational prediction, X-ray crystallography	65	gp120	V	1.017	1.023	0.310	BG505 SOSIP contact
336	12A21 contacts	Umotoy2019	contacts	12A21(CD4BS)	computational prediction, X-ray crystallography	197	gp120	N	0.133	0.082	0.109	BG505 SOSIP glycan contact
336	12A21 contacts	Umotoy2019	contacts	12A21(CD4BS)	computational prediction, X-ray crystallography	234	gp120	N	0.598	0.757	0.341	BG505 SOSIP glycan contact
336	12A21 contacts	Umotoy2019	contacts	12A21(CD4BS)	computational prediction, X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	BG505 SOSIP glycan contact
336	12A21 contacts	Umotoy2019	contacts	12A21(CD4BS)	computational prediction, X-ray crystallography	301	gp120, V3 loop	N	0.172	0.176	0.104	BG505 SOSIP glycan contact
336	12A21 contacts	Umotoy2019	contacts	12A21(CD4BS)	computational prediction, X-ray crystallography	362	gp120	K	1.815	1.265	1.997	BG505 SOSIP glycan contact
336	12A21 contacts	Umotoy2019	contacts	12A21(CD4BS)	computational prediction, X-ray crystallography	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	BG505 SOSIP contact
336	12A21 contacts	Umotoy2019	contacts	12A21(CD4BS)	computational prediction, X-ray crystallography	488	gp120	V	0.142	0.098	0.061	BG505 SOSIP glycan contact
337	ACS202 contacts	Yuan2019	contacts	ACS202(gp41 fusion domain)	cryo-EM, X-ray crystallography	88	gp120	N	0.050	0.041	0.048	N88 and N241 are glycan contacts between ACS202 and SOSIP trimer
337	ACS202 contacts	Yuan2019	contacts	ACS202(gp41 fusion domain)	cryo-EM, X-ray crystallography	241	gp120	N	0.191	0.183	0.134	N88 and N241 are glycan contacts between ACS202 and SOSIP trimer
337	ACS202 contacts	Yuan2019	contacts	ACS202(gp41 fusion domain)	cryo-EM, X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	the side chain of A512 is buried in a hydrophobic pocket formed by CDRL3-Y91, L94, F96, and CDRH3-Y100K
337	ACS202 contacts	Yuan2019	contacts	ACS202(gp41 fusion domain)	cryo-EM, X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	hydrophobic interaction with CDRH3
337	ACS202 contacts	Yuan2019	contacts	ACS202(gp41 fusion domain)	cryo-EM, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	hydrophobic interaction with CDRH3
337	ACS202 contacts	Yuan2019	contacts	ACS202(gp41 fusion domain)	cryo-EM, X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	G516-A517 of the FP is stabilized by ACS202
337	ACS202 contacts	Yuan2019	contacts	ACS202(gp41 fusion domain)	cryo-EM, X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	G516-A517 of the FP is stabilized by ACS202
337	ACS202 contacts	Yuan2019	contacts	ACS202(gp41 fusion domain)	cryo-EM, X-ray crystallography	518	gp41, fusion peptide	L	1.166	1.110	0.718	G516-A517 of the FP is stabilized by ACS202
337	ACS202 contacts	Yuan2019	contacts	ACS202(gp41 fusion domain)	cryo-EM, X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	hydrophobic interaction with CDRH3
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	97	gp120	K	0.478	0.421	0.511	HC hydrogen bond and salt bridge
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	275	gp120, Loop D	V	1.141	1.420	0.535	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	LC glycan contact
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	278	gp120, Loop D	T	0.708	0.715	0.481	LC hydrogen bond
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	HC and LC interactions
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	HC and LC interactions
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	HC hydrogen bond
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	HC hydrogen bond and salt bridge
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	283	gp120, Loop D	T	1.005	1.091	0.474	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	HC hydrogen bond and salt bridge
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	426	gp120, beta20/beta21	M	0.724	0.866	0.274	HC hydrogen bond
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	427	gp120, beta20/beta21	W	0.083	0.061	0.038	HC hydrogen bond
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	429	gp120, beta20/beta21	K	1.325	0.961	1.308	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	430	gp120, beta20/beta21	V	0.267	0.080	0.073	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	HC hydrogen bond
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	HC and LC interactions
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	HC and LC interactions
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	HC and LC interactions
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	HC and LC interactions
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	466	gp120, V5 loop, beta24	E	0.205	0.091	0.239	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	467	gp120, V5 loop, beta24	I	0.912	0.955	0.870	HC and LC interactions
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	468	gp120, V5 loop, beta24	F	0.104	0.050	0.084	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	470	gp120, beta24	P	0.043	0.039	0.037	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	472	gp120	G	0.035	0.012	0.043	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	473	gp120	G	0.042	0.033	0.029	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	474	gp120	D	0.696	0.681	0.752	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	475	gp120	M	0.097	0.092	0.106	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	476	gp120	R	0.663	0.615	0.711	HC interaction
338	2411a contacts	Chen2021	contacts	2411a(CD4BS)	X-ray crystallography	477	gp120	D	0.191	0.112	0.249	HC interaction
339	PC39-55D binding	Joyce2023	binding	PC39-55D(V3)	alanine scanning, binding assay	159	gp120, V2	F	0.104	0.034	0.038	F159A affects binding >50 fold
339	PC39-55D binding	Joyce2023	binding	PC39-55D(V3)	alanine scanning, binding assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A affects binding >50 fold
339	PC39-55D binding	Joyce2023	binding	PC39-55D(V3)	alanine scanning, binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A affects binding >50 fold
339	PC39-55D binding	Joyce2023	binding	PC39-55D(V3)	alanine scanning, binding assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A affects binding >50 fold
339	PC39-55D binding	Joyce2023	binding	PC39-55D(V3)	alanine scanning, binding assay	332	gp120	N	0.663	0.491	0.693	N332A affects binding >50 fold
339	PC39-55D binding	Joyce2023	binding	PC39-55D(V3)	alanine scanning, binding assay	334	gp120	S	0.717	0.501	0.890	S334A affects binding >50 fold
340	PC39-23D binding	Joyce2023	binding	PC39-23D(V3)	alanine scanning, binding assay	158	gp120, V2	S	0.263	0.185	0.291	S158A affects binding >50 fold
340	PC39-23D binding	Joyce2023	binding	PC39-23D(V3)	alanine scanning, binding assay	159	gp120, V2	F	0.104	0.034	0.038	F159A affects binding >50 fold
340	PC39-23D binding	Joyce2023	binding	PC39-23D(V3)	alanine scanning, binding assay	298	gp120, V3 loop	R	0.025	0.018	0.022	R298A affects binding >50 fold
340	PC39-23D binding	Joyce2023	binding	PC39-23D(V3)	alanine scanning, binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A affects binding >50 fold
340	PC39-23D binding	Joyce2023	binding	PC39-23D(V3)	alanine scanning, binding assay	324	gp120, V3 loop	G	0.075	0.056	0.092	G324A affects binding >50 fold
340	PC39-23D binding	Joyce2023	binding	PC39-23D(V3)	alanine scanning, binding assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A affects binding >50 fold
340	PC39-23D binding	Joyce2023	binding	PC39-23D(V3)	alanine scanning, binding assay	326	gp120, V3 loop	M	0.143	0.143	0.116	I326A affects binding >50 fold
340	PC39-23D binding	Joyce2023	binding	PC39-23D(V3)	alanine scanning, binding assay	327	gp120, V3 loop	R	0.089	0.066	0.073	R327A affects binding >50 fold
340	PC39-23D binding	Joyce2023	binding	PC39-23D(V3)	alanine scanning, binding assay	329	gp120, V3 loop	A	0.043	0.034	0.022	A329K affects binding >50 fold
340	PC39-23D binding	Joyce2023	binding	PC39-23D(V3)	alanine scanning, binding assay	332	gp120	N	0.663	0.491	0.693	N332A affects binding >50 fold
340	PC39-23D binding	Joyce2023	binding	PC39-23D(V3)	alanine scanning, binding assay	334	gp120	S	0.717	0.501	0.890	S334A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	158	gp120, V2	S	0.263	0.185	0.291	S158A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	159	gp120, V2	F	0.104	0.034	0.038	F159A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	298	gp120, V3 loop	R	0.025	0.018	0.022	R298A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	309	gp120, V3 loop	I	0.863	0.359	0.965	I309A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	318	gp120, V3 loop	V	0.588	0.691	0.507	Y318A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	324	gp120, V3 loop	G	0.075	0.056	0.092	G324A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	326	gp120, V3 loop	M	0.143	0.143	0.116	I326A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	327	gp120, V3 loop	R	0.089	0.066	0.073	R327A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	329	gp120, V3 loop	A	0.043	0.034	0.022	A329K affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	330	gp120, V3 loop	H	0.634	0.559	0.655	H330A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	332	gp120	N	0.663	0.491	0.693	N332A affects binding >50 fold
341	PC39-50I binding	Joyce2023	binding	PC39-50I(V3)	alanine scanning, binding assay	334	gp120	S	0.717	0.501	0.890	S334A affects binding >50 fold
342	PC39-28D binding	Joyce2023	binding	PC39-28D(V3)	alanine scanning, binding assay	159	gp120, V2	F	0.104	0.034	0.038	F159A affects binding >50 fold
342	PC39-28D binding	Joyce2023	binding	PC39-28D(V3)	alanine scanning, binding assay	298	gp120, V3 loop	R	0.025	0.018	0.022	R298A affects binding >50 fold
342	PC39-28D binding	Joyce2023	binding	PC39-28D(V3)	alanine scanning, binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A affects binding >50 fold
342	PC39-28D binding	Joyce2023	binding	PC39-28D(V3)	alanine scanning, binding assay	324	gp120, V3 loop	G	0.075	0.056	0.092	G324A affects binding >50 fold
342	PC39-28D binding	Joyce2023	binding	PC39-28D(V3)	alanine scanning, binding assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A affects binding >50 fold
342	PC39-28D binding	Joyce2023	binding	PC39-28D(V3)	alanine scanning, binding assay	327	gp120, V3 loop	R	0.089	0.066	0.073	R327A affects binding >50 fold
342	PC39-28D binding	Joyce2023	binding	PC39-28D(V3)	alanine scanning, binding assay	329	gp120, V3 loop	A	0.043	0.034	0.022	A329K affects binding >50 fold
342	PC39-28D binding	Joyce2023	binding	PC39-28D(V3)	alanine scanning, binding assay	332	gp120	N	0.663	0.491	0.693	N332A affects binding >50 fold
342	PC39-28D binding	Joyce2023	binding	PC39-28D(V3)	alanine scanning, binding assay	334	gp120	S	0.717	0.501	0.890	S334A affects binding >50 fold
343	PC39-50K binding	Joyce2023	binding	PC39-50K(V3)	alanine scanning, binding assay	159	gp120, V2	F	0.104	0.034	0.038	F159A affects binding >50 fold
343	PC39-50K binding	Joyce2023	binding	PC39-50K(V3)	alanine scanning, binding assay	298	gp120, V3 loop	R	0.025	0.018	0.022	R298A affects binding >50 fold
343	PC39-50K binding	Joyce2023	binding	PC39-50K(V3)	alanine scanning, binding assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A affects binding >50 fold
343	PC39-50K binding	Joyce2023	binding	PC39-50K(V3)	alanine scanning, binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A affects binding >50 fold
343	PC39-50K binding	Joyce2023	binding	PC39-50K(V3)	alanine scanning, binding assay	324	gp120, V3 loop	G	0.075	0.056	0.092	G324A affects binding >50 fold
343	PC39-50K binding	Joyce2023	binding	PC39-50K(V3)	alanine scanning, binding assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A affects binding >50 fold
343	PC39-50K binding	Joyce2023	binding	PC39-50K(V3)	alanine scanning, binding assay	327	gp120, V3 loop	R	0.089	0.066	0.073	R327A affects binding >50 fold
343	PC39-50K binding	Joyce2023	binding	PC39-50K(V3)	alanine scanning, binding assay	329	gp120, V3 loop	A	0.043	0.034	0.022	A329K affects binding >50 fold
343	PC39-50K binding	Joyce2023	binding	PC39-50K(V3)	alanine scanning, binding assay	332	gp120	N	0.663	0.491	0.693	N332A affects binding >50 fold
343	PC39-50K binding	Joyce2023	binding	PC39-50K(V3)	alanine scanning, binding assay	334	gp120	S	0.717	0.501	0.890	S334A affects binding >50 fold
344	PC39-23C binding	Joyce2023	binding	PC39-23C(V3)	alanine scanning, binding assay	158	gp120, V2	S	0.263	0.185	0.291	S158A affects binding >50 fold
344	PC39-23C binding	Joyce2023	binding	PC39-23C(V3)	alanine scanning, binding assay	159	gp120, V2	F	0.104	0.034	0.038	F159A affects binding >50 fold
344	PC39-23C binding	Joyce2023	binding	PC39-23C(V3)	alanine scanning, binding assay	298	gp120, V3 loop	R	0.025	0.018	0.022	R298A affects binding >50 fold
344	PC39-23C binding	Joyce2023	binding	PC39-23C(V3)	alanine scanning, binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A affects binding >50 fold
344	PC39-23C binding	Joyce2023	binding	PC39-23C(V3)	alanine scanning, binding assay	324	gp120, V3 loop	G	0.075	0.056	0.092	G324A affects binding >50 fold
344	PC39-23C binding	Joyce2023	binding	PC39-23C(V3)	alanine scanning, binding assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A affects binding >50 fold
344	PC39-23C binding	Joyce2023	binding	PC39-23C(V3)	alanine scanning, binding assay	327	gp120, V3 loop	R	0.089	0.066	0.073	R327A affects binding >50 fold
344	PC39-23C binding	Joyce2023	binding	PC39-23C(V3)	alanine scanning, binding assay	329	gp120, V3 loop	A	0.043	0.034	0.022	A329K affects binding >50 fold
344	PC39-23C binding	Joyce2023	binding	PC39-23C(V3)	alanine scanning, binding assay	332	gp120	N	0.663	0.491	0.693	N332A affects binding >50 fold
344	PC39-23C binding	Joyce2023	binding	PC39-23C(V3)	alanine scanning, binding assay	334	gp120	S	0.717	0.501	0.890	S334A affects binding >50 fold
345	PC39-50E binding	Joyce2023	binding	PC39-50E(V3)	alanine scanning, binding assay	158	gp120, V2	S	0.263	0.185	0.291	S158A affects binding >50 fold
345	PC39-50E binding	Joyce2023	binding	PC39-50E(V3)	alanine scanning, binding assay	159	gp120, V2	F	0.104	0.034	0.038	F159A affects binding >50 fold
345	PC39-50E binding	Joyce2023	binding	PC39-50E(V3)	alanine scanning, binding assay	298	gp120, V3 loop	R	0.025	0.018	0.022	R298A affects binding >50 fold
345	PC39-50E binding	Joyce2023	binding	PC39-50E(V3)	alanine scanning, binding assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A affects binding >50 fold
345	PC39-50E binding	Joyce2023	binding	PC39-50E(V3)	alanine scanning, binding assay	327	gp120, V3 loop	R	0.089	0.066	0.073	R327A affects binding >50 fold
345	PC39-50E binding	Joyce2023	binding	PC39-50E(V3)	alanine scanning, binding assay	332	gp120	N	0.663	0.491	0.693	N332A affects binding >50 fold
345	PC39-50E binding	Joyce2023	binding	PC39-50E(V3)	alanine scanning, binding assay	334	gp120	S	0.717	0.501	0.890	S334A affects binding >50 fold
346	PC39-55C binding	Joyce2023	binding	PC39-55C(V3)	alanine scanning, binding assay	158	gp120, V2	S	0.263	0.185	0.291	S158A affects binding >50 fold
346	PC39-55C binding	Joyce2023	binding	PC39-55C(V3)	alanine scanning, binding assay	159	gp120, V2	F	0.104	0.034	0.038	F159A affects binding >50 fold
346	PC39-55C binding	Joyce2023	binding	PC39-55C(V3)	alanine scanning, binding assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A affects binding >50 fold
346	PC39-55C binding	Joyce2023	binding	PC39-55C(V3)	alanine scanning, binding assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A affects binding >50 fold
346	PC39-55C binding	Joyce2023	binding	PC39-55C(V3)	alanine scanning, binding assay	327	gp120, V3 loop	R	0.089	0.066	0.073	R327A affects binding >50 fold
346	PC39-55C binding	Joyce2023	binding	PC39-55C(V3)	alanine scanning, binding assay	329	gp120, V3 loop	A	0.043	0.034	0.022	A329K affects binding >50 fold
346	PC39-55C binding	Joyce2023	binding	PC39-55C(V3)	alanine scanning, binding assay	332	gp120	N	0.663	0.491	0.693	N332A affects binding >50 fold
346	PC39-55C binding	Joyce2023	binding	PC39-55C(V3)	alanine scanning, binding assay	334	gp120	S	0.717	0.501	0.890	S334A affects binding >50 fold
347	PC39-39B binding	Joyce2023	binding	PC39-39B(V3)	alanine scanning, binding assay	159	gp120, V2	F	0.104	0.034	0.038	F159A affects binding >50 fold
347	PC39-39B binding	Joyce2023	binding	PC39-39B(V3)	alanine scanning, binding assay	298	gp120, V3 loop	R	0.025	0.018	0.022	R298A affects binding >50 fold
347	PC39-39B binding	Joyce2023	binding	PC39-39B(V3)	alanine scanning, binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A affects binding >50 fold
347	PC39-39B binding	Joyce2023	binding	PC39-39B(V3)	alanine scanning, binding assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A affects binding >50 fold
347	PC39-39B binding	Joyce2023	binding	PC39-39B(V3)	alanine scanning, binding assay	327	gp120, V3 loop	R	0.089	0.066	0.073	R327A affects binding >50 fold
347	PC39-39B binding	Joyce2023	binding	PC39-39B(V3)	alanine scanning, binding assay	329	gp120, V3 loop	A	0.043	0.034	0.022	A329K affects binding >50 fold
347	PC39-39B binding	Joyce2023	binding	PC39-39B(V3)	alanine scanning, binding assay	332	gp120	N	0.663	0.491	0.693	N332A affects binding >50 fold
347	PC39-39B binding	Joyce2023	binding	PC39-39B(V3)	alanine scanning, binding assay	334	gp120	S	0.717	0.501	0.890	S334A affects binding >50 fold
348	PC39-50H binding	Joyce2023	binding	PC39-50H(V3)	alanine scanning, binding assay	298	gp120, V3 loop	R	0.025	0.018	0.022	R298A affects binding >50 fold
348	PC39-50H binding	Joyce2023	binding	PC39-50H(V3)	alanine scanning, binding assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A affects binding >50 fold
348	PC39-50H binding	Joyce2023	binding	PC39-50H(V3)	alanine scanning, binding assay	327	gp120, V3 loop	R	0.089	0.066	0.073	R327A affects binding >50 fold
348	PC39-50H binding	Joyce2023	binding	PC39-50H(V3)	alanine scanning, binding assay	332	gp120	N	0.663	0.491	0.693	N332A affects binding >50 fold
348	PC39-50H binding	Joyce2023	binding	PC39-50H(V3)	alanine scanning, binding assay	334	gp120	S	0.717	0.501	0.890	S334A affects binding >50 fold
349	PC39-50L binding	Joyce2023	binding	PC39-50L(V3)	alanine scanning, binding assay	158	gp120, V2	S	0.263	0.185	0.291	S158A affects binding >50 fold
349	PC39-50L binding	Joyce2023	binding	PC39-50L(V3)	alanine scanning, binding assay	298	gp120, V3 loop	R	0.025	0.018	0.022	R298A affects binding >50 fold
349	PC39-50L binding	Joyce2023	binding	PC39-50L(V3)	alanine scanning, binding assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A affects binding >50 fold
349	PC39-50L binding	Joyce2023	binding	PC39-50L(V3)	alanine scanning, binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A affects binding >50 fold
349	PC39-50L binding	Joyce2023	binding	PC39-50L(V3)	alanine scanning, binding assay	324	gp120, V3 loop	G	0.075	0.056	0.092	G324A affects binding >50 fold
349	PC39-50L binding	Joyce2023	binding	PC39-50L(V3)	alanine scanning, binding assay	327	gp120, V3 loop	R	0.089	0.066	0.073	R327A affects binding >50 fold
349	PC39-50L binding	Joyce2023	binding	PC39-50L(V3)	alanine scanning, binding assay	329	gp120, V3 loop	A	0.043	0.034	0.022	A329K affects binding >50 fold
349	PC39-50L binding	Joyce2023	binding	PC39-50L(V3)	alanine scanning, binding assay	332	gp120	N	0.663	0.491	0.693	N332A affects binding >50 fold
349	PC39-50L binding	Joyce2023	binding	PC39-50L(V3)	alanine scanning, binding assay	334	gp120	S	0.717	0.501	0.890	S334A affects binding >50 fold
350	1605A1, 1605A2, 1605A3, 1607A1 discontinuous epitope	vanHaaren2021	binding	1605A1(other), 1605A2(other), 1605A3(other), 1607A1(other)	binding assay, negative stain EM	620	gp41	E	1.999	1.701	2.182	D620N, N624D, and E662A define the epitope
350	1605A1, 1605A2, 1605A3, 1607A1 discontinuous epitope	vanHaaren2021	binding	1605A1(other), 1605A2(other), 1605A3(other), 1607A1(other)	binding assay, negative stain EM	624	gp41	N	1.580	1.592	1.486	D620N, N624D, and E662A define the epitope
350	1605A1, 1605A2, 1605A3, 1607A1 discontinuous epitope	vanHaaren2021	binding	1605A1(other), 1605A2(other), 1605A3(other), 1607A1(other)	binding assay, negative stain EM	662	gp41	E	1.043	0.874	0.369	D620N, N624D, and E662A define the epitope
351	Mutation affects Env trimer stability	Leaman2013	other feature		other	139	gp120, V1-hypervariable, V1	N	2.097	1.946	2.163	combination of N139del + I140del + N142S increases the thermal and chemical stability of ADA and JRFL
351	Mutation affects Env trimer stability	Leaman2013	other feature		other	140	gp120, V1-hypervariable, V1	T	2.235	2.104	2.340	combination of N139del + I140del + N142S increases the thermal and chemical stability of ADA and JRFL
351	Mutation affects Env trimer stability	Leaman2013	other feature		other	142	gp120, V1-hypervariable, V1	S	2.145	1.992	1.972	combination of N139del + I140del + N142S increases the thermal and chemical stability of ADA and JRFL
351	Mutation affects Env trimer stability	Leaman2013	other feature		other	535	gp41	M	1.280	1.414	0.742	M535I increases the thermal and chemical stability of ADA and JRFL
351	Mutation affects Env trimer stability	Leaman2013	other feature		other	543	gp41, Leu/Ile zipper-like sequence	Q	0.588	0.768	0.202	L543Q increases the thermal and chemical stability of ADA and JRFL
351	Mutation affects Env trimer stability	Leaman2013	other feature		other	574	gp41, Leu/Ile zipper-like sequence	K	0.020	0.036	0.022	K574A decreases the thermostability of ADA; K574R increases the thermal and chemical stability of ADA and 3 other tested strains of subtypes A, B, and C
351	Mutation affects Env trimer stability	Leaman2013	other feature		other	625	gp41	H	0.197	0.185	0.214	combination of H625N + T626M increases the thermal and chemical stability of ADA and JRFL
351	Mutation affects Env trimer stability	Leaman2013	other feature		other	626	gp41	T	0.249	0.201	0.303	combination of H625N + T626M increases the thermal and chemical stability of ADA and JRFL
351	Mutation affects Env trimer stability	Leaman2013	other feature		other	649	gp41	S	0.200	0.274	0.075	S649A increases the thermal and chemical stability of ADA and 3 other tested strains of subtypes A, B, and C
352	Mutation increases neutralization sensitivity	Leaman2013	neutralization	b12(CD4BS), b6(CD4BS)	neutralization assay, other	574	gp41, Leu/Ile zipper-like sequence	K	0.020	0.036	0.022	K574A decreases b6 neutralization IC50 250-fold for ADA and 49 fold for JRFL; K574A decreases b12 neutralization IC50 24-fold for ADA and 2.7 fold for JRFL
353	Mutation increases neutralization sensitivity	Leaman2013	neutralization	2F5(MPER), 4E10(MPER)	neutralization assay, other	574	gp41, Leu/Ile zipper-like sequence	K	0.020	0.036	0.022	K574A decreases 2F5 neutralization IC50 91-fold for ADA and 7.2 fold for JRFL; K574A decreases 4E10 neutralization IC50 48-fold for ADA and 8.8 fold for JRFL
354	Mutation increases neutralization sensitivity	Leaman2013	neutralization	2G12(glycan)	neutralization assay, other	574	gp41, Leu/Ile zipper-like sequence	K	0.020	0.036	0.022	K574A decreases 2G12 neutralization IC50 4 fold for ADA and 2 fold for JRFL
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	304	gp120, V3 loop	R	0.304	0.390	0.141	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	305	gp120, V3 loop	K	0.906	0.713	0.943	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	306	gp120, V3 loop	R	0.714	0.860	0.338	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	308	gp120, V3 loop	R	1.578	0.091	0.127	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	309	gp120, V3 loop	I	0.863	0.359	0.965	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	310	gp120, V3 loop	Q	0.067	1.479	0.283	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	311	gp120, V3 loop	R	0.104	1.050	0.114	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	312	gp120, V3 loop	G	0.237	0.362	0.008	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	313	gp120, V3 loop	P	0.344	0.424	0.078	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	314	gp120, V3 loop	G	0.057	0.095	0.014	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	315	gp120, V3 loop	R	1.211	1.028	0.196	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	316	gp120, V3 loop	A	1.056	0.736	0.966	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	317	gp120, V3 loop	F	0.834	1.090	0.223	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	318	gp120, V3 loop	V	0.588	0.691	0.507	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	319	gp120, V3 loop	T	0.794	0.913	0.339	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	320	gp120, V3 loop	I	0.711	0.564	0.782	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	321	gp120, V3 loop	G	1.042	0.842	1.108	linear epitope binding region
355	BG505 infant V3 mAbs linear epitope	Simonich2021	binding	BG505.13(V3), BG505.34(V3), BG505.48(V3), BG505.49(V3), BG505.50(V3), BG505.56(V3), BG505.57(V3), BG505.61(V3), BG505.63(V3), BG505.68(V3), BG505.69(V3)	binding assay	322	gp120, V3 loop	K	1.797	0.347	0.283	linear epitope binding region
356	Residue that affects binding by VRC42.01	Krebs2019	binding	VRC42.01(MPER)	alanine scanning, binding assay	672	gp41	W	0.014	0.023	0.014	Ala mediates an 8-fold reduction in MPER peptide binding
357	Residues that affect binding by VRC42.04	Krebs2019	binding	VRC42.04(MPER)	alanine scanning, binding assay	672	gp41	W	0.014	0.023	0.014	W672A mediates an ~30-fold reduction in MPER peptide binding
357	Residues that affect binding by VRC42.04	Krebs2019	binding	VRC42.04(MPER)	alanine scanning, binding assay	673	gp41	F	0.048	0.065	0.073	F673A mediates an ~60 fold reduction in MPER peptide binding
358	Residues that affect binding by 4E10	Krebs2019	binding	4E10(MPER)	alanine scanning, binding assay	672	gp41	W	0.014	0.023	0.014	W672A mediates an ~2-fold reduction in MPER peptide binding
358	Residues that affect binding by 4E10	Krebs2019	binding	4E10(MPER)	alanine scanning, binding assay	673	gp41	F	0.048	0.065	0.073	F673A mediates an ~2 fold reduction in MPER peptide binding
359	Residues that affect binding by VRC42.02	Krebs2019	binding	VRC42.02(MPER)	alanine scanning, binding assay	671	gp41	N	0.783	0.669	0.885	N671A mediates an ~20-fold reduction in binding to MPER peptide
359	Residues that affect binding by VRC42.02	Krebs2019	binding	VRC42.02(MPER)	alanine scanning, binding assay	672	gp41	W	0.014	0.023	0.014	Ala mediates an ~30-fold reduction in binding to MPER peptide
359	Residues that affect binding by VRC42.02	Krebs2019	binding	VRC42.02(MPER)	alanine scanning, binding assay	673	gp41	F	0.048	0.065	0.073	Ala mediates an ~30-fold reduction in binding to MPER peptide
359	Residues that affect binding by VRC42.02	Krebs2019	binding	VRC42.02(MPER)	alanine scanning, binding assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A mediates an ~4-fold reduction in binding to MPER peptide
359	Residues that affect binding by VRC42.02	Krebs2019	binding	VRC42.02(MPER)	alanine scanning, binding assay	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	R683A mediates an ~3-fold reduction in binding to MPER peptide
360	Mutation affects neutralization of MEL-1872	Heydarchi2022	neutralization	MEL-1872(CD4BS)	alanine scanning, neutralization assay	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	I371A decreases binding and significantly affects neutralization
360	Mutation affects neutralization of MEL-1872	Heydarchi2022	neutralization	MEL-1872(CD4BS)	alanine scanning, neutralization assay	471	gp120, beta24	G	0.933	0.888	0.866	G471A decreases binding and significantly affects neutralization
361	Residues that affect binding by VRC42.03	Krebs2019	binding	VRC42.03(MPER)	alanine scanning, binding assay	671	gp41	N	0.783	0.669	0.885	N671A mediates an ~20-fold reduction in binding to MPER peptide
361	Residues that affect binding by VRC42.03	Krebs2019	binding	VRC42.03(MPER)	alanine scanning, binding assay	672	gp41	W	0.014	0.023	0.014	Ala mediates an ~50-fold reduction in MPER peptide binding
361	Residues that affect binding by VRC42.03	Krebs2019	binding	VRC42.03(MPER)	alanine scanning, binding assay	673	gp41	F	0.048	0.065	0.073	Ala mediates an ~50 fold reduction in MPER peptide binding
361	Residues that affect binding by VRC42.03	Krebs2019	binding	VRC42.03(MPER)	alanine scanning, binding assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A mediates an ~2.5 fold reduction in binding to MPER peptide
361	Residues that affect binding by VRC42.03	Krebs2019	binding	VRC42.03(MPER)	alanine scanning, binding assay	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	R683A mediates an ~2.5 fold reduction in binding to MPER peptide
362	Q563R affects binding of MPER mAbs	Joshi2020	binding	10E8(MPER), 2F5(MPER), 4E10(MPER), 7H6(MPER), Z13e1(MPER)	binding assay	563	gp41, Leu/Ile zipper-like sequence	Q	0.093	0.086	0.050	Q563R allows for better binding and increased sensitivity to neutralization by MPER mAbs; Q563R dramatically decreases viral infectivity by disrupting membrane fusion and 6-helix bundle formation
363	Mutation affects NC-Cow1 neutralization	Sok2017	neutralization	NC-Cow1(CD4BS)	alanine scanning, neutralization assay	282	gp120, Loop D	K	0.336	0.337	0.297	K282A reduces NC-Cow1 neutralization of JRCSF
363	Mutation affects NC-Cow1 neutralization	Sok2017	neutralization	NC-Cow1(CD4BS)	alanine scanning, neutralization assay	372	gp120, CD4 binding loop	V	1.105	0.776	0.391	V372A reduces NC-Cow1 neutralization of JRCSF
363	Mutation affects NC-Cow1 neutralization	Sok2017	neutralization	NC-Cow1(CD4BS)	alanine scanning, neutralization assay	471	gp120, beta24	G	0.933	0.888	0.866	G471 reduces NC-Cow1 neutralization of JRCSF
363	Mutation affects NC-Cow1 neutralization	Sok2017	neutralization	NC-Cow1(CD4BS)	alanine scanning, neutralization assay	472	gp120	G	0.035	0.012	0.043	V372A reduces NC-Cow1 neutralization of JRCSF
363	Mutation affects NC-Cow1 neutralization	Sok2017	neutralization	NC-Cow1(CD4BS)	alanine scanning, neutralization assay	476	gp120	R	0.663	0.615	0.711	R476A reduces NC-Cow1 neutralization of JRCSF
364	Mutation affects ACS202 binding	vanGils2016	binding	ACS202(gp41 fusion domain)	binding assay, mutational analysis	83	gp120	E	0.042	0.039	0.035	E83A mutation partially affects ACS202 binding to trimer
364	Mutation affects ACS202 binding	vanGils2016	binding	ACS202(gp41 fusion domain)	binding assay, mutational analysis	87	gp120	V	1.565	1.611	1.463	E87A mutation almost completely abrogates ACS202 binding to trimer
364	Mutation affects ACS202 binding	vanGils2016	binding	ACS202(gp41 fusion domain)	binding assay, mutational analysis	88	gp120	N	0.050	0.041	0.048	N88Q mutation almost completely abrogates ACS202 binding to trimer
364	Mutation affects ACS202 binding	vanGils2016	binding	ACS202(gp41 fusion domain)	binding assay, mutational analysis	229	gp120	N	0.707	0.742	0.290	N229K mutation partially affects ACS202 binding to trimer
364	Mutation affects ACS202 binding	vanGils2016	binding	ACS202(gp41 fusion domain)	binding assay, mutational analysis	512	gp41, fusion peptide	A	0.188	0.260	0.110	A512W mutation reduces ACS202 binding to trimer substantially
364	Mutation affects ACS202 binding	vanGils2016	binding	ACS202(gp41 fusion domain)	binding assay, mutational analysis	515	gp41, fusion peptide	I	1.103	1.147	0.877	I515W mutation reduces ACS202 binding to trimer substantially
364	Mutation affects ACS202 binding	vanGils2016	binding	ACS202(gp41 fusion domain)	binding assay, mutational analysis	516	gp41, fusion peptide	G	0.066	0.038	0.048	G516W mutation reduces ACS202 binding to trimer substantially
364	Mutation affects ACS202 binding	vanGils2016	binding	ACS202(gp41 fusion domain)	binding assay, mutational analysis	528	gp41	S	0.030	0.012	0.022	S528W mutation reduces ACS202 binding to trimer substantially
365	Key position for V3 mAb neutralization	Mouquet2012a	neutralization	10-1074(V3), 10-996(V3), PGT121(V3)	neutralization assay	332	gp120	N	0.663	0.491	0.693	Position N332 is key for the binding and neutralization of PGT121, 10-1074, and 10-996, with PGT121 recognizing complex and high-mannose carbohydrates; some PGT121-sensitive strains carry mutations in the N332 gp120-associated PNGS
366	Key position for V3 mAb binding	Mouquet2012a	binding	10-1074(V3), 10-996(V3), PGT121(V3)	binding assay	332	gp120	N	0.663	0.491	0.693	Position N332 is key for the binding and neutralization of PGT121, 10-1074, and 10-996, with PGT121 recognizing complex and high-mannose carbohydrates
367	Loss of glycan at 332 confers resistance to PGT121 and 10-1074	Wang2018a	neutralization	10-1074(V3), PGT121(V3)	neutralization assay	332	gp120	N	0.663	0.491	0.693	Loss of glycan at 332 confers resistance to PGT121 and 10-1074
368	CH59 contacts	Liao2013b	contacts	CH59(V2)	alanine scanning, binding assay, X-ray crystallography	169	gp120, V2	V	2.042	1.770	1.344	CH59 contact
368	CH59 contacts	Liao2013b	contacts	CH59(V2)	alanine scanning, binding assay, X-ray crystallography	173	gp120, V2	Y	1.059	0.808	1.158	CH59 contact
368	CH59 contacts	Liao2013b	contacts	CH59(V2)	alanine scanning, binding assay, X-ray crystallography	176	gp120, V2	F	0.189	0.303	0.042	CH59 contact
368	CH59 contacts	Liao2013b	contacts	CH59(V2)	alanine scanning, binding assay, X-ray crystallography	177	gp120, V2	Y	0.454	0.638	0.144	CH59 contact
369	3BC176 neutralization	Klein2012	neutralization	3BC176(CD4i)	neutralization assay	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	3BC176 and 3BC315: loss of the N295 glycosylation site modestly reduces neutralization sensitivity
369	3BC176 neutralization	Klein2012	neutralization	3BC176(CD4i)	neutralization assay	406	gp120, V4-hypervariable, V4 loop	N	1.939	2.211	1.307	3BC176 and 3BC315: loss of the N406 glycosylation site modestly reduces neutralization sensitivity
369	3BC176 neutralization	Klein2012	neutralization	3BC176(CD4i)	neutralization assay	448	gp120	N	0.662	0.448	0.927	3BC176 and 3BC315: loss of the N448 glycosylation site modestly reduces neutralization sensitivity
369	3BC176 neutralization	Klein2012	neutralization	3BC176(CD4i)	neutralization assay	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	3BC176 and 3BC315: loss of the N463 glycosylation site modestly reduces neutralization sensitivity
370	3BC315 neutralization	Klein2012	neutralization	3BC315(CD4i)	neutralization assay	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	3BC176 and 3BC315: loss of the N295 glycosylation site modestly reduces neutralization sensitivity
370	3BC315 neutralization	Klein2012	neutralization	3BC315(CD4i)	neutralization assay	406	gp120, V4-hypervariable, V4 loop	N	1.939	2.211	1.307	3BC176 and 3BC315: loss of the N406 glycosylation site modestly reduces neutralization sensitivity
370	3BC315 neutralization	Klein2012	neutralization	3BC315(CD4i)	neutralization assay	448	gp120	N	0.662	0.448	0.927	3BC176 and 3BC315: loss of the N448 glycosylation site modestly reduces neutralization sensitivity
370	3BC315 neutralization	Klein2012	neutralization	3BC315(CD4i)	neutralization assay	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	3BC176 and 3BC315: loss of the N463 glycosylation site modestly reduces neutralization sensitivity
371	3BC315 binding	Klein2012	binding	3BC315(CD4i)	binding assay	160	gp120, V2	N	0.416	0.452	0.358	3BC176 and 3BC315: N160K reduces binding
371	3BC315 binding	Klein2012	binding	3BC315(CD4i)	binding assay	420	gp120	I	0.093	0.049	0.078	3BC176 and 3BC315: I420R slightly enhances binding
372	3BC176 binding	Lee2015	binding	3BC176(CD4i)	binding assay	88	gp120	N	0.050	0.041	0.048	3BC176 and 3BC315: N88 glycan plays a role in binding kinetics
373	3BC315 binding	Lee2015	binding	3BC315(CD4i)	binding assay	88	gp120	N	0.050	0.041	0.048	3BC176 and 3BC315: N88 glycan plays a role in binding kinetics
373	3BC315 binding	Lee2015	binding	3BC315(CD4i)	binding assay	623	gp41	W	0.020	0.066	0.043	3BC315: W623A abrogates binding
374	3BC315 neutralization	Lee2015	neutralization	3BC315(CD4i)	neutralization assay	619	gp41	L	1.801	1.312	1.871	3BC315: L619Y reduces neutralization sensitivity
375	vFP5.01 contacts with BG505	Xu2018	contacts	vFP5.01(gp41 fusion domain)	X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	Ala (BG505): H bond and salt bridge with D32 (LC), H bond with Y91 and S92 (LC)
375	vFP5.01 contacts with BG505	Xu2018	contacts	vFP5.01(gp41 fusion domain)	X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	Val (BG505): H bond with Y91 (LC)
375	vFP5.01 contacts with BG505	Xu2018	contacts	vFP5.01(gp41 fusion domain)	X-ray crystallography	514	gp41, fusion peptide	G	0.600	0.691	0.502	Gly (BG505): H bond with Y94 (LC)
375	vFP5.01 contacts with BG505	Xu2018	contacts	vFP5.01(gp41 fusion domain)	X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	Ile (BG505): H bond with Y98 (HC)
375	vFP5.01 contacts with BG505	Xu2018	contacts	vFP5.01(gp41 fusion domain)	X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	Ala (BG505): H bond with N97 (HC)
375	vFP5.01 contacts with BG505	Xu2018	contacts	vFP5.01(gp41 fusion domain)	X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	Phe (BG505): H bond with N97 (HC)
376	vFP16.02 residues important for binding BG505	Xu2018	binding	vFP16.02(gp41 fusion domain)	alanine scanning, binding assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	Gly mutant reduced binding to 0.51 of BG505 Val
376	vFP16.02 residues important for binding BG505	Xu2018	binding	vFP16.02(gp41 fusion domain)	alanine scanning, binding assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	Ala and Gly mutants respectively reduced binding to 0.69 and 0.03 of BG505 Ile
377	vFP20.01 residues important for binding BG505	Xu2018	binding	vFP20.01(gp41 fusion domain)	alanine scanning, binding assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	Gly mutant reduced binding to 0.34 of BG505 Val
377	vFP20.01 residues important for binding BG505	Xu2018	binding	vFP20.01(gp41 fusion domain)	alanine scanning, binding assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	Ala mutant reduced binding to 0.48 of BG505 Gly
377	vFP20.01 residues important for binding BG505	Xu2018	binding	vFP20.01(gp41 fusion domain)	alanine scanning, binding assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	Ala and Gly mutants respectively reduced binding to 0.66 and 0.03 of BG505 Ile
378	vFP7.05 residues important for binding BG505	Xu2018	binding	vFP7.05(gp41 fusion domain)	alanine scanning, binding assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	Gly mutant reduced binding to 0.27 of BG505 Val
378	vFP7.05 residues important for binding BG505	Xu2018	binding	vFP7.05(gp41 fusion domain)	alanine scanning, binding assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	Ala mutant reduced binding to 0.09 of BG505 Gly
378	vFP7.05 residues important for binding BG505	Xu2018	binding	vFP7.05(gp41 fusion domain)	alanine scanning, binding assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	Ala and Gly mutants respectively reduced binding to 0.23 and 0.01 of BG505 Ile
379	vFP7.04 residues important for binding BG505	Xu2018	binding	vFP7.04(gp41 fusion domain)	alanine scanning, binding assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	Gly mutant reduced binding to 0.30 of BG505 Val
379	vFP7.04 residues important for binding BG505	Xu2018	binding	vFP7.04(gp41 fusion domain)	alanine scanning, binding assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	Ala mutant reduced binding to 0.09 of BG505 Gly
379	vFP7.04 residues important for binding BG505	Xu2018	binding	vFP7.04(gp41 fusion domain)	alanine scanning, binding assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	Ala and Gly mutants respectively reduced binding to 0.29 and 0.01 of BG505 Ile
380	Mutations coupling nAb resistance with ceniciviroc sensitivity	Kuwata2016	neutralization	4E9C(CD4i)	neutralization assay, other	315	gp120, V3 loop	R	1.211	1.028	0.196	R315K causes resistance to NAbs 0.5γ and 4E9C, coupled with reversion to ceniciviroc-sensitivity
380	Mutations coupling nAb resistance with ceniciviroc sensitivity	Kuwata2016	neutralization	4E9C(CD4i)	neutralization assay, other	324	gp120, V3 loop	G	0.075	0.056	0.092	G324R causes resistance to NAbs 0.5γ and 4E9C, coupled with reversion to ceniciviroc-sensitivity
380	Mutations coupling nAb resistance with ceniciviroc sensitivity	Kuwata2016	neutralization	4E9C(CD4i)	neutralization assay, other	381	gp120	E	0.050	0.045	0.028	E381K causes resistance to NAbs 0.5γ and 4E9C, coupled with reversion to ceniciviroc-sensitivity
381	Signature Analysis Summary	Bricault2019	signature	PGT145(V2)	computational prediction	291	gp120	S	1.161	1.292	0.739	Amino acid P is associated with resistance
382	MPER membrane fusion mutations confer sensitivity	Fu2018	neutralization	3791(V3)	neutralization assay	670	gp41	W	0.043	0.028	0.035	W670A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
382	MPER membrane fusion mutations confer sensitivity	Fu2018	neutralization	3791(V3)	neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
382	MPER membrane fusion mutations confer sensitivity	Fu2018	neutralization	3791(V3)	neutralization assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
383	MPER membrane fusion mutations confer sensitivity	Fu2018	neutralization	b6(CD4BS)	neutralization assay	670	gp41	W	0.043	0.028	0.035	W670A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
383	MPER membrane fusion mutations confer sensitivity	Fu2018	neutralization	b6(CD4BS)	neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
383	MPER membrane fusion mutations confer sensitivity	Fu2018	neutralization	b6(CD4BS)	neutralization assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
384	Mutation affects neutralization of 4E10	ORourke2009	neutralization	4E10(MPER)	neutralization assay	653	gp41	Q	0.023	0.028	0.008	Q653R mutation gave >30-fold increase in neutralization sensitivity; this affects the assembly of the 6-helix bundle required for virus fusion, and alters the conformational equilibria favoring the prehairpin intermediate conformation required for the binding of the membrane proximal external region-specific neutralizing antibodies 2F5 and 4E10.
385	Mutation affects neutralization of 2F5	ORourke2009	neutralization	2F5(MPER)	neutralization assay	653	gp41	Q	0.023	0.028	0.008	Q653R mutation gave >30-fold increase in neutralization sensitivity; this affects the assembly of the 6-helix bundle required for virus fusion, and alters the conformational equilibria favoring the prehairpin intermediate conformation required for the binding of the membrane proximal external region-specific neutralizing antibodies 2F5 and 4E10.
386	Mutation affects neutralization of 4E10	ORourke2010	neutralization	4E10(MPER)	neutralization assay	180	gp120, V2	D	0.054	0.033	0.029	D180 is located within the LDI/V recognition motif of the alpha-4-beta-7 receptor binding site; the D180N mutation may induce a conformational change that exposes epitopes in both the gp120 and the gp41 portions of the envelope protein, such as the CD4 binding site and the MPER, that are normally concealed by conformational masking.
387	Mutation affects neutralization of 17b	ORourke2010	neutralization	17b(CD4i)	neutralization assay	180	gp120, V2	D	0.054	0.033	0.029	D180 is located within the LDI/V recognition motif of the alpha-4-beta-7 receptor binding site; the D180N mutation may induce a conformational change that exposes epitopes in both the gp120 and the gp41 portions of the envelope protein, such as the CD4 binding site and the MPER, that are normally concealed by conformational masking.
388	Mutation affects neutralization of 2F5	ORourke2010	neutralization	2F5(MPER)	neutralization assay	180	gp120, V2	D	0.054	0.033	0.029	D180 is located within the LDI/V recognition motif of the alpha-4-beta-7 receptor binding site; the D180N mutation may induce a conformational change that exposes epitopes in both the gp120 and the gp41 portions of the envelope protein, such as the CD4 binding site and the MPER, that are normally concealed by conformational masking.
389	Mutation affects neutralization of 4E10	ORourke2012	neutralization	4E10(MPER)	neutralization assay	197	gp120	N	0.133	0.082	0.109	N197H confers generalized sensitivity to b12, sCD4, 4E10, but resistance to PG9, which depends on glycans.
389	Mutation affects neutralization of 4E10	ORourke2012	neutralization	4E10(MPER)	neutralization assay	384	gp120	Y	0.107	0.124	0.023	Y384H/L702P alone and in combination can confer sensitivity to 4E10, CD4 IgG and b12, but not to PG9/PG16 or VRC01
389	Mutation affects neutralization of 4E10	ORourke2012	neutralization	4E10(MPER)	neutralization assay	423	gp120, beta20/beta21	I	0.433	0.383	0.411	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, and 4E10, but simultaneously confers resistance to PG9, PG16, and VRC01
389	Mutation affects neutralization of 4E10	ORourke2012	neutralization	4E10(MPER)	neutralization assay	589	gp41, Leu/Ile zipper-like sequence	D	0.053	0.035	0.029	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, 4E10, but resistance to PG9, PG16, VRC01
389	Mutation affects neutralization of 4E10	ORourke2012	neutralization	4E10(MPER)	neutralization assay	668	gp41	S	0.865	0.596	0.758	S668G/I675V in combination increased sensitivity to 4E10 and CD4 IgG, but not to PG16 or 17b, or VRC01
389	Mutation affects neutralization of 4E10	ORourke2012	neutralization	4E10(MPER)	neutralization assay	675	gp41	I	0.063	0.059	0.069	S668G/I675V in combination increased sensitivity to 4E10 and CD4 igG, but not to PG16 or 17b, or VRC01
389	Mutation affects neutralization of 4E10	ORourke2012	neutralization	4E10(MPER)	neutralization assay	702	gp41, gp41 cytoplasmic tail	L	0.419	0.497	0.316	Y384H/L702P alone and in combination can confer sensitivity to 4E10, CD4 IgG and b12, but not to PG9/PG16 or VRC01
390	Mutation affects neutralization of 17b	ORourke2012	neutralization	17b(CD4i)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167G did not change neutralization by PG9, PG16, b12, 4E10 or VRC01, but increased CD4 Ig and 17b sensitivity.
390	Mutation affects neutralization of 17b	ORourke2012	neutralization	17b(CD4i)	neutralization assay	423	gp120, beta20/beta21	I	0.433	0.383	0.411	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, and 4E10, but simultaneously confers resistance to PG9, PG16, and VRC01
390	Mutation affects neutralization of 17b	ORourke2012	neutralization	17b(CD4i)	neutralization assay	589	gp41, Leu/Ile zipper-like sequence	D	0.053	0.035	0.029	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, 4E10, but resistance to PG9, PG16, VRC01
391	Mutation affects neutralization of b12	ORourke2012	neutralization	b12(CD4BS)	neutralization assay	197	gp120	N	0.133	0.082	0.109	N197H confers generalized sensitivity to b12, sCD4, 4E10, but resistance to PG9, which depends on glycans.
391	Mutation affects neutralization of b12	ORourke2012	neutralization	b12(CD4BS)	neutralization assay	384	gp120	Y	0.107	0.124	0.023	Y384H/L702P alone and in combination can confer sensitivity to 4E10, CD4 IgG and b12, but not to PG9/PG16 or VRC01
391	Mutation affects neutralization of b12	ORourke2012	neutralization	b12(CD4BS)	neutralization assay	423	gp120, beta20/beta21	I	0.433	0.383	0.411	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, and 4E10, but simultaneously confers resistance to PG9, PG16, and VRC01
391	Mutation affects neutralization of b12	ORourke2012	neutralization	b12(CD4BS)	neutralization assay	589	gp41, Leu/Ile zipper-like sequence	D	0.053	0.035	0.029	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, 4E10, but resistance to PG9, PG16, VRC01
391	Mutation affects neutralization of b12	ORourke2012	neutralization	b12(CD4BS)	neutralization assay	702	gp41, gp41 cytoplasmic tail	L	0.419	0.497	0.316	Y384H/L702P alone and in combination can confer sensitivity to 4E10, CD4 IgG and b12, but not to PG9/PG16 or VRC01
392	Mutation affects neutralization of PG16	ORourke2012	neutralization	PG16(V2)	neutralization assay	423	gp120, beta20/beta21	I	0.433	0.383	0.411	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, and 4E10, but simultaneously confers resistance to PG9, PG16, and VRC01
392	Mutation affects neutralization of PG16	ORourke2012	neutralization	PG16(V2)	neutralization assay	589	gp41, Leu/Ile zipper-like sequence	D	0.053	0.035	0.029	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, 4E10, but resistance to PG9, PG16, VRC01
393	Mutation affects neutralization of PG9	ORourke2012	neutralization	PG9(V2)	neutralization assay	197	gp120	N	0.133	0.082	0.109	N197H confers generalized sensitivity to b12, sCD4, 4E10, but resistance to PG9, which depends on glycans.
393	Mutation affects neutralization of PG9	ORourke2012	neutralization	PG9(V2)	neutralization assay	423	gp120, beta20/beta21	I	0.433	0.383	0.411	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, and 4E10, but simultaneously confers resistance to PG9, PG16, and VRC01
393	Mutation affects neutralization of PG9	ORourke2012	neutralization	PG9(V2)	neutralization assay	589	gp41, Leu/Ile zipper-like sequence	D	0.053	0.035	0.029	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, 4E10, but resistance to PG9, PG16, VRC01
394	Mutation affects neutralization of VRC01	ORourke2012	neutralization	VRC01(CD4BS)	neutralization assay	423	gp120, beta20/beta21	I	0.433	0.383	0.411	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, and 4E10, but simultaneously confers resistance to PG9, PG16, and VRC01
394	Mutation affects neutralization of VRC01	ORourke2012	neutralization	VRC01(CD4BS)	neutralization assay	589	gp41, Leu/Ile zipper-like sequence	D	0.053	0.035	0.029	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, 4E10, but resistance to PG9, PG16, VRC01
395	Disulfide bond introduced in V1V2 affects binding of 2G12	deTaeye2019	binding	2G12(glycan)	binding assay, mutational analysis	152	gp120, V1-hypervariable, V1	G	1.800	1.271	1.966	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
395	Disulfide bond introduced in V1V2 affects binding of 2G12	deTaeye2019	binding	2G12(glycan)	binding assay, mutational analysis	153	gp120, V1	E	0.996	0.592	1.034	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
395	Disulfide bond introduced in V1V2 affects binding of 2G12	deTaeye2019	binding	2G12(glycan)	binding assay, mutational analysis	178	gp120, V2	K	1.346	1.386	0.988	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
396	Disulfide bond introduced in V1V2 affects binding of CH01	deTaeye2019	binding	CH01(V2)	binding assay, mutational analysis	152	gp120, V1-hypervariable, V1	G	1.800	1.271	1.966	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
396	Disulfide bond introduced in V1V2 affects binding of CH01	deTaeye2019	binding	CH01(V2)	binding assay, mutational analysis	153	gp120, V1	E	0.996	0.592	1.034	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
396	Disulfide bond introduced in V1V2 affects binding of CH01	deTaeye2019	binding	CH01(V2)	binding assay, mutational analysis	178	gp120, V2	K	1.346	1.386	0.988	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
396	Disulfide bond introduced in V1V2 affects binding of CH01	deTaeye2019	binding	CH01(V2)	binding assay, mutational analysis	184	gp120, V2	I	1.028	0.599	0.530	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
396	Disulfide bond introduced in V1V2 affects binding of CH01	deTaeye2019	binding	CH01(V2)	binding assay, mutational analysis	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
397	Disulfide bond introduced in V1V2 affects neutralization of CH01	deTaeye2019	neutralization	CH01(V2)	mutational analysis, neutralization assay	184	gp120, V2	I	1.028	0.599	0.530	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
397	Disulfide bond introduced in V1V2 affects neutralization of CH01	deTaeye2019	neutralization	CH01(V2)	mutational analysis, neutralization assay	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
398	Disulfide bond introduced in V1V2 affects binding of CH103	deTaeye2019	binding	CH103(CD4BS)	binding assay, mutational analysis	152	gp120, V1-hypervariable, V1	G	1.800	1.271	1.966	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
398	Disulfide bond introduced in V1V2 affects binding of CH103	deTaeye2019	binding	CH103(CD4BS)	binding assay, mutational analysis	153	gp120, V1	E	0.996	0.592	1.034	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
398	Disulfide bond introduced in V1V2 affects binding of CH103	deTaeye2019	binding	CH103(CD4BS)	binding assay, mutational analysis	178	gp120, V2	K	1.346	1.386	0.988	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
398	Disulfide bond introduced in V1V2 affects binding of CH103	deTaeye2019	binding	CH103(CD4BS)	binding assay, mutational analysis	184	gp120, V2	I	1.028	0.599	0.530	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
398	Disulfide bond introduced in V1V2 affects binding of CH103	deTaeye2019	binding	CH103(CD4BS)	binding assay, mutational analysis	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
399	Disulfide bond introduced in V1V2 affects neutralization of CH103	deTaeye2019	neutralization	CH103(CD4BS)	mutational analysis, neutralization assay	184	gp120, V2	I	1.028	0.599	0.530	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
399	Disulfide bond introduced in V1V2 affects neutralization of CH103	deTaeye2019	neutralization	CH103(CD4BS)	mutational analysis, neutralization assay	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
400	Disulfide bond introduced in V1V2 affects binding of PG16	deTaeye2019	binding	PG16(V2)	binding assay, mutational analysis	152	gp120, V1-hypervariable, V1	G	1.800	1.271	1.966	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
400	Disulfide bond introduced in V1V2 affects binding of PG16	deTaeye2019	binding	PG16(V2)	binding assay, mutational analysis	153	gp120, V1	E	0.996	0.592	1.034	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
400	Disulfide bond introduced in V1V2 affects binding of PG16	deTaeye2019	binding	PG16(V2)	binding assay, mutational analysis	178	gp120, V2	K	1.346	1.386	0.988	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
400	Disulfide bond introduced in V1V2 affects binding of PG16	deTaeye2019	binding	PG16(V2)	binding assay, mutational analysis	184	gp120, V2	I	1.028	0.599	0.530	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
400	Disulfide bond introduced in V1V2 affects binding of PG16	deTaeye2019	binding	PG16(V2)	binding assay, mutational analysis	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
401	Disulfide bond introduced in V1V2 affects neutralization of PG16	deTaeye2019	neutralization	PG16(V2)	mutational analysis, neutralization assay	184	gp120, V2	I	1.028	0.599	0.530	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
401	Disulfide bond introduced in V1V2 affects neutralization of PG16	deTaeye2019	neutralization	PG16(V2)	mutational analysis, neutralization assay	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
402	Disulfide bond introduced in V1V2 affects binding of PG9	deTaeye2019	binding	PG9(V2)	binding assay, mutational analysis	152	gp120, V1-hypervariable, V1	G	1.800	1.271	1.966	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
402	Disulfide bond introduced in V1V2 affects binding of PG9	deTaeye2019	binding	PG9(V2)	binding assay, mutational analysis	153	gp120, V1	E	0.996	0.592	1.034	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
402	Disulfide bond introduced in V1V2 affects binding of PG9	deTaeye2019	binding	PG9(V2)	binding assay, mutational analysis	178	gp120, V2	K	1.346	1.386	0.988	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
402	Disulfide bond introduced in V1V2 affects binding of PG9	deTaeye2019	binding	PG9(V2)	binding assay, mutational analysis	184	gp120, V2	I	1.028	0.599	0.530	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
402	Disulfide bond introduced in V1V2 affects binding of PG9	deTaeye2019	binding	PG9(V2)	binding assay, mutational analysis	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
403	Disulfide bond introduced in V1V2 affects neutralization of PG9	deTaeye2019	neutralization	PG9(V2)	mutational analysis, neutralization assay	184	gp120, V2	I	1.028	0.599	0.530	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
403	Disulfide bond introduced in V1V2 affects neutralization of PG9	deTaeye2019	neutralization	PG9(V2)	mutational analysis, neutralization assay	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
404	Disulfide bond introduced in V1V2 affects neutralization of PGDM1400	deTaeye2019	neutralization	PGDM1400(V2)	mutational analysis, neutralization assay	184	gp120, V2	I	1.028	0.599	0.530	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
404	Disulfide bond introduced in V1V2 affects neutralization of PGDM1400	deTaeye2019	neutralization	PGDM1400(V2)	mutational analysis, neutralization assay	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
405	Disulfide bond introduced in V1V2 affects binding of PGT121	deTaeye2019	binding	PGT121(V3)	binding assay, mutational analysis	152	gp120, V1-hypervariable, V1	G	1.800	1.271	1.966	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
405	Disulfide bond introduced in V1V2 affects binding of PGT121	deTaeye2019	binding	PGT121(V3)	binding assay, mutational analysis	153	gp120, V1	E	0.996	0.592	1.034	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
405	Disulfide bond introduced in V1V2 affects binding of PGT121	deTaeye2019	binding	PGT121(V3)	binding assay, mutational analysis	178	gp120, V2	K	1.346	1.386	0.988	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
406	Disulfide bond introduced in V1V2 affects binding of PGT145	deTaeye2019	binding	PGT145(V2)	binding assay, mutational analysis	184	gp120, V2	I	1.028	0.599	0.530	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
406	Disulfide bond introduced in V1V2 affects binding of PGT145	deTaeye2019	binding	PGT145(V2)	binding assay, mutational analysis	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
407	Disulfide bond introduced in V1V2 affects binding of PGT151	deTaeye2019	binding	PGT151(gp41 fusion domain)	binding assay, mutational analysis	152	gp120, V1-hypervariable, V1	G	1.800	1.271	1.966	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
407	Disulfide bond introduced in V1V2 affects binding of PGT151	deTaeye2019	binding	PGT151(gp41 fusion domain)	binding assay, mutational analysis	153	gp120, V1	E	0.996	0.592	1.034	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
407	Disulfide bond introduced in V1V2 affects binding of PGT151	deTaeye2019	binding	PGT151(gp41 fusion domain)	binding assay, mutational analysis	178	gp120, V2	K	1.346	1.386	0.988	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
408	Disulfide bond introduced in V1V2 affects binding of VRC01	deTaeye2019	binding	VRC01(CD4BS)	binding assay, mutational analysis	152	gp120, V1-hypervariable, V1	G	1.800	1.271	1.966	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
408	Disulfide bond introduced in V1V2 affects binding of VRC01	deTaeye2019	binding	VRC01(CD4BS)	binding assay, mutational analysis	153	gp120, V1	E	0.996	0.592	1.034	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
408	Disulfide bond introduced in V1V2 affects binding of VRC01	deTaeye2019	binding	VRC01(CD4BS)	binding assay, mutational analysis	178	gp120, V2	K	1.346	1.386	0.988	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
409	Disulfide bond introduced in V1V2 affects binding of VRC26.09	deTaeye2019	binding	VRC26.09(V2)	binding assay, mutational analysis	184	gp120, V2	I	1.028	0.599	0.530	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
409	Disulfide bond introduced in V1V2 affects binding of VRC26.09	deTaeye2019	binding	VRC26.09(V2)	binding assay, mutational analysis	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
410	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	2158(V2)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
410	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	2158(V2)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
411	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	4E10(MPER)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
411	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	4E10(MPER)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
412	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	17b(CD4i)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
412	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	17b(CD4i)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
413	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	2F5(MPER)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
413	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	2F5(MPER)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
414	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	412d(CD4i)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
414	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	412d(CD4i)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
414	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	412d(CD4i)	alanine scanning, neutralization assay	300	gp120, V3 loop	N	1.017	0.738	1.054	N300A increased viral sensitivity for 412d and 447-52D, but decreased sensitivity for PG9
414	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	412d(CD4i)	alanine scanning, neutralization assay	305	gp120, V3 loop	K	0.906	0.713	0.943	K305A increased viral sensitivity for 412d and 447-52D, but decreased sensitivity for PG9
415	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	447-52D(V3)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
415	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	447-52D(V3)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
415	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	447-52D(V3)	alanine scanning, neutralization assay	300	gp120, V3 loop	N	1.017	0.738	1.054	N300A increased viral sensitivity for 412d and 447-52D, but decreased sensitivity for PG9
415	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	447-52D(V3)	alanine scanning, neutralization assay	305	gp120, V3 loop	K	0.906	0.713	0.943	K305A increased viral sensitivity for 412d and 447-52D, but decreased sensitivity for PG9
416	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	48d(CD4i)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
416	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	48d(CD4i)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
417	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	654-D(CD4BS)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
417	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	654-D(CD4BS)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y177A increased neutralization sensitivity; Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
418	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	b13(CD4BS)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
418	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	b13(CD4BS)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
419	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	CH103(CD4BS)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
419	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	CH103(CD4BS)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
420	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	F105(CD4BS)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
420	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	F105(CD4BS)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
421	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	F425 B4e8(V3)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
421	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	F425 B4e8(V3)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
422	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PG16(V2)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
422	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PG16(V2)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
423	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PG9(V2)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
423	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PG9(V2)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
423	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PG9(V2)	alanine scanning, neutralization assay	300	gp120, V3 loop	N	1.017	0.738	1.054	N300A increased viral sensitivity for 412d and 447-52D, but decreased sensitivity for PG9
423	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PG9(V2)	alanine scanning, neutralization assay	305	gp120, V3 loop	K	0.906	0.713	0.943	K305A increased viral sensitivity for 412d and 447-52D, but decreased sensitivity for PG9
424	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT121(V3)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
424	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT121(V3)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
425	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT122(V3)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
425	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT122(V3)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
426	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT123(V3)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
426	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT123(V3)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
427	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT125(V3)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
427	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT125(V3)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
428	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT126(V3)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
428	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT126(V3)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
429	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT128(V3)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
429	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT128(V3)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
430	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT130(V3)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
430	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT130(V3)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
431	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT135(V3)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
431	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	PGT135(V3)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
432	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	VRC24(V3)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
432	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	VRC24(V3)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
433	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	VRC26.08(V2)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
433	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	VRC26.08(V2)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
434	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	VRC38.01(V2)	alanine scanning, neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
434	Mutations at the trimer apex affect sensitivity	Guzzo2018	neutralization	VRC38.01(V2)	alanine scanning, neutralization assay	177	gp120, V2	Y	0.454	0.638	0.144	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	32	gp120	E	1.554	1.314	0.968	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	33	gp120	K	1.551	1.559	0.973	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	85	gp120	V	1.980	1.797	1.418	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	87	gp120	V	1.565	1.611	1.463	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	97	gp120	K	0.478	0.421	0.511	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	130	gp120	K	1.201	0.883	1.495	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	134	gp120, V1-hypervariable, V1	L	2.224	2.322	1.627	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	135	gp120, V1-hypervariable, V1	K	2.230	2.373	1.848	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	136	gp120, V1-hypervariable, V1	N	2.514	2.300	2.581	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	138	gp120, V1-hypervariable, V1	T	2.312	2.112	2.504	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	139	gp120, V1-hypervariable, V1	N	2.097	1.946	2.163	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	140	gp120, V1-hypervariable, V1	T	2.235	2.104	2.340	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	141	gp120, V1-hypervariable, V1	N	2.227	2.077	2.148	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	142	gp120, V1-hypervariable, V1	S	2.145	1.992	1.972	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	145	gp120, V1-hypervariable, V1	G	2.282	2.228	2.255	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	146	gp120, V1-hypervariable, V1	R	2.649	2.583	2.629	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	151	gp120, V1-hypervariable, V1	K	2.575	2.285	2.605	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	268	gp120	E	1.191	0.886	1.275	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	271	gp120	V	1.126	0.623	0.635	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	275	gp120, Loop D	V	1.141	1.420	0.535	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	322	gp120, V3 loop	K	1.797	0.347	0.283	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	332	gp120	N	0.663	0.491	0.693	N332 glycosylation is associated with lower probability of the development of neutralizing antibody responses; the motif NLS is more often associated with development of neutralizing antibody responses, as compared with NIS.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	333	gp120	I	0.837	0.855	0.293	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	336	gp120	A	2.208	1.826	2.418	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	337	gp120	K	2.037	1.862	2.151	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	343	gp120	K	2.058	1.978	1.742	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	346	gp120	A	1.859	1.083	1.831	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	347	gp120	S	2.085	2.161	1.508	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	396	gp120, V4-hypervariable, V4 loop	F	2.388	2.159	2.350	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	399	gp120, V4-hypervariable, V4 loop	T	2.480	2.243	2.452	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	403	gp120, V4-hypervariable, V4 loop	E	2.421	2.430	2.183	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	404	gp120, V4-hypervariable, V4 loop	G	2.181	2.199	1.740	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	405	gp120, V4-hypervariable, V4 loop	S	2.186	2.388	1.715	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	406	gp120, V4-hypervariable, V4 loop	N	1.939	2.211	1.307	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	407	gp120, V4-hypervariable, V4 loop	N	1.615	1.992	1.038	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	412	gp120, V4 loop	D	2.245	2.094	2.182	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	440	gp120	S	1.844	1.712	1.017	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	464	gp120, V5-hypervariable, V5 loop	E	2.353	2.269	2.299	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
435	Env sites associated with development of nAb responses	vandenKerkhof2013	Env feature	polyclonal(other)	computational prediction	621	gp41	Q	1.808	2.097	1.208	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
436	mutation increases sensitivity to 4E10	Blish2008	neutralization	4E10(MPER)	neutralization assay	569	gp41, Leu/Ile zipper-like sequence	T	0.025	0.017	0.022	T569A, I675V, and their double mutation increase the neutralization sensitivity of nAbs 4E10, 2F5, and b12 
436	mutation increases sensitivity to 4E10	Blish2008	neutralization	4E10(MPER)	neutralization assay	675	gp41	I	0.063	0.059	0.069	T569A, I675V, and their double mutation increase the neutralization sensitivity of nAbs 4E10, 2F5, and b12 
437	mutation increases sensitivity to b12	Blish2008	neutralization	b12(CD4BS)	neutralization assay	569	gp41, Leu/Ile zipper-like sequence	T	0.025	0.017	0.022	T569A, I675V, and their double mutation increase the neutralization sensitivity of nAbs 4E10, 2F5, and b12 
437	mutation increases sensitivity to b12	Blish2008	neutralization	b12(CD4BS)	neutralization assay	675	gp41	I	0.063	0.059	0.069	T569A, I675V, and their double mutation increase the neutralization sensitivity of nAbs 4E10, 2F5, and b12 
438	mutation increases sensitivity to 2F5	Blish2008	neutralization	2F5(MPER)	neutralization assay	569	gp41, Leu/Ile zipper-like sequence	T	0.025	0.017	0.022	T569A, I675V, and their double mutation increase the neutralization sensitivity of nAbs 4E10, 2F5, and b12 
438	mutation increases sensitivity to 2F5	Blish2008	neutralization	2F5(MPER)	neutralization assay	675	gp41	I	0.063	0.059	0.069	T569A, I675V, and their double mutation increase the neutralization sensitivity of nAbs 4E10, 2F5, and b12 
439	mutation increases sensitivity to 4E10	Ringe2012a	neutralization	4E10(MPER)	neutralization assay	681	gp41, gp41 transmembrane	Y	0.020	0.012	0.036	Y681H increases neutralization sensitivity of nAbs 4E10, 2F5, and b12 
440	mutation increases sensitivity to b12	Ringe2012a	neutralization	b12(CD4BS)	neutralization assay	681	gp41, gp41 transmembrane	Y	0.020	0.012	0.036	Y681H increases neutralization sensitivity of nAbs 4E10, 2F5, and b12 
441	mutation increases sensitivity to 2F5	Ringe2012a	neutralization	2F5(MPER)	neutralization assay	681	gp41, gp41 transmembrane	Y	0.020	0.012	0.036	Y681H increases neutralization sensitivity of nAbs 4E10, 2F5, and b12 
442	mutation increases sensitivity to 4E10	Shen2010	neutralization	4E10(MPER)	neutralization assay	669	gp41	L	0.017	0.023	0.000	L669S increases neutralization sensitivity of nAbs 4E10 and 2F5
443	mutation increases sensitivity to 2F5	Shen2010	neutralization	2F5(MPER)	neutralization assay	669	gp41	L	0.017	0.023	0.000	L669S increases neutralization sensitivity of nAbs 4E10 and 2F5
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	275	gp120, Loop D	V	1.141	1.420	0.535	NC-Cow1 contact; buried surface area 1.3 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	NC-Cow1 contact; buried surface area 9.5 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	NC-Cow1 contact; buried surface area 16.8 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	NC-Cow1 contact; buried surface area 50.5 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	NC-Cow1 contact; buried surface area 28.1 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	283	gp120, Loop D	T	1.005	1.091	0.474	NC-Cow1 contact; buried surface area 33.4 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	364	gp120, CD4 binding loop	S	0.924	0.588	1.191	NC-Cow1 contact; buried surface area 32.7 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	NC-Cow1 contact; buried surface area 22.4 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	NC-Cow1 contact; buried surface area 35 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	NC-Cow1 contact; buried surface area 26 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	NC-Cow1 contact; buried surface area 54.3 Angstroms on BG505 SOSIP.664; salt bridge contact (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	NC-Cow1 contact; buried surface area 2.5 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	NC-Cow1 contact; buried surface area 34.8 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	NC-Cow1 contact; buried surface area 59.2 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	372	gp120, CD4 binding loop	V	1.105	0.776	0.391	NC-Cow1 contact; buried surface area 4.8 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	375	gp120	S	0.668	0.753	0.372	NC-Cow1 contact; buried surface area 2 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	425	gp120, beta20/beta21	N	0.295	0.138	0.177	NC-Cow1 contact; buried surface area 5.3 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	426	gp120, beta20/beta21	M	0.724	0.866	0.274	NC-Cow1 contact; buried surface area 22.2 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	NC-Cow1 contact; buried surface area 0.6 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	429	gp120, beta20/beta21	K	1.325	0.961	1.308	NC-Cow1 contact; buried surface area 11.2 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	NC-Cow1 contact; buried surface area 37.5 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	NC-Cow1 contact; buried surface area 12.9 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	NC-Cow1 contact; buried surface area 18.5 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	NC-Cow1 contact; buried surface area 46.8 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	470	gp120, beta24	P	0.043	0.039	0.037	NC-Cow1 contact; buried surface area 5.5 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	471	gp120, beta24	G	0.933	0.888	0.866	NC-Cow1 contact; buried surface area 21.1 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	472	gp120	G	0.035	0.012	0.043	NC-Cow1 contact; buried surface area 4.8 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	473	gp120	G	0.042	0.033	0.029	NC-Cow1 contact; buried surface area 45.8 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	474	gp120	D	0.696	0.681	0.752	NC-Cow1 contact; buried surface area 28.2 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	475	gp120	M	0.097	0.092	0.106	NC-Cow1 contact; buried surface area 15.4 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	476	gp120	R	0.663	0.615	0.711	NC-Cow1 contact; buried surface area 4.3 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
444	NC-Cow1 contacts	Stanfield2020	contacts	NC-Cow1(CD4BS)	X-ray crystallography	477	gp120	D	0.191	0.112	0.249	NC-Cow1 contact; buried surface area 6.2 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	49	gp120	T	1.482	0.958	0.335	NIH45-46 scFv contact; buried surface area 17.3 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	96	gp120	W	0.063	0.091	0.020	NIH45-46 scFv contact; buried surface area 12.6 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	97	gp120	K	0.478	0.421	0.511	NIH45-46 scFv contact; buried surface area 29.2 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	98	gp120	N	0.042	0.045	0.022	NIH45-46 scFv contact; buried surface area 5.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	99	gp120	D	1.048	0.830	0.366	NIH45-46 scFv contact; buried surface area 16.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	102	gp120	E	0.782	0.522	0.426	NIH45-46 scFv contact; buried surface area 31.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	105	gp120	H	0.342	0.429	0.187	NIH45-46 scFv contact; buried surface area 12.2 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	109	gp120	I	0.112	0.116	0.051	NIH45-46 scFv contact; buried surface area 3 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	197	gp120	N	0.133	0.082	0.109	NIH45-46 scFv contact; buried surface area 8.8 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	198	gp120	T	0.430	0.264	0.469	NIH45-46 scFv contact; buried surface area 33.4 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	199	gp120	S	0.094	0.108	0.068	NIH45-46 scFv contact; buried surface area 12.1 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	275	gp120, Loop D	V	1.141	1.420	0.535	NIH45-46 scFv contact; buried surface area 27.2 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	NIH45-46 scFv contact; buried surface area 19.4 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	278	gp120, Loop D	T	0.708	0.715	0.481	NIH45-46 scFv contact; buried surface area 42.3 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	NIH45-46 scFv contact; buried surface area 42.3 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	NIH45-46 scFv contact; buried surface area 47.7 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	NIH45-46 scFv contact; buried surface area 55.7 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	NIH45-46 scFv contact; buried surface area 30.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	283	gp120, Loop D	T	1.005	1.091	0.474	NIH45-46 scFv contact; buried surface area 29.6 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	364	gp120, CD4 binding loop	S	0.924	0.588	1.191	NIH45-46 scFv contact; buried surface area 5.1 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	NIH45-46 scFv contact; buried surface area 47.1 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	NIH45-46 scFv contact; buried surface area 20.8 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	NIH45-46 scFv contact; buried surface area 18.2 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	NIH45-46 scFv contact; buried surface area 35.6 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	NIH45-46 scFv contact; buried surface area 2.5 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	NIH45-46 scFv contact; buried surface area 35.5 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	425	gp120, beta20/beta21	N	0.295	0.138	0.177	NIH45-46 scFv contact; buried surface area 11.8 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	427	gp120, beta20/beta21	W	0.083	0.061	0.038	NIH45-46 scFv contact; buried surface area 21.6 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	NIH45-46 scFv contact; buried surface area 66 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	430	gp120, beta20/beta21	V	0.267	0.080	0.073	NIH45-46 scFv contact; buried surface area 41.4 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	NIH45-46 scFv contact; buried surface area 38.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	NIH45-46 scFv contact; buried surface area 19.8 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	NIH45-46 scFv contact; buried surface area 54.3 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	NIH45-46 scFv contact; buried surface area 40.4 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	NIH45-46 scFv contact; buried surface area 38.5 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	NIH45-46 scFv contact; buried surface area 36.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	NIH45-46 scFv contact; buried surface area 48.7 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	NIH45-46 scFv contact; buried surface area 1.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	NIH45-46 scFv contact; buried surface area 10.4 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.567	1.466	1.517	NIH45-46 scFv contact; buried surface area 18.8 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	466	gp120, V5 loop, beta24	E	0.205	0.091	0.239	NIH45-46 scFv contact; buried surface area 4 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	467	gp120, V5 loop, beta24	I	0.912	0.955	0.870	NIH45-46 scFv contact; buried surface area 27.6 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	NIH45-46 scFv contact; buried surface area 34.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	470	gp120, beta24	P	0.043	0.039	0.037	NIH45-46 scFv contact; buried surface area 3.1 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	471	gp120, beta24	G	0.933	0.888	0.866	NIH45-46 scFv contact; buried surface area 7.2 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	472	gp120	G	0.035	0.012	0.043	NIH45-46 scFv contact; buried surface area 1.5 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	473	gp120	G	0.042	0.033	0.029	NIH45-46 scFv contact; buried surface area 30.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	474	gp120	D	0.696	0.681	0.752	NIH45-46 scFv contact; buried surface area 39 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	475	gp120	M	0.097	0.092	0.106	NIH45-46 scFv contact; buried surface area 9.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	476	gp120	R	0.663	0.615	0.711	NIH45-46 scFv contact; buried surface area 34.8 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	477	gp120	D	0.191	0.112	0.249	NIH45-46 scFv contact; buried surface area 5 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
445	NIH45-46 scFv contacts	Stanfield2020	contacts	NIH45-46(CD4BS)	X-ray crystallography	480	gp120	R	0.061	0.047	0.049	NIH45-46 scFv contact; buried surface area 14.6 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	96	gp120	W	0.063	0.091	0.020	VRC13 contact; buried surface area 21.5 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	97	gp120	K	0.478	0.421	0.511	VRC13 contact; buried surface area 10.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	275	gp120, Loop D	V	1.141	1.420	0.535	VRC13 contact; buried surface area 17.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	VRC13 contact; buried surface area 4.1 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	VRC13 contact; buried surface area 10.1 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	VRC13 contact; buried surface area 52.9 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	VRC13 contact; buried surface area 35.9 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	283	gp120, Loop D	T	1.005	1.091	0.474	VRC13 contact; buried surface area 23.6 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	327	gp120, V3 loop	R	0.089	0.066	0.073	VRC13 contact; buried surface area 11.9 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	364	gp120, CD4 binding loop	S	0.924	0.588	1.191	VRC13 contact; buried surface area 15.8 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	VRC13 contact; buried surface area 44.1 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	VRC13 contact; buried surface area 45.5 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	VRC13 contact; buried surface area 44.1 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	VRC13 contact; buried surface area 48.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	VRC13 contact; buried surface area 57.2 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	VRC13 contact; buried surface area 1.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	VRC13 contact; buried surface area 44.7 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	372	gp120, CD4 binding loop	V	1.105	0.776	0.391	VRC13 contact; buried surface area 23.8 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	373	gp120, CD4 binding loop	T	1.024	0.872	0.371	VRC13 contact; buried surface area 14.1 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	375	gp120	S	0.668	0.753	0.372	VRC13 contact; buried surface area 21.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	384	gp120	Y	0.107	0.124	0.023	VRC13 contact; buried surface area 18.2 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	419	gp120	R	0.463	0.341	0.500	VRC13 contact; buried surface area 29.3 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	420	gp120	I	0.093	0.049	0.078	VRC13 contact; buried surface area 6.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	421	gp120, beta20/beta21	K	0.332	0.374	0.203	VRC13 contact; buried surface area 56.5 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	423	gp120, beta20/beta21	I	0.433	0.383	0.411	VRC13 contact; buried surface area 26.2 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	VRC13 contact; buried surface area 43 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	VRC13 contact; buried surface area 2.1 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	VRC13 contact; buried surface area 4.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	VRC13 contact; buried surface area 7.3 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	VRC13 contact; buried surface area 20.2 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	470	gp120, beta24	P	0.043	0.039	0.037	VRC13 contact; buried surface area 5.7 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	471	gp120, beta24	G	0.933	0.888	0.866	VRC13 contact; buried surface area 3.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	472	gp120	G	0.035	0.012	0.043	VRC13 contact; buried surface area 6.6 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	473	gp120	G	0.042	0.033	0.029	VRC13 contact; buried surface area 31.5 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	474	gp120	D	0.696	0.681	0.752	VRC13 contact; buried surface area 23.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	476	gp120	R	0.663	0.615	0.711	VRC13 contact; buried surface area 1.9 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	477	gp120	D	0.191	0.112	0.249	VRC13 contact; buried surface area 8.6 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
446	VRC13 contacts	Stanfield2020	contacts	VRC13(CD4BS)	X-ray crystallography	480	gp120	R	0.061	0.047	0.049	VRC13 contact; buried surface area 11.6 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	124	gp120	P	0.045	0.018	0.029	CD4 contact; buried surface area 32.5 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	125	gp120	L	0.135	0.153	0.058	CD4 contact; buried surface area 8.4 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	126	gp120, Cys 126 linked to Cys 196	C	0.034	0.028	0.008	CD4 contact; buried surface area 41.2 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	127	gp120	V	0.102	0.112	0.093	CD4 contact; buried surface area 0.4 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	128	gp120	S	0.267	0.339	0.088	CD4 contact; buried surface area 20.1 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	192	gp120, V2	K	0.940	0.835	0.851	CD4 contact; buried surface area 23.5 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	194	gp120, V2	T	0.662	0.906	0.161	CD4 contact; buried surface area 34.8 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	196	gp120, Cys 126 linked to Cys 196, V2 loop end	C	0.036	0.034	0.038	CD4 contact; buried surface area 19 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	198	gp120	T	0.430	0.264	0.469	CD4 contact; buried surface area 6.3 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	257	gp120	T	0.029	0.024	0.015	CD4 contact; buried surface area 9 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	278	gp120, Loop D	T	0.708	0.715	0.481	CD4 contact; buried surface area 3.2 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	CD4 contact; buried surface area 34.1 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	CD4 contact; buried surface area 34.1 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	CD4 contact; buried surface area 52.9 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	CD4 contact; buried surface area 23.8 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	283	gp120, Loop D	T	1.005	1.091	0.474	CD4 contact; buried surface area 26.4 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	CD4 contact; buried surface area 45.8 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	CD4 contact; buried surface area 16.2 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	CD4 contact; buried surface area 25.2 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	CD4 contact; buried surface area 42 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	CD4 contact; buried surface area 16.9 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	CD4 contact; buried surface area 39.4 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	375	gp120	S	0.668	0.753	0.372	CD4 contact; buried surface area 1.8 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	425	gp120, beta20/beta21	N	0.295	0.138	0.177	CD4 contact; buried surface area 34.6 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	426	gp120, beta20/beta21	M	0.724	0.866	0.274	CD4 contact; buried surface area 13.7 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	427	gp120, beta20/beta21	W	0.083	0.061	0.038	CD4 contact; buried surface area 29.9 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	CD4 contact; buried surface area 1.6 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	429	gp120, beta20/beta21	K	1.325	0.961	1.308	CD4 contact; buried surface area 20.7 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	430	gp120, beta20/beta21	V	0.267	0.080	0.073	CD4 contact; buried surface area 90.4 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	431	gp120, beta20/beta21	G	0.072	0.036	0.039	CD4 contact; buried surface area 13.3 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	432	gp120, beta20/beta21	K	1.037	0.339	0.564	CD4 contact; buried surface area 5.9 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	CD4 contact; buried surface area 25.4 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	CD4 contact; buried surface area 14.7 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	CD4 contact; buried surface area 26.3 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	CD4 contact; buried surface area 33.1 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	CD4 contact; buried surface area 10.1 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	CD4 contact; buried surface area 9.3 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	CD4 contact; buried surface area 20.6 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	471	gp120, beta24	G	0.933	0.888	0.866	CD4 contact; buried surface area 6.6 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	472	gp120	G	0.035	0.012	0.043	CD4 contact; buried surface area 17.8 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	473	gp120	G	0.042	0.033	0.029	CD4 contact; buried surface area 23.9 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	474	gp120	D	0.696	0.681	0.752	CD4 contact; buried surface area 32.8 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	475	gp120	M	0.097	0.092	0.106	CD4 contact; buried surface area 7 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	476	gp120	R	0.663	0.615	0.711	CD4 contact; buried surface area 16.5 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
447	CD4 contacts	Stanfield2020	Env feature		X-ray crystallography	477	gp120	D	0.191	0.112	0.249	CD4 contact; buried surface area 2 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
448	Mutation affects PGT135 neutralization	Kong2013	neutralization	PGT135(V3)	alanine scanning, neutralization assay	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	N295A increases neutralization resistance in some strains; N295A increases neutralization resistance of JRCSF 26-fold
448	Mutation affects PGT135 neutralization	Kong2013	neutralization	PGT135(V3)	alanine scanning, neutralization assay	330	gp120, V3 loop	H	0.634	0.559	0.655	N330A increases neutralization resistance in all strains tested; H330A in JRCSF confers neutralization resistance >950-fold
448	Mutation affects PGT135 neutralization	Kong2013	neutralization	PGT135(V3)	alanine scanning, neutralization assay	332	gp120	N	0.663	0.491	0.693	N332A confers neutralization resistance in all strains tested; N332A in JRCSF confers neutralization resistance >950-fold
448	Mutation affects PGT135 neutralization	Kong2013	neutralization	PGT135(V3)	alanine scanning, neutralization assay	339	gp120	N	1.149	1.082	1.026	The impact of a N339A mutation is strain specific, and can enhance PGT135 sensitivity
448	Mutation affects PGT135 neutralization	Kong2013	neutralization	PGT135(V3)	alanine scanning, neutralization assay	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	N386A has strain-specific effect on neutralization; N386A increases neutralization resistance of JRCSF 4.1-fold
448	Mutation affects PGT135 neutralization	Kong2013	neutralization	PGT135(V3)	alanine scanning, neutralization assay	392	gp120, V4 loop	N	0.605	0.454	0.804	N392A confers neutralization resistance in all strains tested; N392A in JRCSF confers neutralization resistance >950-fold
448	Mutation affects PGT135 neutralization	Kong2013	neutralization	PGT135(V3)	alanine scanning, neutralization assay	415	gp120, V4 loop	T	0.754	0.760	0.656	T415A increases neutralization resistance of JRCSF 5-fold
448	Mutation affects PGT135 neutralization	Kong2013	neutralization	PGT135(V3)	alanine scanning, neutralization assay	417	gp120, V4 loop	P	0.864	0.736	0.922	P417A increases neutralization resistance of JRCSF 5-fold
448	Mutation affects PGT135 neutralization	Kong2013	neutralization	PGT135(V3)	alanine scanning, neutralization assay	419	gp120	R	0.463	0.341	0.500	R419A increases neutralization resistance of JRCSF 3.9-fold
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	87	gp120	V	1.565	1.611	1.463	E87A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	95	gp120	M	0.267	0.338	0.093	M95A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	125	gp120	L	0.135	0.153	0.058	L125A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	127	gp120	V	0.102	0.112	0.093	V127A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	165	gp120, V2	I	1.327	1.292	1.011	I165A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	166	gp120, V2	R	1.237	1.398	0.772	R166A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	172	gp120, V2	E	1.527	1.172	1.484	E172A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	176	gp120, V2	F	0.189	0.303	0.042	F176A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	180	gp120, V2	D	0.054	0.033	0.029	D180A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	184	gp120, V2	I	1.028	0.599	0.530	I184A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	185	gp120, V2-hypervariable, V2	D	1.697	1.370	1.762	D185A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	T190A increases b3 binding to >200% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	197	gp120	N	0.133	0.082	0.109	N197A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	199	gp120	S	0.094	0.108	0.068	S199A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	207	gp120	K	0.065	0.029	0.029	K207A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	210	gp120	F	0.138	0.056	0.107	F210A increases b3 binding to >200% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	213	gp120	I	0.070	0.048	0.065	I213A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	252	gp120	R	0.725	0.592	0.148	R252A increases b3 binding to >200% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	257	gp120	T	0.029	0.024	0.015	T257A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	276	gp120, Loop D	N	0.118	0.063	0.169	N276A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	279	gp120, Loop D	D	0.900	0.850	0.898	D279A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	350	gp120	R	1.756	1.273	1.912	R350A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	S365A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	E370A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	I371A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	384	gp120	Y	0.107	0.124	0.023	Y384A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	N386A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	395	gp120, V4 loop	W	1.700	0.454	2.171	W395A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	425	gp120, beta20/beta21	N	0.295	0.138	0.177	N425A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	426	gp120, beta20/beta21	M	0.724	0.866	0.274	M426A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	427	gp120, beta20/beta21	W	0.083	0.061	0.038	W427A increases b3 binding to >200% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	439	gp120	I	0.183	0.096	0.174	I439A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	450	gp120	T	0.039	0.018	0.022	T450A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	455	gp120, beta23	T	0.709	0.426	0.972	T455A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	E462A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	S463A increases b3 binding to >200% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	467	gp120, V5 loop, beta24	I	0.912	0.955	0.870	I467A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	470	gp120, beta24	P	0.043	0.039	0.037	P470A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	472	gp120	G	0.035	0.012	0.043	G472A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	473	gp120	G	0.042	0.033	0.029	G473A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	474	gp120	D	0.696	0.681	0.752	D474A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	475	gp120	M	0.097	0.092	0.106	M475A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	476	gp120	R	0.663	0.615	0.711	R476A decreases b3 binding to <50% of WT in strain JRCSF
449	b3 binding alanine scanning	Pantophlet2003	binding	b3(CD4BS)	alanine scanning, binding assay	479	gp120	W	0.029	0.035	0.023	W479A decreases b3 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	87	gp120	V	1.565	1.611	1.463	E87A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	112	gp120	W	0.023	0.018	0.000	W112A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	113	gp120	D	0.138	0.092	0.134	D113A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	121	gp120	K	0.349	0.360	0.187	K121A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	122	gp120	L	0.150	0.101	0.121	L122A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	125	gp120	L	0.135	0.153	0.058	L125A increases b6 binding to >200% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	127	gp120	V	0.102	0.112	0.093	V127A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	165	gp120, V2	I	1.327	1.292	1.011	I165A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	166	gp120, V2	R	1.237	1.398	0.772	R166A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	176	gp120, V2	F	0.189	0.303	0.042	F176A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	180	gp120, V2	D	0.054	0.033	0.029	D180A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	184	gp120, V2	I	1.028	0.599	0.530	I184A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	T190A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	198	gp120	T	0.430	0.264	0.469	T198A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	202	gp120	T	0.506	0.291	0.547	T202A increases b6 binding to >200% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	207	gp120	K	0.065	0.029	0.029	K207A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	210	gp120	F	0.138	0.056	0.107	F210A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	213	gp120	I	0.070	0.048	0.065	I213A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	252	gp120	R	0.725	0.592	0.148	R252A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	256	gp120	S	0.081	0.070	0.078	S256A increases b6 binding to >200% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	257	gp120	T	0.029	0.024	0.015	T257A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	262	gp120	N	0.027	0.029	0.028	N262A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	273	gp120	R	0.279	0.162	0.341	R273A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	276	gp120, Loop D	N	0.118	0.063	0.169	N276A increases b6 binding to >200% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	282	gp120, Loop D	K	0.336	0.337	0.297	K282A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	283	gp120, Loop D	T	1.005	1.091	0.474	T283A increases b6 binding to >200% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	337	gp120	K	2.037	1.862	2.151	Q337A increases b6 binding to >200% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	350	gp120	R	1.756	1.273	1.912	R350A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	S365A increases b6 binding to >200% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	G366A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	G367A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	E370A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	I371A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	373	gp120, CD4 binding loop	T	1.024	0.872	0.371	M373A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	384	gp120	Y	0.107	0.124	0.023	Y384A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	N386A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	388	gp120, V4 loop	T	0.877	0.778	0.701	T388A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	395	gp120, V4 loop	W	1.700	0.454	2.171	W395A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	421	gp120, beta20/beta21	K	0.332	0.374	0.203	K421A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	426	gp120, beta20/beta21	M	0.724	0.866	0.274	M426A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	430	gp120, beta20/beta21	V	0.267	0.080	0.073	V430A increases b6 binding to >200% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	432	gp120, beta20/beta21	K	1.037	0.339	0.564	K432A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	439	gp120	I	0.183	0.096	0.174	I439A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	450	gp120	T	0.039	0.018	0.022	T450A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	455	gp120, beta23	T	0.709	0.426	0.972	T455A increases b6 binding to >200% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	456	gp120, beta23	R	0.233	0.079	0.323	R456A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	457	gp120, beta23	D	0.079	0.054	0.043	D457A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	458	gp120, beta23	G	0.112	0.045	0.095	G458A increases b6 binding to >200% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	N461A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	467	gp120, V5 loop, beta24	I	0.912	0.955	0.870	I467A increases b6 binding to >200% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	R469A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	470	gp120, beta24	P	0.043	0.039	0.037	P470A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	471	gp120, beta24	G	0.933	0.888	0.866	G471A increases b6 binding to >200% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	472	gp120	G	0.035	0.012	0.043	G472A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	474	gp120	D	0.696	0.681	0.752	D474A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	475	gp120	M	0.097	0.092	0.106	M475A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	476	gp120	R	0.663	0.615	0.711	R476A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	477	gp120	D	0.191	0.112	0.249	D477A decreases b6 binding to <50% of WT in strain JRCSF
450	b6 binding alanine scanning	Pantophlet2003	binding	b6(CD4BS)	alanine scanning, binding assay	479	gp120	W	0.029	0.035	0.023	W479A decreases b6 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	87	gp120	V	1.565	1.611	1.463	E87A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	112	gp120	W	0.023	0.018	0.000	W112A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	113	gp120	D	0.138	0.092	0.134	D113A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	121	gp120	K	0.349	0.360	0.187	K121A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	122	gp120	L	0.150	0.101	0.121	L122A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	123	gp120	T	0.047	0.028	0.038	T123A increases b12 binding to >200% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	125	gp120	L	0.135	0.153	0.058	L125A increases b12 binding to >200% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	165	gp120, V2	I	1.327	1.292	1.011	I165A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	176	gp120, V2	F	0.189	0.303	0.042	F176A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	180	gp120, V2	D	0.054	0.033	0.029	D180A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	184	gp120, V2	I	1.028	0.599	0.530	I184A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	185	gp120, V2-hypervariable, V2	D	1.697	1.370	1.762	D185A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	190	gp120, V2-hypervariable, V2	S	1.863	1.204	1.698	T190A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	197	gp120	N	0.133	0.082	0.109	N197A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	198	gp120	T	0.430	0.264	0.469	T198A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	202	gp120	T	0.506	0.291	0.547	T202A increases b12 binding to >200% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	207	gp120	K	0.065	0.029	0.029	K207A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	213	gp120	I	0.070	0.048	0.065	I213A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	252	gp120	R	0.725	0.592	0.148	R252A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	256	gp120	S	0.081	0.070	0.078	S256A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	257	gp120	T	0.029	0.024	0.015	T257A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	262	gp120	N	0.027	0.029	0.028	N262A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	272	gp120	I	0.304	0.341	0.107	V272A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	273	gp120	R	0.279	0.162	0.341	R273A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	276	gp120, Loop D	N	0.118	0.063	0.169	N276A increases b12 binding to >200% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	279	gp120, Loop D	D	0.900	0.850	0.898	D279A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	282	gp120, Loop D	K	0.336	0.337	0.297	K282A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	343	gp120	K	2.058	1.978	1.742	K343A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	350	gp120	R	1.756	1.273	1.912	R350A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	S365A increases b12 binding to >200% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	G366A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	G367A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	370	gp120, CD4 binding loop	E	0.049	0.017	0.055	E370A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	I371A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	373	gp120, CD4 binding loop	T	1.024	0.872	0.371	M373A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	384	gp120	Y	0.107	0.124	0.023	Y384A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	N386A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	388	gp120, V4 loop	T	0.877	0.778	0.701	T388A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	395	gp120, V4 loop	W	1.700	0.454	2.171	W395A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	421	gp120, beta20/beta21	K	0.332	0.374	0.203	K421A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	426	gp120, beta20/beta21	M	0.724	0.866	0.274	M426A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	427	gp120, beta20/beta21	W	0.083	0.061	0.038	W427A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	430	gp120, beta20/beta21	V	0.267	0.080	0.073	V430A increases b12 binding to >200% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	432	gp120, beta20/beta21	K	1.037	0.339	0.564	K432A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	439	gp120	I	0.183	0.096	0.174	I439A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	450	gp120	T	0.039	0.018	0.022	T450A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	455	gp120, beta23	T	0.709	0.426	0.972	T455A increases b12 binding to >200% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	456	gp120, beta23	R	0.233	0.079	0.323	R456A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	457	gp120, beta23	D	0.079	0.054	0.043	D457A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	458	gp120, beta23	G	0.112	0.045	0.095	G458A increases b12 binding to >200% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	N461A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	E462A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	R469A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	470	gp120, beta24	P	0.043	0.039	0.037	P470A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	471	gp120, beta24	G	0.933	0.888	0.866	G471A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	472	gp120	G	0.035	0.012	0.043	G472A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	473	gp120	G	0.042	0.033	0.029	G473A increases b12 binding to >200% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	476	gp120	R	0.663	0.615	0.711	R476A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	477	gp120	D	0.191	0.112	0.249	D477A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	479	gp120	W	0.029	0.035	0.023	W479A decreases b12 binding to <50% of WT in strain JRCSF
451	b12 binding alanine scanning	Pantophlet2003	binding	b12(CD4BS)	alanine scanning, binding assay	480	gp120	R	0.061	0.047	0.049	R480A decreases b12 binding to <50% of WT in strain JRCSF
452	2G12 binding alanine scanning	Pantophlet2003	binding	2G12(glycan)	alanine scanning, binding assay	176	gp120, V2	F	0.189	0.303	0.042	F176A increases 2G12 binding to >200% of WT in strain JRCSF
452	2G12 binding alanine scanning	Pantophlet2003	binding	2G12(glycan)	alanine scanning, binding assay	197	gp120	N	0.133	0.082	0.109	N197A increases 2G12 binding to >200% of WT in strain JRCSF
452	2G12 binding alanine scanning	Pantophlet2003	binding	2G12(glycan)	alanine scanning, binding assay	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	S365A increases 2G12 binding to >200% of WT in strain JRCSF
452	2G12 binding alanine scanning	Pantophlet2003	binding	2G12(glycan)	alanine scanning, binding assay	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	N386A decreases 2G12 binding to <50% of WT in strain JRCSF
452	2G12 binding alanine scanning	Pantophlet2003	binding	2G12(glycan)	alanine scanning, binding assay	395	gp120, V4 loop	W	1.700	0.454	2.171	W395A decreases 2G12 binding to <50% of WT in strain JRCSF
452	2G12 binding alanine scanning	Pantophlet2003	binding	2G12(glycan)	alanine scanning, binding assay	479	gp120	W	0.029	0.035	0.023	W479A decreases 2G12 binding to <50% of WT in strain JRCSF
453	PG16 contacts with clade C strain ZM109	Pancera2013	contacts	PG16(V2)	X-ray crystallography	158	gp120, V2	S	0.263	0.185	0.291	PG16 contact with C clade strain ZM109 S158
453	PG16 contacts with clade C strain ZM109	Pancera2013	contacts	PG16(V2)	X-ray crystallography	160	gp120, V2	N	0.416	0.452	0.358	PG16 contact with C clade strain ZM109 N160
453	PG16 contacts with clade C strain ZM109	Pancera2013	contacts	PG16(V2)	X-ray crystallography	163	gp120, V2	T	0.463	0.638	0.154	PG16 contact with C clade strain ZM109 T163
453	PG16 contacts with clade C strain ZM109	Pancera2013	contacts	PG16(V2)	X-ray crystallography	166	gp120, V2	R	1.237	1.398	0.772	PG16 contact with C clade strain ZM109 L166
453	PG16 contacts with clade C strain ZM109	Pancera2013	contacts	PG16(V2)	X-ray crystallography	167	gp120, V2	G	0.779	1.122	0.185	PG16 contact with C clade strain ZM109 D167
453	PG16 contacts with clade C strain ZM109	Pancera2013	contacts	PG16(V2)	X-ray crystallography	168	gp120, V2	K	0.566	0.666	0.396	PG16 contact with C clade strain ZM109 R168
453	PG16 contacts with clade C strain ZM109	Pancera2013	contacts	PG16(V2)	X-ray crystallography	169	gp120, V2	V	2.042	1.770	1.344	PG16 contact with C clade strain ZM109 L169
453	PG16 contacts with clade C strain ZM109	Pancera2013	contacts	PG16(V2)	X-ray crystallography	170	gp120, V2	Q	1.493	1.423	1.428	PG16 contact with C clade strain ZM109 Q170
453	PG16 contacts with clade C strain ZM109	Pancera2013	contacts	PG16(V2)	X-ray crystallography	171	gp120, V2	K	1.247	0.957	1.413	PG16 contact with C clade strain ZM109 L171
453	PG16 contacts with clade C strain ZM109	Pancera2013	contacts	PG16(V2)	X-ray crystallography	172	gp120, V2	E	1.527	1.172	1.484	PG16 contact with C clade strain ZM109 V172
453	PG16 contacts with clade C strain ZM109	Pancera2013	contacts	PG16(V2)	X-ray crystallography	173	gp120, V2	Y	1.059	0.808	1.158	PG16 contact with C clade strain ZM109 N173
454	O.1  linear epitope	Spencer2021	binding	O.1(V3)	binding assay	304	gp120, V3 loop	R	0.304	0.390	0.141	O.1  linear epitope RKSIHI
454	O.1  linear epitope	Spencer2021	binding	O.1(V3)	binding assay	305	gp120, V3 loop	K	0.906	0.713	0.943	O.1  linear epitope RKSIHI
454	O.1  linear epitope	Spencer2021	binding	O.1(V3)	binding assay	306	gp120, V3 loop	R	0.714	0.860	0.338	O.1  linear epitope RKSIHI
454	O.1  linear epitope	Spencer2021	binding	O.1(V3)	binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	O.1  linear epitope RKSIHI
454	O.1  linear epitope	Spencer2021	binding	O.1(V3)	binding assay	308	gp120, V3 loop	R	1.578	0.091	0.127	O.1  linear epitope RKSIHI
454	O.1  linear epitope	Spencer2021	binding	O.1(V3)	binding assay	309	gp120, V3 loop	I	0.863	0.359	0.965	O.1  linear epitope RKSIHI
455	O.3  linear epitope	Spencer2021	binding	O.3(V3)	binding assay	304	gp120, V3 loop	R	0.304	0.390	0.141	O.3  linear epitope RKSIHI
455	O.3  linear epitope	Spencer2021	binding	O.3(V3)	binding assay	305	gp120, V3 loop	K	0.906	0.713	0.943	O.3  linear epitope RKSIHI
455	O.3  linear epitope	Spencer2021	binding	O.3(V3)	binding assay	306	gp120, V3 loop	R	0.714	0.860	0.338	O.3  linear epitope RKSIHI
455	O.3  linear epitope	Spencer2021	binding	O.3(V3)	binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	O.3  linear epitope RKSIHI
455	O.3  linear epitope	Spencer2021	binding	O.3(V3)	binding assay	308	gp120, V3 loop	R	1.578	0.091	0.127	O.3  linear epitope RKSIHI
455	O.3  linear epitope	Spencer2021	binding	O.3(V3)	binding assay	309	gp120, V3 loop	I	0.863	0.359	0.965	O.3  linear epitope RKSIHI
456	O.4 linear epitope	Spencer2021	binding	O.4(V3)	binding assay	309	gp120, V3 loop	I	0.863	0.359	0.965	O.4 linear epitope IHIGPGR
456	O.4 linear epitope	Spencer2021	binding	O.4(V3)	binding assay	310	gp120, V3 loop	Q	0.067	1.479	0.283	O.4 linear epitope IHIGPGR
456	O.4 linear epitope	Spencer2021	binding	O.4(V3)	binding assay	311	gp120, V3 loop	R	0.104	1.050	0.114	O.4 linear epitope IHIGPGR
456	O.4 linear epitope	Spencer2021	binding	O.4(V3)	binding assay	312	gp120, V3 loop	G	0.237	0.362	0.008	O.4 linear epitope IHIGPGR
456	O.4 linear epitope	Spencer2021	binding	O.4(V3)	binding assay	313	gp120, V3 loop	P	0.344	0.424	0.078	O.4 linear epitope IHIGPGR
456	O.4 linear epitope	Spencer2021	binding	O.4(V3)	binding assay	314	gp120, V3 loop	G	0.057	0.095	0.014	O.4 linear epitope IHIGPGR
456	O.4 linear epitope	Spencer2021	binding	O.4(V3)	binding assay	315	gp120, V3 loop	R	1.211	1.028	0.196	O.4 linear epitope IHIGPGR
457	O.5 linear epitope	Spencer2021	binding	O.5(V3)	binding assay	304	gp120, V3 loop	R	0.304	0.390	0.141	O.5  linear epitope RKSIHI
457	O.5 linear epitope	Spencer2021	binding	O.5(V3)	binding assay	305	gp120, V3 loop	K	0.906	0.713	0.943	O.5  linear epitope RKSIHI
457	O.5 linear epitope	Spencer2021	binding	O.5(V3)	binding assay	306	gp120, V3 loop	R	0.714	0.860	0.338	O.5  linear epitope RKSIHI
457	O.5 linear epitope	Spencer2021	binding	O.5(V3)	binding assay	307	gp120, V3 loop	I	0.802	0.030	0.111	O.5  linear epitope RKSIHI
457	O.5 linear epitope	Spencer2021	binding	O.5(V3)	binding assay	308	gp120, V3 loop	R	1.578	0.091	0.127	O.5  linear epitope RKSIHI
457	O.5 linear epitope	Spencer2021	binding	O.5(V3)	binding assay	309	gp120, V3 loop	I	0.863	0.359	0.965	O.5  linear epitope RKSIHI
458	Mutations associated with resistance or susceptibility to 17b	Wang2019	neutralization	17b(CD4i)	neutralization assay	77	gp120	T	0.103	0.088	0.020	Mutation A77T in SHIV-CNE40 decreased neutralization by 17b
458	Mutations associated with resistance or susceptibility to 17b	Wang2019	neutralization	17b(CD4i)	neutralization assay	658	gp41	Q	1.038	0.813	0.600	Mutation of E658 to K, Q, or L in SHIV-CNE40 abrogated neutralization by 17b; mutation of K658 to E in other viruses was associated with increased neutralization by 17b
459	Mutation in SHIV-CNE40 associated with resistance to PGT121	Wang2019	neutralization	PGT121(V3)	neutralization assay	658	gp41	Q	1.038	0.813	0.600	E658K in SHIV-CNE40 decreased neutralization by PGT121
460	Mutation in SHIV-CNE40 associated with resistance to 35O22	Wang2019	neutralization	35O22(gp120/gp41 interface)	neutralization assay	624	gp41	N	1.580	1.592	1.486	N624D in SHIV-CNE40 decreased neutralization by 35O22
461	Mutation in SHIV-CNE40 associated with resistance to 10E8	Wang2019	neutralization	10E8(MPER)	neutralization assay	658	gp41	Q	1.038	0.813	0.600	E658K in SHIV-CNE40 decreased neutralization by 10E8
462	Mutation in SHIV-CNE40 associated with resistance to 3BNC117	Wang2019	neutralization	3BNC117(CD4BS)	neutralization assay	276	gp120, Loop D	N	0.118	0.063	0.169	N276D in SHIV-CNE40 abrograted neutralization by 3BNC117
463	2C06 contacts with BG505	Wang2023	contacts	2C06(gp41 fusion domain)	molecular modeling, X-ray crystallography	85	gp120	V	1.980	1.797	1.418	contact with BG505; buried surface area >20A
463	2C06 contacts with BG505	Wang2023	contacts	2C06(gp41 fusion domain)	molecular modeling, X-ray crystallography	87	gp120	V	1.565	1.611	1.463	contact with BG505; buried surface area >20A
463	2C06 contacts with BG505	Wang2023	contacts	2C06(gp41 fusion domain)	molecular modeling, X-ray crystallography	241	gp120	N	0.191	0.183	0.134	contact with BG505; buried surface area >20A
463	2C06 contacts with BG505	Wang2023	contacts	2C06(gp41 fusion domain)	molecular modeling, X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	contact with BG505; buried surface area >20A
463	2C06 contacts with BG505	Wang2023	contacts	2C06(gp41 fusion domain)	molecular modeling, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	contact with BG505; buried surface area >20A
463	2C06 contacts with BG505	Wang2023	contacts	2C06(gp41 fusion domain)	molecular modeling, X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	contact with BG505; buried surface area >20A
463	2C06 contacts with BG505	Wang2023	contacts	2C06(gp41 fusion domain)	molecular modeling, X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	contact with BG505; buried surface area >20A
463	2C06 contacts with BG505	Wang2023	contacts	2C06(gp41 fusion domain)	molecular modeling, X-ray crystallography	518	gp41, fusion peptide	L	1.166	1.110	0.718	contact with BG505; buried surface area >20A
463	2C06 contacts with BG505	Wang2023	contacts	2C06(gp41 fusion domain)	molecular modeling, X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	contact with BG505; buried surface area >20A
463	2C06 contacts with BG505	Wang2023	contacts	2C06(gp41 fusion domain)	molecular modeling, X-ray crystallography	520	gp41, fusion peptide	L	0.393	0.253	0.390	contact with BG505; buried surface area >20A
463	2C06 contacts with BG505	Wang2023	contacts	2C06(gp41 fusion domain)	molecular modeling, X-ray crystallography	648	gp41	E	1.506	1.332	1.379	contact with BG505; buried surface area >20A
463	2C06 contacts with BG505	Wang2023	contacts	2C06(gp41 fusion domain)	molecular modeling, X-ray crystallography	651	gp41	N	1.164	0.818	1.387	contact with BG505; buried surface area >20A
464	2C09 contacts with BG505	Wang2023	contacts	2C09(gp41 fusion domain)	molecular modeling, X-ray crystallography	85	gp120	V	1.980	1.797	1.418	contact with BG505; buried surface area >20A
464	2C09 contacts with BG505	Wang2023	contacts	2C09(gp41 fusion domain)	molecular modeling, X-ray crystallography	87	gp120	V	1.565	1.611	1.463	contact with BG505; buried surface area >20A
464	2C09 contacts with BG505	Wang2023	contacts	2C09(gp41 fusion domain)	molecular modeling, X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	contact with BG505; buried surface area >20A
464	2C09 contacts with BG505	Wang2023	contacts	2C09(gp41 fusion domain)	molecular modeling, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	contact with BG505; buried surface area >20A
464	2C09 contacts with BG505	Wang2023	contacts	2C09(gp41 fusion domain)	molecular modeling, X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	contact with BG505; buried surface area >20A
464	2C09 contacts with BG505	Wang2023	contacts	2C09(gp41 fusion domain)	molecular modeling, X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	contact with BG505; buried surface area >20A
464	2C09 contacts with BG505	Wang2023	contacts	2C09(gp41 fusion domain)	molecular modeling, X-ray crystallography	518	gp41, fusion peptide	L	1.166	1.110	0.718	contact with BG505; buried surface area >20A
464	2C09 contacts with BG505	Wang2023	contacts	2C09(gp41 fusion domain)	molecular modeling, X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	contact with BG505; buried surface area >20A
464	2C09 contacts with BG505	Wang2023	contacts	2C09(gp41 fusion domain)	molecular modeling, X-ray crystallography	520	gp41, fusion peptide	L	0.393	0.253	0.390	contact with BG505; buried surface area >20A
465	A12V163-a.01 contacts with BG505	Wang2023	contacts	A12V163-a.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	85	gp120	V	1.980	1.797	1.418	contact with BG505; buried surface area >20A
465	A12V163-a.01 contacts with BG505	Wang2023	contacts	A12V163-a.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	87	gp120	V	1.565	1.611	1.463	contact with BG505; buried surface area >20A
465	A12V163-a.01 contacts with BG505	Wang2023	contacts	A12V163-a.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	contact with BG505; buried surface area >20A
465	A12V163-a.01 contacts with BG505	Wang2023	contacts	A12V163-a.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	contact with BG505; buried surface area >20A
465	A12V163-a.01 contacts with BG505	Wang2023	contacts	A12V163-a.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	514	gp41, fusion peptide	G	0.600	0.691	0.502	contact with BG505; buried surface area >20A
465	A12V163-a.01 contacts with BG505	Wang2023	contacts	A12V163-a.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	contact with BG505; buried surface area >20A
465	A12V163-a.01 contacts with BG505	Wang2023	contacts	A12V163-a.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	contact with BG505; buried surface area >20A
465	A12V163-a.01 contacts with BG505	Wang2023	contacts	A12V163-a.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	contact with BG505; buried surface area >20A
465	A12V163-a.01 contacts with BG505	Wang2023	contacts	A12V163-a.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	518	gp41, fusion peptide	L	1.166	1.110	0.718	contact with BG505; buried surface area >20A
465	A12V163-a.01 contacts with BG505	Wang2023	contacts	A12V163-a.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	contact with BG505; buried surface area >20A
465	A12V163-a.01 contacts with BG505	Wang2023	contacts	A12V163-a.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	520	gp41, fusion peptide	L	0.393	0.253	0.390	contact with BG505; buried surface area >20A
466	A12V163-b.01 contacts with BG505	Wang2023	contacts	A12V163-b.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	85	gp120	V	1.980	1.797	1.418	contact with BG505; buried surface area >20A
466	A12V163-b.01 contacts with BG505	Wang2023	contacts	A12V163-b.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	87	gp120	V	1.565	1.611	1.463	contact with BG505; buried surface area >20A
466	A12V163-b.01 contacts with BG505	Wang2023	contacts	A12V163-b.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	contact with BG505; buried surface area >20A
466	A12V163-b.01 contacts with BG505	Wang2023	contacts	A12V163-b.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	contact with BG505; buried surface area >20A
466	A12V163-b.01 contacts with BG505	Wang2023	contacts	A12V163-b.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	514	gp41, fusion peptide	G	0.600	0.691	0.502	contact with BG505; buried surface area >20A
466	A12V163-b.01 contacts with BG505	Wang2023	contacts	A12V163-b.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	contact with BG505; buried surface area >20A
466	A12V163-b.01 contacts with BG505	Wang2023	contacts	A12V163-b.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	contact with BG505; buried surface area >20A
466	A12V163-b.01 contacts with BG505	Wang2023	contacts	A12V163-b.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	contact with BG505; buried surface area >20A
466	A12V163-b.01 contacts with BG505	Wang2023	contacts	A12V163-b.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	518	gp41, fusion peptide	L	1.166	1.110	0.718	contact with BG505; buried surface area >20A
466	A12V163-b.01 contacts with BG505	Wang2023	contacts	A12V163-b.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	contact with BG505; buried surface area >20A
466	A12V163-b.01 contacts with BG505	Wang2023	contacts	A12V163-b.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	640	gp41	S	2.033	1.971	1.834	contact with BG505; buried surface area >20A
467	VRC34.01 contacts with BG505	Wang2023	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	85	gp120	V	1.980	1.797	1.418	contact with BG505; buried surface area >20A
467	VRC34.01 contacts with BG505	Wang2023	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	241	gp120	N	0.191	0.183	0.134	contact with BG505; buried surface area >20A
467	VRC34.01 contacts with BG505	Wang2023	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	contact with BG505; buried surface area >20A
467	VRC34.01 contacts with BG505	Wang2023	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	contact with BG505; buried surface area >20A
467	VRC34.01 contacts with BG505	Wang2023	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	514	gp41, fusion peptide	G	0.600	0.691	0.502	contact with BG505; buried surface area >20A
467	VRC34.01 contacts with BG505	Wang2023	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	contact with BG505; buried surface area >20A
467	VRC34.01 contacts with BG505	Wang2023	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	contact with BG505; buried surface area >20A
467	VRC34.01 contacts with BG505	Wang2023	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	contact with BG505; buried surface area >20A
467	VRC34.01 contacts with BG505	Wang2023	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	518	gp41, fusion peptide	L	1.166	1.110	0.718	contact with BG505; buried surface area >20A
467	VRC34.01 contacts with BG505	Wang2023	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	contact with BG505; buried surface area >20A
467	VRC34.01 contacts with BG505	Wang2023	contacts	VRC34.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	520	gp41, fusion peptide	L	0.393	0.253	0.390	contact with BG505; buried surface area >20A
468	vFP16.02 contacts with BG505	Wang2023	contacts	vFP16.02(gp41 fusion domain)	molecular modeling, X-ray crystallography	85	gp120	V	1.980	1.797	1.418	contact with BG505; buried surface area >20A
468	vFP16.02 contacts with BG505	Wang2023	contacts	vFP16.02(gp41 fusion domain)	molecular modeling, X-ray crystallography	87	gp120	V	1.565	1.611	1.463	contact with BG505; buried surface area >20A
468	vFP16.02 contacts with BG505	Wang2023	contacts	vFP16.02(gp41 fusion domain)	molecular modeling, X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	contact with BG505; buried surface area >20A
468	vFP16.02 contacts with BG505	Wang2023	contacts	vFP16.02(gp41 fusion domain)	molecular modeling, X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	contact with BG505; buried surface area >20A
468	vFP16.02 contacts with BG505	Wang2023	contacts	vFP16.02(gp41 fusion domain)	molecular modeling, X-ray crystallography	514	gp41, fusion peptide	G	0.600	0.691	0.502	contact with BG505; buried surface area >20A
468	vFP16.02 contacts with BG505	Wang2023	contacts	vFP16.02(gp41 fusion domain)	molecular modeling, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	contact with BG505; buried surface area >20A
468	vFP16.02 contacts with BG505	Wang2023	contacts	vFP16.02(gp41 fusion domain)	molecular modeling, X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	contact with BG505; buried surface area >20A
468	vFP16.02 contacts with BG505	Wang2023	contacts	vFP16.02(gp41 fusion domain)	molecular modeling, X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	contact with BG505; buried surface area >20A
468	vFP16.02 contacts with BG505	Wang2023	contacts	vFP16.02(gp41 fusion domain)	molecular modeling, X-ray crystallography	518	gp41, fusion peptide	L	1.166	1.110	0.718	contact with BG505; buried surface area >20A
468	vFP16.02 contacts with BG505	Wang2023	contacts	vFP16.02(gp41 fusion domain)	molecular modeling, X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	contact with BG505; buried surface area >20A
469	0PV-c.01 contacts with BG505	Wang2023	contacts	0PV-c.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	85	gp120	V	1.980	1.797	1.418	contact with BG505; buried surface area >20A
469	0PV-c.01 contacts with BG505	Wang2023	contacts	0PV-c.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	87	gp120	V	1.565	1.611	1.463	contact with BG505; buried surface area >20A
469	0PV-c.01 contacts with BG505	Wang2023	contacts	0PV-c.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	contact with BG505; buried surface area >20A
469	0PV-c.01 contacts with BG505	Wang2023	contacts	0PV-c.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	contact with BG505; buried surface area >20A
469	0PV-c.01 contacts with BG505	Wang2023	contacts	0PV-c.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	514	gp41, fusion peptide	G	0.600	0.691	0.502	contact with BG505; buried surface area >20A
469	0PV-c.01 contacts with BG505	Wang2023	contacts	0PV-c.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	contact with BG505; buried surface area >20A
469	0PV-c.01 contacts with BG505	Wang2023	contacts	0PV-c.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	contact with BG505; buried surface area >20A
469	0PV-c.01 contacts with BG505	Wang2023	contacts	0PV-c.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	contact with BG505; buried surface area >20A
469	0PV-c.01 contacts with BG505	Wang2023	contacts	0PV-c.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	518	gp41, fusion peptide	L	1.166	1.110	0.718	contact with BG505; buried surface area >20A
469	0PV-c.01 contacts with BG505	Wang2023	contacts	0PV-c.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	contact with BG505; buried surface area >20A
469	0PV-c.01 contacts with BG505	Wang2023	contacts	0PV-c.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	520	gp41, fusion peptide	L	0.393	0.253	0.390	contact with BG505; buried surface area >20A
469	0PV-c.01 contacts with BG505	Wang2023	contacts	0PV-c.01(gp41 fusion domain)	molecular modeling, X-ray crystallography	535	gp41	M	1.280	1.414	0.742	contact with BG505; buried surface area >20A
470	mutation affects binding to BG505-SOSIP	Wang2023	binding	2C06(gp41 fusion domain)	bio-layer interferometry	85	gp120	V	1.980	1.797	1.418	BG505 DS-SOSIP-H85V or H85E reduces binding to half or less of binding to BG505 DS-SOSIP
470	mutation affects binding to BG505-SOSIP	Wang2023	binding	2C06(gp41 fusion domain)	bio-layer interferometry	241	gp120	N	0.191	0.183	0.134	BG505 DS-SOSIP-S241N reduces binding to half or less of binding to BG505 DS-SOSIP
470	mutation affects binding to BG505-SOSIP	Wang2023	binding	2C06(gp41 fusion domain)	bio-layer interferometry	644	gp41	S	2.005	1.538	1.732	BG505 DS-SOSIP-G644R or G644T reduces binding to half or less of binding to BG505 DS-SOSIP
471	mutation affects binding to BG505-SOSIP	Wang2023	binding	2C09(gp41 fusion domain)	bio-layer interferometry	85	gp120	V	1.980	1.797	1.418	BG505 DS-SOSIP-H85V or H85E reduces binding to half or less of binding to BG505 DS-SOSIP
471	mutation affects binding to BG505-SOSIP	Wang2023	binding	2C09(gp41 fusion domain)	bio-layer interferometry	241	gp120	N	0.191	0.183	0.134	BG505 DS-SOSIP-S241N reduces binding to half or less of binding to BG505 DS-SOSIP
471	mutation affects binding to BG505-SOSIP	Wang2023	binding	2C09(gp41 fusion domain)	bio-layer interferometry	644	gp41	S	2.005	1.538	1.732	BG505 DS-SOSIP-G644R or G644T reduces binding to half or less of binding to BG505 DS-SOSIP
472	PCT64-LMCA contacts with germline-targeted BG505-based ApexGT2.2MUT Env trimer	Willis2022	contacts	PCT64-LMCA(V2)	cryo-EM	160	gp120, V2	N	0.416	0.452	0.358	N160 glycan forms hydrogen bonds
472	PCT64-LMCA contacts with germline-targeted BG505-based ApexGT2.2MUT Env trimer	Willis2022	contacts	PCT64-LMCA(V2)	cryo-EM	166	gp120, V2	R	1.237	1.398	0.772	R166 likely forms cation-pi interactions
472	PCT64-LMCA contacts with germline-targeted BG505-based ApexGT2.2MUT Env trimer	Willis2022	contacts	PCT64-LMCA(V2)	cryo-EM	167	gp120, V2	G	0.779	1.122	0.185	N167 forms hydrogen bonds
472	PCT64-LMCA contacts with germline-targeted BG505-based ApexGT2.2MUT Env trimer	Willis2022	contacts	PCT64-LMCA(V2)	cryo-EM	169	gp120, V2	V	2.042	1.770	1.344	R169 forms hydrogen bonds
473	PCT64-35S contacts with germline-targeted BG505-based ApexGT2 Env trimer	Willis2022	contacts	PCT64-35S(V2)	cryo-EM	123	gp120	T	0.047	0.028	0.038	T123 forms hydrogen bond
473	PCT64-35S contacts with germline-targeted BG505-based ApexGT2 Env trimer	Willis2022	contacts	PCT64-35S(V2)	cryo-EM	156	gp120, V1	N	0.246	0.220	0.224	N156 glycan forms hydrogen bonds
473	PCT64-35S contacts with germline-targeted BG505-based ApexGT2 Env trimer	Willis2022	contacts	PCT64-35S(V2)	cryo-EM	160	gp120, V2	N	0.416	0.452	0.358	N160 glycan forms hydrogen bonds
473	PCT64-35S contacts with germline-targeted BG505-based ApexGT2 Env trimer	Willis2022	contacts	PCT64-35S(V2)	cryo-EM	166	gp120, V2	R	1.237	1.398	0.772	R166 forms cation-pi interactions and h-bonds
474	PG9-iGL contacts with germline-targeted BG505-based ApexGT3 Env trimer	Willis2022	contacts	PG9-iGL(V2)	cryo-EM	156	gp120, V1	N	0.246	0.220	0.224	N156 glycan forms hydrogen bond
474	PG9-iGL contacts with germline-targeted BG505-based ApexGT3 Env trimer	Willis2022	contacts	PG9-iGL(V2)	cryo-EM	160	gp120, V2	N	0.416	0.452	0.358	N160 glycan forms hydrogen bonds
474	PG9-iGL contacts with germline-targeted BG505-based ApexGT3 Env trimer	Willis2022	contacts	PG9-iGL(V2)	cryo-EM	168	gp120, V2	K	0.566	0.666	0.396	K168 is a structural contact
474	PG9-iGL contacts with germline-targeted BG505-based ApexGT3 Env trimer	Willis2022	contacts	PG9-iGL(V2)	cryo-EM	169	gp120, V2	V	2.042	1.770	1.344	R169 forms H-bonds and likely cation-pi interactions
474	PG9-iGL contacts with germline-targeted BG505-based ApexGT3 Env trimer	Willis2022	contacts	PG9-iGL(V2)	cryo-EM	171	gp120, V2	K	1.247	0.957	1.413	K171 forms hydrogen bond
475	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	Willis2022	contacts	PG9(V2)	cryo-EM	156	gp120, V1	N	0.246	0.220	0.224	N156 glycan forms hydrogen bonds
475	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	Willis2022	contacts	PG9(V2)	cryo-EM	160	gp120, V2	N	0.416	0.452	0.358	N160 glycan forms hydrogen bonds
475	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	Willis2022	contacts	PG9(V2)	cryo-EM	167	gp120, V2	G	0.779	1.122	0.185	N167 forms hydrogen bond, N167 glycan interactions
475	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	Willis2022	contacts	PG9(V2)	cryo-EM	168	gp120, V2	K	0.566	0.666	0.396	K168 is a structural contact
475	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	Willis2022	contacts	PG9(V2)	cryo-EM	169	gp120, V2	V	2.042	1.770	1.344	R169 forms H-bonds and likely cation-pi interactions
475	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	Willis2022	contacts	PG9(V2)	cryo-EM	171	gp120, V2	K	1.247	0.957	1.413	K171 forms hydrogen bond
475	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	Willis2022	contacts	PG9(V2)	cryo-EM	172	gp120, V2	E	1.527	1.172	1.484	R172 is a structural contact
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	156	gp120, V1	N	0.246	0.220	0.224	LC glycan contact with CDRL3
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	160	gp120, V2	N	0.416	0.452	0.358	HC glycan contact with CDRH3
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	163	gp120, V2	T	0.463	0.638	0.154	side chain contact
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	164	gp120, V2	S	1.840	1.925	0.453	side chain and main chain contact; H bond and salt bridge with LC
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	165	gp120, V2	I	1.327	1.292	1.011	side chain contact
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	166	gp120, V2	R	1.237	1.398	0.772	side chain and main chain contact; H bond with HC
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	167	gp120, V2	G	0.779	1.122	0.185	side chain and main chain contact; H bond with HC and LC
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	168	gp120, V2	K	0.566	0.666	0.396	side chain contact; H bond with HC and LC
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	169	gp120, V2	V	2.042	1.770	1.344	side chain and main chain contactH bond with HC
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	170	gp120, V2	Q	1.493	1.423	1.428	side chain and main chain contact
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	171	gp120, V2	K	1.247	0.957	1.413	side chain and main chain contact; H bond with HC
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	173	gp120, V2	Y	1.059	0.808	1.158	side chain contact; H bond with HC
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	185	gp120, V2-hypervariable, V2	D	1.697	1.370	1.762	side chain and main chain contact
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	186	gp120, V2-hypervariable, V2	N	1.854	1.592	1.819	side chain and main chain contact; H bond with LC
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	187	gp120, V2-hypervariable, V2	D	1.785	1.813	1.638	side chain and main chain contact
476	J038 contacts with clade C strain C1080	Gao2022	contacts	J038(V2)	cryo-EM	188	gp120, V2-hypervariable, V2	T	1.866	1.618	1.850	side chain contact
477	Mutation affects neutralization of CAP45	Gao2022	neutralization	J029(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
477	Mutation affects neutralization of CAP45	Gao2022	neutralization	J029(V2)	neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	T162A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
477	Mutation affects neutralization of CAP45	Gao2022	neutralization	J029(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
477	Mutation affects neutralization of CAP45	Gao2022	neutralization	J029(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N makes CAP45 more sensitive to neutralization by J029, J031, J033, J038, and J040
477	Mutation affects neutralization of CAP45	Gao2022	neutralization	J029(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
478	Mutation affects neutralization of CAP45	Gao2022	neutralization	J031(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
478	Mutation affects neutralization of CAP45	Gao2022	neutralization	J031(V2)	neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	T162A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
478	Mutation affects neutralization of CAP45	Gao2022	neutralization	J031(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
478	Mutation affects neutralization of CAP45	Gao2022	neutralization	J031(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N makes CAP45 more sensitive to neutralization by J029, J031, J033, J038, and J040
478	Mutation affects neutralization of CAP45	Gao2022	neutralization	J031(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
479	Mutation affects neutralization of CAP45	Gao2022	neutralization	J033(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
479	Mutation affects neutralization of CAP45	Gao2022	neutralization	J033(V2)	neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	T162A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
479	Mutation affects neutralization of CAP45	Gao2022	neutralization	J033(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
479	Mutation affects neutralization of CAP45	Gao2022	neutralization	J033(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N makes CAP45 more sensitive to neutralization by J029, J031, J033, J038, and J040
479	Mutation affects neutralization of CAP45	Gao2022	neutralization	J033(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
480	Mutation affects neutralization of CAP45	Gao2022	neutralization	J038(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
480	Mutation affects neutralization of CAP45	Gao2022	neutralization	J038(V2)	neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	T162A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
480	Mutation affects neutralization of CAP45	Gao2022	neutralization	J038(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
480	Mutation affects neutralization of CAP45	Gao2022	neutralization	J038(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N makes CAP45 more sensitive to neutralization by J029, J031, J033, J038, and J040
480	Mutation affects neutralization of CAP45	Gao2022	neutralization	J038(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
481	Mutation affects neutralization of CAP45	Gao2022	neutralization	J040(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
481	Mutation affects neutralization of CAP45	Gao2022	neutralization	J040(V2)	neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	T162A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
481	Mutation affects neutralization of CAP45	Gao2022	neutralization	J040(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
481	Mutation affects neutralization of CAP45	Gao2022	neutralization	J040(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N makes CAP45 more sensitive to neutralization by J029, J031, J033, J038, and J040
481	Mutation affects neutralization of CAP45	Gao2022	neutralization	J040(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
482	N279K and G458Y act synergistically to allow neutralization by CH235 UCA and intermediates	LaBranche2019	neutralization	CH235 IA1(CD4BS), CH235 IA3(CD4BS), CH235 IA4(CD4BS), CH235 UCA2(CD4BS)	neutralization assay	279	gp120, Loop D	D	0.900	0.850	0.898	N279K and G458Y act synergistically to render autologous CH505 transmitted/founder virus susceptible to neutralization by CH235 UCA and intermediates
482	N279K and G458Y act synergistically to allow neutralization by CH235 UCA and intermediates	LaBranche2019	neutralization	CH235 IA1(CD4BS), CH235 IA3(CD4BS), CH235 IA4(CD4BS), CH235 UCA2(CD4BS)	neutralization assay	458	gp120, beta23	G	0.112	0.045	0.095	N279K and G458Y act synergistically to render autologous CH505 transmitted/founder virus susceptible to neutralization by CH235 UCA and intermediates
483	EPTC112 contacts	Molinos-Albert2023	contacts	EPTC112(V3)	cryo-EM	103	gp120	Q	0.021	0.018	0.008	contact between EPTC112 HC and BG505 SOSIP.664
483	EPTC112 contacts	Molinos-Albert2023	contacts	EPTC112(V3)	cryo-EM	156	gp120, V1	N	0.246	0.220	0.224	contact between EPTC112 HC and BG505 SOSIP.664
483	EPTC112 contacts	Molinos-Albert2023	contacts	EPTC112(V3)	cryo-EM	301	gp120, V3 loop	N	0.172	0.176	0.104	contact between EPTC112 HC and BG505 SOSIP.664
483	EPTC112 contacts	Molinos-Albert2023	contacts	EPTC112(V3)	cryo-EM	321	gp120, V3 loop	G	1.042	0.842	1.108	contact between EPTC112 HC and BG505 SOSIP.664
483	EPTC112 contacts	Molinos-Albert2023	contacts	EPTC112(V3)	cryo-EM	323	gp120, V3 loop	I	0.476	0.531	0.263	contact between EPTC112 HC and BG505 SOSIP.664
483	EPTC112 contacts	Molinos-Albert2023	contacts	EPTC112(V3)	cryo-EM	325	gp120, V3 loop	N	0.648	0.622	0.622	contact between EPTC112 HC and BG505 SOSIP.664
484	EPTC112 binding	Molinos-Albert2023	binding	EPTC112(V3)	binding assay	262	gp120	N	0.027	0.029	0.028	N262A reduced binding
484	EPTC112 binding	Molinos-Albert2023	binding	EPTC112(V3)	binding assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A reduced binding
485	10-1074 binding	Molinos-Albert2023	binding	10-1074(V3)	binding assay	332	gp120	N	0.663	0.491	0.693	N332A reduced binding
486	PGT135 binding	Molinos-Albert2023	binding	PGT135(V3)	binding assay	332	gp120	N	0.663	0.491	0.693	N332A reduced binding
487	3BNC117 binding	Molinos-Albert2023	binding	3BNC117(CD4BS)	binding assay	262	gp120	N	0.027	0.029	0.028	N262A reduced binding
488	8ANC195 binding	Molinos-Albert2023	binding	8ANC195(gp120/gp41 interface)	binding assay	262	gp120	N	0.027	0.029	0.028	N262A reduced binding
489	SF12 binding	Molinos-Albert2023	binding	SF12(silent face)	binding assay	262	gp120	N	0.027	0.029	0.028	N262A reduced binding
490	2C6 binding sites	Sojar2019	binding	2C6(CD4i)	alanine scanning, binding assay	524	gp41, fusion peptide	G	0.152	0.129	0.125	G524A reduced binding
490	2C6 binding sites	Sojar2019	binding	2C6(CD4i)	alanine scanning, binding assay	579	gp41, Leu/Ile zipper-like sequence	R	0.022	0.030	0.028	R579A reduced binding; R579A/L592A double mutant abrogated binding
490	2C6 binding sites	Sojar2019	binding	2C6(CD4i)	alanine scanning, binding assay	588	gp41, Leu/Ile zipper-like sequence	K	1.146	1.197	0.871	R588A reduced binding; K588G or K588G abrogated 2C6 peptide recognition in multiple HIV strains
490	2C6 binding sites	Sojar2019	binding	2C6(CD4i)	alanine scanning, binding assay	592	gp41	L	0.109	0.093	0.126	L592A abrogated binding; R579A/L592A double mutant abrogated binding
490	2C6 binding sites	Sojar2019	binding	2C6(CD4i)	alanine scanning, binding assay	595	gp41, gp41 fusion domain (595,602,603,617)	I	0.667	0.310	0.971	I595A abrogated binding
490	2C6 binding sites	Sojar2019	binding	2C6(CD4i)	alanine scanning, binding assay	596	gp41	W	0.014	0.028	0.000	W596A abrogated binding
491	Mutation disrupts binding to 7B6	Hicar2016a	binding	7B6(other)	alanine scanning, binding assay	596	gp41	W	0.014	0.028	0.000	W596A  disrupts binding to M consensus
491	Mutation disrupts binding to 7B6	Hicar2016a	binding	7B6(other)	alanine scanning, binding assay	598	gp41	C	0.014	0.017	0.008	C598A  disrupts binding to M consensus
491	Mutation disrupts binding to 7B6	Hicar2016a	binding	7B6(other)	alanine scanning, binding assay	600	gp41	G	0.046	0.046	0.062	G600A  disrupts binding to M consensus
491	Mutation disrupts binding to 7B6	Hicar2016a	binding	7B6(other)	alanine scanning, binding assay	604	gp41	C	0.012	0.024	0.000	C604A  disrupts binding to M consensus
492	Mutation disrupts binding to 6F5	Hicar2016a	binding	6F5(other)	alanine scanning, binding assay	557	gp41, Leu/Ile zipper-like sequence	R	0.515	0.582	0.393	R557A  disrupts binding to M consensus
492	Mutation disrupts binding to 6F5	Hicar2016a	binding	6F5(other)	alanine scanning, binding assay	654	gp41	E	0.167	0.174	0.105	E654A  disrupts binding to M consensus
492	Mutation disrupts binding to 6F5	Hicar2016a	binding	6F5(other)	alanine scanning, binding assay	657	gp41	E	0.034	0.040	0.023	E657A  disrupts binding to M consensus
493	Mutation disrupts binding to 5C2	Hicar2016a	binding	5C2(other)	alanine scanning, binding assay	596	gp41	W	0.014	0.028	0.000	W596A  disrupts binding to M consensus
493	Mutation disrupts binding to 5C2	Hicar2016a	binding	5C2(other)	alanine scanning, binding assay	598	gp41	C	0.014	0.017	0.008	C598A  disrupts binding to M consensus
493	Mutation disrupts binding to 5C2	Hicar2016a	binding	5C2(other)	alanine scanning, binding assay	600	gp41	G	0.046	0.046	0.062	G600A  disrupts binding to M consensus
493	Mutation disrupts binding to 5C2	Hicar2016a	binding	5C2(other)	alanine scanning, binding assay	602	gp41, gp41 fusion domain (595,602,603,617)	L	0.447	0.268	0.467	L602A  disrupts binding to M consensus
493	Mutation disrupts binding to 5C2	Hicar2016a	binding	5C2(other)	alanine scanning, binding assay	604	gp41	C	0.012	0.024	0.000	C604A  disrupts binding to M consensus
494	Mutation disrupts binding to 5F4	Hicar2016a	binding	5F4(other)	alanine scanning, binding assay	596	gp41	W	0.014	0.028	0.000	W596A  disrupts binding to M consensus
494	Mutation disrupts binding to 5F4	Hicar2016a	binding	5F4(other)	alanine scanning, binding assay	598	gp41	C	0.014	0.017	0.008	C598A  disrupts binding to M consensus
494	Mutation disrupts binding to 5F4	Hicar2016a	binding	5F4(other)	alanine scanning, binding assay	600	gp41	G	0.046	0.046	0.062	G600A  disrupts binding to M consensus
494	Mutation disrupts binding to 5F4	Hicar2016a	binding	5F4(other)	alanine scanning, binding assay	604	gp41	C	0.012	0.024	0.000	C604A  disrupts binding to M consensus
495	Mutation disrupts binding to 8F6	Hicar2016a	binding	8F6(other)	alanine scanning, binding assay	596	gp41	W	0.014	0.028	0.000	W596A  disrupts binding to M consensus
495	Mutation disrupts binding to 8F6	Hicar2016a	binding	8F6(other)	alanine scanning, binding assay	598	gp41	C	0.014	0.017	0.008	C598A  disrupts binding to M consensus
495	Mutation disrupts binding to 8F6	Hicar2016a	binding	8F6(other)	alanine scanning, binding assay	600	gp41	G	0.046	0.046	0.062	G600A  disrupts binding to M consensus
495	Mutation disrupts binding to 8F6	Hicar2016a	binding	8F6(other)	alanine scanning, binding assay	602	gp41, gp41 fusion domain (595,602,603,617)	L	0.447	0.268	0.467	L602A  disrupts binding to M consensus
495	Mutation disrupts binding to 8F6	Hicar2016a	binding	8F6(other)	alanine scanning, binding assay	603	gp41, gp41 fusion domain (595,602,603,617)	I	0.065	0.038	0.087	I603A  disrupts binding to M consensus
495	Mutation disrupts binding to 8F6	Hicar2016a	binding	8F6(other)	alanine scanning, binding assay	604	gp41	C	0.012	0.024	0.000	C604A  disrupts binding to M consensus
496	Mutation disrupts binding to 4E4	Hicar2016a	binding	4E4(other)	alanine scanning, binding assay	340	gp120	N	1.893	1.537	1.869	N340A  disrupts binding to M consensus
496	Mutation disrupts binding to 4E4	Hicar2016a	binding	4E4(other)	alanine scanning, binding assay	657	gp41	E	0.034	0.040	0.023	E657A  disrupts binding to M consensus
497	Mutation disrupts binding to 6F11	Hicar2016a	binding	6F11(other)	alanine scanning, binding assay	657	gp41	E	0.034	0.040	0.023	E657A  disrupts binding to M consensus
498	Mutation disrupts binding to 7C6	Hicar2016a	binding	7C6(other)	alanine scanning, binding assay	657	gp41	E	0.034	0.040	0.023	E657A  disrupts binding to M consensus
499	N167 contacts PG9 heavy chain binding pocket	Willis2015	contacts	PG9(V2)	X-ray crystallography	167	gp120, V2	G	0.779	1.122	0.185	N167 on the antigen face of gp120 contacts a pocket on the heavy chain of PG9; this effect is enhanced in PG9-N100fY
500	N160 affects neutralization by PG9 and PG9_N100fY	Willis2015	neutralization	PG9_N100fY(V2), PG9(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	PG9 failed to neutralize 9 pseudoviruses lacking N160, but PG9_N100fY neutralized 7/9
501	FP amino acids associated with resistance to VRC34.01_mm28	Banach2023	neutralization	VRC34.01_mm28(gp41 fusion domain)	computational prediction, neutralization assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	513A associated with resistance to VRC34.01_mm28
501	FP amino acids associated with resistance to VRC34.01_mm28	Banach2023	neutralization	VRC34.01_mm28(gp41 fusion domain)	computational prediction, neutralization assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	deletion of the amino acid at position 514, or the insertion of Met or Thr after position 514  associated with resistance to VRC34.01_mm28
501	FP amino acids associated with resistance to VRC34.01_mm28	Banach2023	neutralization	VRC34.01_mm28(gp41 fusion domain)	computational prediction, neutralization assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	515F associated with resistance to VRC34.01_mm28
502	mutation causes sensitivity to 447-52D	Wang2017	neutralization	447-52D(V3)	mutational analysis, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160A in JR-CSF  causes increased sensitivity to 447-52D
502	mutation causes sensitivity to 447-52D	Wang2017	neutralization	447-52D(V3)	mutational analysis, neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A in JR-CSF causes increased sensitivity to 447-52D
502	mutation causes sensitivity to 447-52D	Wang2017	neutralization	447-52D(V3)	mutational analysis, neutralization assay	332	gp120	N	0.663	0.491	0.693	N332A in JR-CSF  causes increased sensitivity to 447-52D
503	mutation causes sensitivity to 2219	Wang2017	neutralization	2219(V3)	mutational analysis, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160A in JR-CSF causes increased sensitivity to 2219
503	mutation causes sensitivity to 2219	Wang2017	neutralization	2219(V3)	mutational analysis, neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A in JR-CSF causes increased sensitivity to 2219
503	mutation causes sensitivity to 2219	Wang2017	neutralization	2219(V3)	mutational analysis, neutralization assay	332	gp120	N	0.663	0.491	0.693	N332A in JR-CSF causes increased sensitivity to 2219
504	mutation causes resistance to PG9	Wang2017	neutralization	PG9(V2)	mutational analysis, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160A in JR-CSF causes resistance to PG9
505	mutation causes sensitivity to S96	Wang2017	neutralization	S96(V3)	mutational analysis, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160A in JR-CSF causes increased sensitivity to S96
505	mutation causes sensitivity to S96	Wang2017	neutralization	S96(V3)	mutational analysis, neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A in JR-CSF causes increased sensitivity to S96
505	mutation causes sensitivity to S96	Wang2017	neutralization	S96(V3)	mutational analysis, neutralization assay	332	gp120	N	0.663	0.491	0.693	N332A in JR-CSF causes increased sensitivity to S96
506	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT121(V3)	neutralization assay	332	gp120	N	0.663	0.491	0.693	N332A in strain JRCSF decreases neutralization >30 fold
506	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT121(V3)	neutralization assay	334	gp120	S	0.717	0.501	0.890	S334A in strain JRCSF decreases neutralization >30 fold
507	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT122(V3)	neutralization assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A in strain JRCSF decreases neutralization >30 fold
507	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT122(V3)	neutralization assay	332	gp120	N	0.663	0.491	0.693	N332A in strain JRCSF decreases neutralization >30 fold
507	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT122(V3)	neutralization assay	334	gp120	S	0.717	0.501	0.890	S334A in strain JRCSF decreases neutralization >30 fold
508	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT123(V3)	neutralization assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A in strain JRCSF decreases neutralization >30 fold
508	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT123(V3)	neutralization assay	332	gp120	N	0.663	0.491	0.693	N332A in strain JRCSF decreases neutralization >30 fold
508	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT123(V3)	neutralization assay	334	gp120	S	0.717	0.501	0.890	S334A in strain JRCSF decreases neutralization >30 fold
509	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT125(V3)	neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A in strain JRCSF decreases neutralization >30 fold
509	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT125(V3)	neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A in strain JRCSF decreases neutralization >30 fold
510	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT126(V3)	neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A in strain JRCSF decreases neutralization >30 fold
510	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT126(V3)	neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A in strain JRCSF decreases neutralization >30 fold
510	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT126(V3)	neutralization assay	332	gp120	N	0.663	0.491	0.693	N332A in strain JRCSF decreases neutralization >30 fold
510	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT126(V3)	neutralization assay	334	gp120	S	0.717	0.501	0.890	S334A in strain JRCSF decreases neutralization >30 fold
511	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT127(V3)	neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A in strain JRCSF decreases neutralization >30 fold
511	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT127(V3)	neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A in strain JRCSF decreases neutralization >30 fold
511	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT127(V3)	neutralization assay	332	gp120	N	0.663	0.491	0.693	N332A in strain JRCSF decreases neutralization >30 fold
511	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT127(V3)	neutralization assay	334	gp120	S	0.717	0.501	0.890	S334A in strain JRCSF decreases neutralization >30 fold
512	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT128(V3)	neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A in strain JRCSF decreases neutralization >30 fold
513	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT130(V3)	neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A in strain JRCSF decreases neutralization >30 fold
513	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT130(V3)	neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A in strain JRCSF decreases neutralization >30 fold
513	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT130(V3)	neutralization assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A in strain JRCSF decreases neutralization >30 fold
513	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT130(V3)	neutralization assay	309	gp120, V3 loop	I	0.863	0.359	0.965	I309A in strain JRCSF decreases neutralization >30 fold
513	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT130(V3)	neutralization assay	324	gp120, V3 loop	G	0.075	0.056	0.092	G324A in strain JRCSF decreases neutralization >30 fold
513	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT130(V3)	neutralization assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A in strain JRCSF decreases neutralization >30 fold
513	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT130(V3)	neutralization assay	423	gp120, beta20/beta21	I	0.433	0.383	0.411	I423A in strain JRCSF decreases neutralization >30 fold
514	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT131(V3)	neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A in strain JRCSF decreases neutralization >30 fold
514	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT131(V3)	neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A in strain JRCSF decreases neutralization >30 fold
514	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT131(V3)	neutralization assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A in strain JRCSF decreases neutralization >30 fold
514	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT131(V3)	neutralization assay	317	gp120, V3 loop	F	0.834	1.090	0.223	F317A in strain JRCSF decreases neutralization >30 fold
514	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT131(V3)	neutralization assay	325	gp120, V3 loop	N	0.648	0.622	0.622	D325A in strain JRCSF decreases neutralization >30 fold
514	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT131(V3)	neutralization assay	423	gp120, beta20/beta21	I	0.433	0.383	0.411	I423A in strain JRCSF decreases neutralization >30 fold
515	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT135(V3)	neutralization assay	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.823	0.654	0.977	N297A in strain JRCSF decreases neutralization >30 fold
515	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT135(V3)	neutralization assay	330	gp120, V3 loop	H	0.634	0.559	0.655	H330A in strain JRCSF decreases neutralization >30 fold
515	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT135(V3)	neutralization assay	332	gp120	N	0.663	0.491	0.693	N332A in strain JRCSF decreases neutralization >30 fold
515	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT135(V3)	neutralization assay	334	gp120	S	0.717	0.501	0.890	S334A in strain JRCSF decreases neutralization >30 fold
515	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT135(V3)	neutralization assay	392	gp120, V4 loop	N	0.605	0.454	0.804	N392Q in strain JRCSF decreases neutralization >30 fold
515	Mutation greatly reduces neutralization	Walker2011	neutralization	PGT135(V3)	neutralization assay	394	gp120, V4 loop	T	1.077	0.715	1.439	T394A in strain JRCSF decreases neutralization >30 fold
516	Mutation reduces binding	McLellan2011	binding	PG9(V2)	binding assay	156	gp120, V1	N	0.246	0.220	0.224	N156D decreases binding >10 fold to strain CAP45
516	Mutation reduces binding	McLellan2011	binding	PG9(V2)	binding assay	160	gp120, V2	N	0.416	0.452	0.358	N160Q abrogates binding to strains CAP45 or ZM109
516	Mutation reduces binding	McLellan2011	binding	PG9(V2)	binding assay	173	gp120, V2	Y	1.059	0.808	1.158	N173D decreases binding >10 fold to strain ZM109
517	Mutation reduces binding	McLellan2011	binding	PG16(V2)	binding assay	156	gp120, V1	N	0.246	0.220	0.224	N156D abrogates binding to strain CAP45
517	Mutation reduces binding	McLellan2011	binding	PG16(V2)	binding assay	160	gp120, V2	N	0.416	0.452	0.358	N160Q abrogates binding to strains CAP45 and ZM109
517	Mutation reduces binding	McLellan2011	binding	PG16(V2)	binding assay	173	gp120, V2	Y	1.059	0.808	1.158	N173D abrogates binding to strain ZM109
517	Mutation reduces binding	McLellan2011	binding	PG16(V2)	binding assay	192	gp120, V2	K	0.940	0.835	0.851	N160D decreases binding >3 fold to strain CAP45
518	DH511.2_K3 contacts	Williams2017	contacts	DH511.2_K3(MPER)	molecular modeling, X-ray crystallography	669	gp41	L	0.017	0.023	0.000	contacts VH3-15 region residues of DH511.2 and DH511.2_K3
518	DH511.2_K3 contacts	Williams2017	contacts	DH511.2_K3(MPER)	molecular modeling, X-ray crystallography	670	gp41	W	0.043	0.028	0.035	contacts VH3-15 region residues of DH511.2 and DH511.2_K3
518	DH511.2_K3 contacts	Williams2017	contacts	DH511.2_K3(MPER)	molecular modeling, X-ray crystallography	671	gp41	N	0.783	0.669	0.885	contacts VH3-15 region residues of DH511.2 and DH511.2_K3
518	DH511.2_K3 contacts	Williams2017	contacts	DH511.2_K3(MPER)	molecular modeling, X-ray crystallography	672	gp41	W	0.014	0.023	0.014	contacts VH3-15 region residues of DH511.2 and DH511.2_K3
518	DH511.2_K3 contacts	Williams2017	contacts	DH511.2_K3(MPER)	molecular modeling, X-ray crystallography	673	gp41	F	0.048	0.065	0.073	contacts VH3-15 region residues of DH511.2 and DH511.2_K3
518	DH511.2_K3 contacts	Williams2017	contacts	DH511.2_K3(MPER)	molecular modeling, X-ray crystallography	674	gp41	N	1.179	1.029	1.344	contacts VH3-15 region residues of DH511.2 and DH511.2_K3
518	DH511.2_K3 contacts	Williams2017	contacts	DH511.2_K3(MPER)	molecular modeling, X-ray crystallography	675	gp41	I	0.063	0.059	0.069	van der Waals interaction
518	DH511.2_K3 contacts	Williams2017	contacts	DH511.2_K3(MPER)	molecular modeling, X-ray crystallography	676	gp41	T	0.671	0.610	0.674	contacts HCDR3 residues of DH511.2 and DH511.2_K3
518	DH511.2_K3 contacts	Williams2017	contacts	DH511.2_K3(MPER)	molecular modeling, X-ray crystallography	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	contacts HCDR3 residues of DH511.2 and DH511.2_K3
518	DH511.2_K3 contacts	Williams2017	contacts	DH511.2_K3(MPER)	molecular modeling, X-ray crystallography	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	contacts HCDR3 residues of DH511.2 and DH511.2_K3
518	DH511.2_K3 contacts	Williams2017	contacts	DH511.2_K3(MPER)	molecular modeling, X-ray crystallography	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	contacts HCDR3 residues of DH511.2 and DH511.2_K3
519	DH517 epitope mapping	Williams2017	binding	DH517(MPER)	alanine scanning, binding assay	661	gp41	L	0.047	0.050	0.008	L661A decreases binding to MPER peptides
519	DH517 epitope mapping	Williams2017	binding	DH517(MPER)	alanine scanning, binding assay	663	gp41	L	0.092	0.094	0.053	L663A decreases binding to MPER peptides
519	DH517 epitope mapping	Williams2017	binding	DH517(MPER)	alanine scanning, binding assay	664	gp41	D	0.222	0.156	0.346	D664A decreases binding to MPER peptides
519	DH517 epitope mapping	Williams2017	binding	DH517(MPER)	alanine scanning, binding assay	665	gp41	K	1.039	0.656	0.879	K665A decreases binding to MPER peptides
519	DH517 epitope mapping	Williams2017	binding	DH517(MPER)	alanine scanning, binding assay	666	gp41	W	0.008	0.000	0.000	W666A decreases binding to MPER peptides
519	DH517 epitope mapping	Williams2017	binding	DH517(MPER)	alanine scanning, binding assay	667	gp41	A	1.424	0.545	1.537	A667N decreases binding to MPER peptides
519	DH517 epitope mapping	Williams2017	binding	DH517(MPER)	alanine scanning, binding assay	669	gp41	L	0.017	0.023	0.000	L669A decreases binding to MPER peptides
519	DH517 epitope mapping	Williams2017	binding	DH517(MPER)	alanine scanning, binding assay	670	gp41	W	0.043	0.028	0.035	W670A decreases binding to MPER peptides
519	DH517 epitope mapping	Williams2017	binding	DH517(MPER)	alanine scanning, binding assay	673	gp41	F	0.048	0.065	0.073	F673A decreases binding to MPER peptides
519	DH517 epitope mapping	Williams2017	binding	DH517(MPER)	alanine scanning, binding assay	677	gp41	N	1.203	1.199	1.100	N667A decreases binding to MPER peptides
519	DH517 epitope mapping	Williams2017	binding	DH517(MPER)	alanine scanning, binding assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A decreases binding to MPER peptides
519	DH517 epitope mapping	Williams2017	binding	DH517(MPER)	alanine scanning, binding assay	681	gp41, gp41 transmembrane	Y	0.020	0.012	0.036	Y681A decreases binding to MPER peptides
519	DH517 epitope mapping	Williams2017	binding	DH517(MPER)	alanine scanning, binding assay	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	K683A decreases binding to MPER peptides
520	DH511.1 contacts	Williams2017	contacts	DH511.1(MPER)	molecular modeling, X-ray crystallography	656	gp41	N	0.031	0.034	0.033	van der Waals interaction
520	DH511.1 contacts	Williams2017	contacts	DH511.1(MPER)	molecular modeling, X-ray crystallography	657	gp41	E	0.034	0.040	0.023	van der Waals interaction
520	DH511.1 contacts	Williams2017	contacts	DH511.1(MPER)	molecular modeling, X-ray crystallography	669	gp41	L	0.017	0.023	0.000	contacts VH3-15 region
520	DH511.1 contacts	Williams2017	contacts	DH511.1(MPER)	molecular modeling, X-ray crystallography	670	gp41	W	0.043	0.028	0.035	contacts VH3-15 region
520	DH511.1 contacts	Williams2017	contacts	DH511.1(MPER)	molecular modeling, X-ray crystallography	671	gp41	N	0.783	0.669	0.885	contacts VH3-15 region
520	DH511.1 contacts	Williams2017	contacts	DH511.1(MPER)	molecular modeling, X-ray crystallography	672	gp41	W	0.014	0.023	0.014	contacts both VH3-15 region and HCDR3
520	DH511.1 contacts	Williams2017	contacts	DH511.1(MPER)	molecular modeling, X-ray crystallography	673	gp41	F	0.048	0.065	0.073	contacts VH3-15 region
520	DH511.1 contacts	Williams2017	contacts	DH511.1(MPER)	molecular modeling, X-ray crystallography	674	gp41	N	1.179	1.029	1.344	contacts VH3-15 region
520	DH511.1 contacts	Williams2017	contacts	DH511.1(MPER)	molecular modeling, X-ray crystallography	676	gp41	T	0.671	0.610	0.674	contacts HCDR3
520	DH511.1 contacts	Williams2017	contacts	DH511.1(MPER)	molecular modeling, X-ray crystallography	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	contacts HCDR3
520	DH511.1 contacts	Williams2017	contacts	DH511.1(MPER)	molecular modeling, X-ray crystallography	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	contacts HCDR3
520	DH511.1 contacts	Williams2017	contacts	DH511.1(MPER)	molecular modeling, X-ray crystallography	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	van der Waals interaction
520	DH511.1 contacts	Williams2017	contacts	DH511.1(MPER)	molecular modeling, X-ray crystallography	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	contacts HCDR3
521	DH511.11P contacts	Williams2017	contacts	DH511.11P(MPER)	molecular modeling, X-ray crystallography	669	gp41	L	0.017	0.023	0.000	contacts VH3-15 region
521	DH511.11P contacts	Williams2017	contacts	DH511.11P(MPER)	molecular modeling, X-ray crystallography	670	gp41	W	0.043	0.028	0.035	contacts VH3-15 region
521	DH511.11P contacts	Williams2017	contacts	DH511.11P(MPER)	molecular modeling, X-ray crystallography	671	gp41	N	0.783	0.669	0.885	contacts VH3-15 region
521	DH511.11P contacts	Williams2017	contacts	DH511.11P(MPER)	molecular modeling, X-ray crystallography	672	gp41	W	0.014	0.023	0.014	contacts both VH3-15 region and HCDR3
521	DH511.11P contacts	Williams2017	contacts	DH511.11P(MPER)	molecular modeling, X-ray crystallography	673	gp41	F	0.048	0.065	0.073	contacts VH3-15 region
521	DH511.11P contacts	Williams2017	contacts	DH511.11P(MPER)	molecular modeling, X-ray crystallography	674	gp41	N	1.179	1.029	1.344	contacts VH3-15 region
521	DH511.11P contacts	Williams2017	contacts	DH511.11P(MPER)	molecular modeling, X-ray crystallography	676	gp41	T	0.671	0.610	0.674	contacts HCDR3
521	DH511.11P contacts	Williams2017	contacts	DH511.11P(MPER)	molecular modeling, X-ray crystallography	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	contacts HCDR3
521	DH511.11P contacts	Williams2017	contacts	DH511.11P(MPER)	molecular modeling, X-ray crystallography	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	contacts HCDR3
521	DH511.11P contacts	Williams2017	contacts	DH511.11P(MPER)	molecular modeling, X-ray crystallography	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	van der Waals interaction
521	DH511.11P contacts	Williams2017	contacts	DH511.11P(MPER)	molecular modeling, X-ray crystallography	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	contacts HCDR3
522	DH511.12P contacts	Williams2017	contacts	DH511.12P(MPER)	molecular modeling, X-ray crystallography	669	gp41	L	0.017	0.023	0.000	contacts VH3-15 region
522	DH511.12P contacts	Williams2017	contacts	DH511.12P(MPER)	molecular modeling, X-ray crystallography	670	gp41	W	0.043	0.028	0.035	contacts VH3-15 region
522	DH511.12P contacts	Williams2017	contacts	DH511.12P(MPER)	molecular modeling, X-ray crystallography	671	gp41	N	0.783	0.669	0.885	contacts VH3-15 region
522	DH511.12P contacts	Williams2017	contacts	DH511.12P(MPER)	molecular modeling, X-ray crystallography	672	gp41	W	0.014	0.023	0.014	contacts both VH3-15 region and HCDR3
522	DH511.12P contacts	Williams2017	contacts	DH511.12P(MPER)	molecular modeling, X-ray crystallography	673	gp41	F	0.048	0.065	0.073	contacts VH3-15 region
522	DH511.12P contacts	Williams2017	contacts	DH511.12P(MPER)	molecular modeling, X-ray crystallography	674	gp41	N	1.179	1.029	1.344	contacts VH3-15 region
522	DH511.12P contacts	Williams2017	contacts	DH511.12P(MPER)	molecular modeling, X-ray crystallography	676	gp41	T	0.671	0.610	0.674	contacts HCDR3
522	DH511.12P contacts	Williams2017	contacts	DH511.12P(MPER)	molecular modeling, X-ray crystallography	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	contacts HCDR3
522	DH511.12P contacts	Williams2017	contacts	DH511.12P(MPER)	molecular modeling, X-ray crystallography	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	contacts HCDR3
522	DH511.12P contacts	Williams2017	contacts	DH511.12P(MPER)	molecular modeling, X-ray crystallography	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	van der Waals interaction
522	DH511.12P contacts	Williams2017	contacts	DH511.12P(MPER)	molecular modeling, X-ray crystallography	683	gp41, gp41 transmembrane	K	0.558	0.499	0.569	contacts HCDR3
523	resistance-associated mutations	Williams2017	neutralization	DH511.1(MPER)	alanine scanning, neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A causes resistance to neutralization of strain COT6.15
523	resistance-associated mutations	Williams2017	neutralization	DH511.1(MPER)	alanine scanning, neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A causes resistance to neutralization of strain COT6.15
523	resistance-associated mutations	Williams2017	neutralization	DH511.1(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A or D674S causes resistance to neutralization of strain COT6.15
524	resistance-associated mutations	Williams2017	neutralization	DH511.2(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A or D674S causes resistance to neutralization of strain COT6.15
525	resistance-associated mutations	Williams2017	neutralization	DH511.3(MPER)	alanine scanning, neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A causes resistance to neutralization of strain COT6.15
525	resistance-associated mutations	Williams2017	neutralization	DH511.3(MPER)	alanine scanning, neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A causes resistance to neutralization of strain COT6.15
525	resistance-associated mutations	Williams2017	neutralization	DH511.3(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A or D674S causes resistance to neutralization of strain COT6.15
526	resistance-associated mutations	Williams2017	neutralization	DH511.4(MPER)	alanine scanning, neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A causes resistance to neutralization of strain COT6.15
526	resistance-associated mutations	Williams2017	neutralization	DH511.4(MPER)	alanine scanning, neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A causes resistance to neutralization of strain COT6.15
526	resistance-associated mutations	Williams2017	neutralization	DH511.4(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A or D674S causes resistance to neutralization of strain COT6.15
527	resistance-associated mutations	Williams2017	neutralization	DH511.5(MPER)	alanine scanning, neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A causes resistance to neutralization of strain COT6.15
527	resistance-associated mutations	Williams2017	neutralization	DH511.5(MPER)	alanine scanning, neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A causes resistance to neutralization of strain COT6.15
527	resistance-associated mutations	Williams2017	neutralization	DH511.5(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A or D674S causes resistance to neutralization of strain COT6.15
528	resistance-associated mutations	Williams2017	neutralization	DH511.6(MPER)	alanine scanning, neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A causes resistance to neutralization of strain COT6.15
528	resistance-associated mutations	Williams2017	neutralization	DH511.6(MPER)	alanine scanning, neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A causes resistance to neutralization of strain COT6.15
528	resistance-associated mutations	Williams2017	neutralization	DH511.6(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A or D674S causes resistance to neutralization of strain COT6.15
529	resistance-associated mutations	Williams2017	neutralization	DH511.11P(MPER)	alanine scanning, neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A causes resistance to neutralization of strain COT6.15
529	resistance-associated mutations	Williams2017	neutralization	DH511.11P(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A causes resistance to neutralization of strain COT6.15
530	resistance-associated mutations	Williams2017	neutralization	DH511.12P(MPER)	alanine scanning, neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A causes resistance to neutralization of strain COT6.15
530	resistance-associated mutations	Williams2017	neutralization	DH511.12P(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A causes resistance to neutralization of strain COT6.15
531	resistance-associated mutations	Williams2017	neutralization	DH511.2_K3(MPER)	alanine scanning, neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A causes resistance to neutralization of strain COT6.15
531	resistance-associated mutations	Williams2017	neutralization	DH511.2_K3(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A causes resistance to neutralization of strain COT6.15
532	resistance-associated mutations	Williams2017	neutralization	10E8(MPER)	alanine scanning, neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A causes resistance to neutralization of strain COT6.15
532	resistance-associated mutations	Williams2017	neutralization	10E8(MPER)	alanine scanning, neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A causes resistance to neutralization of strain COT6.15
532	resistance-associated mutations	Williams2017	neutralization	10E8(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A or D674S causes resistance to neutralization of strain COT6.15
533	resistance-associated mutations	Williams2017	neutralization	4E10(MPER)	alanine scanning, neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A causes resistance to neutralization of strain COT6.15
533	resistance-associated mutations	Williams2017	neutralization	4E10(MPER)	alanine scanning, neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A causes resistance to neutralization of strain COT6.15
533	resistance-associated mutations	Williams2017	neutralization	4E10(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A or D674S causes resistance to neutralization of strain COT6.15
533	resistance-associated mutations	Williams2017	neutralization	4E10(MPER)	alanine scanning, neutralization assay	676	gp41	T	0.671	0.610	0.674	T676A causes resistance to neutralization of strain COT6.15
533	resistance-associated mutations	Williams2017	neutralization	4E10(MPER)	alanine scanning, neutralization assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A causes resistance to neutralization of strain COT6.15
534	Z13e1 neutralization associated sites	Nelson2007	neutralization	Z13e1(MPER)	alanine scanning, neutralization assay	660	gp41	L	0.020	0.006	0.000	L660A in strain JR2 causes neutralization hypersensitivity
534	Z13e1 neutralization associated sites	Nelson2007	neutralization	Z13e1(MPER)	alanine scanning, neutralization assay	661	gp41	L	0.047	0.050	0.008	L661A in strain JR2 causes neutralization hypersensitivity
534	Z13e1 neutralization associated sites	Nelson2007	neutralization	Z13e1(MPER)	alanine scanning, neutralization assay	671	gp41	N	0.783	0.669	0.885	N671A in strain JR2 causes neutralization resistance > 3 fold
534	Z13e1 neutralization associated sites	Nelson2007	neutralization	Z13e1(MPER)	alanine scanning, neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A in strain JR2 causes neutralization resistance > 3 fold
534	Z13e1 neutralization associated sites	Nelson2007	neutralization	Z13e1(MPER)	alanine scanning, neutralization assay	675	gp41	I	0.063	0.059	0.069	I675A in strain JR2 causes neutralization hypersensitivity
534	Z13e1 neutralization associated sites	Nelson2007	neutralization	Z13e1(MPER)	alanine scanning, neutralization assay	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	W678A in strain JR2 causes neutralization hypersensitivity
534	Z13e1 neutralization associated sites	Nelson2007	neutralization	Z13e1(MPER)	alanine scanning, neutralization assay	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	L679A in strain JR2 causes neutralization hypersensitivity
535	CH58 contacts	vanEeden2018	contacts	CH58(V2)	X-ray crystallography	168	gp120, V2	K	0.566	0.666	0.396	buried surface area >50A; salt bridge
535	CH58 contacts	vanEeden2018	contacts	CH58(V2)	X-ray crystallography	169	gp120, V2	V	2.042	1.770	1.344	buried surface area >50A; salt bridge
535	CH58 contacts	vanEeden2018	contacts	CH58(V2)	X-ray crystallography	171	gp120, V2	K	1.247	0.957	1.413	salt bridge
535	CH58 contacts	vanEeden2018	contacts	CH58(V2)	X-ray crystallography	172	gp120, V2	E	1.527	1.172	1.484	buried surface area >50A
535	CH58 contacts	vanEeden2018	contacts	CH58(V2)	X-ray crystallography	173	gp120, V2	Y	1.059	0.808	1.158	buried surface area >50A; H-bond
535	CH58 contacts	vanEeden2018	contacts	CH58(V2)	X-ray crystallography	175	gp120, V2	F	0.606	0.868	0.271	buried surface area >50A
535	CH58 contacts	vanEeden2018	contacts	CH58(V2)	X-ray crystallography	176	gp120, V2	F	0.189	0.303	0.042	buried surface area >50A
535	CH58 contacts	vanEeden2018	contacts	CH58(V2)	X-ray crystallography	177	gp120, V2	Y	0.454	0.638	0.144	buried surface area >50A
535	CH58 contacts	vanEeden2018	contacts	CH58(V2)	X-ray crystallography	178	gp120, V2	K	1.346	1.386	0.988	buried surface area >50A; salt bridge
535	CH58 contacts	vanEeden2018	contacts	CH58(V2)	X-ray crystallography	180	gp120, V2	D	0.054	0.033	0.029	buried surface area >50A; salt bridge
536	CAP228-3D contacts	Wibmer2018	contacts	CAP228-3D(V2)	X-ray crystallography	168	gp120, V2	K	0.566	0.666	0.396	light chain contact; salt bridge; H-bond
536	CAP228-3D contacts	Wibmer2018	contacts	CAP228-3D(V2)	X-ray crystallography	169	gp120, V2	V	2.042	1.770	1.344	heavy and light chain contact;
536	CAP228-3D contacts	Wibmer2018	contacts	CAP228-3D(V2)	X-ray crystallography	171	gp120, V2	K	1.247	0.957	1.413	light chain contact; salt bridge; H-bond
536	CAP228-3D contacts	Wibmer2018	contacts	CAP228-3D(V2)	X-ray crystallography	172	gp120, V2	E	1.527	1.172	1.484	heavy and light chain contact
536	CAP228-3D contacts	Wibmer2018	contacts	CAP228-3D(V2)	X-ray crystallography	173	gp120, V2	Y	1.059	0.808	1.158	heavy chain contact; H-bond
536	CAP228-3D contacts	Wibmer2018	contacts	CAP228-3D(V2)	X-ray crystallography	174	gp120, V2	A	0.333	0.155	0.145	light chain contact
536	CAP228-3D contacts	Wibmer2018	contacts	CAP228-3D(V2)	X-ray crystallography	175	gp120, V2	F	0.606	0.868	0.271	light chain contact
536	CAP228-3D contacts	Wibmer2018	contacts	CAP228-3D(V2)	X-ray crystallography	176	gp120, V2	F	0.189	0.303	0.042	heavy and light chain contact
536	CAP228-3D contacts	Wibmer2018	contacts	CAP228-3D(V2)	X-ray crystallography	177	gp120, V2	Y	0.454	0.638	0.144	heavy chain contact
536	CAP228-3D contacts	Wibmer2018	contacts	CAP228-3D(V2)	X-ray crystallography	178	gp120, V2	K	1.346	1.386	0.988	heavy chain contact; salt bridge; H-bond
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	80	gp120	N	0.669	0.695	0.562	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	82	gp120	Q	0.290	0.200	0.268	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	83	gp120	E	0.042	0.039	0.035	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	84	gp120	V	1.366	0.916	1.327	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	85	gp120	V	1.980	1.797	1.418	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	87	gp120	V	1.565	1.611	1.463	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	88	gp120	N	0.050	0.041	0.048	glycan contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	229	gp120	N	0.707	0.742	0.290	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	230	gp120	N	0.931	0.896	0.544	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	231	gp120	K	0.799	0.578	0.780	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	241	gp120	N	0.191	0.183	0.134	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	512	gp41, fusion peptide	A	0.188	0.260	0.110	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	513	gp41, fusion peptide	V	0.761	0.736	0.506	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	514	gp41, fusion peptide	G	0.600	0.691	0.502	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	515	gp41, fusion peptide	I	1.103	1.147	0.877	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	516	gp41, fusion peptide	G	0.066	0.038	0.048	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	517	gp41, fusion peptide	A	0.113	0.109	0.058	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	518	gp41, fusion peptide	L	1.166	1.110	0.718	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	519	gp41, fusion peptide	F	0.518	0.243	0.837	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	520	gp41, fusion peptide	L	0.393	0.253	0.390	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	521	gp41, fusion peptide	G	0.035	0.028	0.008	contact; no lower bound was used for interactive surface area
537	VRC34.01 contacts	Chuang2019	contacts	VRC34.01(gp41 fusion domain)	X-ray crystallography	648	gp41	E	1.506	1.332	1.379	contact; no lower bound was used for interactive surface area
538	4E10 contacts	Zhang2019a	contacts	4E10(MPER)	X-ray crystallography	671	gp41	N	0.783	0.669	0.885	4E10 contact
538	4E10 contacts	Zhang2019a	contacts	4E10(MPER)	X-ray crystallography	672	gp41	W	0.014	0.023	0.014	4E10 contact
538	4E10 contacts	Zhang2019a	contacts	4E10(MPER)	X-ray crystallography	673	gp41	F	0.048	0.065	0.073	4E10 contact
538	4E10 contacts	Zhang2019a	contacts	4E10(MPER)	X-ray crystallography	675	gp41	I	0.063	0.059	0.069	4E10 contact
538	4E10 contacts	Zhang2019a	contacts	4E10(MPER)	X-ray crystallography	676	gp41	T	0.671	0.610	0.674	4E10 contact
538	4E10 contacts	Zhang2019a	contacts	4E10(MPER)	X-ray crystallography	677	gp41	N	1.203	1.199	1.100	4E10 contact
538	4E10 contacts	Zhang2019a	contacts	4E10(MPER)	X-ray crystallography	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	4E10 contact
538	4E10 contacts	Zhang2019a	contacts	4E10(MPER)	X-ray crystallography	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	4E10 contact
538	4E10 contacts	Zhang2019a	contacts	4E10(MPER)	X-ray crystallography	681	gp41, gp41 transmembrane	Y	0.020	0.012	0.036	4E10 contact
539	VRC38.01 contacts	Gorman2020	contacts	VRC38.01(V2)	X-ray crystallography	132	gp120, V1-hypervariable, V1	T	1.312	0.849	1.573	HC contact
539	VRC38.01 contacts	Gorman2020	contacts	VRC38.01(V2)	X-ray crystallography	133	gp120, V1-hypervariable, V1	D	1.376	1.052	1.360	HC contact
539	VRC38.01 contacts	Gorman2020	contacts	VRC38.01(V2)	X-ray crystallography	156	gp120, V1	N	0.246	0.220	0.224	HC contact
539	VRC38.01 contacts	Gorman2020	contacts	VRC38.01(V2)	X-ray crystallography	158	gp120, V2	S	0.263	0.185	0.291	HC contact
539	VRC38.01 contacts	Gorman2020	contacts	VRC38.01(V2)	X-ray crystallography	168	gp120, V2	K	0.566	0.666	0.396	HC contact
539	VRC38.01 contacts	Gorman2020	contacts	VRC38.01(V2)	X-ray crystallography	171	gp120, V2	K	1.247	0.957	1.413	HC contact
540	Mutation affects b12 neutralization	Falkowska2012	neutralization	b12(CD4BS)	alanine scanning, neutralization assay	199	gp120	S	0.094	0.108	0.068	S199A in strain JRCSF enhances PGV04, VRC01, CD4-IgG, and b12 neutralization
540	Mutation affects b12 neutralization	Falkowska2012	neutralization	b12(CD4BS)	alanine scanning, neutralization assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
540	Mutation affects b12 neutralization	Falkowska2012	neutralization	b12(CD4BS)	alanine scanning, neutralization assay	309	gp120, V3 loop	I	0.863	0.359	0.965	I309A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
540	Mutation affects b12 neutralization	Falkowska2012	neutralization	b12(CD4BS)	alanine scanning, neutralization assay	317	gp120, V3 loop	F	0.834	1.090	0.223	F317A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
540	Mutation affects b12 neutralization	Falkowska2012	neutralization	b12(CD4BS)	alanine scanning, neutralization assay	318	gp120, V3 loop	V	0.588	0.691	0.507	Y318A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
540	Mutation affects b12 neutralization	Falkowska2012	neutralization	b12(CD4BS)	alanine scanning, neutralization assay	420	gp120	I	0.093	0.049	0.078	I420A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
540	Mutation affects b12 neutralization	Falkowska2012	neutralization	b12(CD4BS)	alanine scanning, neutralization assay	423	gp120, beta20/beta21	I	0.433	0.383	0.411	I423A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
541	Mutation affects VRC01 neutralization	Falkowska2012	neutralization	VRC01(CD4BS)	alanine scanning, neutralization assay	199	gp120	S	0.094	0.108	0.068	S199A in strain JRCSF enhances PGV04, VRC01, CD4-IgG, and b12 neutralization
541	Mutation affects VRC01 neutralization	Falkowska2012	neutralization	VRC01(CD4BS)	alanine scanning, neutralization assay	276	gp120, Loop D	N	0.118	0.063	0.169	N276A in strain JRCSF reduces PGV04 neutralization, in strain JRCSF enhances VRC01, no impact on CD4-IgG or b12. The N276 glycan forms contacts with VRC01, but VRC01 increases potency when it is absent, suggesting VRC01 has evolved to avoid obstruction by the N276 glycan.
541	Mutation affects VRC01 neutralization	Falkowska2012	neutralization	VRC01(CD4BS)	alanine scanning, neutralization assay	279	gp120, Loop D	D	0.900	0.850	0.898	D279A in strain JRCSF reduces PGV04, VRC01, CD4-IgG neutralization, no impact on b12 neutralization
541	Mutation affects VRC01 neutralization	Falkowska2012	neutralization	VRC01(CD4BS)	alanine scanning, neutralization assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
541	Mutation affects VRC01 neutralization	Falkowska2012	neutralization	VRC01(CD4BS)	alanine scanning, neutralization assay	309	gp120, V3 loop	I	0.863	0.359	0.965	I309A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
541	Mutation affects VRC01 neutralization	Falkowska2012	neutralization	VRC01(CD4BS)	alanine scanning, neutralization assay	317	gp120, V3 loop	F	0.834	1.090	0.223	F317A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
541	Mutation affects VRC01 neutralization	Falkowska2012	neutralization	VRC01(CD4BS)	alanine scanning, neutralization assay	318	gp120, V3 loop	V	0.588	0.691	0.507	Y318A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
541	Mutation affects VRC01 neutralization	Falkowska2012	neutralization	VRC01(CD4BS)	alanine scanning, neutralization assay	420	gp120	I	0.093	0.049	0.078	I420A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
541	Mutation affects VRC01 neutralization	Falkowska2012	neutralization	VRC01(CD4BS)	alanine scanning, neutralization assay	423	gp120, beta20/beta21	I	0.433	0.383	0.411	I423A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
541	Mutation affects VRC01 neutralization	Falkowska2012	neutralization	VRC01(CD4BS)	alanine scanning, neutralization assay	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	N461A in strain JRCSF enhances PGV04 and VRC01 neutralization, no impact on CD4-IgG and b12
541	Mutation affects VRC01 neutralization	Falkowska2012	neutralization	VRC01(CD4BS)	alanine scanning, neutralization assay	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	S463A in strain JRCSF enhances PGV04 and VRC01 neutralization, no impact on CD4-IgG and b12
542	Mutation affects CD4-Ig neutralization	Falkowska2012	neutralization		alanine scanning, neutralization assay	199	gp120	S	0.094	0.108	0.068	S199A in strain JRCSF enhances PGV04, VRC01, CD4-IgG, and b12 neutralization
542	Mutation affects CD4-Ig neutralization	Falkowska2012	neutralization		alanine scanning, neutralization assay	279	gp120, Loop D	D	0.900	0.850	0.898	D279A in strain JRCSF reduces PGV04, VRC01, CD4-IgG neutralization, no impact on b12 neutralization
542	Mutation affects CD4-Ig neutralization	Falkowska2012	neutralization		alanine scanning, neutralization assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
542	Mutation affects CD4-Ig neutralization	Falkowska2012	neutralization		alanine scanning, neutralization assay	309	gp120, V3 loop	I	0.863	0.359	0.965	I309A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
542	Mutation affects CD4-Ig neutralization	Falkowska2012	neutralization		alanine scanning, neutralization assay	317	gp120, V3 loop	F	0.834	1.090	0.223	F317A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
542	Mutation affects CD4-Ig neutralization	Falkowska2012	neutralization		alanine scanning, neutralization assay	318	gp120, V3 loop	V	0.588	0.691	0.507	Y318A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
542	Mutation affects CD4-Ig neutralization	Falkowska2012	neutralization		alanine scanning, neutralization assay	420	gp120	I	0.093	0.049	0.078	I420A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
542	Mutation affects CD4-Ig neutralization	Falkowska2012	neutralization		alanine scanning, neutralization assay	423	gp120, beta20/beta21	I	0.433	0.383	0.411	I423A in strain JRCSF reduces PGV04 and VRC01 neutralization, in strain JRCSF enhances CD4-IgG and b12 neutralization
543	Mutation affects VRC-PG04 binding	Falkowska2012	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	160	gp120, V2	N	0.416	0.452	0.358	N160K in strain JRCSF increases binding of PGV04
543	Mutation affects VRC-PG04 binding	Falkowska2012	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	276	gp120, Loop D	N	0.118	0.063	0.169	N276A in strain JRCSF decreases binding of PGV04
543	Mutation affects VRC-PG04 binding	Falkowska2012	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	279	gp120, Loop D	D	0.900	0.850	0.898	D279A in strain JRCSF decreases binding of PGV04
543	Mutation affects VRC-PG04 binding	Falkowska2012	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	280	gp120, Loop D	N	0.142	0.090	0.170	N280A in strain JRCSF decreases binding of PGV04
543	Mutation affects VRC-PG04 binding	Falkowska2012	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	N461A in strain JRCSF increases binding of PGV04
543	Mutation affects VRC-PG04 binding	Falkowska2012	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	S463A in strain JRCSF increases binding of PGV04
543	Mutation affects VRC-PG04 binding	Falkowska2012	binding	VRC-PG04(CD4BS)	alanine scanning, binding assay	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	R469A in strain JRCSF decreases binding of PGV04
544	Mutation associated with resistance to PG9 and PG16	Wang2018a	neutralization	PG9(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Mutations at position 160, 169, 171 were associated with resistance to PG9 and PG16
544	Mutation associated with resistance to PG9 and PG16	Wang2018a	neutralization	PG9(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	Mutations at position 160, 169, 171 were associated with resistance to PG9 and PG16
544	Mutation associated with resistance to PG9 and PG16	Wang2018a	neutralization	PG9(V2)	neutralization assay	171	gp120, V2	K	1.247	0.957	1.413	Mutations at position 160, 169, 171 were associated with resistance to PG9 and PG16
545	Mutation associated with resistance to PG9 and PG16	Wang2018a	neutralization	PG16(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Mutations at position 160, 169, 171 were associated with resistance to PG9 and PG16
545	Mutation associated with resistance to PG9 and PG16	Wang2018a	neutralization	PG16(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	Mutations at position 160, 169, 171 were associated with resistance to PG9 and PG16
545	Mutation associated with resistance to PG9 and PG16	Wang2018a	neutralization	PG16(V2)	neutralization assay	171	gp120, V2	K	1.247	0.957	1.413	Mutations at position 160, 169, 171 were associated with resistance to PG9 and PG16
546	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PG16(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of glycan confers resistance to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
546	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PG16(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
546	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PG16(V2)	neutralization assay	171	gp120, V2	K	1.247	0.957	1.413	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
546	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PG16(V2)	neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y increases sensitivity to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04 .
547	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PGT145(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of glycan confers resistance to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
547	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PGT145(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
547	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PGT145(V2)	neutralization assay	171	gp120, V2	K	1.247	0.957	1.413	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
547	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PGT145(V2)	neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y increases sensitivity to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04 .
548	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PGT141(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of glycan confers resistance to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
548	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PGT141(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
548	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PGT141(V2)	neutralization assay	171	gp120, V2	K	1.247	0.957	1.413	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
548	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	PGT141(V2)	neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y increases sensitivity to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04 .
549	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH01(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of glycan confers resistance to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
549	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH01(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
549	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH01(V2)	neutralization assay	171	gp120, V2	K	1.247	0.957	1.413	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
549	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH01(V2)	neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y increases sensitivity to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04 .
550	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH02(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of glycan confers resistance to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
550	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH02(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
550	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH02(V2)	neutralization assay	171	gp120, V2	K	1.247	0.957	1.413	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
550	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH02(V2)	neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y increases sensitivity to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04 .
551	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH03(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of glycan confers resistance to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
551	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH03(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
551	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH03(V2)	neutralization assay	171	gp120, V2	K	1.247	0.957	1.413	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
551	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH03(V2)	neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y increases sensitivity to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04 .
552	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH04(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of glycan confers resistance to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
552	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH04(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
552	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH04(V2)	neutralization assay	171	gp120, V2	K	1.247	0.957	1.413	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04.
552	Mutation affects PG9-like Ab sensitivity	Doria-RoseNA2012	neutralization	CH04(V2)	neutralization assay	173	gp120, V2	Y	1.059	0.808	1.158	Y increases sensitivity to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04 .
553	CH103 and CH235 neutralization associated sites	Gao2014	neutralization	CH103(CD4BS)	neutralization assay	275	gp120, Loop D	V	1.141	1.420	0.535	CH103 and CH235: E275K + 279 + 281 mutations increased sensitivity to the bNAb CH103 lineage, but were escape mutations from the autologous neutralizing CH235 mAB lineage, that was present simultaneously in the infected donor, CH505. 275 is a contact residue for the CH103 light chain.
553	CH103 and CH235 neutralization associated sites	Gao2014	neutralization	CH103(CD4BS)	neutralization assay	279	gp120, Loop D	D	0.900	0.850	0.898	CH103 and CH235: N279K increased sensitivity to the bNAb CH103 lineage, but was an escape mutations from the autologous neutralizing CH235 mAb lineage, that was present simultaneously in the infected donor, CH505. 279 is a contact residue for the CH103 light chain.
553	CH103 and CH235 neutralization associated sites	Gao2014	neutralization	CH103(CD4BS)	neutralization assay	280	gp120, Loop D	N	0.142	0.090	0.170	CH103 and CH235: N280S + V281 mutations increased sensitivity to the bNAb CH103 lineage, but were escape mutations from the autologous neutralizing CH235 mAB lineage, that was present simultaneously in the infected donor, CH505.
553	CH103 and CH235 neutralization associated sites	Gao2014	neutralization	CH103(CD4BS)	neutralization assay	281	gp120, Loop D	A	1.129	0.814	1.357	CH103 and CH235: V281A, V281G or V281D mutations increased sensitivity to the bNAb CH103 lineage, but were escape mutations from the autologous neutralizing CH235 lineage, that was present simultaneously in the infected donor, CH505. 281 is a contact residue for the CH103 light chain.
554	CH103 and CH235 neutralization associated sites	Gao2014	neutralization	CH235(CD4BS)	neutralization assay	275	gp120, Loop D	V	1.141	1.420	0.535	CH103 and CH235: E275K + 279 + 281 mutations increased sensitivity to the bNAb CH103 lineage, but were escape mutations from the autologous neutralizing CH235 mAB lineage, that was present simultaneously in the infected donor, CH505. 275 is a contact residue for the CH103 light chain.
554	CH103 and CH235 neutralization associated sites	Gao2014	neutralization	CH235(CD4BS)	neutralization assay	279	gp120, Loop D	D	0.900	0.850	0.898	CH103 and CH235: N279K increased sensitivity to the bNAb CH103 lineage, but was an escape mutations from the autologous neutralizing CH235 mAb lineage, that was present simultaneously in the infected donor, CH505. 279 is a contact residue for the CH103 light chain.
554	CH103 and CH235 neutralization associated sites	Gao2014	neutralization	CH235(CD4BS)	neutralization assay	280	gp120, Loop D	N	0.142	0.090	0.170	CH103 and CH235: N280S + V281 mutations increased sensitivity to the bNAb CH103 lineage, but were escape mutations from the autologous neutralizing CH235 mAB lineage, that was present simultaneously in the infected donor, CH505.
554	CH103 and CH235 neutralization associated sites	Gao2014	neutralization	CH235(CD4BS)	neutralization assay	281	gp120, Loop D	A	1.129	0.814	1.357	CH103 and CH235: V281A, V281G or V281D mutations increased sensitivity to the bNAb CH103 lineage, but were escape mutations from the autologous neutralizing CH235 lineage, that was present simultaneously in the infected donor, CH505. 281 is a contact residue for the CH103 light chain.
555	Mutation affects PGT151 binding	Blattner2014	binding	PGT151(gp41 fusion domain)	binding assay	490	gp120	K	1.214	0.943	0.157	K490F mutation in BG505 SOSIP.664 reduces PGT151 binding.
555	Mutation affects PGT151 binding	Blattner2014	binding	PGT151(gp41 fusion domain)	binding assay	499	gp120	T	0.220	0.203	0.161	T499A mutation in BG505 SOSIP.664 reduces PGT151 binding.
555	Mutation affects PGT151 binding	Blattner2014	binding	PGT151(gp41 fusion domain)	binding assay	500	gp120	K	1.473	0.816	1.832	R500K mutation in BG505 SOSIP.664 reduces PGT151 binding; R500S + R503S abrogates binding.
555	Mutation affects PGT151 binding	Blattner2014	binding	PGT151(gp41 fusion domain)	binding assay	502	gp120	K	0.547	0.512	0.348	K502A mutation in BG505 SOSIP.664 reduces PGT151 binding.
555	Mutation affects PGT151 binding	Blattner2014	binding	PGT151(gp41 fusion domain)	binding assay	503	gp120	R	0.028	0.012	0.020	R503S mutation in BG505 SOSIP.664 abrogates PGT151 binding; R500S + R503S abrogates binding.
555	Mutation affects PGT151 binding	Blattner2014	binding	PGT151(gp41 fusion domain)	binding assay	601	gp41	K	0.157	0.140	0.080	K601A mutation in BG505 SOSIP.664 reduces PGT151 binding.
555	Mutation affects PGT151 binding	Blattner2014	binding	PGT151(gp41 fusion domain)	binding assay	607	gp41	A	1.276	1.190	1.219	N607K mutation in BG505 SOSIP.664 reduces PGT151 binding.
555	Mutation affects PGT151 binding	Blattner2014	binding	PGT151(gp41 fusion domain)	binding assay	611	gp41	N	0.048	0.039	0.054	N611Q mutation in BG505 SOSIP.664 reduces PGT151 binding; N611Q+N637Q abrogates PGT151 binding
555	Mutation affects PGT151 binding	Blattner2014	binding	PGT151(gp41 fusion domain)	binding assay	637	gp41	N	0.192	0.168	0.186	N637Q mutation in BG505 SOSIP.664 reduces PGT151 binding; N611Q+N637Q abrogates PGT151 binding
556	Mutation affects PGT151 neutralization	Blattner2014	neutralization	PGT151(gp41 fusion domain)	alanine scanning, neutralization assay	611	gp41	N	0.048	0.039	0.054	N611A or N611D decreases neutralization of JRCSF and LAI strains by PGT151
556	Mutation affects PGT151 neutralization	Blattner2014	neutralization	PGT151(gp41 fusion domain)	alanine scanning, neutralization assay	613	gp41	S	0.243	0.207	0.216	S613A decreases neutralization of JRCSF by PGT151
556	Mutation affects PGT151 neutralization	Blattner2014	neutralization	PGT151(gp41 fusion domain)	alanine scanning, neutralization assay	637	gp41	N	0.192	0.168	0.186	N637K decreases neutralization of JRCSF and LAI strains by PGT151
556	Mutation affects PGT151 neutralization	Blattner2014	neutralization	PGT151(gp41 fusion domain)	alanine scanning, neutralization assay	647	gp41	E	0.328	0.372	0.224	E647K, E647A, or E647G greatly decreases JRCSF neutralization by PGT151, but does not affect LAI neutralization
557	Mutation affects PGT151 neutralization	Falkowska2014	neutralization	PGT151(gp41 fusion domain)	neutralization assay	611	gp41	N	0.048	0.039	0.054	N611A and N611D reduce neutralization by PGT151 in strains JRCSF, JRFL, and LAI
557	Mutation affects PGT151 neutralization	Falkowska2014	neutralization	PGT151(gp41 fusion domain)	neutralization assay	613	gp41	S	0.243	0.207	0.216	S613A reduces neutralization by PGT151 in JRCSF
557	Mutation affects PGT151 neutralization	Falkowska2014	neutralization	PGT151(gp41 fusion domain)	neutralization assay	637	gp41	N	0.192	0.168	0.186	N637K reduces neutralization by PGT151 in multiple strains; N637K + E647A further reduces it
557	Mutation affects PGT151 neutralization	Falkowska2014	neutralization	PGT151(gp41 fusion domain)	neutralization assay	647	gp41	E	0.328	0.372	0.224	E647A or E647G reduce neutralization by PGT151 in strain JRCSF, but have no effect in strains JRFL, LAI, or BG505
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	124	gp120	P	0.045	0.018	0.029	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	198	gp120	T	0.430	0.264	0.469	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	207	gp120	K	0.065	0.029	0.029	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	275	gp120, Loop D	V	1.141	1.420	0.535	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	276	gp120, Loop D	N	0.118	0.063	0.169	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	278	gp120, Loop D	T	0.708	0.715	0.481	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	279	gp120, Loop D	D	0.900	0.850	0.898	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	281	gp120, Loop D	A	1.129	0.814	1.357	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	282	gp120, Loop D	K	0.336	0.337	0.297	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	308	gp120, V3 loop	R	1.578	0.091	0.127	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	318	gp120, V3 loop	V	0.588	0.691	0.507	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	429	gp120, beta20/beta21	K	1.325	0.961	1.308	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	430	gp120, beta20/beta21	V	0.267	0.080	0.073	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	455	gp120, beta23	T	0.709	0.426	0.972	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	456	gp120, beta23	R	0.233	0.079	0.323	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	457	gp120, beta23	D	0.079	0.054	0.043	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	458	gp120, beta23	G	0.112	0.045	0.095	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	469	gp120, V5 loop, beta24	R	0.063	0.051	0.051	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
558	3BNC117 contacts	Scheid2016	contacts	3BNC117(CD4BS)	cryo-EM, X-ray crystallography	473	gp120	G	0.042	0.033	0.029	3BNC117 contact (shown in Supp Fig 2, referenced to Zhou2010 and Lyumkis2103)
559	2G12 contacts	Chuang2019	contacts	2G12(glycan)	cryo-EM	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	2G12 glycan contact
559	2G12 contacts	Chuang2019	contacts	2G12(glycan)	cryo-EM	332	gp120	N	0.663	0.491	0.693	2G12 glycan contact
559	2G12 contacts	Chuang2019	contacts	2G12(glycan)	cryo-EM	339	gp120	N	1.149	1.082	1.026	2G12 glycan contact
559	2G12 contacts	Chuang2019	contacts	2G12(glycan)	cryo-EM	392	gp120, V4 loop	N	0.605	0.454	0.804	2G12 glycan contact
559	2G12 contacts	Chuang2019	contacts	2G12(glycan)	cryo-EM	411	gp120, V4 loop	S	1.657	1.682	1.577	2G12 contact
560	N160 affects neutralization	Doria-Rose2016	neutralization	CH01(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160K in BG505 abrogates neutralization
561	N160 affects neutralization	Doria-Rose2014	neutralization	VRC26.01(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of N160 glycan decreased neutralization sensitivity in 3/4 strains tested; the lineage was evolving away from dependency on this glycan
562	N160 affects neutralization	Doria-Rose2014	neutralization	VRC26.02(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of N160 glycan decreased neutralization sensitivity in 2/4 strains tested; the lineage was evolving away from dependency on this glycan
563	N160 affects neutralization	Doria-Rose2014	neutralization	VRC26.04(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of N160 glycan decreased neutralization sensitivity in 2/4 strains tested; the lineage was evolving away from dependency on this glycan
564	N160 affects neutralization	Doria-Rose2014	neutralization	VRC26.05(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of N160 glycan decreased neutralization sensitivity in 3/4 strains tested; the lineage was evolving away from dependency on this glycan
565	N160 affects neutralization	Doria-Rose2014	neutralization	VRC26.06(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of N160 glycan decreased neutralization sensitivity in 3/4 strains tested; the lineage was evolving away from dependency on this glycan
566	N160 affects neutralization	Doria-Rose2014	neutralization	VRC26.10(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of N160 glycan decreased neutralization sensitivity in 2/4 strains tested; the lineage was evolving away from dependency on this glycan
567	N160 affects neutralization	Doria-Rose2014	neutralization	VRC26.11(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of N160 glycan decreased neutralization sensitivity in 3/4 strains tested; the lineage was evolving away from dependency on this glycan
568	Neutralization associated sites	Doria-Rose2016	neutralization	CH01(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of N160 glycan abrogated neutralization in all 7 strains tested
568	Neutralization associated sites	Doria-Rose2016	neutralization	CH01(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E in BG505 decreases neutralization
569	Neutralization associated sites	Doria-Rose2016	neutralization	CH04(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of N160 glycan abrogated neutralization in all 7 strains tested
569	Neutralization associated sites	Doria-Rose2016	neutralization	CH04(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E in BG505 decreases neutralization
570	Neutralization associated sites	Doria-Rose2016	neutralization	PG16(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of N160 glycan abrogated neutralization in all 7 strains tested
570	Neutralization associated sites	Doria-Rose2016	neutralization	PG16(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E in BG505 abrogates neutralization
571	Neutralization associated sites	Doria-Rose2016	neutralization	PG9(V2)	neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	removal of N156 glycan decreased neutralization in 2/3 strains tested, and increased neutralization in 1 strain
571	Neutralization associated sites	Doria-Rose2016	neutralization	PG9(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	Loss of N160 glycan abrogated neutralization in all 7 strains tested
571	Neutralization associated sites	Doria-Rose2016	neutralization	PG9(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E in BG505 abrogates neutralization
572	Neutralization associated sites	Doria-Rose2016	neutralization	PGT142(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160K in BG505 abrogates neutralization
572	Neutralization associated sites	Doria-Rose2016	neutralization	PGT142(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E in BG505 abrogates neutralization
573	Neutralization associated sites	Doria-Rose2016	neutralization	PGT145(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160K in BG505 abrogates neutralization
573	Neutralization associated sites	Doria-Rose2016	neutralization	PGT145(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E in BG505 abrogates neutralization
574	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.01(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
574	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.01(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
574	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.01(V2)	neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	K168A decreased neutralization of ConC by VRC26.01, but not by all lineage members
574	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.01(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
575	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.02(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
575	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.02(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
575	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.02(V2)	neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	K168A decreased neutralization of ConC by VRC26.02, but not by all lineage members
575	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.02(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
576	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.03(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
576	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.03(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
576	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.03(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
577	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.04(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
577	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.04(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
577	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.04(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
578	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.05(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
578	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.05(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
578	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.05(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
579	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.06(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
579	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.06(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
579	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.06(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
580	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.07(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
580	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.07(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
580	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.07(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
581	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.08(V2)	neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	removal of N156 glycan decreased neutralization in 2/3 strains tested
581	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.08(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
581	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.08(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
581	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.08(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
582	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.09(V2)	neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	removal of N156 glycan decreased neutralization in 2/3 strains tested
582	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.09(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160K in BG505 abrogates neutralization (although this mutation did not affect neutralization of other strains tested by Doria-Rose2014)
582	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.09(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
582	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.09(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
582	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.09(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members; K169E in BG505 abrogates neutralization by VRC26.09
583	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.10(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
583	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.10(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
583	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.10(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
584	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.11(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
584	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.11(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
584	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.11(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
585	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.12(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
585	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.12(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
585	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.12(V2)	neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	K168A decreased neutralization of ConC by VRC26.12, but not by all lineage members
585	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.12(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
586	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.13(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
586	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.13(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
586	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.13(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
587	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.14(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
587	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.14(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
587	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.14(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
588	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.15(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
588	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.15(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
588	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.15(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
589	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.16(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
589	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.16(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
589	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.16(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
590	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.17(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
590	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.17(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
590	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.17(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
591	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.18(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
591	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.18(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
591	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.18(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
592	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.19(V2)	neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	removal of N156 glycan decreased neutralization in 2/3 strains tested, and increased neutralization in 1 strain
592	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.19(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
592	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.19(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
592	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.19(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
593	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.20(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
593	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.20(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
593	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.20(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
594	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.21(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
594	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.21(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
594	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.21(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
595	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.22(V2)	neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	removal of N156 glycan decreased neutralization in 3/3 strains tested
595	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.22(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
595	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.22(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
595	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.22(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
596	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.23(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
596	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.23(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
596	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.23(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
597	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.24(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
597	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.24(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
597	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.24(V2)	neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	K168A decreased neutralization of ConC by VRC26.24, but not by all lineage members
597	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.24(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
598	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.26(V2)	neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	removal of N156 glycan decreased neutralization in 2/3 strains tested
598	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.26(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
598	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.26(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
598	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.26(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
599	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.27(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
599	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.27(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
599	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.27(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
600	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.28(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
600	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.28(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
600	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.28(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
601	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.29(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
601	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.29(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
601	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.29(V2)	neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	K168A decreased neutralization of ConC by VRC26.29, but not by all lineage members
601	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.29(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
602	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.30(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
602	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.30(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
602	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.30(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
603	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.31(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
603	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.31(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
603	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.31(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
604	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.32(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
604	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.32(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
604	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.32(V2)	neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	K168A decreased neutralization of ConC by VRC26.32, but not by all lineage members
604	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.32(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
605	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.33(V2)	neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	R166A abrogated neutralization of ConC by all 33 VRC26 lineage members
605	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.33(V2)	neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	D167N decreased neutralization of ConC by all 33 VRC26 lineage members
605	Neutralization associated sites	Doria-Rose2016	neutralization	VRC26.33(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E abrogated neutralization of ConC by all 33 VRC26 lineage members
606	Key contacts of CH235.9	Bonsignori2016	contacts	CH235.9(CD4BS)	negative stain EM, X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	N280 forms three hydrogen bonds with two residues in the CDR L3
606	Key contacts of CH235.9	Bonsignori2016	contacts	CH235.9(CD4BS)	negative stain EM, X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368 contacts the CDR H2 loop by electrostatic interactions
607	Key contacts of CH235.12	Bonsignori2016	contacts	CH235.12(CD4BS)	negative stain EM, X-ray crystallography	280	gp120, Loop D	N	0.142	0.090	0.170	N280 forms three hydrogen bonds with two residues in the CDR L3
607	Key contacts of CH235.12	Bonsignori2016	contacts	CH235.12(CD4BS)	negative stain EM, X-ray crystallography	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368 contacts the CDR H2 loop by electrostatic interactions
608	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38A(V3)	alanine scanning, neutralization assay	158	gp120, V2	S	0.263	0.185	0.291	S158A abrogates neutralization by PCDN 33A, 38A, 38B.
608	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38A(V3)	alanine scanning, neutralization assay	159	gp120, V2	F	0.104	0.034	0.038	F159A abrogates neutralization by PCDN 33A, 38A, 38B.
608	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38A(V3)	alanine scanning, neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	Loss of glycosylation site at N301 knocks out PCDN mAb neutralization; N301A abrogates neutralization by PCDN 33A, 38A, 38B.
608	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38A(V3)	alanine scanning, neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A abrogates neutralization by PCDN 33A, 38A, 38B.
608	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38A(V3)	alanine scanning, neutralization assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A abrogates neutralization by PCDN 38A, 38B.
608	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38A(V3)	alanine scanning, neutralization assay	328	gp120, V3 loop	Q	0.923	0.816	0.882	Early E328K or later A328K, along with deletion of glycan site at N335 by mutating T337A, causes sensitivity to PCDN antibodies.
608	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38A(V3)	alanine scanning, neutralization assay	332	gp120	N	0.663	0.491	0.693	Loss of glycosylation site at N332 knocks out PCDN mAb neutralization; N332A abrogates neutralization by PCDN 33A, 38A, 38B.
608	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38A(V3)	alanine scanning, neutralization assay	334	gp120	S	0.717	0.501	0.890	S334A abrogates neutralization by PCDN 33A, 38A, 38B.
608	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38A(V3)	alanine scanning, neutralization assay	335	gp120	R	1.898	1.758	1.937	Early E328K or later A328K, along with deletion of glycan site at N335 by mutating T337A, causes sensitivity to PCDN antibodies.
608	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38A(V3)	alanine scanning, neutralization assay	337	gp120	K	2.037	1.862	2.151	Early E328K or later A328K, along with deletion of glycan site at N335 by mutating T337A, causes sensitivity to PCDN antibodies.
609	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38B(V3)	alanine scanning, neutralization assay	158	gp120, V2	S	0.263	0.185	0.291	S158A abrogates neutralization by PCDN 33A, 38A, 38B.
609	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38B(V3)	alanine scanning, neutralization assay	159	gp120, V2	F	0.104	0.034	0.038	F159A abrogates neutralization by PCDN 33A, 38A, 38B.
609	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38B(V3)	alanine scanning, neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	Loss of glycosylation site at N301 knocks out PCDN mAb neutralization; N301A abrogates neutralization by PCDN 33A, 38A, 38B.
609	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38B(V3)	alanine scanning, neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A abrogates neutralization by PCDN 33A, 38A, 38B.
609	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38B(V3)	alanine scanning, neutralization assay	307	gp120, V3 loop	I	0.802	0.030	0.111	I307A abrogates neutralization by PCDN 38A, 38B.
609	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38B(V3)	alanine scanning, neutralization assay	328	gp120, V3 loop	Q	0.923	0.816	0.882	Early E328K or later A328K, along with deletion of glycan site at N335 by mutating T337A, causes sensitivity to PCDN antibodies.
609	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38B(V3)	alanine scanning, neutralization assay	332	gp120	N	0.663	0.491	0.693	Loss of glycosylation site at N332 knocks out PCDN mAb neutralization; N332A abrogates neutralization by PCDN 33A, 38A, 38B.
609	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38B(V3)	alanine scanning, neutralization assay	334	gp120	S	0.717	0.501	0.890	S334A abrogates neutralization by PCDN 33A, 38A, 38B.
609	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38B(V3)	alanine scanning, neutralization assay	335	gp120	R	1.898	1.758	1.937	Early E328K or later A328K, along with deletion of glycan site at N335 by mutating T337A, causes sensitivity to PCDN antibodies.
609	Sites affecting neutralization of PCDN lineage mAbs	MacLeod2016	neutralization	PCDN-38B(V3)	alanine scanning, neutralization assay	337	gp120	K	2.037	1.862	2.151	Early E328K or later A328K, along with deletion of glycan site at N335 by mutating T337A, causes sensitivity to PCDN antibodies.
610	Mutation affects PGT151 neutralization	Dingens2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	637	gp41	N	0.192	0.168	0.186	K was the most strongly selected escape mutation and it increased the IC50 by 3.7 fold
610	Mutation affects PGT151 neutralization	Dingens2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	647	gp41	E	0.328	0.372	0.224	E647G was the most strongly selected escape mutation with IC50 change of 5.3 fold
610	Mutation affects PGT151 neutralization	Dingens2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	648	gp41	E	1.506	1.332	1.379	E648K and E648R showed substantially reduced PGT151 neutralization (IC50 fold-change of 7.7 and 3.7, respectively); mutations to other amino acids (D, A, and H) had less than 1.5-fold change in IC50
611	Mutation affects PGT151 neutralization	Kong2016a	neutralization	PGT151(gp41 fusion domain)	neutralization assay	512	gp41, fusion peptide	A	0.188	0.260	0.110	A512W abrogates neutralization of CAP45
611	Mutation affects PGT151 neutralization	Kong2016a	neutralization	PGT151(gp41 fusion domain)	neutralization assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	G514W reduces neutralization of CAP45
611	Mutation affects PGT151 neutralization	Kong2016a	neutralization	PGT151(gp41 fusion domain)	neutralization assay	611	gp41	N	0.048	0.039	0.054	N611Q or N611D decreases PGT151 neutralization of BG505
612	Mutation affects PGT151 neutralization	vanGils2016	neutralization	PGT151(gp41 fusion domain)	neutralization assay	90	gp120	T	0.079	0.063	0.051	T90A in strain JRCSF decreases PGT151 neutralization 56-fold
612	Mutation affects PGT151 neutralization	vanGils2016	neutralization	PGT151(gp41 fusion domain)	neutralization assay	512	gp41, fusion peptide	A	0.188	0.260	0.110	A512W in strain JRCSF decreases PGT151 neutralization >240-fold
612	Mutation affects PGT151 neutralization	vanGils2016	neutralization	PGT151(gp41 fusion domain)	neutralization assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	G514W in strain JRCSF decreases PGT151 neutralization >240-fold
612	Mutation affects PGT151 neutralization	vanGils2016	neutralization	PGT151(gp41 fusion domain)	neutralization assay	521	gp41, fusion peptide	G	0.035	0.028	0.008	G521W in strain JRCSF decreases PGT151 neutralization 11-fold
612	Mutation affects PGT151 neutralization	vanGils2016	neutralization	PGT151(gp41 fusion domain)	neutralization assay	533	gp41	A	0.086	0.103	0.041	A533W in strain JRCSF decreases PGT151 neutralization >240-fold
612	Mutation affects PGT151 neutralization	vanGils2016	neutralization	PGT151(gp41 fusion domain)	neutralization assay	536	gp41	T	0.378	0.396	0.366	T536W in strain JRCSF decreases PGT151 neutralization 124-fold
612	Mutation affects PGT151 neutralization	vanGils2016	neutralization	PGT151(gp41 fusion domain)	neutralization assay	537	gp41	L	0.012	0.006	0.008	L537W in strain JRCSF decreases PGT151 neutralization >240-fold
612	Mutation affects PGT151 neutralization	vanGils2016	neutralization	PGT151(gp41 fusion domain)	neutralization assay	538	gp41	T	0.028	0.022	0.045	T538W in strain JRCSF decreases PGT151 neutralization 144-fold
612	Mutation affects PGT151 neutralization	vanGils2016	neutralization	PGT151(gp41 fusion domain)	neutralization assay	540	gp41, Leu/Ile zipper-like sequence	Q	0.038	0.029	0.072	Q540W in strain JRCSF decreases PGT151 neutralization >240-fold
613	Mutation affects PGT151 neutralization	Wibmer2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	501	gp120	A	0.107	0.017	0.221	A501C abrogates PGT151 neutralization of CAP45
613	Mutation affects PGT151 neutralization	Wibmer2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	502	gp120	K	0.547	0.512	0.348	R502A reduces PGT151 neutralization of CAP45
613	Mutation affects PGT151 neutralization	Wibmer2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	512	gp41, fusion peptide	A	0.188	0.260	0.110	A512W abrogates neutralization of CAP45
613	Mutation affects PGT151 neutralization	Wibmer2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	G514W reduces neutralization of CAP45
613	Mutation affects PGT151 neutralization	Wibmer2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	518	gp41, fusion peptide	L	1.166	1.110	0.718	V518W reduces PGT151 neutralization of CAP45
613	Mutation affects PGT151 neutralization	Wibmer2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	613	gp41	S	0.243	0.207	0.216	S613A reduces PGT151 neutralization of CAP45
613	Mutation affects PGT151 neutralization	Wibmer2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	641	gp41	L	1.694	1.530	0.830	T641A reduces PGT151 neutralization of CAP45
613	Mutation affects PGT151 neutralization	Wibmer2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	647	gp41	E	0.328	0.372	0.224	E647A abrogates neutralization of CAP45
613	Mutation affects PGT151 neutralization	Wibmer2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	654	gp41	E	0.167	0.174	0.105	E654A reduces PGT151 neutralization of CAP45
613	Mutation affects PGT151 neutralization	Wibmer2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	657	gp41	E	0.034	0.040	0.023	E657A reduces PGT151 neutralization of CAP45
613	Mutation affects PGT151 neutralization	Wibmer2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	659	gp41	E	0.755	0.523	0.383	D659A reduces PGT151 neutralization of CAP45
613	Mutation affects PGT151 neutralization	Wibmer2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	661	gp41	L	0.047	0.050	0.008	L661A reduces PGT151 neutralization of CAP45
613	Mutation affects PGT151 neutralization	Wibmer2017	neutralization	PGT151(gp41 fusion domain)	neutralization assay	663	gp41	L	0.092	0.094	0.053	L663A reduces PGT151 neutralization of CAP45
614	VRC01 functional escape mutation mapping	Dingens2019	other feature	VRC01(CD4BS)	mutational analysis, other, sequence analysis	120	gp120	V	0.070	0.046	0.046	BG505.T332N (V): site of viral escape - greatest effect with N (moderate)
614	VRC01 functional escape mutation mapping	Dingens2019	other feature	VRC01(CD4BS)	mutational analysis, other, sequence analysis	197	gp120	N	0.133	0.082	0.109	BG505.T332N (N): significant site of viral escape - greatest effects with T or S (very strong); glycosylation motif
614	VRC01 functional escape mutation mapping	Dingens2019	other feature	VRC01(CD4BS)	mutational analysis, other, sequence analysis	198	gp120	T	0.430	0.264	0.469	BG505.T332N (T): site of viral escape - greatest effect with A (moderate); glycosylation motif
614	VRC01 functional escape mutation mapping	Dingens2019	other feature	VRC01(CD4BS)	mutational analysis, other, sequence analysis	209	gp120	S	0.707	0.531	0.791	BG505.T332N (S): significant site of viral escape
614	VRC01 functional escape mutation mapping	Dingens2019	other feature	VRC01(CD4BS)	mutational analysis, other, sequence analysis	279	gp120, Loop D	D	0.900	0.850	0.898	BG505.T332N (N): significant site of viral escape in - greatest effects with R or L (moderate)
614	VRC01 functional escape mutation mapping	Dingens2019	other feature	VRC01(CD4BS)	mutational analysis, other, sequence analysis	326	gp120, V3 loop	M	0.143	0.143	0.116	BG505.T332N (I): significant site of viral escape - greatest effects with Y or G (moderate)
614	VRC01 functional escape mutation mapping	Dingens2019	other feature	VRC01(CD4BS)	mutational analysis, other, sequence analysis	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	BG505.T332N (L): significant site of viral escape - greatest effect with K (moderate)
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	119	gp120, Cys 119 linked to Cys 205	C	0.022	0.012	0.022	BG505.T332N (C): significant site of viral escape; greatest effect with Q (moderate)
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	120	gp120	V	0.070	0.046	0.046	BG505.T332N (V): significant site of viral escape
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	122	gp120	L	0.150	0.101	0.121	BG505.T332N (L): site of viral escape; greatest effect with V (moderate)
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	182	gp120, V2	I	0.830	0.957	0.587	BG505.T332N (V): significant site of viral escape
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	197	gp120	N	0.133	0.082	0.109	BG505.T332N (N): site of viral escape; greatest effect with S or T (very strong); glycosylation motif
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	204	gp120	A	0.156	0.127	0.131	BG505.T332N (A): significant site of viral escape
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	206	gp120	P	0.053	0.035	0.022	BG505.T332N (P): significant site of viral escape
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	207	gp120	K	0.065	0.029	0.029	BG505.T332N (K): significant site of viral escape; greatest effect with Q or N (moderate)
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	209	gp120	S	0.707	0.531	0.791	BG505.T332N (S): significant site of viral escape
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	274	gp120	S	0.209	0.121	0.230	BG505.T332N (S): significant site of viral escape; greatest effect with Y (moderate)
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	279	gp120, Loop D	D	0.900	0.850	0.898	BG505.T332N (N): significant site of viral escape, greatest effect with R (moderate)
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	304	gp120, V3 loop	R	0.304	0.390	0.141	BG505.T332N (R): significant site of viral escape; greatest effect with S (moderate)
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	308	gp120, V3 loop	R	1.578	0.091	0.127	BG505.T332N (R): significant site of viral escape; greatest effect with D (moderate)
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	318	gp120, V3 loop	V	0.588	0.691	0.507	BG505.T332N (Y): significant site of viral escape; greatest effect with E (moderate)
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	BG505.T332N (L): significant site of viral escape
615	3BNC117 functional escape mutation mapping	Dingens2019	other feature	3BNC117(CD4BS)	mutational analysis, other, sequence analysis	471	gp120, beta24	G	0.933	0.888	0.866	BG505.T332N (G): significant site of viral escape; greatest effects with L (strong) or I (moderate)
616	Mutation affects neutralization of V3 mAbs	Alam2017	neutralization	PGT121(V3)	neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A increased the resistance of the BG505 virus for neutralization by PGT121 and PGT128
616	Mutation affects neutralization of V3 mAbs	Alam2017	neutralization	PGT121(V3)	neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A increased the resistance of the RW020 virus for neutralization by PGT121, PGT128, VRC41.01, and VRC41.02
617	Mutation affects neutralization of V3 mAbs	Alam2017	neutralization	PGT128(V3)	neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A increased the resistance of the BG505 virus for neutralization by PGT121 and PGT128
617	Mutation affects neutralization of V3 mAbs	Alam2017	neutralization	PGT128(V3)	neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A increased the resistance of the RW020 virus for neutralization by PGT121, PGT128, VRC41.01, and VRC41.02
618	Mutation affects neutralization of V3 mAbs	Alam2017	neutralization	VRC41.01(V3)	neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A increased the resistance of the RW020 virus for neutralization by PGT121, PGT128, VRC41.01, and VRC41.02
618	Mutation affects neutralization of V3 mAbs	Alam2017	neutralization	VRC41.01(V3)	neutralization assay	332	gp120	N	0.663	0.491	0.693	T332N decreased the resistance of the BG505 virus for neutralization by VRC41.01 and VRC41.02
619	Mutation affects neutralization of V3 mAbs	Alam2017	neutralization	VRC41.02(V3)	neutralization assay	303	gp120, V3 loop	T	0.213	0.190	0.202	T303A increased the resistance of the RW020 virus for neutralization by PGT121, PGT128, VRC41.01, and VRC41.02
619	Mutation affects neutralization of V3 mAbs	Alam2017	neutralization	VRC41.02(V3)	neutralization assay	332	gp120	N	0.663	0.491	0.693	T332N decreased the resistance of the BG505 virus for neutralization by VRC41.01 and VRC41.02
620	Mutation affects binding of V3 mAbs	Alam2017	binding	PGT128(V3)	binding assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A decreased the binding of JRCSF by VRC41.01 and PGT128
620	Mutation affects binding of V3 mAbs	Alam2017	binding	PGT128(V3)	binding assay	332	gp120	N	0.663	0.491	0.693	 N332A reduced binding by VRC41.01, VRC41.02, PGT128, and DH563
621	Mutation affects binding of V3 mAbs	Alam2017	binding	VRC41.01(V3)	binding assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301A decreased the binding of JRCSF by VRC41.01 and PGT128
621	Mutation affects binding of V3 mAbs	Alam2017	binding	VRC41.01(V3)	binding assay	332	gp120	N	0.663	0.491	0.693	 N332A reduced binding by VRC41.01, VRC41.02, PGT128, and DH563
622	Mutation affects binding of V3 mAbs	Alam2017	binding	VRC41.02(V3)	binding assay	332	gp120	N	0.663	0.491	0.693	 N332A reduced binding by VRC41.01, VRC41.02, PGT128, and DH563
623	Mutation affects binding of V3 mAbs	Alam2017	binding	DH563(V3)	binding assay	332	gp120	N	0.663	0.491	0.693	 N332A reduced binding by VRC41.01, VRC41.02, PGT128, and DH563
624	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	b6(CD4BS)	binding assay	476	gp120	R	0.663	0.615	0.711	R476V mutation of subtype B strain YU2 decreases binding of mAb B6 to <25% of wt binding
625	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	b12(CD4BS)	binding assay	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH13, and VRC01 to <25% of wt binding; D368R mutation of subtype B strain YU2 decreases binding of mAbs VRC01, PGV04, and B12 to <25% of wt binding
625	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	b12(CD4BS)	binding assay	419	gp120	R	0.463	0.341	0.500	R419G mutation of subtype B strain YU2 decreases binding of mAb B12 to <25% of wt binding
625	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	b12(CD4BS)	binding assay	455	gp120, beta23	T	0.709	0.426	0.972	T455E mutation of subtype B strain YU2 decreases binding of mAb B12 to <25% of wt binding
626	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	CH13(CD4BS)	binding assay	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH13, and VRC01 to <25% of wt binding; D368R mutation of subtype B strain YU2 decreases binding of mAbs VRC01, PGV04, and B12 to <25% of wt binding
627	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	CH28(CD4BS)	binding assay	276	gp120, Loop D	N	0.118	0.063	0.169	N276A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH28, and HJ16 to <2% of wt binding
627	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	CH28(CD4BS)	binding assay	278	gp120, Loop D	T	0.708	0.715	0.481	T278A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH28, and HJ16 to <25% of wt binding
628	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	CH98(CD4BS)	binding assay	276	gp120, Loop D	N	0.118	0.063	0.169	N276A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH28, and HJ16 to <2% of wt binding
628	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	CH98(CD4BS)	binding assay	278	gp120, Loop D	T	0.708	0.715	0.481	T278A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH28, and HJ16 to <25% of wt binding
628	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	CH98(CD4BS)	binding assay	363	gp120	Q	1.825	1.587	1.352	delta371I/P363 double mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98 and VRC01 to <2% of wt binding
628	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	CH98(CD4BS)	binding assay	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH13, and VRC01 to <25% of wt binding; D368R mutation of subtype B strain YU2 decreases binding of mAbs VRC01, PGV04, and B12 to <25% of wt binding
628	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	CH98(CD4BS)	binding assay	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	delta371I/P363 double mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98 and VRC01 to <2% of wt binding
629	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	HJ16(CD4BS)	binding assay	276	gp120, Loop D	N	0.118	0.063	0.169	N276A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH28, and HJ16 to <2% of wt binding
629	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	HJ16(CD4BS)	binding assay	278	gp120, Loop D	T	0.708	0.715	0.481	T278A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH28, and HJ16 to <25% of wt binding
630	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	VRC01(CD4BS)	binding assay	363	gp120	Q	1.825	1.587	1.352	delta371I/P363 double mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98 and VRC01 to <2% of wt binding
630	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	VRC01(CD4BS)	binding assay	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH13, and VRC01 to <25% of wt binding; D368R mutation of subtype B strain YU2 decreases binding of mAbs VRC01, PGV04, and B12 to <25% of wt binding
630	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	VRC01(CD4BS)	binding assay	371	gp120, CD4 binding loop	I	0.466	0.389	0.507	delta371I/P363 double mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98 and VRC01 to <2% of wt binding
630	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	VRC01(CD4BS)	binding assay	473	gp120	G	0.042	0.033	0.029	G473R mutation of subtype B strain YU2 decreases binding of mAbs VRC01 and PGV04 to <25% of wt binding
631	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	VRC-PG04(CD4BS)	binding assay	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	S365K mutation of subtype B strain YU2 decreases binding of mAb PGV04 to <25% of wt binding
631	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	VRC-PG04(CD4BS)	binding assay	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	D368A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH13, and VRC01 to <25% of wt binding; D368R mutation of subtype B strain YU2 decreases binding of mAbs VRC01, PGV04, and B12 to <25% of wt binding
631	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	VRC-PG04(CD4BS)	binding assay	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	G459E mutation of subtype B strain YU2 decreases binding of mAb PGV04 to <25% of wt binding
631	Mutation decreases binding to CD4BS mAbs	Easterhoff2017	binding	VRC-PG04(CD4BS)	binding assay	473	gp120	G	0.042	0.033	0.029	G473R mutation of subtype B strain YU2 decreases binding of mAbs VRC01 and PGV04 to <25% of wt binding
632	Mutation affects neutralization	Gristick2016	neutralization	10-1074(V3)	neutralization assay	136	gp120, V1-hypervariable, V1	N	2.514	2.300	2.581	N136S in YU2 greatly enhances neutralization
633	Mutation affects neutralization	Gristick2016	neutralization	IOMA(CD4BS)	neutralization assay	276	gp120, Loop D	N	0.118	0.063	0.169	N276K in YU2 greatly enhances neutralization
634	Mutation affects neutralization	Gristick2016	neutralization	VRC01(CD4BS)	neutralization assay	197	gp120	N	0.133	0.082	0.109	N197K in YU2 greatly enhances neutralization
635	Mutation affects neutralization	Gristick2016	neutralization	NIH45-46(CD4BS)	neutralization assay	197	gp120	N	0.133	0.082	0.109	N197K in YU2 greatly enhances neutralization
635	Mutation affects neutralization	Gristick2016	neutralization	NIH45-46(CD4BS)	neutralization assay	276	gp120, Loop D	N	0.118	0.063	0.169	N276K in YU2 greatly enhances neutralization
635	Mutation affects neutralization	Gristick2016	neutralization	NIH45-46(CD4BS)	neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	N301S in YU2 greatly enhances neutralization
636	10-1074 neutralization	Schommers2020	neutralization	10-1074(V3)	neutralization assay	332	gp120	N	0.663	0.491	0.693	YU2 mutations N332K, N332S, or N332Y decrease 10-1074 neutralization >9 fold
636	10-1074 neutralization	Schommers2020	neutralization	10-1074(V3)	neutralization assay	334	gp120	S	0.717	0.501	0.890	YU2 mutations S334D or S334N decrease 10-1074 neutralization >9 fold
637	Removal of glycosylation sites confers binding to germline-reverted NIH45-46 and VRC01	McGuire2013	binding	glNIH45-46(CD4BS)	binding assay	276	gp120, Loop D	N	0.118	0.063	0.169	Elimination of the 276 NLGS from the 426c Env confers binding to germline-reverted NIH45-46 and VRC01. If NLGS at positions 460 and 463 are also eliminated, the binding is improved.
637	Removal of glycosylation sites confers binding to germline-reverted NIH45-46 and VRC01	McGuire2013	binding	glNIH45-46(CD4BS)	binding assay	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	In combination with the elimination of the 276 NLGS, elimination of the 460 and 463 (V5) from the 426c Env confers and improves binding to germline-reverted NIH45-46 and VRC01.
637	Removal of glycosylation sites confers binding to germline-reverted NIH45-46 and VRC01	McGuire2013	binding	glNIH45-46(CD4BS)	binding assay	463	gp120, V5-hypervariable, V5 loop	N	2.097	1.967	2.042	In combination with the elimination of the 276 NLGS, elimination of the 460 and 463 (V5) from the 426c Env confers and improves binding to germline-reverted NIH45-46 and VRC01.
638	Mutation affects neutralization by 2F5 and 4E10	Tang2023	neutralization	2F5(MPER)	neutralization assay	659	gp41	E	0.755	0.523	0.383	E659D increased the IC50 up to 9-fold for 4E10 and 4-fold for 2F5
638	Mutation affects neutralization by 2F5 and 4E10	Tang2023	neutralization	2F5(MPER)	neutralization assay	677	gp41	N	1.203	1.199	1.100	K677R increased the IC50 2-fold for 4E10 and 2F5
639	Mutation affects neutralization by 2F5 and 4E10	Tang2023	neutralization	4E10(MPER)	neutralization assay	659	gp41	E	0.755	0.523	0.383	E659D increased the IC50 up to 9-fold for 4E10 and 4-fold for 2F5
639	Mutation affects neutralization by 2F5 and 4E10	Tang2023	neutralization	4E10(MPER)	neutralization assay	677	gp41	N	1.203	1.199	1.100	K677R increased the IC50 2-fold for 4E10 and 2F5
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	660	gp41	L	0.020	0.006	0.000	L660A increases sensitivity to 2F5 and 4E10 and decreases viral infectivity
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	661	gp41	L	0.047	0.050	0.008	L661A increases sensitivity to 2F5 and 4E10
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	663	gp41	L	0.092	0.094	0.053	L663A increases sensitivity to 2F5 and 4E10
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	664	gp41	D	0.222	0.156	0.346	D664A increases resistance to 2F5, but not 4E10 
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	665	gp41	K	1.039	0.656	0.879	K665A increases resistance to 2F5, but not 4E10 
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	666	gp41	W	0.008	0.000	0.000	W666A increases resistance to 2F5, increases sensitivity to 4E10, and greatly decreases viral infectivity 
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	669	gp41	L	0.017	0.023	0.000	L669A increases sensitivity to 2F5 and 4E10 and decreases viral infectivity
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	670	gp41	W	0.043	0.028	0.035	W670A increases sensitivity to 2F5 and 4E10
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	671	gp41	N	0.783	0.669	0.885	N671A increases sensitivity to 2F5 and 4E10
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A increases sensitivity to 2F5, increases resistance to 4E10, and decreases viral infectivity; W672F or W672Y increases sensitivity to both 2F5 and 4E10 
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A increases sensitivity to 2F5, but increases resistance to 4E10 
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	675	gp41	I	0.063	0.059	0.069	I675A increases sensitivity to 2F5 and 4E10 and decreases viral infectivity
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	W678A increases sensitivity to 2F5 and 4E10
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	L679A increases sensitivity to 2F5 and 4E10 and decreases viral infectivity
640	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	2F5(MPER)	neutralization assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A increases sensitivity to 2F5, but increases resistance to 4E10 
641	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	4E10(MPER)	neutralization assay	660	gp41	L	0.020	0.006	0.000	L660A increases sensitivity to 2F5 and 4E10 and decreases viral infectivity
641	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	4E10(MPER)	neutralization assay	661	gp41	L	0.047	0.050	0.008	L661A increases sensitivity to 2F5 and 4E10
641	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	4E10(MPER)	neutralization assay	663	gp41	L	0.092	0.094	0.053	L663A increases sensitivity to 2F5 and 4E10
641	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	4E10(MPER)	neutralization assay	666	gp41	W	0.008	0.000	0.000	W666A increases resistance to 2F5, increases sensitivity to 4E10, and greatly decreases viral infectivity 
641	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	4E10(MPER)	neutralization assay	669	gp41	L	0.017	0.023	0.000	L669A increases sensitivity to 2F5 and 4E10 and decreases viral infectivity
641	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	4E10(MPER)	neutralization assay	670	gp41	W	0.043	0.028	0.035	W670A increases sensitivity to 2F5 and 4E10
641	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	4E10(MPER)	neutralization assay	671	gp41	N	0.783	0.669	0.885	N671A increases sensitivity to 2F5 and 4E10
641	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	4E10(MPER)	neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A increases sensitivity to 2F5, increases resistance to 4E10, and decreases viral infectivity; W672F or W672Y increases sensitivity to both 2F5 and 4E10 
641	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	4E10(MPER)	neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A increases sensitivity to 2F5, but increases resistance to 4E10 
641	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	4E10(MPER)	neutralization assay	675	gp41	I	0.063	0.059	0.069	I675A increases sensitivity to 2F5 and 4E10 and decreases viral infectivity
641	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	4E10(MPER)	neutralization assay	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	W678A increases sensitivity to 2F5 and 4E10
641	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	4E10(MPER)	neutralization assay	679	gp41, gp41 transmembrane	L	0.021	0.034	0.008	L679A increases sensitivity to 2F5 and 4E10 and decreases viral infectivity
641	Mutation affects neutralization by 2F5 and 4E10	Zwick2005	neutralization	4E10(MPER)	neutralization assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A increases sensitivity to 2F5, but increases resistance to 4E10 
642	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	4E10(MPER)	neutralization assay	662	gp41	E	1.043	0.874	0.369	A662G increased sensitivity 10-fold or more for PGXZL1, H4K3, 4E10
642	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	4E10(MPER)	neutralization assay	666	gp41	W	0.008	0.000	0.000	W666A increased sensitivity 10-fold or more for PGXZL1, H4K3, 4E10
642	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	4E10(MPER)	neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A increased resistance 10-fold or more for PGXZL1, H4K3, 4E10
642	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	4E10(MPER)	neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A increased resistance 10-fold or more for PGXZL1, H4K3, 4E10
642	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	4E10(MPER)	neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A, D674E or D674T increased resistance 10-fold or more for PGXZL1, H4K3, 4E10
642	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	4E10(MPER)	neutralization assay	675	gp41	I	0.063	0.059	0.069	I675A increased sensitivity 10-fold or more for 4E10
642	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	4E10(MPER)	neutralization assay	677	gp41	N	1.203	1.199	1.100	K677A increased sensitivity 10-fold or more for H4K3, 4E10
642	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	4E10(MPER)	neutralization assay	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	W678A increased sensitivity 10-fold or more for PGXZL1, H4K3, 4E10
643	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1.H4K3(MPER)	neutralization assay	662	gp41	E	1.043	0.874	0.369	A662G increased sensitivity 10-fold or more for PGXZL1, H4K3, 4E10
643	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1.H4K3(MPER)	neutralization assay	663	gp41	L	0.092	0.094	0.053	L663A increased sensitivity 10-fold or more for H4K3
643	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1.H4K3(MPER)	neutralization assay	666	gp41	W	0.008	0.000	0.000	W666A increased sensitivity 10-fold or more for PGXZL1, H4K3, 4E10
643	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1.H4K3(MPER)	neutralization assay	669	gp41	L	0.017	0.023	0.000	L669A increased sensitivity 10-fold or more for H4K3
643	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1.H4K3(MPER)	neutralization assay	671	gp41	N	0.783	0.669	0.885	S671A increased resistance 10-fold or more for H4K3
643	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1.H4K3(MPER)	neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A increased resistance 10-fold or more for PGXZL1, H4K3, 4E10
643	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1.H4K3(MPER)	neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A increased resistance 10-fold or more for PGXZL1, H4K3, 4E10
643	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1.H4K3(MPER)	neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A, D674E or D674T increased resistance 10-fold or more for PGXZL1, H4K3, 4E10
643	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1.H4K3(MPER)	neutralization assay	677	gp41	N	1.203	1.199	1.100	K677A increased sensitivity 10-fold or more for H4K3, 4E10
643	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1.H4K3(MPER)	neutralization assay	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	W678A increased sensitivity 10-fold or more for PGXZL1, H4K3, 4E10
643	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1.H4K3(MPER)	neutralization assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A increased resistance 10-fold or more for PGXZL1, H4K3
644	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1(MPER)	neutralization assay	662	gp41	E	1.043	0.874	0.369	A662G increased sensitivity 10-fold or more for PGXZL1, H4K3, 4E10
644	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1(MPER)	neutralization assay	666	gp41	W	0.008	0.000	0.000	W666A increased sensitivity 10-fold or more for PGXZL1, H4K3, 4E10
644	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1(MPER)	neutralization assay	672	gp41	W	0.014	0.023	0.014	W672A increased resistance 10-fold or more for PGXZL1, H4K3, 4E10
644	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1(MPER)	neutralization assay	673	gp41	F	0.048	0.065	0.073	F673A increased resistance 10-fold or more for PGXZL1, H4K3, 4E10
644	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1(MPER)	neutralization assay	674	gp41	N	1.179	1.029	1.344	D674A, D674E or D674T increased resistance 10-fold or more for PGXZL1, H4K3, 4E10
644	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1(MPER)	neutralization assay	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.012	0.018	0.008	W678A increased sensitivity 10-fold or more for PGXZL1, H4K3, 4E10
644	Mutation affects neutralization by PGZL1, H4K3, or 4E10	Zhang2019a	neutralization	PGZL1(MPER)	neutralization assay	680	gp41, gp41 transmembrane	W	0.090	0.083	0.081	W680A increased resistance 10-fold or more for PGXZL1, H4K3
645	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1400(V2)	alanine scanning, neutralization assay	127	gp120	V	0.102	0.112	0.093	BG505 V127A associated with resistance to neutralization
645	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1400(V2)	alanine scanning, neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	BG505 N156K associated with resistance to neutralization
645	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1400(V2)	alanine scanning, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	BG505 N160K or N160A associated with resistance to neutralization
645	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1400(V2)	alanine scanning, neutralization assay	161	gp120, V2	I	1.493	0.964	1.568	BG505 M161A associated with resistance to neutralization
645	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1400(V2)	alanine scanning, neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	BG505 T162A associated with resistance to neutralization
645	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1400(V2)	alanine scanning, neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	BG505 R166A associated with resistance to neutralization
645	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1400(V2)	alanine scanning, neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	BG505 D167A associated with resistance to neutralization
645	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1400(V2)	alanine scanning, neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	BG505 K168A associated with resistance to neutralization
645	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1400(V2)	alanine scanning, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	BG505 K169A associated with resistance to neutralization
646	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1401(V2)	alanine scanning, neutralization assay	127	gp120	V	0.102	0.112	0.093	BG505 V127A associated with resistance to neutralization
646	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1401(V2)	alanine scanning, neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	BG505 N156K associated with resistance to neutralization
646	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1401(V2)	alanine scanning, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	BG505 N160K or N160A associated with resistance to neutralization
646	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1401(V2)	alanine scanning, neutralization assay	161	gp120, V2	I	1.493	0.964	1.568	BG505 M161A associated with resistance to neutralization
646	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1401(V2)	alanine scanning, neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	BG505 T162A associated with resistance to neutralization
646	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1401(V2)	alanine scanning, neutralization assay	165	gp120, V2	I	1.327	1.292	1.011	BG505 L165A associated with resistance to neutralization
646	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1401(V2)	alanine scanning, neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	BG505 R166A associated with resistance to neutralization
646	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1401(V2)	alanine scanning, neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	BG505 D167A associated with resistance to neutralization
646	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1401(V2)	alanine scanning, neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	BG505 K168A associated with resistance to neutralization
646	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGDM1401(V2)	alanine scanning, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	BG505 K169A associated with resistance to neutralization
647	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT143(V2)	alanine scanning, neutralization assay	121	gp120	K	0.349	0.360	0.187	BG505 K121A associated with resistance to neutralization
647	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT143(V2)	alanine scanning, neutralization assay	127	gp120	V	0.102	0.112	0.093	BG505 V127A associated with resistance to neutralization
647	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT143(V2)	alanine scanning, neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	BG505 N156K associated with resistance to neutralization
647	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT143(V2)	alanine scanning, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	BG505 N160K or N160A associated with resistance to neutralization
647	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT143(V2)	alanine scanning, neutralization assay	161	gp120, V2	I	1.493	0.964	1.568	BG505 M161A associated with resistance to neutralization
647	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT143(V2)	alanine scanning, neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	BG505 T162A associated with resistance to neutralization
647	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT143(V2)	alanine scanning, neutralization assay	165	gp120, V2	I	1.327	1.292	1.011	BG505 L165A associated with resistance to neutralization
647	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT143(V2)	alanine scanning, neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	BG505 R166A associated with resistance to neutralization
647	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT143(V2)	alanine scanning, neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	BG505 D167A associated with resistance to neutralization
647	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT143(V2)	alanine scanning, neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	BG505 K168A associated with resistance to neutralization
647	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT143(V2)	alanine scanning, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	BG505 K169A associated with resistance to neutralization
648	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT145(V2)	alanine scanning, neutralization assay	121	gp120	K	0.349	0.360	0.187	BG505 K121A associated with resistance to neutralization
648	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT145(V2)	alanine scanning, neutralization assay	127	gp120	V	0.102	0.112	0.093	BG505 V127A associated with resistance to neutralization
648	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT145(V2)	alanine scanning, neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	BG505 N156K associated with resistance to neutralization
648	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT145(V2)	alanine scanning, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	BG505 N160K or N160A associated with resistance to neutralization
648	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT145(V2)	alanine scanning, neutralization assay	161	gp120, V2	I	1.493	0.964	1.568	BG505 M161A associated with resistance to neutralization
648	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT145(V2)	alanine scanning, neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	BG505 T162A associated with resistance to neutralization
648	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT145(V2)	alanine scanning, neutralization assay	165	gp120, V2	I	1.327	1.292	1.011	BG505 L165A associated with resistance to neutralization
648	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT145(V2)	alanine scanning, neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	BG505 R166A associated with resistance to neutralization
648	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT145(V2)	alanine scanning, neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	BG505 D167A associated with resistance to neutralization
648	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT145(V2)	alanine scanning, neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	BG505 K168A associated with resistance to neutralization
648	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT145(V2)	alanine scanning, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	BG505 K169A associated with resistance to neutralization
648	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PGT145(V2)	alanine scanning, neutralization assay	420	gp120	I	0.093	0.049	0.078	BG505 I420A associated with resistance to neutralization
649	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PG9(V2)	alanine scanning, neutralization assay	127	gp120	V	0.102	0.112	0.093	BG505 V127A associated with resistance to neutralization
649	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PG9(V2)	alanine scanning, neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	BG505 N156K associated with resistance to neutralization
649	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PG9(V2)	alanine scanning, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	BG505 N160K or N160A associated with resistance to neutralization
649	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PG9(V2)	alanine scanning, neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	BG505 T162A associated with resistance to neutralization
649	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	PG9(V2)	alanine scanning, neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	BG505 K168A associated with resistance to neutralization
650	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	CH01(V2)	alanine scanning, neutralization assay	121	gp120	K	0.349	0.360	0.187	BG505 K121A associated with sensitivity
650	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	CH01(V2)	alanine scanning, neutralization assay	127	gp120	V	0.102	0.112	0.093	BG505 V127A associated with resistance to neutralization
650	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	CH01(V2)	alanine scanning, neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	BG505 N156K associated with resistance to neutralization
650	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	CH01(V2)	alanine scanning, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	BG505 N160K or N160A associated with resistance to neutralization
650	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	CH01(V2)	alanine scanning, neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	BG505 T162A associated with resistance to neutralization
650	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	CH01(V2)	alanine scanning, neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	BG505 K168A associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	121	gp120	K	0.349	0.360	0.187	BG505 K121A associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	127	gp120	V	0.102	0.112	0.093	BG505 V127A associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	BG505 N156K associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	BG505 N160K or N160A associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	162	gp120, V2	S	0.353	0.445	0.179	BG505 T162A associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	164	gp120, V2	S	1.840	1.925	0.453	BG505 E164A associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	165	gp120, V2	I	1.327	1.292	1.011	BG505 L165A associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	166	gp120, V2	R	1.237	1.398	0.772	BG505 R166A associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	167	gp120, V2	G	0.779	1.122	0.185	BG505 D167A associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	168	gp120, V2	K	0.566	0.666	0.396	BG505 K168A associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	BG505 K169A associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	307	gp120, V3 loop	I	0.802	0.030	0.111	BG505 I307A associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	420	gp120	I	0.093	0.049	0.078	BG505 I420A associated with resistance to neutralization
651	Mutation causes resistance to V2 bnAbs	Lee2017	neutralization	VRC26.09(V2)	alanine scanning, neutralization assay	423	gp120, beta20/beta21	I	0.433	0.383	0.411	BG505 I423A associated with resistance to neutralization
652	VRC01 mutations affecting neutralization	Dingens2019	neutralization	VRC01(CD4BS)	neutralization assay	113	gp120	D	0.138	0.092	0.134	D113N mediated a 4.1-fold decrease in neutralization potency in BG505.T332N
652	VRC01 mutations affecting neutralization	Dingens2019	neutralization	VRC01(CD4BS)	neutralization assay	119	gp120, Cys 119 linked to Cys 205	C	0.022	0.012	0.022	C119R mediated a 1.6-fold decrease in neutralization potency in BG505.T332N
652	VRC01 mutations affecting neutralization	Dingens2019	neutralization	VRC01(CD4BS)	neutralization assay	140	gp120, V1-hypervariable, V1	T	2.235	2.104	2.340	D140E mediated a 1.8-fold decrease in neutralization potency in BG505.T332N
652	VRC01 mutations affecting neutralization	Dingens2019	neutralization	VRC01(CD4BS)	neutralization assay	151	gp120, V1-hypervariable, V1	K	2.575	2.285	2.605	R151K mediated a 1.7-fold decrease in neutralization potency in BG505.T332N
652	VRC01 mutations affecting neutralization	Dingens2019	neutralization	VRC01(CD4BS)	neutralization assay	197	gp120	N	0.133	0.082	0.109	N197E and N197S mediated respective ~50-fold increase and 26-fold decrease in neutralization potency; glycosylation motif in BG505.T332N
652	VRC01 mutations affecting neutralization	Dingens2019	neutralization	VRC01(CD4BS)	neutralization assay	198	gp120	T	0.430	0.264	0.469	T198A mediated a 3.6-fold decrease in neutralization potency; glycosylation motif in BG505.T332N
652	VRC01 mutations affecting neutralization	Dingens2019	neutralization	VRC01(CD4BS)	neutralization assay	279	gp120, Loop D	D	0.900	0.850	0.898	N279K mediated a >175-fold decrease in neutralization potency in BG505.T332N
652	VRC01 mutations affecting neutralization	Dingens2019	neutralization	VRC01(CD4BS)	neutralization assay	326	gp120, V3 loop	M	0.143	0.143	0.116	I326Y mediated a 2.9-fold decrease in neutralization potency in BG505.T332N
652	VRC01 mutations affecting neutralization	Dingens2019	neutralization	VRC01(CD4BS)	neutralization assay	327	gp120, V3 loop	R	0.089	0.066	0.073	R327A mediated a 1.3-fold decrease in neutralization potency in BG505.T332N
652	VRC01 mutations affecting neutralization	Dingens2019	neutralization	VRC01(CD4BS)	neutralization assay	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	L369K mediated a 4.01-fold decrease in neutralization potency in BG505.T332N
652	VRC01 mutations affecting neutralization	Dingens2019	neutralization	VRC01(CD4BS)	neutralization assay	441	gp120	G	0.045	0.041	0.037	G441P mediated a 1.4-fold decrease in neutralization potency in BG505.T332N
653	Mutation affects neutralization	Schommers2020	neutralization	VRC01(CD4BS)	neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	YU2 double mutation T278I/A281T decreases VRC01 neutralization >20 fold
653	Mutation affects neutralization	Schommers2020	neutralization	VRC01(CD4BS)	neutralization assay	279	gp120, Loop D	D	0.900	0.850	0.898	YU2 mutation N279K decreases VRC01 neutralization >20 fold
653	Mutation affects neutralization	Schommers2020	neutralization	VRC01(CD4BS)	neutralization assay	280	gp120, Loop D	N	0.142	0.090	0.170	YU2 mutation N280Y decreases VRC01 neutralization >20 fold
653	Mutation affects neutralization	Schommers2020	neutralization	VRC01(CD4BS)	neutralization assay	281	gp120, Loop D	A	1.129	0.814	1.357	YU2 mutation A281T, or double mutation T278I/A281T, decreases VRC01 neutralization >20 fold
654	Mutation affects neutralization	Schommers2020	neutralization	8ANC195(gp120/gp41 interface)	neutralization assay	276	gp120, Loop D	N	0.118	0.063	0.169	YU2 N276D decreases 8ANC195 neutralization >5 fold
654	Mutation affects neutralization	Schommers2020	neutralization	8ANC195(gp120/gp41 interface)	neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	YU2 T278K, T278A, or T278I decreases 8ANC195 neutralization >5 fold; double mutation T278I/A281T decreases 8ANC195 neutralization >5 fold
654	Mutation affects neutralization	Schommers2020	neutralization	8ANC195(gp120/gp41 interface)	neutralization assay	281	gp120, Loop D	A	1.129	0.814	1.357	YU2 double mutation T278I/A281T decreases 8ANC195 neutralization >5 fold
655	Mutation affects neutralization	Kong2016a	neutralization	2G12(glycan)	neutralization assay	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.369	0.739	1.557	N295A decreases 2G12 neutralization of JRCSF by >218 fold
655	Mutation affects neutralization	Kong2016a	neutralization	2G12(glycan)	neutralization assay	332	gp120	N	0.663	0.491	0.693	N332A decreases 2G12 neutralization of JRCSF by >218 fold
655	Mutation affects neutralization	Kong2016a	neutralization	2G12(glycan)	neutralization assay	339	gp120	N	1.149	1.082	1.026	N339A decreases 2G12 neutralization of JRCSF by 27.5 fold
655	Mutation affects neutralization	Kong2016a	neutralization	2G12(glycan)	neutralization assay	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.451	0.494	0.392	N386A decreases 2G12 neutralization of JRCSF by 50 fold
655	Mutation affects neutralization	Kong2016a	neutralization	2G12(glycan)	neutralization assay	392	gp120, V4 loop	N	0.605	0.454	0.804	N392A decreases 2G12 neutralization of JRCSF by >218 fold
656	Mutation affects neutralization	Kong2016a	neutralization	PG9(V2)	neutralization assay	160	gp120, V2	N	0.416	0.452	0.358	N160A in BG505 decreases PG9 neutralization by >1000 fold
656	Mutation affects neutralization	Kong2016a	neutralization	PG9(V2)	neutralization assay	169	gp120, V2	V	2.042	1.770	1.344	K169E in BG505 decreases PG9 neutralization by >1000 fold
657	Mutations associated with immunotherapy	Barnes2022	immunotherapy	BG24(CD4BS)	sequence analysis	276	gp120, Loop D	N	0.118	0.063	0.169	YU2-infected mice injected with BG24 developed N276D mutation at high frequency
657	Mutations associated with immunotherapy	Barnes2022	immunotherapy	BG24(CD4BS)	sequence analysis	279	gp120, Loop D	D	0.900	0.850	0.898	YU2-infected mice injected with BG24 or VRC01 developed N279K mutation at high frequency
657	Mutations associated with immunotherapy	Barnes2022	immunotherapy	BG24(CD4BS)	sequence analysis	280	gp120, Loop D	N	0.142	0.090	0.170	YU2-infected mice injected with BG24 or VRC01 developed N280D mutation at high frequency
657	Mutations associated with immunotherapy	Barnes2022	immunotherapy	BG24(CD4BS)	sequence analysis	366	gp120, CD4 binding loop	G	0.043	0.012	0.028	YU2-infected mice injected with BG24 developed G366R mutation at high frequency
657	Mutations associated with immunotherapy	Barnes2022	immunotherapy	BG24(CD4BS)	sequence analysis	458	gp120, beta23	G	0.112	0.045	0.095	YU2-infected mice injected with BG24 or VRC01 developed G459 mutations at high frequency
658	Mutations associated with immunotherapy	Barnes2022	immunotherapy	VRC01(CD4BS)	sequence analysis	279	gp120, Loop D	D	0.900	0.850	0.898	YU2-infected mice injected with BG24 or VRC01 developed N279K mutation at high frequency
658	Mutations associated with immunotherapy	Barnes2022	immunotherapy	VRC01(CD4BS)	sequence analysis	280	gp120, Loop D	N	0.142	0.090	0.170	YU2-infected mice injected with BG24 or VRC01 developed N280D mutation at high frequency
658	Mutations associated with immunotherapy	Barnes2022	immunotherapy	VRC01(CD4BS)	sequence analysis	375	gp120	S	0.668	0.753	0.372	YU2-infected mice injected with VRC01 developed S375R mutation at high frequency
658	Mutations associated with immunotherapy	Barnes2022	immunotherapy	VRC01(CD4BS)	sequence analysis	458	gp120, beta23	G	0.112	0.045	0.095	YU2-infected mice injected with BG24 or VRC01 developed G459 mutations at high frequency
659	Mutation abrogates neutralization	Barnes2022	neutralization	BG24(CD4BS)	neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	T278I/A281T double mutant in YU2 abrogates BG24 and VRC01 neutralization
659	Mutation abrogates neutralization	Barnes2022	neutralization	BG24(CD4BS)	neutralization assay	279	gp120, Loop D	D	0.900	0.850	0.898	N279K in YU2 abrogates BG24 neutralization; N279H in YU2 abrogates BG24 neutralization, but not VRC01
659	Mutation abrogates neutralization	Barnes2022	neutralization	BG24(CD4BS)	neutralization assay	280	gp120, Loop D	N	0.142	0.090	0.170	N280Y in YU2 abrogates BG24 and VRC01 neutralization
659	Mutation abrogates neutralization	Barnes2022	neutralization	BG24(CD4BS)	neutralization assay	281	gp120, Loop D	A	1.129	0.814	1.357	A281T or T278I/A281T double mutant in YU2 abrogates or greatly reduces BG24 and VRC01 neutralization
660	Mutation abrogates neutralization	Barnes2022	neutralization	VRC01(CD4BS)	neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	T278I/A281T double mutant in YU2 abrogates BG24 and VRC01 neutralization
660	Mutation abrogates neutralization	Barnes2022	neutralization	VRC01(CD4BS)	neutralization assay	280	gp120, Loop D	N	0.142	0.090	0.170	N280Y in YU2 abrogates BG24 and VRC01 neutralization
660	Mutation abrogates neutralization	Barnes2022	neutralization	VRC01(CD4BS)	neutralization assay	281	gp120, Loop D	A	1.129	0.814	1.357	A281T or T278I/A281T double mutant in YU2 abrogates or greatly reduces BG24 and VRC01 neutralization
661	VRC26.25 contacts	Yin2021	contacts	VRC26.25(V2)	cryo-EM	160	gp120, V2	N	0.416	0.452	0.358	HC Q100n contacts a critical glycan at SOSIP N160
661	VRC26.25 contacts	Yin2021	contacts	VRC26.25(V2)	cryo-EM	170	gp120, V2	Q	1.493	1.423	1.428	HC E100b interacts with a network basic of residues including SOSIP R170
662	vFP1.01 residues important for binding BG505	Xu2018	binding	vFP1.01(gp41 fusion domain)	alanine scanning, binding assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	Gly mutant reduced binding to 0.12 of BG505 Val
662	vFP1.01 residues important for binding BG505	Xu2018	binding	vFP1.01(gp41 fusion domain)	alanine scanning, binding assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	Ala mutant reduced binding to 0.24 of BG505 Gly
662	vFP1.01 residues important for binding BG505	Xu2018	binding	vFP1.01(gp41 fusion domain)	alanine scanning, binding assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	Ala and Gly mutants respectively reduced binding to 0.44 and 0.05 of BG505 Ile
663	vFP5.01 residues important for binding BG505	Xu2018	binding	vFP5.01(gp41 fusion domain)	alanine scanning, binding assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	Ala and Gly mutants respectively reduced binding to 0.59 and 0.43 of BG505 Val
663	vFP5.01 residues important for binding BG505	Xu2018	binding	vFP5.01(gp41 fusion domain)	alanine scanning, binding assay	514	gp41, fusion peptide	G	0.600	0.691	0.502	Ala mutant reduced binding to 0.41 of BG505 Gly
663	vFP5.01 residues important for binding BG505	Xu2018	binding	vFP5.01(gp41 fusion domain)	alanine scanning, binding assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	Ala and Gly mutants respectively reduced binding to 0.07 and 0.01 of BG505 Ile
663	vFP5.01 residues important for binding BG505	Xu2018	binding	vFP5.01(gp41 fusion domain)	alanine scanning, binding assay	516	gp41, fusion peptide	G	0.066	0.038	0.048	Ala mutant reduced binding to 0.56 of BG505 Gly
663	vFP5.01 residues important for binding BG505	Xu2018	binding	vFP5.01(gp41 fusion domain)	alanine scanning, binding assay	519	gp41, fusion peptide	F	0.518	0.243	0.837	Ala and Gly mutants respectively reduced binding to 0.14 and 0.09 of BG505 Phe
664	VRC34.01 residues important for binding BG505	Xu2018	binding	VRC34.01(gp41 fusion domain)	alanine scanning, binding assay	512	gp41, fusion peptide	A	0.188	0.260	0.110	Gly mutant reduced binding to 0.52 of BG505 Ala
664	VRC34.01 residues important for binding BG505	Xu2018	binding	VRC34.01(gp41 fusion domain)	alanine scanning, binding assay	513	gp41, fusion peptide	V	0.761	0.736	0.506	Ala and Gly mutants respectively reduced binding to 0.05 and 0.00 of BG505 Val
664	VRC34.01 residues important for binding BG505	Xu2018	binding	VRC34.01(gp41 fusion domain)	alanine scanning, binding assay	515	gp41, fusion peptide	I	1.103	1.147	0.877	Ala and Gly mutants respectively reduced binding to 0.03 and 0.00 of BG505 Ile
664	VRC34.01 residues important for binding BG505	Xu2018	binding	VRC34.01(gp41 fusion domain)	alanine scanning, binding assay	516	gp41, fusion peptide	G	0.066	0.038	0.048	Ala mutant reduced binding to 0.01 of BG505 Gly
664	VRC34.01 residues important for binding BG505	Xu2018	binding	VRC34.01(gp41 fusion domain)	alanine scanning, binding assay	518	gp41, fusion peptide	L	1.166	1.110	0.718	Ala and Gly mutants respectively reduced binding to 0.73 and 0.49 of BG505 Val
664	VRC34.01 residues important for binding BG505	Xu2018	binding	VRC34.01(gp41 fusion domain)	alanine scanning, binding assay	519	gp41, fusion peptide	F	0.518	0.243	0.837	Ala and Gly mutants respectively reduced binding to 0.80 and 0.49 of BG505 Phe
665	44m contacts	Kumar2023	contacts	AIIMS-44m(V3)	cryo-EM	137	gp120, V1-hypervariable, V1	D	1.934	1.887	1.875	BG505.SOSIP interaction with heavy chain
665	44m contacts	Kumar2023	contacts	AIIMS-44m(V3)	cryo-EM	301	gp120, V3 loop	N	0.172	0.176	0.104	BG505.SOSIP glycan interaction with heavy chain
665	44m contacts	Kumar2023	contacts	AIIMS-44m(V3)	cryo-EM	322	gp120, V3 loop	K	1.797	0.347	0.283	BG505.SOSIP interaction with heavy chain
665	44m contacts	Kumar2023	contacts	AIIMS-44m(V3)	cryo-EM	323	gp120, V3 loop	I	0.476	0.531	0.263	BG505.SOSIP interaction with heavy chain
665	44m contacts	Kumar2023	contacts	AIIMS-44m(V3)	cryo-EM	324	gp120, V3 loop	G	0.075	0.056	0.092	BG505.SOSIP interaction with heavy chain
665	44m contacts	Kumar2023	contacts	AIIMS-44m(V3)	cryo-EM	325	gp120, V3 loop	N	0.648	0.622	0.622	BG505.SOSIP interaction with heavy chain
665	44m contacts	Kumar2023	contacts	AIIMS-44m(V3)	cryo-EM	326	gp120, V3 loop	M	0.143	0.143	0.116	BG505.SOSIP interaction with heavy chain
665	44m contacts	Kumar2023	contacts	AIIMS-44m(V3)	cryo-EM	327	gp120, V3 loop	R	0.089	0.066	0.073	BG505.SOSIP interaction with heavy chain
665	44m contacts	Kumar2023	contacts	AIIMS-44m(V3)	cryo-EM	330	gp120, V3 loop	H	0.634	0.559	0.655	BG505.SOSIP interaction with heavy chain
665	44m contacts	Kumar2023	contacts	AIIMS-44m(V3)	cryo-EM	332	gp120	N	0.663	0.491	0.693	BG505.SOSIP glycan interaction with heavy chain
666	mutations affecting neutralization by VRC33.01	Cottrell2021	neutralization	VRC33.01(CD4BS)	alanine scanning, mutational analysis, neutralization assay	276	gp120, Loop D	N	0.118	0.063	0.169	Q168.a2: N276A, which eliminates 276 glycan, decreased neutralization by >400 fold
666	mutations affecting neutralization by VRC33.01	Cottrell2021	neutralization	VRC33.01(CD4BS)	alanine scanning, mutational analysis, neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	Q168.a2: T278A, which eliminates 276 glycan, decreased neutralization by >400 fold
666	mutations affecting neutralization by VRC33.01	Cottrell2021	neutralization	VRC33.01(CD4BS)	alanine scanning, mutational analysis, neutralization assay	280	gp120, Loop D	N	0.142	0.090	0.170	Q168.a2: N280A decreased neutralization by >400 fold
666	mutations affecting neutralization by VRC33.01	Cottrell2021	neutralization	VRC33.01(CD4BS)	alanine scanning, mutational analysis, neutralization assay	456	gp120, beta23	R	0.233	0.079	0.323	Q168.a2: R456W decreased neutralization by >400 fold
666	mutations affecting neutralization by VRC33.01	Cottrell2021	neutralization	VRC33.01(CD4BS)	alanine scanning, mutational analysis, neutralization assay	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	Q168.a2: N462A decreased neutralization by 50.16 fold
667	mutations affecting neutralization by VRC40.01	Cottrell2021	neutralization	VRC40.01(CD4BS)	alanine scanning, neutralization assay	276	gp120, Loop D	N	0.118	0.063	0.169	Q168.a2: N276A, which eliminates 276 glycan, decreased neutralization by >574 fold
667	mutations affecting neutralization by VRC40.01	Cottrell2021	neutralization	VRC40.01(CD4BS)	alanine scanning, neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	Q168.a2: T278A, which eliminates 276 glycan,  decreased neutralization by >574 fold
667	mutations affecting neutralization by VRC40.01	Cottrell2021	neutralization	VRC40.01(CD4BS)	alanine scanning, neutralization assay	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	Q168.a2: N462A decreased neutralization by 8.70 fold
668	mutations affecting neutralization by HJ16	Cottrell2021	neutralization	HJ16(CD4BS)	alanine scanning, mutational analysis, neutralization assay	276	gp120, Loop D	N	0.118	0.063	0.169	Q168.a2: N276A, which eliminates 276 glycan, decreased neutralization by >1562 fold
668	mutations affecting neutralization by HJ16	Cottrell2021	neutralization	HJ16(CD4BS)	alanine scanning, mutational analysis, neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	Q168.a2: T278A, which eliminates 276 glycan, decreased neutralization by >1562 fold
668	mutations affecting neutralization by HJ16	Cottrell2021	neutralization	HJ16(CD4BS)	alanine scanning, mutational analysis, neutralization assay	280	gp120, Loop D	N	0.142	0.090	0.170	Q168.a2: N280A decreased neutralization by >1562 fold
668	mutations affecting neutralization by HJ16	Cottrell2021	neutralization	HJ16(CD4BS)	alanine scanning, mutational analysis, neutralization assay	456	gp120, beta23	R	0.233	0.079	0.323	Q168.a2: R456W decreased neutralization by 15.78 fold
668	mutations affecting neutralization by HJ16	Cottrell2021	neutralization	HJ16(CD4BS)	alanine scanning, mutational analysis, neutralization assay	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	Q168.a2: G459A decreased neutralization by >1562 fold
668	mutations affecting neutralization by HJ16	Cottrell2021	neutralization	HJ16(CD4BS)	alanine scanning, mutational analysis, neutralization assay	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	Q168.a2: N460A decreased neutralization by 6.78 fold
668	mutations affecting neutralization by HJ16	Cottrell2021	neutralization	HJ16(CD4BS)	alanine scanning, mutational analysis, neutralization assay	461	gp120, V5-hypervariable, V5 loop	S	2.131	1.979	2.218	Q168.a2: N461A decreased neutralization by 4.91 fold
668	mutations affecting neutralization by HJ16	Cottrell2021	neutralization	HJ16(CD4BS)	alanine scanning, mutational analysis, neutralization assay	462	gp120, V5-hypervariable, V5 loop	N	1.967	1.948	1.969	Q168.a2: N462A decreased neutralization by 38.75 fold
669	mutations affecting neutralization by 8ANC195	Cottrell2021	neutralization	8ANC195(gp120/gp41 interface)	alanine scanning, neutralization assay	234	gp120	N	0.598	0.757	0.341	Q168.a2: N234A, which eliminates 234 glycan, decreased neutralization by >108 fold
669	mutations affecting neutralization by 8ANC195	Cottrell2021	neutralization	8ANC195(gp120/gp41 interface)	alanine scanning, neutralization assay	236	gp120	T	0.877	1.013	0.551	Q168.a2: T236A, which eliminates 234 glyacn, decreased neutralization by >108 fold
669	mutations affecting neutralization by 8ANC195	Cottrell2021	neutralization	8ANC195(gp120/gp41 interface)	alanine scanning, neutralization assay	276	gp120, Loop D	N	0.118	0.063	0.169	Q168.a2: N276A, which eliminates 276 glycan, decreased neutralization by 22.51 fold
669	mutations affecting neutralization by 8ANC195	Cottrell2021	neutralization	8ANC195(gp120/gp41 interface)	alanine scanning, neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	Q168.a2: T278A, which eliminates 276 glycan, decreased neutralization by 92.42 fold
670	mutations affecting neutralization by VRC01	Cottrell2021	neutralization	VRC01(CD4BS)	alanine scanning, neutralization assay	276	gp120, Loop D	N	0.118	0.063	0.169	Q168.a2: N276A, which eliminates 276 glycan, increased neutralization by ~3 fold
670	mutations affecting neutralization by VRC01	Cottrell2021	neutralization	VRC01(CD4BS)	alanine scanning, neutralization assay	278	gp120, Loop D	T	0.708	0.715	0.481	Q168.a2: T278A, which eliminates 276 glycan,  increased neutralization by ~3 fold
671	VRC40.01 contacts	Cottrell2021	contacts	VRC40.01(CD4BS)	cryo-EM	276	gp120, Loop D	N	0.118	0.063	0.169	BG505 (N): extensive interactions with glycan
671	VRC40.01 contacts	Cottrell2021	contacts	VRC40.01(CD4BS)	cryo-EM	279	gp120, Loop D	D	0.900	0.850	0.898	BG505 (N): H bond with HC A100A
671	VRC40.01 contacts	Cottrell2021	contacts	VRC40.01(CD4BS)	cryo-EM	280	gp120, Loop D	N	0.142	0.090	0.170	BG505 (N): H bonds with HC N100 and A100A
671	VRC40.01 contacts	Cottrell2021	contacts	VRC40.01(CD4BS)	cryo-EM	282	gp120, Loop D	K	0.336	0.337	0.297	BG505 (K): 2 H-bonds with HC D31
671	VRC40.01 contacts	Cottrell2021	contacts	VRC40.01(CD4BS)	cryo-EM	365	gp120, CD4 binding loop	S	0.602	0.489	0.619	BG505 (S): H-bond with HC M57
671	VRC40.01 contacts	Cottrell2021	contacts	VRC40.01(CD4BS)	cryo-EM	367	gp120, CD4 binding loop	G	0.042	0.034	0.008	BG505 (G): 2 H-bonds with HC R70
671	VRC40.01 contacts	Cottrell2021	contacts	VRC40.01(CD4BS)	cryo-EM	428	gp120, beta20/beta21	Q	0.062	0.053	0.054	BG505 (Q): pi-pi interactions with HC W72C
671	VRC40.01 contacts	Cottrell2021	contacts	VRC40.01(CD4BS)	cryo-EM	457	gp120, beta23	D	0.079	0.054	0.043	BG505 (D): salt bridge with HC R50
671	VRC40.01 contacts	Cottrell2021	contacts	VRC40.01(CD4BS)	cryo-EM	459	gp120, V5-hypervariable, V5 loop	G	0.290	0.205	0.268	BG505 (G): H bond with LC W94
672	VRC33.01 contacts	Cottrell2021	contacts	VRC33.01(CD4BS)	cryo-EM	276	gp120, Loop D	N	0.118	0.063	0.169	BG505 (N): extensive interactions with glycan
672	VRC33.01 contacts	Cottrell2021	contacts	VRC33.01(CD4BS)	cryo-EM	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	BG505 (D): salt bridge with LC R66C
673	mutations that affect VRC40.01 binding to HXB2	Cottrell2021	binding	VRC40.01(CD4BS)	binding assay, mutational analysis	234	gp120	N	0.598	0.757	0.341	HXB2: D368R/N234S moderately reduced binding
673	mutations that affect VRC40.01 binding to HXB2	Cottrell2021	binding	VRC40.01(CD4BS)	binding assay, mutational analysis	276	gp120, Loop D	N	0.118	0.063	0.169	HXB2: D368R/N276D eliminated N276 glycan and abrogated binding
673	mutations that affect VRC40.01 binding to HXB2	Cottrell2021	binding	VRC40.01(CD4BS)	binding assay, mutational analysis	280	gp120, Loop D	N	0.142	0.090	0.170	HXB2: D368R/N280S moderately reduced binding
673	mutations that affect VRC40.01 binding to HXB2	Cottrell2021	binding	VRC40.01(CD4BS)	binding assay, mutational analysis	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	HXB2: D368R slightly reduced binding
673	mutations that affect VRC40.01 binding to HXB2	Cottrell2021	binding	VRC40.01(CD4BS)	binding assay, mutational analysis	456	gp120, beta23	R	0.233	0.079	0.323	HXB2: D368R/R456S nearly abrogated binding
673	mutations that affect VRC40.01 binding to HXB2	Cottrell2021	binding	VRC40.01(CD4BS)	binding assay, mutational analysis	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	HXB2: D368R/N460P moderately reduced binding
674	mutations that affect VRC33.01 binding to HXB2	Cottrell2021	binding	VRC33.01(CD4BS)	binding assay, mutational analysis	234	gp120	N	0.598	0.757	0.341	HXB2: D368R/N234S abrogated binding
674	mutations that affect VRC33.01 binding to HXB2	Cottrell2021	binding	VRC33.01(CD4BS)	binding assay, mutational analysis	276	gp120, Loop D	N	0.118	0.063	0.169	HXB2: D368R/N276D eliminated N276 glycan and abrogated binding
674	mutations that affect VRC33.01 binding to HXB2	Cottrell2021	binding	VRC33.01(CD4BS)	binding assay, mutational analysis	280	gp120, Loop D	N	0.142	0.090	0.170	HXB2: D368R/N280S abrogated binding
674	mutations that affect VRC33.01 binding to HXB2	Cottrell2021	binding	VRC33.01(CD4BS)	binding assay, mutational analysis	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	HXB2: D368R moderately reduced binding
674	mutations that affect VRC33.01 binding to HXB2	Cottrell2021	binding	VRC33.01(CD4BS)	binding assay, mutational analysis	456	gp120, beta23	R	0.233	0.079	0.323	HXB2: D368R/R456S abrogated binding
674	mutations that affect VRC33.01 binding to HXB2	Cottrell2021	binding	VRC33.01(CD4BS)	binding assay, mutational analysis	460	gp120, V5-hypervariable, V5 loop	N	2.292	2.056	2.373	HXB2: D368R/N460P abrogated binding
675	mutations that affect HJ16 binding to HXB2	Cottrell2021	binding	HJ16(CD4BS)	binding assay, mutational analysis	234	gp120	N	0.598	0.757	0.341	HXB2: D368R/N234S moderately reduced binding (D368 alone had minimal effect)
675	mutations that affect HJ16 binding to HXB2	Cottrell2021	binding	HJ16(CD4BS)	binding assay, mutational analysis	276	gp120, Loop D	N	0.118	0.063	0.169	HXB2: D368R/N276D eliminated N276 glycan and moderately reduced binding (D368 alone had minimal effect)
675	mutations that affect HJ16 binding to HXB2	Cottrell2021	binding	HJ16(CD4BS)	binding assay, mutational analysis	280	gp120, Loop D	N	0.142	0.090	0.170	HXB2: D368R/N280S substantailly reduced binding  (D368 alone had minimal effect)
675	mutations that affect HJ16 binding to HXB2	Cottrell2021	binding	HJ16(CD4BS)	binding assay, mutational analysis	456	gp120, beta23	R	0.233	0.079	0.323	HXB2: D368R/R456S abrogated binding  (D368 alone had minimal effect)
676	mutations that affect 8ANC195 binding to HXB2	Cottrell2021	binding	8ANC195(gp120/gp41 interface)	binding assay, mutational analysis	276	gp120, Loop D	N	0.118	0.063	0.169	HXB2: D368R/N276D eliminated N276 glycan and abrogated binding
676	mutations that affect 8ANC195 binding to HXB2	Cottrell2021	binding	8ANC195(gp120/gp41 interface)	binding assay, mutational analysis	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	HXB2: D368R moderately reduced binding
676	mutations that affect 8ANC195 binding to HXB2	Cottrell2021	binding	8ANC195(gp120/gp41 interface)	binding assay, mutational analysis	456	gp120, beta23	R	0.233	0.079	0.323	HXB2: D368R/R456S substantially reduced binding
677	mutations that affect VRC01 binding to HXB2	Cottrell2021	binding	VRC01(CD4BS)	binding assay, mutational analysis	276	gp120, Loop D	N	0.118	0.063	0.169	HXB2: D368R/N276D eliminated N276 glycan and slightly increased binding
677	mutations that affect VRC01 binding to HXB2	Cottrell2021	binding	VRC01(CD4BS)	binding assay, mutational analysis	280	gp120, Loop D	N	0.142	0.090	0.170	HXB2: D368R/N280S abrogated binding
677	mutations that affect VRC01 binding to HXB2	Cottrell2021	binding	VRC01(CD4BS)	binding assay, mutational analysis	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	HXB2: D368R moderately reduced binding
677	mutations that affect VRC01 binding to HXB2	Cottrell2021	binding	VRC01(CD4BS)	binding assay, mutational analysis	456	gp120, beta23	R	0.233	0.079	0.323	HXB2: D368R/R456S abrogated binding
678	mutations that affect b12 binding to HXB2	Cottrell2021	binding	b12(CD4BS)	binding assay, mutational analysis	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	HXB2: D368R abrogated binding
679	mutations that affect 17b binding to HXB2	Cottrell2021	binding	17b(CD4i)	binding assay, mutational analysis	276	gp120, Loop D	N	0.118	0.063	0.169	HXB2: D368R/N276D moderately reduced binding
679	mutations that affect 17b binding to HXB2	Cottrell2021	binding	17b(CD4i)	binding assay, mutational analysis	368	gp120, CD4 binding loop	D	0.039	0.023	0.029	HXB2: D368R slightly reduced binding
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	44	gp120	V	0.054	0.023	0.039	BG505.T332N (Val): viral escape - Leu (strong effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	85	gp120	V	1.980	1.797	1.418	BG505.T332N (His): viral escape - Q/V (strong effect) and N/D/S/L/K/F/R/C/Y/A/P/I (moderate effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	88	gp120	N	0.050	0.041	0.048	BG505.T332N (Asn): N88 glycosylation motif; viral escape - T/G/S/H/R/A (strong effect) and F/L/Q/W/E/K/M/D (moderate effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	90	gp120	T	0.079	0.063	0.051	BG505.T332N (Thr): N88 glycosylation motif; viral escape - R/N/V/A/G (strong effect) and K/I/H/L/E/Y/Q (moderate effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	227	gp120	K	0.272	0.288	0.161	BG505.T332N (Lys): viral esacpe - E/V/H/N/L (moderately effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	229	gp120	N	0.707	0.742	0.290	BG505.T332N (Lys): viral escape - M/R/S/L/T/I/G/A/E/V/D (moderate effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	241	gp120	N	0.191	0.183	0.134	BG505.T332N (Ser): viral escape - G/D/I/F (moderate effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	243	gp120	S	0.067	0.058	0.051	BG505.T332N (Ser): viral escape - R/D/Q/G/H/V/T/F (moderate effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	287	gp120	Q	0.693	0.363	0.618	BG505.T332N (Gln): viral escape - His (strong effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	345	gp120	I	0.809	0.820	0.238	BG505.T332N (Val): viral escape - Ala (strong effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	403	gp120, V4-hypervariable, V4 loop	E	2.421	2.430	2.183	BG505.T332N (Gln): viral escape - Ile (strong effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	407	gp120, V4-hypervariable, V4 loop	N	1.615	1.992	1.038	BG505.T332N (Ser): viral escape - Lys (strong effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	491	gp120	I	0.423	0.358	0.441	BG505.T332N (Ile): viral escape - Tyr (strong effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	512	gp41, fusion peptide	A	0.188	0.260	0.110	BG505.T332N (Ala): viral escape - L/E (strong effect) and M/G/T/V/Y/Q/F/C/I/N/W (moderate effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	513	gp41, fusion peptide	V	0.761	0.736	0.506	BG505.T332N (Val): viral escape - P/L (strong effect) and G/S/N/A/F/T/M/W/I (moderate effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	514	gp41, fusion peptide	G	0.600	0.691	0.502	BG505.T332N (Gly): viral escape - P/S/T/Y/M/F/A/G/H (moderate effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	515	gp41, fusion peptide	I	1.103	1.147	0.877	BG505.T332N (Ile): viral escape - P/S/T/Y (strong effect) and M/F/A/G/H (moderate effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	516	gp41, fusion peptide	G	0.066	0.038	0.048	BG505.T332N (Gly): viral escape - L/A/V (strong effect) and E/Y/I/P/N/Q/K/D/T (moderate effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	518	gp41, fusion peptide	L	1.166	1.110	0.718	BG505.T332N (Val): viral escape - W/F/L/Y/M/Q/I (moderate effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	524	gp41, fusion peptide	G	0.152	0.129	0.125	BG505.T332N (Gly): viral escape - S/V/A/I (strong effect) and Q/H/E/T/F/L (moderate effect)
680	VRC34.01 functional escape mapping	Dingens2018	other feature	VRC34.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	629	gp41	M	0.563	0.350	0.132	BG505.T332N (Leu): viral escape - P/A/N/Q/V/T (moderate effect)
681	vFP16.02 functional escape mapping	Dingens2018	other feature	vFP16.02(gp41 fusion domain)	mutational analysis, other, sequence analysis	85	gp120	V	1.980	1.797	1.418	BG505.T332N (His): viral escape - D/V/Q (moderate effect)
681	vFP16.02 functional escape mapping	Dingens2018	other feature	vFP16.02(gp41 fusion domain)	mutational analysis, other, sequence analysis	138	gp120, V1-hypervariable, V1	T	2.312	2.112	2.504	BG505.T332N (Ile): viral escape - Arg (strong effect)
681	vFP16.02 functional escape mapping	Dingens2018	other feature	vFP16.02(gp41 fusion domain)	mutational analysis, other, sequence analysis	241	gp120	N	0.191	0.183	0.134	BG505.T332N (Ser): viral escape - G/D/I/F (moderate effect)
681	vFP16.02 functional escape mapping	Dingens2018	other feature	vFP16.02(gp41 fusion domain)	mutational analysis, other, sequence analysis	512	gp41, fusion peptide	A	0.188	0.260	0.110	BG505.T332N (Ala): viral escape - L (strong effect) and S/W/Y/Q/E/M/G/V/T/F/C/D (moderate effect)
681	vFP16.02 functional escape mapping	Dingens2018	other feature	vFP16.02(gp41 fusion domain)	mutational analysis, other, sequence analysis	513	gp41, fusion peptide	V	0.761	0.736	0.506	BG505.T332N (Val): viral escape - P/A (strong effect) and L/I/G/T/S/F/N/M/Y/W (moderate effect)
681	vFP16.02 functional escape mapping	Dingens2018	other feature	vFP16.02(gp41 fusion domain)	mutational analysis, other, sequence analysis	514	gp41, fusion peptide	G	0.600	0.691	0.502	BG505.T332N (Gly): viral escape - A/P/V/E (strong effect) and D/L/Y/S/T/H/N/F/I/Q/R (moderate effect)
681	vFP16.02 functional escape mapping	Dingens2018	other feature	vFP16.02(gp41 fusion domain)	mutational analysis, other, sequence analysis	515	gp41, fusion peptide	I	1.103	1.147	0.877	BG505.T332N (Ile): viral escape - P/S/M/T/Y (strong effect) and A/L/G/F (moderate effect)
681	vFP16.02 functional escape mapping	Dingens2018	other feature	vFP16.02(gp41 fusion domain)	mutational analysis, other, sequence analysis	516	gp41, fusion peptide	G	0.066	0.038	0.048	BG505.T332N (Gly): viral escape - V/L/P/A (strong effect) and I/S/D/F/Q/N/E/T/Y/M/H (moderate effect)
681	vFP16.02 functional escape mapping	Dingens2018	other feature	vFP16.02(gp41 fusion domain)	mutational analysis, other, sequence analysis	524	gp41, fusion peptide	G	0.152	0.129	0.125	BG505.T332N (Gly): viral escape - E/V (moderate effect)
682	vFP20.01 functional escape mapping	Dingens2018	other feature	vFP20.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	85	gp120	V	1.980	1.797	1.418	BG505.T332N (His): viral escape - Val (moderate effect)
682	vFP20.01 functional escape mapping	Dingens2018	other feature	vFP20.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	89	gp120	V	0.108	0.081	0.117	BG505.T332N (Val): viral escape - A/H (moderate effect)
682	vFP20.01 functional escape mapping	Dingens2018	other feature	vFP20.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	241	gp120	N	0.191	0.183	0.134	BG505.T332N (Ser): viral escape - N (adds glycosylation, moderate effect)
682	vFP20.01 functional escape mapping	Dingens2018	other feature	vFP20.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	299	gp120, V3 loop	P	0.188	0.188	0.200	BG505.T332N (Pro): viral escape - A (strong effect) and H (moderate effect)
682	vFP20.01 functional escape mapping	Dingens2018	other feature	vFP20.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	348	gp120	K	0.592	0.227	0.454	BG505.T332N (Gln): viral escape - M (strong effect) and L (moderate effect)
682	vFP20.01 functional escape mapping	Dingens2018	other feature	vFP20.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	512	gp41, fusion peptide	A	0.188	0.260	0.110	BG505.T332N (Ala): viral escape - L/Q/Y/E/V/G/S (strong effect) and F/T/I/W/D/M/H (moderate effect)
682	vFP20.01 functional escape mapping	Dingens2018	other feature	vFP20.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	513	gp41, fusion peptide	V	0.761	0.736	0.506	BG505.T332N (Val): viral escape - P/A/L/F (strong effect) and M/S/G/T/Y/I/W (moderate effect)
682	vFP20.01 functional escape mapping	Dingens2018	other feature	vFP20.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	514	gp41, fusion peptide	G	0.600	0.691	0.502	BG505.T332N (Gly): viral escape -V/A/D/E/T/P (strong effect) and S/L/Q/Y/H/N/M/I/W (moderate effect)
682	vFP20.01 functional escape mapping	Dingens2018	other feature	vFP20.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	515	gp41, fusion peptide	I	1.103	1.147	0.877	BG505.T332N (Ile): viral escape - S/P/M/T/Y/F/L (strong effect) and G/A/V (moderate effect)
682	vFP20.01 functional escape mapping	Dingens2018	other feature	vFP20.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	516	gp41, fusion peptide	G	0.066	0.038	0.048	BG505.T332N (Gly): viral escape - P/V (strong effect) and D/I/F/T/L/Y/K (moderate effect)
682	vFP20.01 functional escape mapping	Dingens2018	other feature	vFP20.01(gp41 fusion domain)	mutational analysis, other, sequence analysis	524	gp41, fusion peptide	G	0.152	0.129	0.125	BG505.T332N (Gly): viral escape - S/A/Q/I/V/H/T (moderate effect)
683	Mutation affects neutralization by 12A12	Sok2016	neutralization	12A12(CD4BS)	alanine scanning, neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	JRCSF sensitivity was associated with double mutation N156A+Q328A
683	Mutation affects neutralization by 12A12	Sok2016	neutralization	12A12(CD4BS)	alanine scanning, neutralization assay	328	gp120, V3 loop	Q	0.923	0.816	0.882	JRCSF sensitivity was associated with double mutation N156A+Q328A
684	Mutation affects neutralization by PGDM12	Sok2016	neutralization	PGDM12(V3)	alanine scanning, neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	JRCSF resistance was associated with double mutations N156A+I326A and N156A+Q328A
684	Mutation affects neutralization by PGDM12	Sok2016	neutralization	PGDM12(V3)	alanine scanning, neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	JRCSF resistance was associated with double mutations N301A+H330A and N301A+R327A
684	Mutation affects neutralization by PGDM12	Sok2016	neutralization	PGDM12(V3)	alanine scanning, neutralization assay	324	gp120, V3 loop	G	0.075	0.056	0.092	JRCSF resistance was associated with double mutation N332A+G324A
684	Mutation affects neutralization by PGDM12	Sok2016	neutralization	PGDM12(V3)	alanine scanning, neutralization assay	325	gp120, V3 loop	N	0.648	0.622	0.622	JRCSF resistance was associated with double mutations N332A+D325A and D325A+R327A
684	Mutation affects neutralization by PGDM12	Sok2016	neutralization	PGDM12(V3)	alanine scanning, neutralization assay	326	gp120, V3 loop	M	0.143	0.143	0.116	JRCSF resistance was associated with double mutations N156A+I326A and N332A+I326A
684	Mutation affects neutralization by PGDM12	Sok2016	neutralization	PGDM12(V3)	alanine scanning, neutralization assay	327	gp120, V3 loop	R	0.089	0.066	0.073	JRCSF resistance was associated with R327A and double mutations N301A+R327A and D325A+R327A
684	Mutation affects neutralization by PGDM12	Sok2016	neutralization	PGDM12(V3)	alanine scanning, neutralization assay	328	gp120, V3 loop	Q	0.923	0.816	0.882	JRCSF resistance was associated with double mutation N156A+Q328A
684	Mutation affects neutralization by PGDM12	Sok2016	neutralization	PGDM12(V3)	alanine scanning, neutralization assay	330	gp120, V3 loop	H	0.634	0.559	0.655	JRCSF resistance was associated with double mutation N301A+H330A
684	Mutation affects neutralization by PGDM12	Sok2016	neutralization	PGDM12(V3)	alanine scanning, neutralization assay	332	gp120	N	0.663	0.491	0.693	JRCSF resistance was associated with N332A and double mutations N332A+D325A, N332A+G324A, and N332A+I326A
685	Mutation affects neutralization by PGDM21	Sok2016	neutralization	PGDM21(V3)	alanine scanning, neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	JRCSF resistance was associated with N156A and double mutation N156A+D325A
685	Mutation affects neutralization by PGDM21	Sok2016	neutralization	PGDM21(V3)	alanine scanning, neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	JRCSF resistance was associated with double mutations N301A+D325A and N301A+H330A
685	Mutation affects neutralization by PGDM21	Sok2016	neutralization	PGDM21(V3)	alanine scanning, neutralization assay	324	gp120, V3 loop	G	0.075	0.056	0.092	JRCSF resistance was associated with double mutation N332A+G324A
685	Mutation affects neutralization by PGDM21	Sok2016	neutralization	PGDM21(V3)	alanine scanning, neutralization assay	325	gp120, V3 loop	N	0.648	0.622	0.622	JRCSF resistance was associated with D325A and double mutations N156A+D325A, N301A+D325A, N332A+D325A and D325A+R327A
685	Mutation affects neutralization by PGDM21	Sok2016	neutralization	PGDM21(V3)	alanine scanning, neutralization assay	326	gp120, V3 loop	M	0.143	0.143	0.116	JRCSF resistance was associated with double mutation N332A+I326A
685	Mutation affects neutralization by PGDM21	Sok2016	neutralization	PGDM21(V3)	alanine scanning, neutralization assay	330	gp120, V3 loop	H	0.634	0.559	0.655	JRCSF resistance was associated with double mutations N301A+H330A and D325A+R327A
685	Mutation affects neutralization by PGDM21	Sok2016	neutralization	PGDM21(V3)	alanine scanning, neutralization assay	332	gp120	N	0.663	0.491	0.693	JRCSF resistance was associated with N332A and double mutations N332A+D325A, N332A+G324A, and N332A+I326A
686	Mutation affects neutralization by PGT121	Sok2016	neutralization	PGT121(V3)	alanine scanning, neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	JRCSF resistance was associated with double mutation N156A+D325A
686	Mutation affects neutralization by PGT121	Sok2016	neutralization	PGT121(V3)	alanine scanning, neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	JRCSF resistance was associated with double mutations N301A+D325A and N301A+R327A
686	Mutation affects neutralization by PGT121	Sok2016	neutralization	PGT121(V3)	alanine scanning, neutralization assay	324	gp120, V3 loop	G	0.075	0.056	0.092	JRCSF resistance was associated with double mutation N332A+G324A
686	Mutation affects neutralization by PGT121	Sok2016	neutralization	PGT121(V3)	alanine scanning, neutralization assay	325	gp120, V3 loop	N	0.648	0.622	0.622	JRCSF resistance was associated with double mutations N156A+D325A, N301A+D325A, N332A+D325A, and D325A+R327A
686	Mutation affects neutralization by PGT121	Sok2016	neutralization	PGT121(V3)	alanine scanning, neutralization assay	326	gp120, V3 loop	M	0.143	0.143	0.116	JRCSF resistance was associated with double mutation N332A+I326A
686	Mutation affects neutralization by PGT121	Sok2016	neutralization	PGT121(V3)	alanine scanning, neutralization assay	327	gp120, V3 loop	R	0.089	0.066	0.073	JRCSF resistance was associated with double mutations N301A+R327A and D325A+R327A
686	Mutation affects neutralization by PGT121	Sok2016	neutralization	PGT121(V3)	alanine scanning, neutralization assay	332	gp120	N	0.663	0.491	0.693	JRCSF resistance was associated with N332A and double mutations N332A+D325A, N332A+G324A, and N332A+I326A
687	Mutation affects neutralization by PGT124	Sok2016	neutralization	PGT124(V3)	alanine scanning, neutralization assay	324	gp120, V3 loop	G	0.075	0.056	0.092	JRCSF resistance was associated with double mutation N332A+G324A
687	Mutation affects neutralization by PGT124	Sok2016	neutralization	PGT124(V3)	alanine scanning, neutralization assay	325	gp120, V3 loop	N	0.648	0.622	0.622	JRCSF resistance was associated with double mutations N332A+D325A and D325A+R327A
687	Mutation affects neutralization by PGT124	Sok2016	neutralization	PGT124(V3)	alanine scanning, neutralization assay	326	gp120, V3 loop	M	0.143	0.143	0.116	JRCSF resistance was associated with double mutation N332A+I326A
687	Mutation affects neutralization by PGT124	Sok2016	neutralization	PGT124(V3)	alanine scanning, neutralization assay	327	gp120, V3 loop	R	0.089	0.066	0.073	JRCSF resistance was associated with double mutation D325A+R327A
687	Mutation affects neutralization by PGT124	Sok2016	neutralization	PGT124(V3)	alanine scanning, neutralization assay	332	gp120	N	0.663	0.491	0.693	JRCSF resistance was associated with N332A and double mutations N332A+D325A, N332A+G324A, and N332A+I326A
688	Mutation affects neutralization by PGT128	Sok2016	neutralization	PGT128(V3)	alanine scanning, neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	JRCSF resistance was associated with double mutations N301A+D325A, N301A+H330A, N301A+I326A, and N301A+R327A
688	Mutation affects neutralization by PGT128	Sok2016	neutralization	PGT128(V3)	alanine scanning, neutralization assay	324	gp120, V3 loop	G	0.075	0.056	0.092	JRCSF resistance was associated with double mutation N332A+G324A
688	Mutation affects neutralization by PGT128	Sok2016	neutralization	PGT128(V3)	alanine scanning, neutralization assay	325	gp120, V3 loop	N	0.648	0.622	0.622	JRCSF resistance was associated with double mutations N301A+D325A and N332A+D325A
688	Mutation affects neutralization by PGT128	Sok2016	neutralization	PGT128(V3)	alanine scanning, neutralization assay	326	gp120, V3 loop	M	0.143	0.143	0.116	JRCSF resistance was associated with double mutations N301A+I326A and N332A+I326A
688	Mutation affects neutralization by PGT128	Sok2016	neutralization	PGT128(V3)	alanine scanning, neutralization assay	327	gp120, V3 loop	R	0.089	0.066	0.073	JRCSF resistance was associated with double mutation N301A+R327A
688	Mutation affects neutralization by PGT128	Sok2016	neutralization	PGT128(V3)	alanine scanning, neutralization assay	330	gp120, V3 loop	H	0.634	0.559	0.655	JRCSF resistance was associated with double mutation N301A+H330A
688	Mutation affects neutralization by PGT128	Sok2016	neutralization	PGT128(V3)	alanine scanning, neutralization assay	332	gp120	N	0.663	0.491	0.693	JRCSF resistance was associated with double mutations N332A+D325A, N332A+G324A, N332A+I326A
689	Mutation affects neutralization by PGT130	Sok2016	neutralization	PGT130(V3)	alanine scanning, neutralization assay	156	gp120, V1	N	0.246	0.220	0.224	JRCSF resistance was associated with double mutations N156A+D325A and N156A+I326A
689	Mutation affects neutralization by PGT130	Sok2016	neutralization	PGT130(V3)	alanine scanning, neutralization assay	301	gp120, V3 loop	N	0.172	0.176	0.104	JRCSF resistance was associated with N301A and double mutations N301A+D325A, N301A+H330A, N301A+I326A, N301A+Q328A and N301A+R327A
689	Mutation affects neutralization by PGT130	Sok2016	neutralization	PGT130(V3)	alanine scanning, neutralization assay	324	gp120, V3 loop	G	0.075	0.056	0.092	JRCSF resistance was associated with G324A and double mutation N332A+G324A
689	Mutation affects neutralization by PGT130	Sok2016	neutralization	PGT130(V3)	alanine scanning, neutralization assay	325	gp120, V3 loop	N	0.648	0.622	0.622	JRCSF resistance was associated with D325A and double mutations N156A+D325A, N301A+D325A, N332A+D325A, and D325A+R327A
689	Mutation affects neutralization by PGT130	Sok2016	neutralization	PGT130(V3)	alanine scanning, neutralization assay	326	gp120, V3 loop	M	0.143	0.143	0.116	JRCSF resistance was associated with double mutations N156A+I326A, N301A+I326A, N332A+I326A
689	Mutation affects neutralization by PGT130	Sok2016	neutralization	PGT130(V3)	alanine scanning, neutralization assay	327	gp120, V3 loop	R	0.089	0.066	0.073	JRCSF resistance was associated with double mutations N301A+R327A and D325A+R327A
689	Mutation affects neutralization by PGT130	Sok2016	neutralization	PGT130(V3)	alanine scanning, neutralization assay	328	gp120, V3 loop	Q	0.923	0.816	0.882	JRCSF resistance was associated with double mutation N301A+Q328A
689	Mutation affects neutralization by PGT130	Sok2016	neutralization	PGT130(V3)	alanine scanning, neutralization assay	330	gp120, V3 loop	H	0.634	0.559	0.655	JRCSF resistance was associated with double mutation N301A+H330A
689	Mutation affects neutralization by PGT130	Sok2016	neutralization	PGT130(V3)	alanine scanning, neutralization assay	332	gp120	N	0.663	0.491	0.693	JRCSF resistance was associated with double mutations N332A+D325A, N332A+G324A, N332A+I326A
690	Mutation affects neutralization by PGDM11	Sok2016	neutralization	PGDM11(V3)	alanine scanning, neutralization assay	325	gp120, V3 loop	N	0.648	0.622	0.622	JRCSF resistance was associated with double mutation D325A+R327A
690	Mutation affects neutralization by PGDM11	Sok2016	neutralization	PGDM11(V3)	alanine scanning, neutralization assay	327	gp120, V3 loop	R	0.089	0.066	0.073	JRCSF resistance was associated with double mutation D325A+R327A
690	Mutation affects neutralization by PGDM11	Sok2016	neutralization	PGDM11(V3)	alanine scanning, neutralization assay	330	gp120, V3 loop	H	0.634	0.559	0.655	JRCSF resistance was associated with H330A
691	VRC13 escape mutations	Joshi2024	neutralization	VRC13(CD4BS)	mutational analysis, neutralization assay	359	gp120	I	0.210	0.177	0.105	T359I associated with escape
691	VRC13 escape mutations	Joshi2024	neutralization	VRC13(CD4BS)	mutational analysis, neutralization assay	362	gp120	K	1.815	1.265	1.997	exchange of a potential N-linked glycosylation site to residue S362 from N363 associated with escape
691	VRC13 escape mutations	Joshi2024	neutralization	VRC13(CD4BS)	mutational analysis, neutralization assay	363	gp120	Q	1.825	1.587	1.352	exchange of a potential N-linked glycosylation site to residue S362 from N363 associated with escape
691	VRC13 escape mutations	Joshi2024	neutralization	VRC13(CD4BS)	mutational analysis, neutralization assay	369	gp120, CD4 binding loop	P	0.941	0.591	0.470	P369L associated with escape
